id	sid	tid	token	lemma	pos
aiua-13880	1	1	stesura	stesura	PROPN
aiua-13880	1	2	seveso	seveso	PROPN
aiua-13880	1	3	archivio	archivio	PROPN
aiua-13880	1	4	italiano	italiano	X
aiua-13880	1	5	di	di	X
aiua-13880	1	6	urologia	urologia	PROPN
aiua-13880	1	7	e	e	PROPN
aiua-13880	1	8	andrologia	andrologia	NOUN
aiua-13880	1	9	2025	2025	NUM
aiua-13880	1	10	;	;	PUNCT
aiua-13880	1	11	97(2):13880	97(2):13880	NUM
aiua-13880	1	12	1	1	NUM
aiua-13880	1	13	review	review	VERB
aiua-13880	1	14	the	the	DET
aiua-13880	1	15	patient	patient	NOUN
aiua-13880	1	16	’s	’s	PART
aiua-13880	1	17	tumor	tumor	NOUN
aiua-13880	1	18	stage	stage	NOUN
aiua-13880	1	19	,	,	PUNCT
aiua-13880	1	20	grade	grade	NOUN
aiua-13880	1	21	,	,	PUNCT
aiua-13880	1	22	comorbidity	comorbidity	NOUN
aiua-13880	1	23	,	,	PUNCT
aiua-13880	1	24	and	and	CCONJ
aiua-13880	1	25	performance	performance	NOUN
aiua-13880	1	26	.	.	PUNCT
aiua-13880	2	1	when	when	SCONJ
aiua-13880	2	2	the	the	DET
aiua-13880	2	3	disease	disease	NOUN
aiua-13880	2	4	progresses	progress	VERB
aiua-13880	2	5	to	to	PART
aiua-13880	2	6	unresectable	unresectable	ADJ
aiua-13880	2	7	,	,	PUNCT
aiua-13880	2	8	locally	locally	ADV
aiua-13880	2	9	advanced	advanced	ADJ
aiua-13880	2	10	,	,	PUNCT
aiua-13880	2	11	or	or	CCONJ
aiua-13880	2	12	metastatic	metastatic	ADJ
aiua-13880	2	13	ucs	ucs	NOUN
aiua-13880	2	14	(	(	PUNCT
aiua-13880	2	15	muc	muc	X
aiua-13880	2	16	)	)	PUNCT
aiua-13880	2	17	,	,	PUNCT
aiua-13880	2	18	the	the	DET
aiua-13880	2	19	administration	administration	NOUN
aiua-13880	2	20	of	of	ADP
aiua-13880	2	21	systemic	systemic	ADJ
aiua-13880	2	22	therapy	therapy	NOUN
aiua-13880	2	23	is	be	AUX
aiua-13880	2	24	generally	generally	ADV
aiua-13880	2	25	recommended	recommend	VERB
aiua-13880	2	26	(	(	PUNCT
aiua-13880	2	27	3	3	NUM
aiua-13880	2	28	)	)	PUNCT
aiua-13880	2	29	.	.	PUNCT
aiua-13880	3	1	for	for	ADP
aiua-13880	3	2	many	many	ADJ
aiua-13880	3	3	years	year	NOUN
aiua-13880	3	4	,	,	PUNCT
aiua-13880	3	5	cisplatin	cisplatin	NOUN
aiua-13880	3	6	-	-	PUNCT
aiua-13880	3	7	based	base	VERB
aiua-13880	3	8	cytotoxic	cytotoxic	ADJ
aiua-13880	3	9	chemotherapy	chemotherapy	NOUN
aiua-13880	3	10	has	have	AUX
aiua-13880	3	11	been	be	AUX
aiua-13880	3	12	the	the	DET
aiua-13880	3	13	standard	standard	ADJ
aiua-13880	3	14	treatment	treatment	NOUN
aiua-13880	3	15	for	for	ADP
aiua-13880	3	16	muc	muc	X
aiua-13880	3	17	.	.	PUNCT
aiua-13880	4	1	however	however	ADV
aiua-13880	4	2	,	,	PUNCT
aiua-13880	4	3	as	as	SCONJ
aiua-13880	4	4	the	the	DET
aiua-13880	4	5	disease	disease	NOUN
aiua-13880	4	6	advances	advance	VERB
aiua-13880	4	7	,	,	PUNCT
aiua-13880	4	8	up	up	ADP
aiua-13880	4	9	to	to	PART
aiua-13880	4	10	50	50	NUM
aiua-13880	4	11	%	%	NOUN
aiua-13880	4	12	of	of	ADP
aiua-13880	4	13	patients	patient	NOUN
aiua-13880	4	14	requiring	require	VERB
aiua-13880	4	15	chemotherapy	chemotherapy	NOUN
aiua-13880	4	16	may	may	AUX
aiua-13880	4	17	be	be	AUX
aiua-13880	4	18	considered	consider	VERB
aiua-13880	4	19	unfit	unfit	ADJ
aiua-13880	4	20	for	for	ADP
aiua-13880	4	21	cisplatinbased	cisplatinbase	VERB
aiua-13880	4	22	treatment	treatment	NOUN
aiua-13880	4	23	due	due	ADP
aiua-13880	4	24	to	to	ADP
aiua-13880	4	25	the	the	DET
aiua-13880	4	26	presence	presence	NOUN
aiua-13880	4	27	of	of	ADP
aiua-13880	4	28	comorbidities	comorbiditie	NOUN
aiua-13880	4	29	(	(	PUNCT
aiua-13880	4	30	4	4	NUM
aiua-13880	4	31	)	)	PUNCT
aiua-13880	4	32	.	.	PUNCT
aiua-13880	5	1	recently	recently	ADV
aiua-13880	5	2	,	,	PUNCT
aiua-13880	5	3	immunotherapy	immunotherapy	NOUN
aiua-13880	5	4	using	use	VERB
aiua-13880	5	5	immune	immune	ADJ
aiua-13880	5	6	checkpoint	checkpoint	NOUN
aiua-13880	5	7	inhibitors	inhibitor	NOUN
aiua-13880	5	8	have	have	AUX
aiua-13880	5	9	emerged	emerge	VERB
aiua-13880	5	10	as	as	ADP
aiua-13880	5	11	alternative	alternative	ADJ
aiua-13880	5	12	treatment	treatment	NOUN
aiua-13880	5	13	options	option	NOUN
aiua-13880	5	14	for	for	ADP
aiua-13880	5	15	individuals	individual	NOUN
aiua-13880	5	16	with	with	ADP
aiua-13880	5	17	muc	muc	PROPN
aiua-13880	5	18	(	(	PUNCT
aiua-13880	5	19	5	5	NUM
aiua-13880	5	20	)	)	PUNCT
aiua-13880	5	21	.	.	PUNCT
aiua-13880	6	1	one	one	NUM
aiua-13880	6	2	notable	notable	ADJ
aiua-13880	6	3	example	example	NOUN
aiua-13880	6	4	of	of	ADP
aiua-13880	6	5	this	this	DET
aiua-13880	6	6	class	class	NOUN
aiua-13880	6	7	of	of	ADP
aiua-13880	6	8	drugs	drug	NOUN
aiua-13880	6	9	is	be	AUX
aiua-13880	6	10	pembrolizumab	pembrolizumab	NOUN
aiua-13880	6	11	,	,	PUNCT
aiua-13880	6	12	a	a	DET
aiua-13880	6	13	pd-1	pd-1	ADJ
aiua-13880	6	14	inhibitor	inhibitor	NOUN
aiua-13880	6	15	agent	agent	NOUN
aiua-13880	6	16	that	that	SCONJ
aiua-13880	6	17	functions	function	NOUN
aiua-13880	6	18	by	by	ADP
aiua-13880	6	19	inhibiting	inhibit	VERB
aiua-13880	6	20	the	the	DET
aiua-13880	6	21	interaction	interaction	NOUN
aiua-13880	6	22	between	between	ADP
aiua-13880	6	23	programmed	program	VERB
aiua-13880	6	24	cell	cell	NOUN
aiua-13880	6	25	death	death	NOUN
aiua-13880	6	26	protein-1	protein-1	PROPN
aiua-13880	6	27	(	(	PUNCT
aiua-13880	6	28	pd-1	pd-1	X
aiua-13880	6	29	)	)	PUNCT
aiua-13880	6	30	and	and	CCONJ
aiua-13880	6	31	its	its	PRON
aiua-13880	6	32	ligand	ligand	NOUN
aiua-13880	6	33	(	(	PUNCT
aiua-13880	6	34	pd	pd	NOUN
aiua-13880	6	35	-	-	PUNCT
aiua-13880	6	36	l1	l1	NOUN
aiua-13880	6	37	)	)	PUNCT
aiua-13880	6	38	(	(	PUNCT
aiua-13880	6	39	6	6	NUM
aiua-13880	6	40	)	)	PUNCT
aiua-13880	6	41	.	.	PUNCT
aiua-13880	7	1	numerous	numerous	ADJ
aiua-13880	7	2	ongoing	ongoing	ADJ
aiua-13880	7	3	studies	study	NOUN
aiua-13880	7	4	are	be	AUX
aiua-13880	7	5	investigating	investigate	VERB
aiua-13880	7	6	these	these	DET
aiua-13880	7	7	agents	agent	NOUN
aiua-13880	7	8	as	as	ADP
aiua-13880	7	9	firstand	firstand	NOUN
aiua-13880	7	10	second	second	ADJ
aiua-13880	7	11	-	-	PUNCT
aiua-13880	7	12	line	line	NOUN
aiua-13880	7	13	therapies	therapy	NOUN
aiua-13880	7	14	,	,	PUNCT
aiua-13880	7	15	both	both	CCONJ
aiua-13880	7	16	alone	alone	ADJ
aiua-13880	7	17	and	and	CCONJ
aiua-13880	7	18	in	in	ADP
aiua-13880	7	19	combination	combination	NOUN
aiua-13880	7	20	with	with	ADP
aiua-13880	7	21	chemotherapy	chemotherapy	NOUN
aiua-13880	7	22	or	or	CCONJ
aiua-13880	7	23	in	in	ADP
aiua-13880	7	24	a	a	DET
aiua-13880	7	25	maintenance	maintenance	NOUN
aiua-13880	7	26	regimen	regiman	NOUN
aiua-13880	7	27	,	,	PUNCT
aiua-13880	7	28	thereby	thereby	ADV
aiua-13880	7	29	signaling	signal	VERB
aiua-13880	7	30	their	their	PRON
aiua-13880	7	31	steadily	steadily	ADV
aiua-13880	7	32	increasing	increase	VERB
aiua-13880	7	33	importance	importance	NOUN
aiua-13880	7	34	(	(	PUNCT
aiua-13880	7	35	7	7	NUM
aiua-13880	7	36	)	)	PUNCT
aiua-13880	7	37	.	.	PUNCT
aiua-13880	8	1	consequently	consequently	ADV
aiua-13880	8	2	,	,	PUNCT
aiua-13880	8	3	the	the	DET
aiua-13880	8	4	european	european	PROPN
aiua-13880	8	5	association	association	PROPN
aiua-13880	8	6	of	of	ADP
aiua-13880	8	7	urology	urology	NOUN
aiua-13880	8	8	(	(	PUNCT
aiua-13880	8	9	eau	eau	PROPN
aiua-13880	8	10	)	)	PUNCT
aiua-13880	8	11	has	have	AUX
aiua-13880	8	12	recently	recently	ADV
aiua-13880	8	13	recommended	recommend	VERB
aiua-13880	8	14	the	the	DET
aiua-13880	8	15	use	use	NOUN
aiua-13880	8	16	of	of	ADP
aiua-13880	8	17	enfortumab	enfortumab	NOUN
aiua-13880	8	18	vedotin	vedotin	ADJ
aiua-13880	8	19	(	(	PUNCT
aiua-13880	8	20	ev	ev	NOUN
aiua-13880	8	21	)	)	PUNCT
aiua-13880	8	22	in	in	ADP
aiua-13880	8	23	combination	combination	NOUN
aiua-13880	8	24	with	with	ADP
aiua-13880	8	25	pembrolizumab	pembrolizumab	NOUN
aiua-13880	8	26	as	as	ADP
aiua-13880	8	27	a	a	DET
aiua-13880	8	28	first	first	ADJ
aiua-13880	8	29	-	-	PUNCT
aiua-13880	8	30	line	line	NOUN
aiua-13880	8	31	treatment	treatment	NOUN
aiua-13880	8	32	for	for	ADP
aiua-13880	8	33	patients	patient	NOUN
aiua-13880	8	34	considered	consider	VERB
aiua-13880	8	35	suitable	suitable	ADJ
aiua-13880	8	36	for	for	ADP
aiua-13880	8	37	combination	combination	NOUN
aiua-13880	8	38	therapies	therapy	NOUN
aiua-13880	8	39	,	,	PUNCT
aiua-13880	8	40	irrespective	irrespective	ADV
aiua-13880	8	41	of	of	ADP
aiua-13880	8	42	their	their	PRON
aiua-13880	8	43	cisplatin	cisplatin	NOUN
aiua-13880	8	44	eligibility	eligibility	NOUN
aiua-13880	8	45	,	,	PUNCT
aiua-13880	8	46	which	which	PRON
aiua-13880	8	47	significantly	significantly	ADV
aiua-13880	8	48	reduces	reduce	VERB
aiua-13880	8	49	treatment	treatment	NOUN
aiua-13880	8	50	-	-	PUNCT
aiua-13880	8	51	related	relate	VERB
aiua-13880	8	52	toxicity	toxicity	NOUN
aiua-13880	8	53	(	(	PUNCT
aiua-13880	8	54	3	3	NUM
aiua-13880	8	55	,	,	PUNCT
aiua-13880	8	56	8)	8)	NUM
aiua-13880	8	57	.	.	PUNCT
aiua-13880	8	58	despite	despite	SCONJ
aiua-13880	8	59	these	these	DET
aiua-13880	8	60	recommendations	recommendation	NOUN
aiua-13880	8	61	,	,	PUNCT
aiua-13880	8	62	ev	ev	X
aiua-13880	8	63	may	may	AUX
aiua-13880	8	64	not	not	PART
aiua-13880	8	65	be	be	AUX
aiua-13880	8	66	accessible	accessible	ADJ
aiua-13880	8	67	in	in	ADP
aiua-13880	8	68	various	various	ADJ
aiua-13880	8	69	countries	country	NOUN
aiua-13880	8	70	.	.	PUNCT
aiua-13880	9	1	furthermore	furthermore	ADV
aiua-13880	9	2	,	,	PUNCT
aiua-13880	9	3	certain	certain	ADJ
aiua-13880	9	4	patients	patient	NOUN
aiua-13880	9	5	may	may	AUX
aiua-13880	9	6	be	be	AUX
aiua-13880	9	7	ineligible	ineligible	ADJ
aiua-13880	9	8	for	for	ADP
aiua-13880	9	9	ev	ev	PROPN
aiua-13880	9	10	treatment	treatment	NOUN
aiua-13880	9	11	,	,	PUNCT
aiua-13880	9	12	including	include	VERB
aiua-13880	9	13	those	those	PRON
aiua-13880	9	14	with	with	ADP
aiua-13880	9	15	uncontrolled	uncontrolled	ADJ
aiua-13880	9	16	diabetes	diabetes	NOUN
aiua-13880	9	17	,	,	PUNCT
aiua-13880	9	18	peripheral	peripheral	ADJ
aiua-13880	9	19	neuropathy	neuropathy	ADJ
aiua-13880	9	20	,	,	PUNCT
aiua-13880	9	21	and	and	CCONJ
aiua-13880	9	22	significant	significant	ADJ
aiua-13880	9	23	skin	skin	NOUN
aiua-13880	9	24	disorders	disorder	NOUN
aiua-13880	9	25	(	(	PUNCT
aiua-13880	9	26	9	9	NUM
aiua-13880	9	27	)	)	PUNCT
aiua-13880	9	28	.	.	PUNCT
aiua-13880	10	1	therefore	therefore	ADV
aiua-13880	10	2	,	,	PUNCT
aiua-13880	10	3	for	for	ADP
aiua-13880	10	4	this	this	DET
aiua-13880	10	5	patient	patient	ADJ
aiua-13880	10	6	population	population	NOUN
aiua-13880	10	7	comprising	comprise	VERB
aiua-13880	10	8	those	those	PRON
aiua-13880	10	9	who	who	PRON
aiua-13880	10	10	are	be	AUX
aiua-13880	10	11	either	either	CCONJ
aiua-13880	10	12	(	(	PUNCT
aiua-13880	10	13	1	1	X
aiua-13880	10	14	)	)	PUNCT
aiua-13880	10	15	ineligible	ineligible	ADJ
aiua-13880	10	16	for	for	ADP
aiua-13880	10	17	combination	combination	NOUN
aiua-13880	10	18	therapy	therapy	NOUN
aiua-13880	10	19	or	or	CCONJ
aiua-13880	10	20	ev	ev	ADP
aiua-13880	10	21	,	,	PUNCT
aiua-13880	10	22	(	(	PUNCT
aiua-13880	10	23	2	2	X
aiua-13880	10	24	)	)	PUNCT
aiua-13880	10	25	eligible	eligible	ADJ
aiua-13880	10	26	for	for	ADP
aiua-13880	10	27	combination	combination	NOUN
aiua-13880	10	28	therapy	therapy	NOUN
aiua-13880	10	29	but	but	CCONJ
aiua-13880	10	30	without	without	ADP
aiua-13880	10	31	access	access	NOUN
aiua-13880	10	32	to	to	ADP
aiua-13880	10	33	ev	ev	NUM
aiua-13880	10	34	,	,	PUNCT
aiua-13880	10	35	or	or	CCONJ
aiua-13880	10	36	(	(	PUNCT
aiua-13880	10	37	3	3	X
aiua-13880	10	38	)	)	PUNCT
aiua-13880	10	39	ineligible	ineligible	ADJ
aiua-13880	10	40	for	for	ADP
aiua-13880	10	41	both	both	DET
aiua-13880	10	42	combination	combination	NOUN
aiua-13880	10	43	therapy	therapy	NOUN
aiua-13880	10	44	and	and	CCONJ
aiua-13880	10	45	unfit	unfit	ADJ
aiua-13880	10	46	for	for	ADP
aiua-13880	10	47	platinum	platinum	NOUN
aiua-13880	10	48	-	-	PUNCT
aiua-13880	10	49	based	base	VERB
aiua-13880	10	50	chemotherapies	chemotherapy	NOUN
aiua-13880	10	51	there	there	PRON
aiua-13880	10	52	exists	exist	VERB
aiua-13880	10	53	uncertainty	uncertainty	NOUN
aiua-13880	10	54	concerning	concern	VERB
aiua-13880	10	55	the	the	DET
aiua-13880	10	56	optimal	optimal	ADJ
aiua-13880	10	57	treatment	treatment	NOUN
aiua-13880	10	58	options	option	NOUN
aiua-13880	10	59	available	available	ADJ
aiua-13880	10	60	to	to	ADP
aiua-13880	10	61	them	they	PRON
aiua-13880	10	62	.	.	PUNCT
aiua-13880	11	1	for	for	ADP
aiua-13880	11	2	patients	patient	NOUN
aiua-13880	11	3	who	who	PRON
aiua-13880	11	4	are	be	AUX
aiua-13880	11	5	ineligible	ineligible	ADJ
aiua-13880	11	6	for	for	ADP
aiua-13880	11	7	platinum	platinum	NOUN
aiua-13880	11	8	-	-	PUNCT
aiua-13880	11	9	based	base	VERB
aiua-13880	11	10	chemotherapies	chemotherapy	NOUN
aiua-13880	11	11	,	,	PUNCT
aiua-13880	11	12	current	current	ADJ
aiua-13880	11	13	guidelines	guideline	NOUN
aiua-13880	11	14	recommend	recommend	VERB
aiua-13880	11	15	assessing	assess	VERB
aiua-13880	11	16	pd	pd	PROPN
aiua-13880	11	17	-	-	PUNCT
aiua-13880	11	18	l1	l1	PROPN
aiua-13880	11	19	positivity	positivity	NOUN
aiua-13880	11	20	status	status	NOUN
aiua-13880	11	21	through	through	ADP
aiua-13880	11	22	immunohistochemistry	immunohistochemistry	NOUN
aiua-13880	11	23	.	.	PUNCT
aiua-13880	12	1	the	the	DET
aiua-13880	12	2	european	european	PROPN
aiua-13880	12	3	medicines	medicines	PROPN
aiua-13880	12	4	agency	agency	NOUN
aiua-13880	12	5	(	(	PUNCT
aiua-13880	12	6	ema	ema	PROPN
aiua-13880	12	7	)	)	PUNCT
aiua-13880	12	8	has	have	AUX
aiua-13880	12	9	approved	approve	VERB
aiua-13880	12	10	pembrolizumab	pembrolizumab	NOUN
aiua-13880	12	11	and	and	CCONJ
aiua-13880	12	12	atezolizumab	atezolizumab	NOUN
aiua-13880	12	13	for	for	ADP
aiua-13880	12	14	first	first	ADJ
aiua-13880	12	15	-	-	PUNCT
aiua-13880	12	16	line	line	NOUN
aiua-13880	12	17	treatment	treatment	NOUN
aiua-13880	12	18	in	in	ADP
aiua-13880	12	19	patients	patient	NOUN
aiua-13880	12	20	with	with	ADP
aiua-13880	12	21	positive	positive	ADJ
aiua-13880	12	22	pd	pd	PROPN
aiua-13880	12	23	-	-	PUNCT
aiua-13880	12	24	l1	l1	PROPN
aiua-13880	12	25	staining	staining	NOUN
aiua-13880	12	26	,	,	PUNCT
aiua-13880	12	27	while	while	SCONJ
aiua-13880	12	28	the	the	DET
aiua-13880	12	29	u.s	u.s	PROPN
aiua-13880	12	30	.	.	PROPN
aiua-13880	12	31	food	food	PROPN
aiua-13880	12	32	and	and	CCONJ
aiua-13880	12	33	drug	drug	PROPN
aiua-13880	12	34	administration	administration	PROPN
aiua-13880	12	35	(	(	PUNCT
aiua-13880	12	36	fda	fda	PROPN
aiua-13880	12	37	)	)	PUNCT
aiua-13880	12	38	has	have	VERB
aiua-13880	12	39	introduction	introduction	NOUN
aiua-13880	12	40	:	:	PUNCT
aiua-13880	12	41	recent	recent	ADJ
aiua-13880	12	42	studies	study	NOUN
aiua-13880	12	43	have	have	AUX
aiua-13880	12	44	shown	show	VERB
aiua-13880	12	45	the	the	DET
aiua-13880	12	46	therapeutic	therapeutic	ADJ
aiua-13880	12	47	benefits	benefit	NOUN
aiua-13880	12	48	of	of	ADP
aiua-13880	12	49	pembrolizumab	pembrolizumab	NOUN
aiua-13880	12	50	in	in	ADP
aiua-13880	12	51	locally	locally	ADV
aiua-13880	12	52	advanced	advanced	ADJ
aiua-13880	12	53	or	or	CCONJ
aiua-13880	12	54	metastatic	metastatic	ADJ
aiua-13880	12	55	urothelial	urothelial	ADJ
aiua-13880	12	56	carcinoma	carcinoma	NOUN
aiua-13880	12	57	(	(	PUNCT
aiua-13880	12	58	muc	muc	NOUN
aiua-13880	12	59	)	)	PUNCT
aiua-13880	12	60	.	.	PUNCT
aiua-13880	13	1	however	however	ADV
aiua-13880	13	2	,	,	PUNCT
aiua-13880	13	3	its	its	PRON
aiua-13880	13	4	high	high	ADJ
aiua-13880	13	5	cost	cost	NOUN
aiua-13880	13	6	and	and	CCONJ
aiua-13880	13	7	variable	variable	ADJ
aiua-13880	13	8	patient	patient	NOUN
aiua-13880	13	9	responses	response	NOUN
aiua-13880	13	10	remain	remain	VERB
aiua-13880	13	11	challenges	challenge	NOUN
aiua-13880	13	12	.	.	PUNCT
aiua-13880	14	1	this	this	DET
aiua-13880	14	2	study	study	NOUN
aiua-13880	14	3	aims	aim	VERB
aiua-13880	14	4	to	to	PART
aiua-13880	14	5	investigate	investigate	VERB
aiua-13880	14	6	the	the	DET
aiua-13880	14	7	prognostic	prognostic	ADJ
aiua-13880	14	8	value	value	NOUN
aiua-13880	14	9	of	of	ADP
aiua-13880	14	10	pre	pre	ADJ
aiua-13880	14	11	-	-	ADJ
aiua-13880	14	12	treatment	treatment	ADJ
aiua-13880	14	13	hematologic	hematologic	NOUN
aiua-13880	14	14	and	and	CCONJ
aiua-13880	14	15	clinical	clinical	ADJ
aiua-13880	14	16	parameters	parameter	NOUN
aiua-13880	14	17	in	in	ADP
aiua-13880	14	18	predicting	predict	VERB
aiua-13880	14	19	outcomes	outcome	NOUN
aiua-13880	14	20	in	in	ADP
aiua-13880	14	21	muc	muc	ADJ
aiua-13880	14	22	patients	patient	NOUN
aiua-13880	14	23	.	.	PUNCT
aiua-13880	15	1	methods	method	NOUN
aiua-13880	15	2	:	:	PUNCT
aiua-13880	15	3	a	a	DET
aiua-13880	15	4	comprehensive	comprehensive	ADJ
aiua-13880	15	5	search	search	NOUN
aiua-13880	15	6	was	be	AUX
aiua-13880	15	7	conducted	conduct	VERB
aiua-13880	15	8	across	across	ADP
aiua-13880	15	9	five	five	NUM
aiua-13880	15	10	databases	database	NOUN
aiua-13880	15	11	for	for	ADP
aiua-13880	15	12	relevant	relevant	ADJ
aiua-13880	15	13	articles	article	NOUN
aiua-13880	15	14	.	.	PUNCT
aiua-13880	16	1	studies	study	NOUN
aiua-13880	16	2	that	that	PRON
aiua-13880	16	3	assessed	assess	VERB
aiua-13880	16	4	the	the	DET
aiua-13880	16	5	relationship	relationship	NOUN
aiua-13880	16	6	between	between	ADP
aiua-13880	16	7	pre	pre	ADJ
aiua-13880	16	8	-	-	ADJ
aiua-13880	16	9	treatment	treatment	ADJ
aiua-13880	16	10	hematological	hematological	ADJ
aiua-13880	16	11	and	and	CCONJ
aiua-13880	16	12	clinical	clinical	ADJ
aiua-13880	16	13	parameters	parameter	NOUN
aiua-13880	16	14	and	and	CCONJ
aiua-13880	16	15	either	either	CCONJ
aiua-13880	16	16	progression	progression	NOUN
aiua-13880	16	17	free	free	ADJ
aiua-13880	16	18	survival	survival	NOUN
aiua-13880	16	19	(	(	PUNCT
aiua-13880	16	20	pfs	pfs	PROPN
aiua-13880	16	21	)	)	PUNCT
aiua-13880	16	22	or	or	CCONJ
aiua-13880	16	23	overall	overall	ADJ
aiua-13880	16	24	survival	survival	NOUN
aiua-13880	16	25	(	(	PUNCT
aiua-13880	16	26	os	os	NOUN
aiua-13880	16	27	)	)	PUNCT
aiua-13880	16	28	were	be	AUX
aiua-13880	16	29	included	include	VERB
aiua-13880	16	30	and	and	CCONJ
aiua-13880	16	31	evaluated	evaluate	VERB
aiua-13880	16	32	for	for	ADP
aiua-13880	16	33	bias	bias	NOUN
aiua-13880	16	34	.	.	PUNCT
aiua-13880	17	1	results	result	NOUN
aiua-13880	17	2	:	:	PUNCT
aiua-13880	17	3	the	the	DET
aiua-13880	17	4	literature	literature	NOUN
aiua-13880	17	5	search	search	NOUN
aiua-13880	17	6	identified	identify	VERB
aiua-13880	17	7	27	27	NUM
aiua-13880	17	8	studies	study	NOUN
aiua-13880	17	9	encompassing	encompass	VERB
aiua-13880	17	10	a	a	DET
aiua-13880	17	11	total	total	NOUN
aiua-13880	17	12	of	of	ADP
aiua-13880	17	13	4,731	4,731	NUM
aiua-13880	17	14	patients	patient	NOUN
aiua-13880	17	15	.	.	PUNCT
aiua-13880	18	1	several	several	ADJ
aiua-13880	18	2	prognostic	prognostic	ADJ
aiua-13880	18	3	factors	factor	NOUN
aiua-13880	18	4	linked	link	VERB
aiua-13880	18	5	to	to	ADP
aiua-13880	18	6	os	os	NOUN
aiua-13880	18	7	were	be	AUX
aiua-13880	18	8	identified	identify	VERB
aiua-13880	18	9	,	,	PUNCT
aiua-13880	18	10	with	with	ADP
aiua-13880	18	11	the	the	DET
aiua-13880	18	12	most	most	ADV
aiua-13880	18	13	adverse	adverse	ADJ
aiua-13880	18	14	survival	survival	NOUN
aiua-13880	18	15	outcomes	outcome	NOUN
aiua-13880	18	16	associated	associate	VERB
aiua-13880	18	17	with	with	ADP
aiua-13880	18	18	hypoalbuminemia	hypoalbuminemia	NOUN
aiua-13880	18	19	(	(	PUNCT
aiua-13880	18	20	hr	hr	NOUN
aiua-13880	18	21	3.13	3.13	NUM
aiua-13880	18	22	,	,	PUNCT
aiua-13880	18	23	95	95	NUM
aiua-13880	18	24	%	%	NOUN
aiua-13880	18	25	ci	ci	NOUN
aiua-13880	18	26	:	:	PUNCT
aiua-13880	18	27	2.52	2.52	NUM
aiua-13880	18	28	-	-	SYM
aiua-13880	18	29	3.88	3.88	NUM
aiua-13880	18	30	)	)	PUNCT
aiua-13880	18	31	,	,	PUNCT
aiua-13880	18	32	ecog	ecog	VERB
aiua-13880	18	33	-	-	PUNCT
aiua-13880	18	34	ps	ps	NOUN
aiua-13880	18	35	≥2	≥2	PROPN
aiua-13880	18	36	(	(	PUNCT
aiua-13880	18	37	hr	hr	NOUN
aiua-13880	18	38	2.94	2.94	NUM
aiua-13880	18	39	,	,	PUNCT
aiua-13880	18	40	95	95	NUM
aiua-13880	18	41	%	%	NOUN
aiua-13880	18	42	ci	ci	NOUN
aiua-13880	18	43	:	:	PUNCT
aiua-13880	18	44	2.65	2.65	NUM
aiua-13880	18	45	-	-	SYM
aiua-13880	18	46	3.26	3.26	NUM
aiua-13880	18	47	)	)	PUNCT
aiua-13880	18	48	,	,	PUNCT
aiua-13880	18	49	and	and	CCONJ
aiua-13880	18	50	the	the	DET
aiua-13880	18	51	presence	presence	NOUN
aiua-13880	18	52	of	of	ADP
aiua-13880	18	53	liver	liver	NOUN
aiua-13880	18	54	metastasis	metastasis	NOUN
aiua-13880	18	55	(	(	PUNCT
aiua-13880	18	56	hr	hr	NOUN
aiua-13880	18	57	2.44	2.44	NUM
aiua-13880	18	58	,	,	PUNCT
aiua-13880	18	59	95	95	NUM
aiua-13880	18	60	%	%	NOUN
aiua-13880	18	61	ci	ci	NOUN
aiua-13880	18	62	:	:	PUNCT
aiua-13880	18	63	2.16	2.16	NUM
aiua-13880	18	64	-	-	SYM
aiua-13880	18	65	2.76	2.76	NUM
aiua-13880	18	66	)	)	PUNCT
aiua-13880	18	67	.	.	PUNCT
aiua-13880	19	1	additionally	additionally	ADV
aiua-13880	19	2	,	,	PUNCT
aiua-13880	19	3	the	the	DET
aiua-13880	19	4	presence	presence	NOUN
aiua-13880	19	5	of	of	ADP
aiua-13880	19	6	bone	bone	NOUN
aiua-13880	19	7	,	,	PUNCT
aiua-13880	19	8	liver	liver	NOUN
aiua-13880	19	9	,	,	PUNCT
aiua-13880	19	10	or	or	CCONJ
aiua-13880	19	11	lung	lung	NOUN
aiua-13880	19	12	metastases	metastasis	NOUN
aiua-13880	19	13	,	,	PUNCT
aiua-13880	19	14	ecog	ecog	NOUN
aiua-13880	19	15	-	-	PUNCT
aiua-13880	19	16	ps	ps	NOUN
aiua-13880	19	17	≥	≥	NOUN
aiua-13880	19	18	2	2	NUM
aiua-13880	19	19	,	,	PUNCT
aiua-13880	19	20	surgical	surgical	ADJ
aiua-13880	19	21	excision	excision	NOUN
aiua-13880	19	22	of	of	ADP
aiua-13880	19	23	the	the	DET
aiua-13880	19	24	primary	primary	ADJ
aiua-13880	19	25	tumor	tumor	NOUN
aiua-13880	19	26	,	,	PUNCT
aiua-13880	19	27	elevated	elevated	ADJ
aiua-13880	19	28	c	c	NOUN
aiua-13880	19	29	-	-	ADJ
aiua-13880	19	30	reactive	reactive	ADJ
aiua-13880	19	31	protein	protein	NOUN
aiua-13880	19	32	(	(	PUNCT
aiua-13880	19	33	crp	crp	NOUN
aiua-13880	19	34	)	)	PUNCT
aiua-13880	19	35	and	and	CCONJ
aiua-13880	19	36	neutrophil	neutrophil	ADJ
aiua-13880	19	37	-	-	PUNCT
aiua-13880	19	38	lymphocyte	lymphocyte	ADJ
aiua-13880	19	39	ratio	ratio	NOUN
aiua-13880	19	40	(	(	PUNCT
aiua-13880	19	41	nlr	nlr	PROPN
aiua-13880	19	42	)	)	PUNCT
aiua-13880	19	43	,	,	PUNCT
aiua-13880	19	44	and	and	CCONJ
aiua-13880	19	45	low	low	ADJ
aiua-13880	19	46	hemoglobin	hemoglobin	NOUN
aiua-13880	19	47	levels	level	NOUN
aiua-13880	19	48	were	be	AUX
aiua-13880	19	49	all	all	PRON
aiua-13880	19	50	correlated	correlate	VERB
aiua-13880	19	51	with	with	ADP
aiua-13880	19	52	unfavorable	unfavorable	ADJ
aiua-13880	19	53	pfs	pf	NOUN
aiua-13880	19	54	and	and	CCONJ
aiua-13880	19	55	os	os	NOUN
aiua-13880	19	56	.	.	PUNCT
aiua-13880	20	1	conclusions	conclusion	NOUN
aiua-13880	20	2	:	:	PUNCT
aiua-13880	20	3	patients	patient	NOUN
aiua-13880	20	4	with	with	ADP
aiua-13880	20	5	metastatic	metastatic	ADJ
aiua-13880	20	6	urothelial	urothelial	ADJ
aiua-13880	20	7	carcinoma	carcinoma	NOUN
aiua-13880	20	8	and	and	CCONJ
aiua-13880	20	9	poor	poor	ADJ
aiua-13880	20	10	performance	performance	NOUN
aiua-13880	20	11	status	status	NOUN
aiua-13880	20	12	,	,	PUNCT
aiua-13880	20	13	visceral	visceral	ADJ
aiua-13880	20	14	metastases	metastasis	NOUN
aiua-13880	20	15	,	,	PUNCT
aiua-13880	20	16	high	high	ADJ
aiua-13880	20	17	nlr	nlr	PROPN
aiua-13880	20	18	or	or	CCONJ
aiua-13880	20	19	crp	crp	PROPN
aiua-13880	20	20	,	,	PUNCT
aiua-13880	20	21	or	or	CCONJ
aiua-13880	20	22	low	low	ADJ
aiua-13880	20	23	hemoglobin	hemoglobin	NOUN
aiua-13880	20	24	may	may	AUX
aiua-13880	20	25	have	have	VERB
aiua-13880	20	26	poorer	poor	ADJ
aiua-13880	20	27	survival	survival	NOUN
aiua-13880	20	28	,	,	PUNCT
aiua-13880	20	29	even	even	ADV
aiua-13880	20	30	with	with	ADP
aiua-13880	20	31	pembrolizumab	pembrolizumab	NOUN
aiua-13880	20	32	.	.	PUNCT
aiua-13880	21	1	these	these	DET
aiua-13880	21	2	factors	factor	NOUN
aiua-13880	21	3	may	may	AUX
aiua-13880	21	4	help	help	VERB
aiua-13880	21	5	guide	guide	VERB
aiua-13880	21	6	clinical	clinical	ADJ
aiua-13880	21	7	decisions	decision	NOUN
aiua-13880	21	8	for	for	ADP
aiua-13880	21	9	patients	patient	NOUN
aiua-13880	21	10	with	with	ADP
aiua-13880	21	11	advanced	advanced	ADJ
aiua-13880	21	12	/	/	SYM
aiua-13880	21	13	metastatic	metastatic	ADJ
aiua-13880	21	14	urothelial	urothelial	ADJ
aiua-13880	21	15	carcinoma	carcinoma	NOUN
aiua-13880	21	16	.	.	PUNCT
aiua-13880	22	1	key	key	ADJ
aiua-13880	22	2	words	word	NOUN
aiua-13880	22	3	:	:	PUNCT
aiua-13880	22	4	urothelial	urothelial	ADJ
aiua-13880	22	5	;	;	PUNCT
aiua-13880	22	6	pembrolizumab	pembrolizumab	NOUN
aiua-13880	22	7	;	;	PUNCT
aiua-13880	22	8	survival	survival	NOUN
aiua-13880	22	9	.	.	PUNCT
aiua-13880	22	10	submitted	submit	VERB
aiua-13880	22	11	9	9	NUM
aiua-13880	22	12	april	april	PROPN
aiua-13880	22	13	2025	2025	NUM
aiua-13880	22	14	;	;	PUNCT
aiua-13880	22	15	accepted	accept	VERB
aiua-13880	22	16	14	14	NUM
aiua-13880	22	17	april	april	PROPN
aiua-13880	22	18	2025	2025	NUM
aiua-13880	22	19	introduction	introduction	NOUN
aiua-13880	22	20	urothelial	urothelial	ADJ
aiua-13880	22	21	carcinoma	carcinoma	NOUN
aiua-13880	22	22	(	(	PUNCT
aiua-13880	22	23	uc	uc	PROPN
aiua-13880	22	24	)	)	PUNCT
aiua-13880	22	25	,	,	PUNCT
aiua-13880	22	26	also	also	ADV
aiua-13880	22	27	known	know	VERB
aiua-13880	22	28	as	as	ADP
aiua-13880	22	29	transitional	transitional	ADJ
aiua-13880	22	30	cell	cell	NOUN
aiua-13880	22	31	carcinoma	carcinoma	NOUN
aiua-13880	22	32	,	,	PUNCT
aiua-13880	22	33	is	be	AUX
aiua-13880	22	34	a	a	DET
aiua-13880	22	35	type	type	NOUN
aiua-13880	22	36	of	of	ADP
aiua-13880	22	37	cancer	cancer	NOUN
aiua-13880	22	38	that	that	PRON
aiua-13880	22	39	originates	originate	VERB
aiua-13880	22	40	in	in	ADP
aiua-13880	22	41	the	the	DET
aiua-13880	22	42	urothelium	urothelium	NOUN
aiua-13880	22	43	.	.	PUNCT
aiua-13880	23	1	uc	uc	PROPN
aiua-13880	23	2	includes	include	VERB
aiua-13880	23	3	all	all	DET
aiua-13880	23	4	tumors	tumor	NOUN
aiua-13880	23	5	found	find	VERB
aiua-13880	23	6	in	in	ADP
aiua-13880	23	7	the	the	DET
aiua-13880	23	8	bladder	bladder	NOUN
aiua-13880	23	9	,	,	PUNCT
aiua-13880	23	10	upper	upper	ADJ
aiua-13880	23	11	urinary	urinary	ADJ
aiua-13880	23	12	tract	tract	NOUN
aiua-13880	23	13	(	(	PUNCT
aiua-13880	23	14	including	include	VERB
aiua-13880	23	15	the	the	DET
aiua-13880	23	16	renal	renal	ADJ
aiua-13880	23	17	pelvis	pelvi	NOUN
aiua-13880	23	18	and	and	CCONJ
aiua-13880	23	19	ureters	ureter	NOUN
aiua-13880	23	20	)	)	PUNCT
aiua-13880	23	21	,	,	PUNCT
aiua-13880	23	22	and	and	CCONJ
aiua-13880	23	23	proximal	proximal	ADJ
aiua-13880	23	24	urethra	urethra	NOUN
aiua-13880	23	25	,	,	PUNCT
aiua-13880	23	26	with	with	ADP
aiua-13880	23	27	bladder	bladder	NOUN
aiua-13880	23	28	cancer	cancer	NOUN
aiua-13880	23	29	constituting	constitute	VERB
aiua-13880	23	30	approximately	approximately	ADV
aiua-13880	23	31	90	90	NUM
aiua-13880	23	32	%	%	NOUN
aiua-13880	23	33	to	to	PART
aiua-13880	23	34	95	95	NUM
aiua-13880	23	35	%	%	NOUN
aiua-13880	23	36	of	of	ADP
aiua-13880	23	37	these	these	DET
aiua-13880	23	38	cases	case	NOUN
aiua-13880	23	39	(	(	PUNCT
aiua-13880	23	40	1	1	NUM
aiua-13880	23	41	)	)	PUNCT
aiua-13880	23	42	.	.	PUNCT
aiua-13880	24	1	it	it	PRON
aiua-13880	24	2	is	be	AUX
aiua-13880	24	3	the	the	DET
aiua-13880	24	4	second	second	ADJ
aiua-13880	24	5	most	most	ADV
aiua-13880	24	6	prevalent	prevalent	ADJ
aiua-13880	24	7	urological	urological	ADJ
aiua-13880	24	8	malignancy	malignancy	NOUN
aiua-13880	24	9	in	in	ADP
aiua-13880	24	10	men	man	NOUN
aiua-13880	24	11	,	,	PUNCT
aiua-13880	24	12	with	with	ADP
aiua-13880	24	13	an	an	DET
aiua-13880	24	14	estimated	estimate	VERB
aiua-13880	24	15	global	global	ADJ
aiua-13880	24	16	mortality	mortality	NOUN
aiua-13880	24	17	exceeding	exceed	VERB
aiua-13880	24	18	200,000	200,000	NUM
aiua-13880	24	19	(	(	PUNCT
aiua-13880	24	20	2).current	2).current	NUM
aiua-13880	24	21	treatment	treatment	NOUN
aiua-13880	24	22	options	option	NOUN
aiua-13880	24	23	are	be	AUX
aiua-13880	24	24	dependent	dependent	ADJ
aiua-13880	24	25	on	on	ADP
aiua-13880	24	26	predicting	predict	VERB
aiua-13880	24	27	outcomes	outcome	NOUN
aiua-13880	24	28	with	with	ADP
aiua-13880	24	29	pembrolizumab	pembrolizumab	NOUN
aiua-13880	24	30	:	:	PUNCT
aiua-13880	24	31	a	a	DET
aiua-13880	24	32	meta	meta	ADJ
aiua-13880	24	33	-	-	PUNCT
aiua-13880	24	34	analysis	analysis	NOUN
aiua-13880	24	35	of	of	ADP
aiua-13880	24	36	pre	pre	ADJ
aiua-13880	24	37	-	-	ADJ
aiua-13880	24	38	treatment	treatment	ADJ
aiua-13880	24	39	hematological	hematological	ADJ
aiua-13880	24	40	and	and	CCONJ
aiua-13880	24	41	clinical	clinical	ADJ
aiua-13880	24	42	prognostic	prognostic	ADJ
aiua-13880	24	43	factors	factor	NOUN
aiua-13880	24	44	in	in	ADP
aiua-13880	24	45	advanced	advanced	ADJ
aiua-13880	24	46	/	/	SYM
aiua-13880	24	47	metastatic	metastatic	ADJ
aiua-13880	24	48	urothelial	urothelial	ADJ
aiua-13880	24	49	carcinoma	carcinoma	NOUN
aiua-13880	24	50	kevin	kevin	PROPN
aiua-13880	24	51	yuwono	yuwono	PROPN
aiua-13880	24	52	1	1	NUM
aiua-13880	24	53	,	,	PUNCT
aiua-13880	24	54	junjungan	junjungan	VERB
aiua-13880	24	55	nimasratu	nimasratu	PROPN
aiua-13880	24	56	rahmatsani	rahmatsani	PROPN
aiua-13880	24	57	1	1	NUM
aiua-13880	24	58	,	,	PUNCT
aiua-13880	24	59	nadhifah	nadhifah	VERB
aiua-13880	24	60	1	1	NUM
aiua-13880	24	61	,	,	PUNCT
aiua-13880	24	62	revina	revina	ADJ
aiua-13880	24	63	maharani	maharani	PROPN
aiua-13880	24	64	2	2	NUM
aiua-13880	24	65	,	,	PUNCT
aiua-13880	24	66	zakaria	zakaria	PROPN
aiua-13880	24	67	aulia	aulia	PROPN
aiua-13880	24	68	rahman	rahman	PROPN
aiua-13880	24	69	3	3	NUM
aiua-13880	24	70	1	1	NUM
aiua-13880	24	71	faculty	faculty	NOUN
aiua-13880	24	72	of	of	ADP
aiua-13880	24	73	medicine	medicine	NOUN
aiua-13880	24	74	,	,	PUNCT
aiua-13880	24	75	airlangga	airlangga	PROPN
aiua-13880	24	76	university	university	PROPN
aiua-13880	24	77	,	,	PUNCT
aiua-13880	24	78	indonesia	indonesia	PROPN
aiua-13880	24	79	;	;	PUNCT
aiua-13880	24	80	2	2	NUM
aiua-13880	24	81	faculty	faculty	NOUN
aiua-13880	24	82	of	of	ADP
aiua-13880	24	83	medicine	medicine	NOUN
aiua-13880	24	84	,	,	PUNCT
aiua-13880	24	85	brawijaya	brawijaya	PROPN
aiua-13880	24	86	university	university	PROPN
aiua-13880	24	87	,	,	PUNCT
aiua-13880	24	88	indonesia	indonesia	PROPN
aiua-13880	24	89	;	;	PUNCT
aiua-13880	24	90	3	3	NUM
aiua-13880	24	91	department	department	NOUN
aiua-13880	24	92	of	of	ADP
aiua-13880	24	93	urology	urology	NOUN
aiua-13880	24	94	,	,	PUNCT
aiua-13880	24	95	faculty	faculty	NOUN
aiua-13880	24	96	of	of	ADP
aiua-13880	24	97	medicine	medicine	NOUN
aiua-13880	24	98	,	,	PUNCT
aiua-13880	24	99	airlangga	airlangga	PROPN
aiua-13880	24	100	university	university	PROPN
aiua-13880	24	101	,	,	PUNCT
aiua-13880	24	102	indonesia	indonesia	PROPN
aiua-13880	24	103	.	.	PUNCT
aiua-13880	25	1	doi	doi	PROPN
aiua-13880	25	2	:	:	PUNCT
aiua-13880	25	3	10.4081	10.4081	NUM
aiua-13880	25	4	/	/	SYM
aiua-13880	25	5	aiua.2025.13880	aiua.2025.13880	NUM
aiua-13880	25	6	summary	summary	NOUN
aiua-13880	25	7	archivio	archivio	NOUN
aiua-13880	25	8	italiano	italiano	NOUN
aiua-13880	25	9	di	di	X
aiua-13880	25	10	urologia	urologia	PROPN
aiua-13880	25	11	e	e	PROPN
aiua-13880	25	12	andrologia	andrologia	NOUN
aiua-13880	25	13	2025	2025	NUM
aiua-13880	25	14	;	;	PUNCT
aiua-13880	25	15	97(2):13880	97(2):13880	NUM
aiua-13880	25	16	k	k	PROPN
aiua-13880	25	17	..	..	PUNCT
aiua-13880	25	18	yuwono	yuwono	PROPN
aiua-13880	25	19	,	,	PUNCT
aiua-13880	25	20	j.	j.	PROPN
aiua-13880	25	21	nimasratu	nimasratu	PROPN
aiua-13880	25	22	rahmatsani	rahmatsani	PROPN
aiua-13880	25	23	,	,	PUNCT
aiua-13880	25	24	nadhifah	nadhifah	VERB
aiua-13880	25	25	,	,	PUNCT
aiua-13880	25	26	et	et	PROPN
aiua-13880	25	27	al	al	PROPN
aiua-13880	25	28	.	.	PROPN
aiua-13880	25	29	2	2	NUM
aiua-13880	25	30	approved	approve	VERB
aiua-13880	25	31	pembrolizumab	pembrolizumab	NOUN
aiua-13880	25	32	for	for	ADP
aiua-13880	25	33	use	use	NOUN
aiua-13880	25	34	regardless	regardless	ADV
aiua-13880	25	35	of	of	ADP
aiua-13880	25	36	pd	pd	PROPN
aiua-13880	25	37	-	-	PUNCT
aiua-13880	25	38	l1	l1	PROPN
aiua-13880	25	39	status	status	NOUN
aiua-13880	25	40	(	(	PUNCT
aiua-13880	25	41	3	3	NUM
aiua-13880	25	42	)	)	PUNCT
aiua-13880	25	43	.	.	PUNCT
aiua-13880	26	1	despite	despite	SCONJ
aiua-13880	26	2	these	these	DET
aiua-13880	26	3	recommendations	recommendation	NOUN
aiua-13880	26	4	,	,	PUNCT
aiua-13880	26	5	the	the	DET
aiua-13880	26	6	historical	historical	ADJ
aiua-13880	26	7	outcomes	outcome	NOUN
aiua-13880	26	8	for	for	ADP
aiua-13880	26	9	this	this	DET
aiua-13880	26	10	patient	patient	ADJ
aiua-13880	26	11	group	group	NOUN
aiua-13880	26	12	have	have	AUX
aiua-13880	26	13	been	be	AUX
aiua-13880	26	14	unfavorable	unfavorable	ADJ
aiua-13880	26	15	.	.	PUNCT
aiua-13880	27	1	often	often	ADV
aiua-13880	27	2	,	,	PUNCT
aiua-13880	27	3	best	good	ADJ
aiua-13880	27	4	supportive	supportive	ADJ
aiua-13880	27	5	care	care	NOUN
aiua-13880	27	6	is	be	AUX
aiua-13880	27	7	preferred	prefer	VERB
aiua-13880	27	8	over	over	ADP
aiua-13880	27	9	systemic	systemic	ADJ
aiua-13880	27	10	therapy	therapy	NOUN
aiua-13880	27	11	.	.	PUNCT
aiua-13880	28	1	this	this	DET
aiua-13880	28	2	highlights	highlight	VERB
aiua-13880	28	3	the	the	DET
aiua-13880	28	4	need	need	NOUN
aiua-13880	28	5	for	for	ADP
aiua-13880	28	6	a	a	DET
aiua-13880	28	7	biomarker	biomarker	NOUN
aiua-13880	28	8	to	to	PART
aiua-13880	28	9	better	well	ADV
aiua-13880	28	10	predict	predict	VERB
aiua-13880	28	11	which	which	DET
aiua-13880	28	12	patient	patient	ADJ
aiua-13880	28	13	populations	population	NOUN
aiua-13880	28	14	will	will	AUX
aiua-13880	28	15	benefit	benefit	VERB
aiua-13880	28	16	from	from	ADP
aiua-13880	28	17	these	these	DET
aiua-13880	28	18	treatments	treatment	NOUN
aiua-13880	28	19	.	.	PUNCT
aiua-13880	29	1	several	several	ADJ
aiua-13880	29	2	biomarkers	biomarker	NOUN
aiua-13880	29	3	have	have	AUX
aiua-13880	29	4	been	be	AUX
aiua-13880	29	5	proposed	propose	VERB
aiua-13880	29	6	,	,	PUNCT
aiua-13880	29	7	including	include	VERB
aiua-13880	29	8	pd	pd	PROPN
aiua-13880	29	9	-	-	PUNCT
aiua-13880	29	10	l1	l1	PROPN
aiua-13880	29	11	expression	expression	NOUN
aiua-13880	29	12	(	(	PUNCT
aiua-13880	29	13	10	10	NUM
aiua-13880	29	14	)	)	PUNCT
aiua-13880	29	15	,	,	PUNCT
aiua-13880	29	16	tumor	tumor	NOUN
aiua-13880	29	17	mutational	mutational	ADJ
aiua-13880	29	18	burden	burden	NOUN
aiua-13880	29	19	(	(	PUNCT
aiua-13880	29	20	tmb	tmb	NOUN
aiua-13880	29	21	)	)	PUNCT
aiua-13880	29	22	,	,	PUNCT
aiua-13880	29	23	microsatellite	microsatellite	ADJ
aiua-13880	29	24	instability	instability	NOUN
aiua-13880	29	25	(	(	PUNCT
aiua-13880	29	26	msi	msi	PROPN
aiua-13880	29	27	)	)	PUNCT
aiua-13880	29	28	,	,	PUNCT
aiua-13880	29	29	and	and	CCONJ
aiua-13880	29	30	mismatch	mismatch	ADJ
aiua-13880	29	31	repair	repair	NOUN
aiua-13880	29	32	deficiency	deficiency	NOUN
aiua-13880	29	33	(	(	PUNCT
aiua-13880	29	34	11	11	NUM
aiua-13880	29	35	)	)	PUNCT
aiua-13880	29	36	.	.	PUNCT
aiua-13880	30	1	however	however	ADV
aiua-13880	30	2	,	,	PUNCT
aiua-13880	30	3	these	these	DET
aiua-13880	30	4	biomarkers	biomarker	NOUN
aiua-13880	30	5	have	have	AUX
aiua-13880	30	6	been	be	AUX
aiua-13880	30	7	found	find	VERB
aiua-13880	30	8	to	to	PART
aiua-13880	30	9	lack	lack	VERB
aiua-13880	30	10	sufficient	sufficient	ADJ
aiua-13880	30	11	predictive	predictive	ADJ
aiua-13880	30	12	accuracy	accuracy	NOUN
aiua-13880	30	13	.	.	PUNCT
aiua-13880	31	1	by	by	ADP
aiua-13880	31	2	systematically	systematically	ADV
aiua-13880	31	3	reviewing	review	VERB
aiua-13880	31	4	existing	exist	VERB
aiua-13880	31	5	literature	literature	NOUN
aiua-13880	31	6	,	,	PUNCT
aiua-13880	31	7	we	we	PRON
aiua-13880	31	8	aim	aim	VERB
aiua-13880	31	9	to	to	PART
aiua-13880	31	10	identify	identify	VERB
aiua-13880	31	11	the	the	DET
aiua-13880	31	12	several	several	ADJ
aiua-13880	31	13	hematological	hematological	ADJ
aiua-13880	31	14	and	and	CCONJ
aiua-13880	31	15	clinical	clinical	ADJ
aiua-13880	31	16	parameters	parameter	NOUN
aiua-13880	31	17	that	that	PRON
aiua-13880	31	18	can	can	AUX
aiua-13880	31	19	better	well	ADV
aiua-13880	31	20	predict	predict	VERB
aiua-13880	31	21	the	the	DET
aiua-13880	31	22	population	population	NOUN
aiua-13880	31	23	of	of	ADP
aiua-13880	31	24	muc	muc	ADJ
aiua-13880	31	25	patients	patient	NOUN
aiua-13880	31	26	who	who	PRON
aiua-13880	31	27	are	be	AUX
aiua-13880	31	28	likely	likely	ADJ
aiua-13880	31	29	to	to	PART
aiua-13880	31	30	benefit	benefit	VERB
aiua-13880	31	31	from	from	ADP
aiua-13880	31	32	pembrolizumab	pembrolizumab	NOUN
aiua-13880	31	33	monotherapy	monotherapy	NOUN
aiua-13880	31	34	.	.	PUNCT
aiua-13880	32	1	methods	method	NOUN
aiua-13880	32	2	this	this	DET
aiua-13880	32	3	systematic	systematic	ADJ
aiua-13880	32	4	review	review	NOUN
aiua-13880	32	5	followed	follow	VERB
aiua-13880	32	6	prisma	prisma	PROPN
aiua-13880	32	7	guidelines	guideline	NOUN
aiua-13880	32	8	(	(	PUNCT
aiua-13880	32	9	preferred	preferred	ADJ
aiua-13880	32	10	reporting	reporting	NOUN
aiua-13880	32	11	items	item	NOUN
aiua-13880	32	12	for	for	ADP
aiua-13880	32	13	systematic	systematic	ADJ
aiua-13880	32	14	reviews	review	NOUN
aiua-13880	32	15	and	and	CCONJ
aiua-13880	32	16	meta	meta	NOUN
aiua-13880	32	17	-	-	PUNCT
aiua-13880	32	18	analyses	analysis	NOUN
aiua-13880	32	19	)	)	PUNCT
aiua-13880	32	20	and	and	CCONJ
aiua-13880	32	21	the	the	DET
aiua-13880	32	22	cochrane	cochrane	PROPN
aiua-13880	32	23	handbook	handbook	NOUN
aiua-13880	32	24	for	for	ADP
aiua-13880	32	25	systematic	systematic	ADJ
aiua-13880	32	26	reviews	review	NOUN
aiua-13880	32	27	of	of	ADP
aiua-13880	32	28	interventions	intervention	NOUN
aiua-13880	32	29	.	.	PUNCT
aiua-13880	33	1	our	our	PRON
aiua-13880	33	2	full	full	ADJ
aiua-13880	33	3	protocol	protocol	NOUN
aiua-13880	33	4	was	be	AUX
aiua-13880	33	5	registered	register	VERB
aiua-13880	33	6	in	in	ADP
aiua-13880	33	7	prospero	prospero	NOUN
aiua-13880	33	8	(	(	PUNCT
aiua-13880	33	9	registration	registration	NOUN
aiua-13880	33	10	number	number	NOUN
aiua-13880	33	11	crd42024608476	crd42024608476	NOUN
aiua-13880	33	12	)	)	PUNCT
aiua-13880	33	13	.	.	PUNCT
aiua-13880	34	1	search	search	NOUN
aiua-13880	34	2	strategy	strategy	NOUN
aiua-13880	34	3	a	a	DET
aiua-13880	34	4	systematic	systematic	ADJ
aiua-13880	34	5	literature	literature	NOUN
aiua-13880	34	6	data	datum	NOUN
aiua-13880	34	7	search	search	NOUN
aiua-13880	34	8	was	be	AUX
aiua-13880	34	9	conducted	conduct	VERB
aiua-13880	34	10	in	in	ADP
aiua-13880	34	11	pubmed	pubmed	PROPN
aiua-13880	34	12	,	,	PUNCT
aiua-13880	34	13	scopus	scopus	PROPN
aiua-13880	34	14	,	,	PUNCT
aiua-13880	34	15	proquest	proquest	PROPN
aiua-13880	34	16	,	,	PUNCT
aiua-13880	34	17	cumulative	cumulative	ADJ
aiua-13880	34	18	index	index	NOUN
aiua-13880	34	19	to	to	ADP
aiua-13880	34	20	nursing	nursing	NOUN
aiua-13880	34	21	and	and	CCONJ
aiua-13880	34	22	allied	ally	VERB
aiua-13880	34	23	health	health	NOUN
aiua-13880	34	24	literature	literature	NOUN
aiua-13880	34	25	(	(	PUNCT
aiua-13880	34	26	cinahl	cinahl	NOUN
aiua-13880	34	27	)	)	PUNCT
aiua-13880	34	28	via	via	ADP
aiua-13880	34	29	ebsco	ebsco	PROPN
aiua-13880	34	30	,	,	PUNCT
aiua-13880	34	31	and	and	CCONJ
aiua-13880	34	32	cochrane	cochrane	PROPN
aiua-13880	34	33	central	central	ADJ
aiua-13880	34	34	register	register	NOUN
aiua-13880	34	35	of	of	ADP
aiua-13880	34	36	controlled	control	VERB
aiua-13880	34	37	trials	trial	NOUN
aiua-13880	34	38	(	(	PUNCT
aiua-13880	34	39	central	central	ADJ
aiua-13880	34	40	)	)	PUNCT
aiua-13880	34	41	for	for	ADP
aiua-13880	34	42	studies	study	NOUN
aiua-13880	34	43	published	publish	VERB
aiua-13880	34	44	up	up	ADP
aiua-13880	34	45	to	to	ADP
aiua-13880	34	46	november	november	PROPN
aiua-13880	34	47	2	2	NUM
aiua-13880	34	48	,	,	PUNCT
aiua-13880	34	49	2024	2024	NUM
aiua-13880	34	50	.	.	PUNCT
aiua-13880	35	1	we	we	PRON
aiua-13880	35	2	additionally	additionally	ADV
aiua-13880	35	3	performed	perform	VERB
aiua-13880	35	4	a	a	DET
aiua-13880	35	5	manual	manual	ADJ
aiua-13880	35	6	hand	hand	NOUN
aiua-13880	35	7	-	-	PUNCT
aiua-13880	35	8	search	search	NOUN
aiua-13880	35	9	on	on	ADP
aiua-13880	35	10	google	google	PROPN
aiua-13880	35	11	and	and	CCONJ
aiua-13880	35	12	the	the	DET
aiua-13880	35	13	reference	reference	NOUN
aiua-13880	35	14	lists	list	NOUN
aiua-13880	35	15	of	of	ADP
aiua-13880	35	16	the	the	DET
aiua-13880	35	17	included	include	VERB
aiua-13880	35	18	studies	study	NOUN
aiua-13880	35	19	to	to	PART
aiua-13880	35	20	maximize	maximize	VERB
aiua-13880	35	21	the	the	DET
aiua-13880	35	22	search	search	NOUN
aiua-13880	35	23	results	result	NOUN
aiua-13880	35	24	.	.	PUNCT
aiua-13880	36	1	the	the	DET
aiua-13880	36	2	following	follow	VERB
aiua-13880	36	3	main	main	ADJ
aiua-13880	36	4	keywords	keyword	NOUN
aiua-13880	36	5	were	be	AUX
aiua-13880	36	6	initially	initially	ADV
aiua-13880	36	7	established	establish	VERB
aiua-13880	36	8	:	:	PUNCT
aiua-13880	36	9	“	"	PUNCT
aiua-13880	36	10	pembrolizumab	pembrolizumab	NOUN
aiua-13880	36	11	”	"	PUNCT
aiua-13880	36	12	,	,	PUNCT
aiua-13880	36	13	“	"	PUNCT
aiua-13880	36	14	urothelial	urothelial	ADJ
aiua-13880	36	15	carcinoma	carcinoma	NOUN
aiua-13880	36	16	”	"	PUNCT
aiua-13880	36	17	,	,	PUNCT
aiua-13880	36	18	along	along	ADP
aiua-13880	36	19	with	with	ADP
aiua-13880	36	20	prognostic	prognostic	ADJ
aiua-13880	36	21	factors	factor	NOUN
aiua-13880	36	22	such	such	ADJ
aiua-13880	36	23	as	as	ADP
aiua-13880	36	24	“	"	PUNCT
aiua-13880	36	25	hemoglobin	hemoglobin	NOUN
aiua-13880	36	26	”	"	PUNCT
aiua-13880	36	27	,	,	PUNCT
aiua-13880	36	28	“	"	PUNCT
aiua-13880	36	29	neutrophil	neutrophil	ADJ
aiua-13880	36	30	”	"	PUNCT
aiua-13880	36	31	,	,	PUNCT
aiua-13880	36	32	“	"	PUNCT
aiua-13880	36	33	c	c	NOUN
aiua-13880	36	34	reactive	reactive	ADJ
aiua-13880	36	35	protein	protein	NOUN
aiua-13880	36	36	”	"	PUNCT
aiua-13880	36	37	and	and	CCONJ
aiua-13880	36	38	“	"	PUNCT
aiua-13880	36	39	lactate	lactate	NOUN
aiua-13880	36	40	dehydrogenase	dehydrogenase	NOUN
aiua-13880	36	41	”	"	PUNCT
aiua-13880	36	42	.	.	PUNCT
aiua-13880	37	1	we	we	PRON
aiua-13880	37	2	subsequently	subsequently	ADV
aiua-13880	37	3	added	add	VERB
aiua-13880	37	4	several	several	ADJ
aiua-13880	37	5	medical	medical	ADJ
aiua-13880	37	6	subject	subject	NOUN
aiua-13880	37	7	headings	heading	NOUN
aiua-13880	37	8	(	(	PUNCT
aiua-13880	37	9	mesh	mesh	NOUN
aiua-13880	37	10	)	)	PUNCT
aiua-13880	37	11	and	and	CCONJ
aiua-13880	37	12	other	other	ADJ
aiua-13880	37	13	free	free	ADJ
aiua-13880	37	14	-	-	PUNCT
aiua-13880	37	15	text	text	NOUN
aiua-13880	37	16	terms	term	NOUN
aiua-13880	37	17	to	to	PART
aiua-13880	37	18	construct	construct	VERB
aiua-13880	37	19	database	database	ADJ
aiua-13880	37	20	-	-	PUNCT
aiua-13880	37	21	specific	specific	ADJ
aiua-13880	37	22	search	search	NOUN
aiua-13880	37	23	terms	term	NOUN
aiua-13880	37	24	.	.	PUNCT
aiua-13880	38	1	the	the	DET
aiua-13880	38	2	full	full	ADJ
aiua-13880	38	3	search	search	NOUN
aiua-13880	38	4	strings	string	NOUN
aiua-13880	38	5	for	for	ADP
aiua-13880	38	6	each	each	DET
aiua-13880	38	7	database	database	NOUN
aiua-13880	38	8	are	be	AUX
aiua-13880	38	9	provided	provide	VERB
aiua-13880	38	10	in	in	ADP
aiua-13880	38	11	supplementary	supplementary	ADJ
aiua-13880	38	12	table	table	NOUN
aiua-13880	38	13	s1	s1	NOUN
aiua-13880	38	14	.	.	PUNCT
aiua-13880	39	1	no	no	DET
aiua-13880	39	2	publication	publication	NOUN
aiua-13880	39	3	date	date	NOUN
aiua-13880	39	4	and	and	CCONJ
aiua-13880	39	5	language	language	NOUN
aiua-13880	39	6	restrictions	restriction	NOUN
aiua-13880	39	7	were	be	AUX
aiua-13880	39	8	set	set	VERB
aiua-13880	39	9	in	in	ADP
aiua-13880	39	10	all	all	DET
aiua-13880	39	11	searches	search	NOUN
aiua-13880	39	12	.	.	PUNCT
aiua-13880	40	1	eligibility	eligibility	NOUN
aiua-13880	40	2	criteria	criterion	NOUN
aiua-13880	40	3	we	we	PRON
aiua-13880	40	4	included	include	VERB
aiua-13880	40	5	clinical	clinical	ADJ
aiua-13880	40	6	studies	study	NOUN
aiua-13880	40	7	that	that	PRON
aiua-13880	40	8	examined	examine	VERB
aiua-13880	40	9	the	the	DET
aiua-13880	40	10	association	association	NOUN
aiua-13880	40	11	between	between	ADP
aiua-13880	40	12	hematological	hematological	ADJ
aiua-13880	40	13	parameters	parameter	NOUN
aiua-13880	40	14	and	and	CCONJ
aiua-13880	40	15	outcomes	outcome	NOUN
aiua-13880	40	16	in	in	ADP
aiua-13880	40	17	patients	patient	NOUN
aiua-13880	40	18	with	with	ADP
aiua-13880	40	19	advanced	advanced	ADJ
aiua-13880	40	20	/	/	SYM
aiua-13880	40	21	metastatic	metastatic	ADJ
aiua-13880	40	22	ucs	ucs	NOUN
aiua-13880	40	23	.	.	PUNCT
aiua-13880	40	24	to	to	PART
aiua-13880	40	25	be	be	AUX
aiua-13880	40	26	included	include	VERB
aiua-13880	40	27	in	in	ADP
aiua-13880	40	28	this	this	DET
aiua-13880	40	29	systematic	systematic	ADJ
aiua-13880	40	30	review	review	NOUN
aiua-13880	40	31	and	and	CCONJ
aiua-13880	40	32	meta	meta	ADJ
aiua-13880	40	33	-	-	PUNCT
aiua-13880	40	34	analysis	analysis	NOUN
aiua-13880	40	35	,	,	PUNCT
aiua-13880	40	36	studies	study	NOUN
aiua-13880	40	37	had	have	VERB
aiua-13880	40	38	to	to	PART
aiua-13880	40	39	meet	meet	VERB
aiua-13880	40	40	the	the	DET
aiua-13880	40	41	following	follow	VERB
aiua-13880	40	42	criteria	criterion	NOUN
aiua-13880	40	43	:	:	PUNCT
aiua-13880	40	44	(	(	PUNCT
aiua-13880	40	45	1	1	X
aiua-13880	40	46	)	)	PUNCT
aiua-13880	40	47	the	the	DET
aiua-13880	40	48	study	study	NOUN
aiua-13880	40	49	population	population	NOUN
aiua-13880	40	50	consisted	consist	VERB
aiua-13880	40	51	of	of	ADP
aiua-13880	40	52	adults	adult	NOUN
aiua-13880	40	53	aged	age	VERB
aiua-13880	40	54	18	18	NUM
aiua-13880	40	55	years	year	NOUN
aiua-13880	40	56	or	or	CCONJ
aiua-13880	40	57	older	old	ADJ
aiua-13880	40	58	;	;	PUNCT
aiua-13880	40	59	(	(	PUNCT
aiua-13880	40	60	2	2	X
aiua-13880	40	61	)	)	PUNCT
aiua-13880	40	62	the	the	DET
aiua-13880	40	63	study	study	NOUN
aiua-13880	40	64	exclusively	exclusively	ADV
aiua-13880	40	65	included	include	VERB
aiua-13880	40	66	uc	uc	ADJ
aiua-13880	40	67	patients	patient	NOUN
aiua-13880	40	68	receiving	receive	VERB
aiua-13880	40	69	pembrolizumab	pembrolizumab	NOUN
aiua-13880	40	70	monotherapy	monotherapy	NOUN
aiua-13880	40	71	;	;	PUNCT
aiua-13880	40	72	(	(	PUNCT
aiua-13880	40	73	3	3	X
aiua-13880	40	74	)	)	PUNCT
aiua-13880	40	75	it	it	PRON
aiua-13880	40	76	assessed	assess	VERB
aiua-13880	40	77	the	the	DET
aiua-13880	40	78	relationship	relationship	NOUN
aiua-13880	40	79	between	between	ADP
aiua-13880	40	80	prognostic	prognostic	ADJ
aiua-13880	40	81	factors	factor	NOUN
aiua-13880	40	82	and	and	CCONJ
aiua-13880	40	83	outcomes	outcome	NOUN
aiua-13880	40	84	;	;	PUNCT
aiua-13880	40	85	and	and	CCONJ
aiua-13880	40	86	(	(	PUNCT
aiua-13880	40	87	4	4	X
aiua-13880	40	88	)	)	PUNCT
aiua-13880	40	89	it	it	PRON
aiua-13880	40	90	was	be	AUX
aiua-13880	40	91	either	either	CCONJ
aiua-13880	40	92	a	a	DET
aiua-13880	40	93	clinical	clinical	ADJ
aiua-13880	40	94	trial	trial	NOUN
aiua-13880	40	95	or	or	CCONJ
aiua-13880	40	96	an	an	DET
aiua-13880	40	97	observational	observational	ADJ
aiua-13880	40	98	study	study	NOUN
aiua-13880	40	99	(	(	PUNCT
aiua-13880	40	100	case	case	NOUN
aiua-13880	40	101	-	-	PUNCT
aiua-13880	40	102	control	control	NOUN
aiua-13880	40	103	or	or	CCONJ
aiua-13880	40	104	cohort	cohort	NOUN
aiua-13880	40	105	studies	study	NOUN
aiua-13880	40	106	)	)	PUNCT
aiua-13880	40	107	.	.	PUNCT
aiua-13880	41	1	we	we	PRON
aiua-13880	41	2	accepted	accept	VERB
aiua-13880	41	3	studies	study	NOUN
aiua-13880	41	4	published	publish	VERB
aiua-13880	41	5	in	in	ADP
aiua-13880	41	6	any	any	DET
aiua-13880	41	7	language	language	NOUN
aiua-13880	41	8	.	.	PUNCT
aiua-13880	42	1	studies	study	NOUN
aiua-13880	42	2	were	be	AUX
aiua-13880	42	3	excluded	exclude	VERB
aiua-13880	42	4	if	if	SCONJ
aiua-13880	42	5	:	:	PUNCT
aiua-13880	42	6	(	(	PUNCT
aiua-13880	42	7	1	1	X
aiua-13880	42	8	)	)	PUNCT
aiua-13880	42	9	the	the	DET
aiua-13880	42	10	study	study	NOUN
aiua-13880	42	11	was	be	AUX
aiua-13880	42	12	a	a	DET
aiua-13880	42	13	review	review	NOUN
aiua-13880	42	14	article	article	NOUN
aiua-13880	42	15	,	,	PUNCT
aiua-13880	42	16	case	case	NOUN
aiua-13880	42	17	report	report	NOUN
aiua-13880	42	18	,	,	PUNCT
aiua-13880	42	19	case	case	NOUN
aiua-13880	42	20	series	series	NOUN
aiua-13880	42	21	,	,	PUNCT
aiua-13880	42	22	or	or	CCONJ
aiua-13880	42	23	conference	conference	NOUN
aiua-13880	42	24	abstract	abstract	NOUN
aiua-13880	42	25	;	;	PUNCT
aiua-13880	42	26	(	(	PUNCT
aiua-13880	42	27	2	2	X
aiua-13880	42	28	)	)	PUNCT
aiua-13880	42	29	the	the	DET
aiua-13880	42	30	full	full	ADJ
aiua-13880	42	31	-	-	PUNCT
aiua-13880	42	32	text	text	NOUN
aiua-13880	42	33	was	be	AUX
aiua-13880	42	34	irretrievable	irretrievable	ADJ
aiua-13880	42	35	;	;	PUNCT
aiua-13880	42	36	or	or	CCONJ
aiua-13880	42	37	(	(	PUNCT
aiua-13880	42	38	3	3	X
aiua-13880	42	39	)	)	PUNCT
aiua-13880	42	40	raw	raw	ADJ
aiua-13880	42	41	data	datum	NOUN
aiua-13880	42	42	could	could	AUX
aiua-13880	42	43	not	not	PART
aiua-13880	42	44	be	be	AUX
aiua-13880	42	45	separated	separate	VERB
aiua-13880	42	46	.	.	PUNCT
aiua-13880	43	1	data	datum	NOUN
aiua-13880	43	2	extraction	extraction	NOUN
aiua-13880	43	3	and	and	CCONJ
aiua-13880	43	4	quality	quality	NOUN
aiua-13880	43	5	assessment	assessment	NOUN
aiua-13880	43	6	two	two	NUM
aiua-13880	43	7	independent	independent	ADJ
aiua-13880	43	8	investigators	investigator	NOUN
aiua-13880	43	9	performed	perform	VERB
aiua-13880	43	10	data	data	NOUN
aiua-13880	43	11	extraction	extraction	NOUN
aiua-13880	43	12	from	from	ADP
aiua-13880	43	13	each	each	DET
aiua-13880	43	14	included	include	VERB
aiua-13880	43	15	study	study	NOUN
aiua-13880	43	16	and	and	CCONJ
aiua-13880	43	17	recorded	record	VERB
aiua-13880	43	18	it	it	PRON
aiua-13880	43	19	within	within	ADP
aiua-13880	43	20	the	the	DET
aiua-13880	43	21	prespecified	prespecified	ADJ
aiua-13880	43	22	form	form	NOUN
aiua-13880	43	23	,	,	PUNCT
aiua-13880	43	24	with	with	ADP
aiua-13880	43	25	discrepancies	discrepancy	NOUN
aiua-13880	43	26	resolved	resolve	VERB
aiua-13880	43	27	by	by	ADP
aiua-13880	43	28	the	the	DET
aiua-13880	43	29	consensus	consensus	NOUN
aiua-13880	43	30	with	with	ADP
aiua-13880	43	31	an	an	DET
aiua-13880	43	32	independent	independent	ADJ
aiua-13880	43	33	third	third	ADJ
aiua-13880	43	34	investigator	investigator	NOUN
aiua-13880	43	35	.	.	PUNCT
aiua-13880	44	1	the	the	DET
aiua-13880	44	2	data	datum	NOUN
aiua-13880	44	3	extracted	extract	VERB
aiua-13880	44	4	include	include	VERB
aiua-13880	44	5	the	the	DET
aiua-13880	44	6	name	name	NOUN
aiua-13880	44	7	of	of	ADP
aiua-13880	44	8	the	the	DET
aiua-13880	44	9	first	first	ADJ
aiua-13880	44	10	author	author	NOUN
aiua-13880	44	11	and	and	CCONJ
aiua-13880	44	12	year	year	NOUN
aiua-13880	44	13	of	of	ADP
aiua-13880	44	14	publication	publication	NOUN
aiua-13880	44	15	,	,	PUNCT
aiua-13880	44	16	study	study	NOUN
aiua-13880	44	17	location	location	NOUN
aiua-13880	44	18	(	(	PUNCT
aiua-13880	44	19	country	country	NOUN
aiua-13880	44	20	and	and	CCONJ
aiua-13880	44	21	region	region	NOUN
aiua-13880	44	22	)	)	PUNCT
aiua-13880	44	23	,	,	PUNCT
aiua-13880	44	24	study	study	NOUN
aiua-13880	44	25	design	design	NOUN
aiua-13880	44	26	,	,	PUNCT
aiua-13880	44	27	sample	sample	NOUN
aiua-13880	44	28	size	size	NOUN
aiua-13880	44	29	,	,	PUNCT
aiua-13880	44	30	pembrolizumab	pembrolizumab	NOUN
aiua-13880	44	31	dose	dose	NOUN
aiua-13880	44	32	used	use	VERB
aiua-13880	44	33	,	,	PUNCT
aiua-13880	44	34	patients	patient	NOUN
aiua-13880	44	35	characteristics	characteristic	NOUN
aiua-13880	44	36	(	(	PUNCT
aiua-13880	44	37	age	age	NOUN
aiua-13880	44	38	,	,	PUNCT
aiua-13880	44	39	sex	sex	NOUN
aiua-13880	44	40	)	)	PUNCT
aiua-13880	44	41	,	,	PUNCT
aiua-13880	44	42	follow	follow	VERB
aiua-13880	44	43	up	up	ADP
aiua-13880	44	44	duration	duration	NOUN
aiua-13880	44	45	,	,	PUNCT
aiua-13880	44	46	clinical	clinical	ADJ
aiua-13880	44	47	characteristics	characteristic	NOUN
aiua-13880	44	48	(	(	PUNCT
aiua-13880	44	49	ecog	ecog	VERB
aiua-13880	44	50	ps	ps	PROPN
aiua-13880	44	51	≥	≥	PROPN
aiua-13880	44	52	2	2	NUM
aiua-13880	44	53	,	,	PUNCT
aiua-13880	44	54	site	site	NOUN
aiua-13880	44	55	of	of	ADP
aiua-13880	44	56	primary	primary	ADJ
aiua-13880	44	57	tumor	tumor	NOUN
aiua-13880	44	58	,	,	PUNCT
aiua-13880	44	59	metastatic	metastatic	ADJ
aiua-13880	44	60	sites	site	NOUN
aiua-13880	44	61	)	)	PUNCT
aiua-13880	44	62	,	,	PUNCT
aiua-13880	44	63	overall	overall	ADJ
aiua-13880	44	64	response	response	NOUN
aiua-13880	44	65	rate	rate	NOUN
aiua-13880	44	66	(	(	PUNCT
aiua-13880	44	67	orr	orr	PROPN
aiua-13880	44	68	)	)	PUNCT
aiua-13880	44	69	,	,	PUNCT
aiua-13880	44	70	and	and	CCONJ
aiua-13880	44	71	relationship	relationship	NOUN
aiua-13880	44	72	between	between	ADP
aiua-13880	44	73	prognostic	prognostic	ADJ
aiua-13880	44	74	factor	factor	NOUN
aiua-13880	44	75	and	and	CCONJ
aiua-13880	44	76	outcomes	outcome	NOUN
aiua-13880	44	77	.	.	PUNCT
aiua-13880	45	1	risk	risk	NOUN
aiua-13880	45	2	of	of	ADP
aiua-13880	45	3	bias	bias	NOUN
aiua-13880	45	4	assessment	assessment	NOUN
aiua-13880	45	5	for	for	ADP
aiua-13880	45	6	the	the	DET
aiua-13880	45	7	risk	risk	NOUN
aiua-13880	45	8	of	of	ADP
aiua-13880	45	9	bias	bias	NOUN
aiua-13880	45	10	assessment	assessment	NOUN
aiua-13880	45	11	,	,	PUNCT
aiua-13880	45	12	quality	quality	NOUN
aiua-13880	45	13	in	in	ADP
aiua-13880	45	14	prognosis	prognosis	NOUN
aiua-13880	45	15	studies	study	NOUN
aiua-13880	45	16	(	(	PUNCT
aiua-13880	45	17	quips	quip	NOUN
aiua-13880	45	18	)	)	PUNCT
aiua-13880	45	19	tool	tool	NOUN
aiua-13880	45	20	was	be	AUX
aiua-13880	45	21	used	use	VERB
aiua-13880	45	22	to	to	PART
aiua-13880	45	23	assess	assess	VERB
aiua-13880	45	24	the	the	DET
aiua-13880	45	25	methodological	methodological	ADJ
aiua-13880	45	26	quality	quality	NOUN
aiua-13880	45	27	of	of	ADP
aiua-13880	45	28	each	each	DET
aiua-13880	45	29	study	study	NOUN
aiua-13880	45	30	and	and	CCONJ
aiua-13880	45	31	subsequently	subsequently	ADV
aiua-13880	45	32	judged	judge	VERB
aiua-13880	45	33	to	to	PART
aiua-13880	45	34	be	be	AUX
aiua-13880	45	35	yielding	yield	VERB
aiua-13880	45	36	low	low	ADJ
aiua-13880	45	37	,	,	PUNCT
aiua-13880	45	38	moderate	moderate	ADJ
aiua-13880	45	39	,	,	PUNCT
aiua-13880	45	40	or	or	CCONJ
aiua-13880	45	41	high	high	ADJ
aiua-13880	45	42	risk	risk	NOUN
aiua-13880	45	43	of	of	ADP
aiua-13880	45	44	bias	bias	NOUN
aiua-13880	45	45	(	(	PUNCT
aiua-13880	45	46	12	12	NUM
aiua-13880	45	47	)	)	PUNCT
aiua-13880	45	48	.	.	PUNCT
aiua-13880	46	1	the	the	DET
aiua-13880	46	2	visualization	visualization	NOUN
aiua-13880	46	3	of	of	ADP
aiua-13880	46	4	the	the	DET
aiua-13880	46	5	bias	bias	NOUN
aiua-13880	46	6	assessment	assessment	NOUN
aiua-13880	46	7	’s	’s	PART
aiua-13880	46	8	summary	summary	NOUN
aiua-13880	46	9	was	be	AUX
aiua-13880	46	10	generated	generate	VERB
aiua-13880	46	11	using	use	VERB
aiua-13880	46	12	the	the	DET
aiua-13880	46	13	robvis	robvis	ADJ
aiua-13880	46	14	tool	tool	NOUN
aiua-13880	46	15	(	(	PUNCT
aiua-13880	46	16	13	13	NUM
aiua-13880	46	17	)	)	PUNCT
aiua-13880	46	18	.	.	PUNCT
aiua-13880	47	1	the	the	DET
aiua-13880	47	2	methodological	methodological	ADJ
aiua-13880	47	3	quality	quality	NOUN
aiua-13880	47	4	assessment	assessment	NOUN
aiua-13880	47	5	of	of	ADP
aiua-13880	47	6	the	the	DET
aiua-13880	47	7	included	include	VERB
aiua-13880	47	8	studies	study	NOUN
aiua-13880	47	9	was	be	AUX
aiua-13880	47	10	conducted	conduct	VERB
aiua-13880	47	11	by	by	ADP
aiua-13880	47	12	two	two	NUM
aiua-13880	47	13	independent	independent	ADJ
aiua-13880	47	14	reviewers	reviewer	NOUN
aiua-13880	47	15	(	(	PUNCT
aiua-13880	47	16	ndf	ndf	NOUN
aiua-13880	47	17	and	and	CCONJ
aiua-13880	47	18	jnr	jnr	PROPN
aiua-13880	47	19	)	)	PUNCT
aiua-13880	47	20	.	.	PUNCT
aiua-13880	48	1	discordance	discordance	NOUN
aiua-13880	48	2	in	in	ADP
aiua-13880	48	3	judgements	judgement	NOUN
aiua-13880	48	4	was	be	AUX
aiua-13880	48	5	resolved	resolve	VERB
aiua-13880	48	6	simultaneously	simultaneously	ADV
aiua-13880	48	7	in	in	ADP
aiua-13880	48	8	a	a	DET
aiua-13880	48	9	consensus	consensus	NOUN
aiua-13880	48	10	with	with	ADP
aiua-13880	48	11	a	a	DET
aiua-13880	48	12	third	third	ADJ
aiua-13880	48	13	reviewer	reviewer	NOUN
aiua-13880	48	14	(	(	PUNCT
aiua-13880	48	15	kyu	kyu	NOUN
aiua-13880	48	16	)	)	PUNCT
aiua-13880	48	17	.	.	PUNCT
aiua-13880	49	1	we	we	PRON
aiua-13880	49	2	planned	plan	VERB
aiua-13880	49	3	to	to	PART
aiua-13880	49	4	conduct	conduct	VERB
aiua-13880	49	5	a	a	DET
aiua-13880	49	6	funnel	funnel	NOUN
aiua-13880	49	7	-	-	PUNCT
aiua-13880	49	8	plot	plot	NOUN
aiua-13880	49	9	and	and	CCONJ
aiua-13880	49	10	egger	egger	NOUN
aiua-13880	49	11	’s	’s	PART
aiua-13880	49	12	test	test	NOUN
aiua-13880	49	13	to	to	PART
aiua-13880	49	14	assess	assess	VERB
aiua-13880	49	15	the	the	DET
aiua-13880	49	16	possibility	possibility	NOUN
aiua-13880	49	17	of	of	ADP
aiua-13880	49	18	publication	publication	NOUN
aiua-13880	49	19	bias	bias	NOUN
aiua-13880	49	20	across	across	ADP
aiua-13880	49	21	studies	study	NOUN
aiua-13880	49	22	.	.	PUNCT
aiua-13880	50	1	statistical	statistical	ADJ
aiua-13880	50	2	analysis	analysis	NOUN
aiua-13880	50	3	for	for	ADP
aiua-13880	50	4	the	the	DET
aiua-13880	50	5	primary	primary	ADJ
aiua-13880	50	6	outcome	outcome	NOUN
aiua-13880	50	7	of	of	ADP
aiua-13880	50	8	overall	overall	ADJ
aiua-13880	50	9	survival	survival	NOUN
aiua-13880	50	10	,	,	PUNCT
aiua-13880	50	11	we	we	PRON
aiua-13880	50	12	reported	report	VERB
aiua-13880	50	13	pooled	pool	VERB
aiua-13880	50	14	hazard	hazard	NOUN
aiua-13880	50	15	ratios	ratio	NOUN
aiua-13880	50	16	(	(	PUNCT
aiua-13880	50	17	hrs	hrs	NOUN
aiua-13880	50	18	)	)	PUNCT
aiua-13880	50	19	with	with	ADP
aiua-13880	50	20	their	their	PRON
aiua-13880	50	21	corresponding	corresponding	ADJ
aiua-13880	50	22	95	95	NUM
aiua-13880	50	23	%	%	NOUN
aiua-13880	50	24	confidence	confidence	NOUN
aiua-13880	50	25	intervals	interval	NOUN
aiua-13880	50	26	(	(	PUNCT
aiua-13880	50	27	cis	cis	NOUN
aiua-13880	50	28	)	)	PUNCT
aiua-13880	50	29	.	.	PUNCT
aiua-13880	51	1	the	the	DET
aiua-13880	51	2	initial	initial	ADJ
aiua-13880	51	3	quantitative	quantitative	ADJ
aiua-13880	51	4	synthesis	synthesis	NOUN
aiua-13880	51	5	was	be	AUX
aiua-13880	51	6	performed	perform	VERB
aiua-13880	51	7	by	by	ADP
aiua-13880	51	8	comparing	compare	VERB
aiua-13880	51	9	each	each	DET
aiua-13880	51	10	prognostic	prognostic	ADJ
aiua-13880	51	11	factor	factor	NOUN
aiua-13880	51	12	,	,	PUNCT
aiua-13880	51	13	applying	apply	VERB
aiua-13880	51	14	the	the	DET
aiua-13880	51	15	generic	generic	ADJ
aiua-13880	51	16	inverse	inverse	NOUN
aiua-13880	51	17	variance	variance	NOUN
aiua-13880	51	18	method	method	NOUN
aiua-13880	51	19	within	within	ADP
aiua-13880	51	20	a	a	DET
aiua-13880	51	21	dersimonian	dersimonian	ADJ
aiua-13880	51	22	-	-	PUNCT
aiua-13880	51	23	laird	laird	NOUN
aiua-13880	51	24	fixed	fix	VERB
aiua-13880	51	25	-	-	PUNCT
aiua-13880	51	26	effects	effect	NOUN
aiua-13880	51	27	model	model	NOUN
aiua-13880	51	28	.	.	PUNCT
aiua-13880	52	1	in	in	ADP
aiua-13880	52	2	cases	case	NOUN
aiua-13880	52	3	where	where	SCONJ
aiua-13880	52	4	significant	significant	ADJ
aiua-13880	52	5	heterogeneity	heterogeneity	NOUN
aiua-13880	52	6	was	be	AUX
aiua-13880	52	7	detected	detect	VERB
aiua-13880	52	8	,	,	PUNCT
aiua-13880	52	9	a	a	DET
aiua-13880	52	10	random	random	ADJ
aiua-13880	52	11	-	-	PUNCT
aiua-13880	52	12	effects	effect	NOUN
aiua-13880	52	13	model	model	NOUN
aiua-13880	52	14	was	be	AUX
aiua-13880	52	15	subsequently	subsequently	ADV
aiua-13880	52	16	applied	apply	VERB
aiua-13880	52	17	.	.	PUNCT
aiua-13880	53	1	in	in	ADP
aiua-13880	53	2	the	the	DET
aiua-13880	53	3	case	case	NOUN
aiua-13880	53	4	where	where	SCONJ
aiua-13880	53	5	two	two	NUM
aiua-13880	53	6	or	or	CCONJ
aiua-13880	53	7	more	more	ADJ
aiua-13880	53	8	studies	study	NOUN
aiua-13880	53	9	involved	involve	VERB
aiua-13880	53	10	overlapping	overlap	VERB
aiua-13880	53	11	populations	population	NOUN
aiua-13880	53	12	,	,	PUNCT
aiua-13880	53	13	analysis	analysis	NOUN
aiua-13880	53	14	was	be	AUX
aiua-13880	53	15	prioritized	prioritize	VERB
aiua-13880	53	16	to	to	ADP
aiua-13880	53	17	studies	study	NOUN
aiua-13880	53	18	with	with	ADP
aiua-13880	53	19	larger	large	ADJ
aiua-13880	53	20	sample	sample	NOUN
aiua-13880	53	21	sizes	size	NOUN
aiua-13880	53	22	.	.	PUNCT
aiua-13880	54	1	the	the	DET
aiua-13880	54	2	presence	presence	NOUN
aiua-13880	54	3	of	of	ADP
aiua-13880	54	4	heterogeneity	heterogeneity	NOUN
aiua-13880	54	5	was	be	AUX
aiua-13880	54	6	analyzed	analyze	VERB
aiua-13880	54	7	using	use	VERB
aiua-13880	54	8	cochran	cochran	NOUN
aiua-13880	54	9	’s	’s	PART
aiua-13880	54	10	q	q	PROPN
aiua-13880	54	11	and	and	CCONJ
aiua-13880	54	12	i2	i2	PROPN
aiua-13880	54	13	statistics	statistic	NOUN
aiua-13880	54	14	,	,	PUNCT
aiua-13880	54	15	where	where	SCONJ
aiua-13880	54	16	heterogeneity	heterogeneity	NOUN
aiua-13880	54	17	was	be	AUX
aiua-13880	54	18	classified	classify	VERB
aiua-13880	54	19	as	as	ADP
aiua-13880	54	20	negligible	negligible	ADJ
aiua-13880	54	21	,	,	PUNCT
aiua-13880	54	22	low	low	ADJ
aiua-13880	54	23	,	,	PUNCT
aiua-13880	54	24	moderate	moderate	ADJ
aiua-13880	54	25	,	,	PUNCT
aiua-13880	54	26	or	or	CCONJ
aiua-13880	54	27	high	high	ADJ
aiua-13880	54	28	to	to	ADP
aiua-13880	54	29	i2	i2	NOUN
aiua-13880	54	30	values	value	NOUN
aiua-13880	54	31	of	of	ADP
aiua-13880	54	32	0	0	NUM
aiua-13880	54	33	%	%	NOUN
aiua-13880	54	34	,	,	PUNCT
aiua-13880	54	35	25	25	NUM
aiua-13880	54	36	%	%	NOUN
aiua-13880	54	37	,	,	PUNCT
aiua-13880	54	38	50	50	NUM
aiua-13880	54	39	%	%	NOUN
aiua-13880	54	40	,	,	PUNCT
aiua-13880	54	41	and	and	CCONJ
aiua-13880	54	42	75	75	NUM
aiua-13880	54	43	%	%	NOUN
aiua-13880	54	44	,	,	PUNCT
aiua-13880	54	45	respectively	respectively	ADV
aiua-13880	54	46	(	(	PUNCT
aiua-13880	54	47	14	14	NUM
aiua-13880	54	48	)	)	PUNCT
aiua-13880	54	49	.	.	PUNCT
aiua-13880	55	1	whenever	whenever	SCONJ
aiua-13880	55	2	appropriate	appropriate	ADJ
aiua-13880	55	3	(	(	PUNCT
aiua-13880	55	4	n	n	CCONJ
aiua-13880	55	5	≥	≥	NOUN
aiua-13880	55	6	10	10	NUM
aiua-13880	55	7	)	)	PUNCT
aiua-13880	55	8	,	,	PUNCT
aiua-13880	55	9	potential	potential	ADJ
aiua-13880	55	10	publication	publication	NOUN
aiua-13880	55	11	bias	bias	NOUN
aiua-13880	55	12	was	be	AUX
aiua-13880	55	13	evaluated	evaluate	VERB
aiua-13880	55	14	visually	visually	ADV
aiua-13880	55	15	by	by	ADP
aiua-13880	55	16	contour	contour	NOUN
aiua-13880	55	17	-	-	PUNCT
aiua-13880	55	18	enhanced	enhance	VERB
aiua-13880	55	19	funnel	funnel	NOUN
aiua-13880	55	20	plot	plot	NOUN
aiua-13880	55	21	and	and	CCONJ
aiua-13880	55	22	quantitatively	quantitatively	ADV
aiua-13880	55	23	by	by	ADP
aiua-13880	55	24	egger	egger	NOUN
aiua-13880	55	25	’s	’s	PART
aiua-13880	55	26	and	and	CCONJ
aiua-13880	55	27	begg	begg	PROPN
aiua-13880	55	28	’s	’s	PART
aiua-13880	55	29	tests	test	NOUN
aiua-13880	55	30	.	.	PUNCT
aiua-13880	56	1	whenever	whenever	SCONJ
aiua-13880	56	2	available	available	ADJ
aiua-13880	56	3	,	,	PUNCT
aiua-13880	56	4	subgroup	subgroup	NOUN
aiua-13880	56	5	analyses	analysis	NOUN
aiua-13880	56	6	were	be	AUX
aiua-13880	56	7	carried	carry	VERB
aiua-13880	56	8	out	out	ADP
aiua-13880	56	9	based	base	VERB
aiua-13880	56	10	on	on	ADP
aiua-13880	56	11	the	the	DET
aiua-13880	56	12	risk	risk	NOUN
aiua-13880	56	13	of	of	ADP
aiua-13880	56	14	bias	bias	NOUN
aiua-13880	56	15	.	.	PUNCT
aiua-13880	57	1	on	on	ADP
aiua-13880	57	2	the	the	DET
aiua-13880	57	3	other	other	ADJ
aiua-13880	57	4	hand	hand	NOUN
aiua-13880	57	5	,	,	PUNCT
aiua-13880	57	6	sensitivity	sensitivity	NOUN
aiua-13880	57	7	analyses	analysis	NOUN
aiua-13880	57	8	were	be	AUX
aiua-13880	57	9	conducted	conduct	VERB
aiua-13880	57	10	by	by	ADP
aiua-13880	57	11	leave	leave	NOUN
aiua-13880	57	12	-	-	PUNCT
aiua-13880	57	13	one	one	NUM
aiua-13880	57	14	-	-	PUNCT
aiua-13880	57	15	out	out	NOUN
aiua-13880	57	16	analysis	analysis	NOUN
aiua-13880	57	17	and	and	CCONJ
aiua-13880	57	18	the	the	DET
aiua-13880	57	19	exclusion	exclusion	NOUN
aiua-13880	57	20	of	of	ADP
aiua-13880	57	21	studies	study	NOUN
aiua-13880	57	22	with	with	ADP
aiua-13880	57	23	high	high	ADJ
aiua-13880	57	24	-	-	PUNCT
aiua-13880	57	25	risk	risk	NOUN
aiua-13880	57	26	of	of	ADP
aiua-13880	57	27	bias	bias	NOUN
aiua-13880	57	28	.	.	PUNCT
aiua-13880	58	1	metaregression	metaregression	NOUN
aiua-13880	58	2	analyses	analysis	NOUN
aiua-13880	58	3	were	be	AUX
aiua-13880	58	4	carried	carry	VERB
aiua-13880	58	5	out	out	ADP
aiua-13880	58	6	for	for	ADP
aiua-13880	58	7	(	(	PUNCT
aiua-13880	58	8	1	1	NUM
aiua-13880	58	9	)	)	PUNCT
aiua-13880	58	10	year	year	NOUN
aiua-13880	58	11	of	of	ADP
aiua-13880	58	12	publication	publication	NOUN
aiua-13880	58	13	,	,	PUNCT
aiua-13880	58	14	(	(	PUNCT
aiua-13880	58	15	2	2	X
aiua-13880	58	16	)	)	PUNCT
aiua-13880	58	17	%	%	NOUN
aiua-13880	58	18	of	of	ADP
aiua-13880	58	19	males	male	NOUN
aiua-13880	58	20	,	,	PUNCT
aiua-13880	58	21	(	(	PUNCT
aiua-13880	58	22	3	3	X
aiua-13880	58	23	)	)	PUNCT
aiua-13880	58	24	sample	sample	NOUN
aiua-13880	58	25	size	size	NOUN
aiua-13880	58	26	;	;	PUNCT
aiua-13880	58	27	(	(	PUNCT
aiua-13880	58	28	4	4	X
aiua-13880	58	29	)	)	PUNCT
aiua-13880	58	30	mean	mean	NOUN
aiua-13880	58	31	age	age	NOUN
aiua-13880	58	32	,	,	PUNCT
aiua-13880	58	33	(	(	PUNCT
aiua-13880	58	34	5	5	X
aiua-13880	58	35	)	)	PUNCT
aiua-13880	58	36	%	%	NOUN
aiua-13880	58	37	of	of	ADP
aiua-13880	58	38	upper	upper	ADJ
aiua-13880	58	39	tract	tract	NOUN
aiua-13880	58	40	primary	primary	ADJ
aiua-13880	58	41	tumor	tumor	NOUN
aiua-13880	58	42	site	site	NOUN
aiua-13880	58	43	,	,	PUNCT
aiua-13880	58	44	and	and	CCONJ
aiua-13880	58	45	(	(	PUNCT
aiua-13880	58	46	6	6	X
aiua-13880	58	47	)	)	PUNCT
aiua-13880	58	48	follow	follow	VERB
aiua-13880	58	49	up	up	ADP
aiua-13880	58	50	duration	duration	NOUN
aiua-13880	58	51	whenever	whenever	SCONJ
aiua-13880	58	52	possible	possible	ADJ
aiua-13880	58	53	.	.	PUNCT
aiua-13880	59	1	all	all	DET
aiua-13880	59	2	analysis	analysis	NOUN
aiua-13880	59	3	was	be	AUX
aiua-13880	59	4	conducted	conduct	VERB
aiua-13880	59	5	with	with	ADP
aiua-13880	59	6	r	r	NOUN
aiua-13880	59	7	ver	ver	NOUN
aiua-13880	59	8	.	.	PUNCT
aiua-13880	60	1	4.3.0	4.3.0	NUM
aiua-13880	60	2	(	(	PUNCT
aiua-13880	60	3	r	r	NOUN
aiua-13880	60	4	foundation	foundation	NOUN
aiua-13880	60	5	for	for	ADP
aiua-13880	60	6	statistical	statistical	ADJ
aiua-13880	60	7	computing	computing	NOUN
aiua-13880	60	8	,	,	PUNCT
aiua-13880	60	9	vienna	vienna	PROPN
aiua-13880	60	10	,	,	PUNCT
aiua-13880	60	11	austria	austria	PROPN
aiua-13880	60	12	)	)	PUNCT
aiua-13880	60	13	.	.	PUNCT
aiua-13880	61	1	conventional	conventional	ADJ
aiua-13880	61	2	meta	meta	ADJ
aiua-13880	61	3	-	-	PUNCT
aiua-13880	61	4	analysis	analysis	NOUN
aiua-13880	61	5	was	be	AUX
aiua-13880	61	6	conducted	conduct	VERB
aiua-13880	61	7	using	use	VERB
aiua-13880	61	8	the	the	DET
aiua-13880	61	9	meta	meta	ADJ
aiua-13880	61	10	package	package	NOUN
aiua-13880	61	11	,	,	PUNCT
aiua-13880	61	12	while	while	SCONJ
aiua-13880	61	13	meta	meta	ADJ
aiua-13880	61	14	-	-	PUNCT
aiua-13880	61	15	regression	regression	NOUN
aiua-13880	61	16	analyses	analysis	NOUN
aiua-13880	61	17	were	be	AUX
aiua-13880	61	18	performed	perform	VERB
aiua-13880	61	19	using	use	VERB
aiua-13880	61	20	the	the	DET
aiua-13880	61	21	metafor	metafor	ADJ
aiua-13880	61	22	package	package	NOUN
aiua-13880	61	23	.	.	PUNCT
aiua-13880	62	1	results	result	NOUN
aiua-13880	62	2	study	study	VERB
aiua-13880	62	3	selection	selection	NOUN
aiua-13880	62	4	a	a	DET
aiua-13880	62	5	prisma	prisma	NOUN
aiua-13880	62	6	flowchart	flowchart	NOUN
aiua-13880	62	7	of	of	ADP
aiua-13880	62	8	the	the	DET
aiua-13880	62	9	study	study	NOUN
aiua-13880	62	10	selection	selection	NOUN
aiua-13880	62	11	process	process	NOUN
aiua-13880	62	12	is	be	AUX
aiua-13880	62	13	depicted	depict	VERB
aiua-13880	62	14	in	in	ADP
aiua-13880	62	15	figure	figure	NOUN
aiua-13880	62	16	1	1	NUM
aiua-13880	62	17	.	.	PUNCT
aiua-13880	62	18	initial	initial	ADJ
aiua-13880	62	19	searches	search	NOUN
aiua-13880	62	20	of	of	ADP
aiua-13880	62	21	the	the	DET
aiua-13880	62	22	five	five	NUM
aiua-13880	62	23	databases	database	NOUN
aiua-13880	62	24	yielded	yield	VERB
aiua-13880	62	25	4449	4449	NUM
aiua-13880	62	26	records	record	NOUN
aiua-13880	62	27	.	.	PUNCT
aiua-13880	63	1	we	we	PRON
aiua-13880	63	2	identified	identify	VERB
aiua-13880	63	3	duplicates	duplicate	NOUN
aiua-13880	63	4	,	,	PUNCT
aiua-13880	63	5	and	and	CCONJ
aiua-13880	63	6	a	a	DET
aiua-13880	63	7	archivio	archivio	NOUN
aiua-13880	63	8	italiano	italiano	X
aiua-13880	63	9	di	di	X
aiua-13880	63	10	urologia	urologia	PROPN
aiua-13880	63	11	e	e	PROPN
aiua-13880	63	12	andrologia	andrologia	NOUN
aiua-13880	63	13	2025	2025	NUM
aiua-13880	63	14	;	;	PUNCT
aiua-13880	63	15	97(2):13880	97(2):13880	NUM
aiua-13880	63	16	3	3	NUM
aiua-13880	63	17	pembrolizumab	pembrolizumab	NOUN
aiua-13880	63	18	in	in	ADP
aiua-13880	63	19	advanced	advanced	ADJ
aiua-13880	63	20	/	/	SYM
aiua-13880	63	21	metastatic	metastatic	ADJ
aiua-13880	63	22	urothelial	urothelial	ADJ
aiua-13880	63	23	carcinoma	carcinoma	NOUN
aiua-13880	63	24	total	total	NOUN
aiua-13880	63	25	of	of	ADP
aiua-13880	63	26	577	577	NUM
aiua-13880	63	27	records	record	NOUN
aiua-13880	63	28	were	be	AUX
aiua-13880	63	29	removed	remove	VERB
aiua-13880	63	30	.	.	PUNCT
aiua-13880	64	1	of	of	ADP
aiua-13880	64	2	the	the	DET
aiua-13880	64	3	remaining	remain	VERB
aiua-13880	64	4	3872	3872	NUM
aiua-13880	64	5	records	record	NOUN
aiua-13880	64	6	,	,	PUNCT
aiua-13880	64	7	3818	3818	NUM
aiua-13880	64	8	records	record	NOUN
aiua-13880	64	9	were	be	AUX
aiua-13880	64	10	excluded	exclude	VERB
aiua-13880	64	11	.	.	PUNCT
aiua-13880	65	1	one	one	NUM
aiua-13880	65	2	conference	conference	NOUN
aiua-13880	65	3	abstract	abstract	NOUN
aiua-13880	65	4	with	with	ADP
aiua-13880	65	5	unavailable	unavailable	ADJ
aiua-13880	65	6	full	full	ADJ
aiua-13880	65	7	-	-	PUNCT
aiua-13880	65	8	text	text	NOUN
aiua-13880	65	9	and	and	CCONJ
aiua-13880	65	10	six	six	NUM
aiua-13880	65	11	other	other	ADJ
aiua-13880	65	12	articles	article	NOUN
aiua-13880	65	13	were	be	AUX
aiua-13880	65	14	not	not	PART
aiua-13880	65	15	retrieved	retrieve	VERB
aiua-13880	65	16	.	.	PUNCT
aiua-13880	66	1	we	we	PRON
aiua-13880	66	2	then	then	ADV
aiua-13880	66	3	thoroughly	thoroughly	ADV
aiua-13880	66	4	reviewed	review	VERB
aiua-13880	66	5	forty	forty	NUM
aiua-13880	66	6	-	-	PUNCT
aiua-13880	66	7	seven	seven	NUM
aiua-13880	66	8	studies	study	NOUN
aiua-13880	66	9	and	and	CCONJ
aiua-13880	66	10	further	far	ADV
aiua-13880	66	11	excluded	exclude	VERB
aiua-13880	66	12	twenty	twenty	NUM
aiua-13880	66	13	-	-	PUNCT
aiua-13880	66	14	one	one	NUM
aiua-13880	66	15	studies	study	NOUN
aiua-13880	66	16	,	,	PUNCT
aiua-13880	66	17	due	due	ADP
aiua-13880	66	18	to	to	ADP
aiua-13880	66	19	the	the	DET
aiua-13880	66	20	following	following	NOUN
aiua-13880	66	21	:	:	PUNCT
aiua-13880	66	22	(	(	PUNCT
aiua-13880	66	23	1	1	X
aiua-13880	66	24	)	)	PUNCT
aiua-13880	66	25	combined	combine	VERB
aiua-13880	66	26	with	with	ADP
aiua-13880	66	27	other	other	ADJ
aiua-13880	66	28	chemotherapies	chemotherapy	NOUN
aiua-13880	66	29	(	(	PUNCT
aiua-13880	66	30	n	n	NOUN
aiua-13880	66	31	=	=	NUM
aiua-13880	66	32	10	10	NUM
aiua-13880	66	33	)	)	PUNCT
aiua-13880	66	34	,	,	PUNCT
aiua-13880	66	35	missing	miss	VERB
aiua-13880	66	36	outcome	outcome	NOUN
aiua-13880	66	37	of	of	ADP
aiua-13880	66	38	interest	interest	NOUN
aiua-13880	66	39	(	(	PUNCT
aiua-13880	66	40	n	n	NOUN
aiua-13880	66	41	=	=	SYM
aiua-13880	66	42	7	7	NUM
aiua-13880	66	43	)	)	PUNCT
aiua-13880	66	44	,	,	PUNCT
aiua-13880	66	45	data	datum	NOUN
aiua-13880	66	46	can	can	AUX
aiua-13880	66	47	not	not	PART
aiua-13880	66	48	be	be	AUX
aiua-13880	66	49	extracted	extract	VERB
aiua-13880	66	50	(	(	PUNCT
aiua-13880	66	51	n	n	NOUN
aiua-13880	66	52	=	=	SYM
aiua-13880	66	53	3	3	NUM
aiua-13880	66	54	)	)	PUNCT
aiua-13880	66	55	,	,	PUNCT
aiua-13880	66	56	and	and	CCONJ
aiua-13880	66	57	use	use	NOUN
aiua-13880	66	58	of	of	ADP
aiua-13880	66	59	intravesical	intravesical	ADJ
aiua-13880	66	60	pembrolizumab	pembrolizumab	NOUN
aiua-13880	66	61	(	(	PUNCT
aiua-13880	66	62	n	n	NOUN
aiua-13880	66	63	=	=	SYM
aiua-13880	66	64	1	1	NUM
aiua-13880	66	65	)	)	PUNCT
aiua-13880	66	66	.	.	PUNCT
aiua-13880	67	1	ultimately	ultimately	ADV
aiua-13880	67	2	,	,	PUNCT
aiua-13880	67	3	the	the	DET
aiua-13880	67	4	entire	entire	ADJ
aiua-13880	67	5	screening	screening	NOUN
aiua-13880	67	6	process	process	NOUN
aiua-13880	67	7	led	lead	VERB
aiua-13880	67	8	to	to	ADP
aiua-13880	67	9	the	the	DET
aiua-13880	67	10	inclusion	inclusion	NOUN
aiua-13880	67	11	of	of	ADP
aiua-13880	67	12	twenty	twenty	NUM
aiua-13880	67	13	-	-	PUNCT
aiua-13880	67	14	six	six	NUM
aiua-13880	67	15	eligible	eligible	ADJ
aiua-13880	67	16	studies	study	NOUN
aiua-13880	67	17	in	in	ADP
aiua-13880	67	18	this	this	DET
aiua-13880	67	19	systematic	systematic	ADJ
aiua-13880	67	20	review	review	NOUN
aiua-13880	67	21	.	.	PUNCT
aiua-13880	68	1	study	study	NOUN
aiua-13880	68	2	characteristics	characteristic	NOUN
aiua-13880	68	3	in	in	ADP
aiua-13880	68	4	our	our	PRON
aiua-13880	68	5	review	review	NOUN
aiua-13880	68	6	,	,	PUNCT
aiua-13880	68	7	we	we	PRON
aiua-13880	68	8	analyzed	analyze	VERB
aiua-13880	68	9	a	a	DET
aiua-13880	68	10	total	total	ADJ
aiua-13880	68	11	cohort	cohort	NOUN
aiua-13880	68	12	of	of	ADP
aiua-13880	68	13	4,679	4,679	NUM
aiua-13880	68	14	patients	patient	NOUN
aiua-13880	68	15	,	,	PUNCT
aiua-13880	68	16	with	with	ADP
aiua-13880	68	17	a	a	DET
aiua-13880	68	18	median	median	ADJ
aiua-13880	68	19	age	age	NOUN
aiua-13880	68	20	ranging	range	VERB
aiua-13880	68	21	from	from	ADP
aiua-13880	68	22	68.9	68.9	NUM
aiua-13880	68	23	to	to	PART
aiua-13880	68	24	76	76	NUM
aiua-13880	68	25	years	year	NOUN
aiua-13880	68	26	.	.	PUNCT
aiua-13880	69	1	among	among	ADP
aiua-13880	69	2	the	the	DET
aiua-13880	69	3	total	total	ADJ
aiua-13880	69	4	population	population	NOUN
aiua-13880	69	5	,	,	PUNCT
aiua-13880	69	6	3,092	3,092	NUM
aiua-13880	69	7	patients	patient	NOUN
aiua-13880	69	8	were	be	AUX
aiua-13880	69	9	male	male	ADJ
aiua-13880	69	10	,	,	PUNCT
aiua-13880	69	11	accounting	account	VERB
aiua-13880	69	12	for	for	ADP
aiua-13880	69	13	71.5	71.5	NUM
aiua-13880	69	14	%	%	NOUN
aiua-13880	69	15	of	of	ADP
aiua-13880	69	16	the	the	DET
aiua-13880	69	17	participants	participant	NOUN
aiua-13880	69	18	.	.	PUNCT
aiua-13880	70	1	the	the	DET
aiua-13880	70	2	majority	majority	NOUN
aiua-13880	70	3	of	of	ADP
aiua-13880	70	4	the	the	DET
aiua-13880	70	5	research	research	NOUN
aiua-13880	70	6	was	be	AUX
aiua-13880	70	7	conducted	conduct	VERB
aiua-13880	70	8	in	in	ADP
aiua-13880	70	9	japan	japan	PROPN
aiua-13880	70	10	,	,	PUNCT
aiua-13880	70	11	with	with	ADP
aiua-13880	70	12	only	only	ADV
aiua-13880	70	13	one	one	NUM
aiua-13880	70	14	study	study	NOUN
aiua-13880	70	15	taking	take	VERB
aiua-13880	70	16	place	place	NOUN
aiua-13880	70	17	in	in	ADP
aiua-13880	70	18	the	the	DET
aiua-13880	70	19	netherlands	netherlands	PROPN
aiua-13880	70	20	.	.	PUNCT
aiua-13880	71	1	all	all	DET
aiua-13880	71	2	studies	study	NOUN
aiua-13880	71	3	used	use	VERB
aiua-13880	71	4	a	a	DET
aiua-13880	71	5	retrospective	retrospective	ADJ
aiua-13880	71	6	comparative	comparative	ADJ
aiua-13880	71	7	design	design	NOUN
aiua-13880	71	8	.	.	PUNCT
aiua-13880	72	1	the	the	DET
aiua-13880	72	2	median	median	ADJ
aiua-13880	72	3	follow	follow	VERB
aiua-13880	72	4	-	-	PUNCT
aiua-13880	72	5	up	up	ADP
aiua-13880	72	6	duration	duration	NOUN
aiua-13880	72	7	was	be	AUX
aiua-13880	72	8	quite	quite	ADV
aiua-13880	72	9	variable	variable	ADJ
aiua-13880	72	10	,	,	PUNCT
aiua-13880	72	11	ranging	range	VERB
aiua-13880	72	12	from	from	ADP
aiua-13880	72	13	5.7	5.7	NUM
aiua-13880	72	14	to	to	PART
aiua-13880	72	15	34	34	NUM
aiua-13880	72	16	months	month	NOUN
aiua-13880	72	17	.	.	PUNCT
aiua-13880	73	1	regarding	regard	VERB
aiua-13880	73	2	ecog	ecog	ADJ
aiua-13880	73	3	performance	performance	NOUN
aiua-13880	73	4	status	status	NOUN
aiua-13880	73	5	(	(	PUNCT
aiua-13880	73	6	ps	ps	NOUN
aiua-13880	73	7	)	)	PUNCT
aiua-13880	73	8	,	,	PUNCT
aiua-13880	73	9	five	five	NUM
aiua-13880	73	10	studies	study	NOUN
aiua-13880	73	11	did	do	AUX
aiua-13880	73	12	not	not	PART
aiua-13880	73	13	disclose	disclose	VERB
aiua-13880	73	14	the	the	DET
aiua-13880	73	15	percentage	percentage	NOUN
aiua-13880	73	16	of	of	ADP
aiua-13880	73	17	patients	patient	NOUN
aiua-13880	73	18	with	with	ADP
aiua-13880	73	19	ps	ps	PROPN
aiua-13880	73	20	≥	≥	PROPN
aiua-13880	73	21	2	2	NUM
aiua-13880	73	22	,	,	PUNCT
aiua-13880	73	23	while	while	SCONJ
aiua-13880	73	24	four	four	NUM
aiua-13880	73	25	studies	study	NOUN
aiua-13880	73	26	only	only	ADV
aiua-13880	73	27	disclosed	disclose	VERB
aiua-13880	73	28	those	those	PRON
aiua-13880	73	29	with	with	ADP
aiua-13880	73	30	a	a	DET
aiua-13880	73	31	ps	ps	PROPN
aiua-13880	73	32	of	of	ADP
aiua-13880	73	33	≥	≥	NOUN
aiua-13880	73	34	1	1	NUM
aiua-13880	73	35	.	.	PUNCT
aiua-13880	74	1	in	in	ADP
aiua-13880	74	2	total	total	ADJ
aiua-13880	74	3	,	,	PUNCT
aiua-13880	74	4	604	604	NUM
aiua-13880	74	5	patients	patient	NOUN
aiua-13880	74	6	(	(	PUNCT
aiua-13880	74	7	18.3	18.3	NUM
aiua-13880	74	8	%	%	NOUN
aiua-13880	74	9	)	)	PUNCT
aiua-13880	74	10	were	be	AUX
aiua-13880	74	11	identified	identify	VERB
aiua-13880	74	12	with	with	ADP
aiua-13880	74	13	a	a	DET
aiua-13880	74	14	ps	ps	PROPN
aiua-13880	74	15	of	of	ADP
aiua-13880	74	16	≥	≥	NOUN
aiua-13880	74	17	2	2	NUM
aiua-13880	74	18	.	.	PUNCT
aiua-13880	75	1	among	among	ADP
aiua-13880	75	2	the	the	DET
aiua-13880	75	3	studies	study	NOUN
aiua-13880	75	4	that	that	PRON
aiua-13880	75	5	reported	report	VERB
aiua-13880	75	6	primary	primary	ADJ
aiua-13880	75	7	tumor	tumor	NOUN
aiua-13880	75	8	sites	site	NOUN
aiua-13880	75	9	,	,	PUNCT
aiua-13880	75	10	1,863	1,863	NUM
aiua-13880	75	11	patients	patient	NOUN
aiua-13880	75	12	(	(	PUNCT
aiua-13880	75	13	43.1	43.1	NUM
aiua-13880	75	14	%	%	NOUN
aiua-13880	75	15	)	)	PUNCT
aiua-13880	75	16	had	have	VERB
aiua-13880	75	17	tumors	tumor	NOUN
aiua-13880	75	18	in	in	ADP
aiua-13880	75	19	the	the	DET
aiua-13880	75	20	upper	upper	ADJ
aiua-13880	75	21	urinary	urinary	ADJ
aiua-13880	75	22	tract	tract	NOUN
aiua-13880	75	23	,	,	PUNCT
aiua-13880	75	24	while	while	SCONJ
aiua-13880	75	25	2,212	2,212	NUM
aiua-13880	75	26	patients	patient	NOUN
aiua-13880	75	27	(	(	PUNCT
aiua-13880	75	28	51.7	51.7	NUM
aiua-13880	75	29	%	%	NOUN
aiua-13880	75	30	)	)	PUNCT
aiua-13880	75	31	had	have	VERB
aiua-13880	75	32	tumors	tumor	NOUN
aiua-13880	75	33	originating	originate	VERB
aiua-13880	75	34	from	from	ADP
aiua-13880	75	35	the	the	DET
aiua-13880	75	36	bladder	bladder	NOUN
aiua-13880	75	37	.	.	PUNCT
aiua-13880	76	1	the	the	DET
aiua-13880	76	2	primary	primary	ADJ
aiua-13880	76	3	outcomes	outcome	NOUN
aiua-13880	76	4	of	of	ADP
aiua-13880	76	5	our	our	PRON
aiua-13880	76	6	review	review	NOUN
aiua-13880	76	7	were	be	AUX
aiua-13880	76	8	orr	orr	PROPN
aiua-13880	76	9	,	,	PUNCT
aiua-13880	76	10	pfs	pfs	PROPN
aiua-13880	76	11	,	,	PUNCT
aiua-13880	76	12	and	and	CCONJ
aiua-13880	76	13	os	os	NOUN
aiua-13880	76	14	.	.	PUNCT
aiua-13880	77	1	the	the	DET
aiua-13880	77	2	values	value	NOUN
aiua-13880	77	3	for	for	ADP
aiua-13880	77	4	each	each	DET
aiua-13880	77	5	outcome	outcome	NOUN
aiua-13880	77	6	are	be	AUX
aiua-13880	77	7	further	far	ADV
aiua-13880	77	8	reported	report	VERB
aiua-13880	77	9	in	in	ADP
aiua-13880	77	10	table	table	NOUN
aiua-13880	77	11	1	1	NUM
aiua-13880	77	12	.	.	PUNCT
aiua-13880	78	1	quantitative	quantitative	ADJ
aiua-13880	78	2	analysis	analysis	NOUN
aiua-13880	78	3	(	(	PUNCT
aiua-13880	78	4	meta	meta	NOUN
aiua-13880	78	5	-	-	PUNCT
aiua-13880	78	6	analysis	analysis	NOUN
aiua-13880	78	7	)	)	PUNCT
aiua-13880	78	8	twenty	twenty	NUM
aiua-13880	78	9	-	-	PUNCT
aiua-13880	78	10	six	six	NUM
aiua-13880	78	11	studies	study	NOUN
aiua-13880	78	12	with	with	ADP
aiua-13880	78	13	a	a	DET
aiua-13880	78	14	total	total	ADJ
aiua-13880	78	15	sample	sample	NOUN
aiua-13880	78	16	of	of	ADP
aiua-13880	78	17	4,679	4,679	NUM
aiua-13880	78	18	patients	patient	NOUN
aiua-13880	78	19	figure	figure	VERB
aiua-13880	78	20	1	1	NUM
aiua-13880	78	21	.	.	PUNCT
aiua-13880	79	1	prisma	prisma	PROPN
aiua-13880	79	2	flowchart	flowchart	PROPN
aiua-13880	79	3	of	of	ADP
aiua-13880	79	4	the	the	DET
aiua-13880	79	5	study	study	NOUN
aiua-13880	79	6	selection	selection	NOUN
aiua-13880	79	7	process	process	NOUN
aiua-13880	79	8	.	.	PUNCT
aiua-13880	80	1	archivio	archivio	NOUN
aiua-13880	80	2	italiano	italiano	PROPN
aiua-13880	80	3	di	di	PROPN
aiua-13880	80	4	urologia	urologia	PROPN
aiua-13880	80	5	e	e	PROPN
aiua-13880	80	6	andrologia	andrologia	NOUN
aiua-13880	80	7	2025	2025	NUM
aiua-13880	80	8	;	;	PUNCT
aiua-13880	80	9	97(2):13880	97(2):13880	NUM
aiua-13880	80	10	k	k	PROPN
aiua-13880	80	11	..	..	PUNCT
aiua-13880	80	12	yuwono	yuwono	PROPN
aiua-13880	80	13	,	,	PUNCT
aiua-13880	80	14	j.	j.	PROPN
aiua-13880	80	15	nimasratu	nimasratu	PROPN
aiua-13880	80	16	rahmatsani	rahmatsani	PROPN
aiua-13880	80	17	,	,	PUNCT
aiua-13880	80	18	nadhifah	nadhifah	VERB
aiua-13880	80	19	,	,	PUNCT
aiua-13880	80	20	et	et	PROPN
aiua-13880	80	21	al	al	PROPN
aiua-13880	80	22	.	.	PROPN
aiua-13880	81	1	4	4	NUM
aiua-13880	81	2	table	table	NOUN
aiua-13880	81	3	1	1	NUM
aiua-13880	81	4	.	.	PUNCT
aiua-13880	81	5	characteristics	characteristic	NOUN
aiua-13880	81	6	of	of	ADP
aiua-13880	81	7	included	include	VERB
aiua-13880	81	8	studies	study	NOUN
aiua-13880	81	9	.	.	PUNCT
aiua-13880	82	1	no	no	DET
aiua-13880	82	2	author	author	NOUN
aiua-13880	82	3	;	;	PUNCT
aiua-13880	82	4	year	year	NOUN
aiua-13880	82	5	location	location	NOUN
aiua-13880	82	6	study	study	NOUN
aiua-13880	82	7	sample	sample	NOUN
aiua-13880	82	8	age	age	NOUN
aiua-13880	82	9	male	male	NOUN
aiua-13880	82	10	follow	follow	VERB
aiua-13880	82	11	up	up	ADP
aiua-13880	82	12	ecog	ecog	PROPN
aiua-13880	82	13	ps	ps	NOUN
aiua-13880	82	14	site	site	NOUN
aiua-13880	82	15	of	of	ADP
aiua-13880	82	16	outcome	outcome	NOUN
aiua-13880	82	17	design	design	NOUN
aiua-13880	82	18	size	size	NOUN
aiua-13880	82	19	(	(	PUNCT
aiua-13880	82	20	years	year	NOUN
aiua-13880	82	21	)	)	PUNCT
aiua-13880	82	22	duration	duration	NOUN
aiua-13880	82	23	(	(	PUNCT
aiua-13880	82	24	months	month	NOUN
aiua-13880	82	25	)	)	PUNCT
aiua-13880	82	26	≥	≥	NOUN
aiua-13880	82	27	2	2	NUM
aiua-13880	82	28	primary	primary	NOUN
aiua-13880	82	29	orr	orr	PROPN
aiua-13880	82	30	pfs	pfs	PROPN
aiua-13880	82	31	os	os	PROPN
aiua-13880	82	32	tumour	tumour	PROPN
aiua-13880	82	33	(	(	PUNCT
aiua-13880	82	34	%	%	NOUN
aiua-13880	82	35	)	)	PUNCT
aiua-13880	82	36	(	(	PUNCT
aiua-13880	82	37	median	median	PROPN
aiua-13880	82	38	)	)	PUNCT
aiua-13880	82	39	(	(	PUNCT
aiua-13880	82	40	median	median	NOUN
aiua-13880	82	41	)	)	PUNCT
aiua-13880	82	42	1	1	NUM
aiua-13880	82	43	akashi	akashi	PROPN
aiua-13880	82	44	;	;	PUNCT
aiua-13880	82	45	2023	2023	NUM
aiua-13880	82	46	(	(	PUNCT
aiua-13880	82	47	40	40	NUM
aiua-13880	82	48	)	)	PUNCT
aiua-13880	82	49	japan	japan	PROPN
aiua-13880	82	50	retrospective	retrospective	ADJ
aiua-13880	82	51	study	study	NOUN
aiua-13880	82	52	41	41	NUM
aiua-13880	82	53	75	75	NUM
aiua-13880	82	54	(	(	PUNCT
aiua-13880	82	55	58	58	NUM
aiua-13880	82	56	-	-	SYM
aiua-13880	82	57	81	81	NUM
aiua-13880	82	58	)	)	PUNCT
aiua-13880	82	59	35	35	NUM
aiua-13880	82	60	(	(	PUNCT
aiua-13880	82	61	85.4	85.4	NUM
aiua-13880	82	62	)	)	PUNCT
aiua-13880	82	63	16.5	16.5	NUM
aiua-13880	82	64	(	(	PUNCT
aiua-13880	82	65	1.0	1.0	NUM
aiua-13880	82	66	-	-	SYM
aiua-13880	82	67	47.8	47.8	NUM
aiua-13880	82	68	)	)	PUNCT
aiua-13880	82	69	4	4	NUM
aiua-13880	82	70	(	(	PUNCT
aiua-13880	82	71	10	10	NUM
aiua-13880	82	72	)	)	PUNCT
aiua-13880	82	73	utuc	utuc	NOUN
aiua-13880	82	74	:	:	PUNCT
aiua-13880	82	75	16	16	NUM
aiua-13880	82	76	(	(	PUNCT
aiua-13880	82	77	40	40	NUM
aiua-13880	82	78	)	)	PUNCT
aiua-13880	82	79	29.3	29.3	NUM
aiua-13880	82	80	4.9	4.9	NUM
aiua-13880	82	81	(	(	PUNCT
aiua-13880	82	82	1.2	1.2	NUM
aiua-13880	82	83	-	-	SYM
aiua-13880	82	84	8.6	8.6	NUM
aiua-13880	82	85	)	)	PUNCT
aiua-13880	82	86	17.8	17.8	NUM
aiua-13880	82	87	(	(	PUNCT
aiua-13880	82	88	11.5	11.5	NUM
aiua-13880	82	89	-	-	SYM
aiua-13880	82	90	24.0	24.0	NUM
aiua-13880	82	91	)	)	PUNCT
aiua-13880	82	92	bc	bc	PROPN
aiua-13880	82	93	:	:	PUNCT
aiua-13880	82	94	25	25	NUM
aiua-13880	82	95	(	(	PUNCT
aiua-13880	82	96	60	60	NUM
aiua-13880	82	97	)	)	SYM
aiua-13880	82	98	2	2	NUM
aiua-13880	82	99	fukata	fukata	ADJ
aiua-13880	82	100	;	;	PUNCT
aiua-13880	82	101	2022	2022	NUM
aiua-13880	82	102	(	(	PUNCT
aiua-13880	82	103	41	41	NUM
aiua-13880	82	104	)	)	PUNCT
aiua-13880	82	105	japan	japan	PROPN
aiua-13880	82	106	retrospective	retrospective	ADJ
aiua-13880	82	107	study	study	NOUN
aiua-13880	82	108	44	44	NUM
aiua-13880	82	109	70	70	NUM
aiua-13880	82	110	(	(	PUNCT
aiua-13880	82	111	54	54	NUM
aiua-13880	82	112	-	-	SYM
aiua-13880	82	113	80	80	NUM
aiua-13880	82	114	)	)	PUNCT
aiua-13880	82	115	30	30	NUM
aiua-13880	82	116	(	(	PUNCT
aiua-13880	82	117	68	68	NUM
aiua-13880	82	118	)	)	PUNCT
aiua-13880	82	119	13.2	13.2	NUM
aiua-13880	82	120	(	(	PUNCT
aiua-13880	82	121	1	1	NUM
aiua-13880	82	122	-	-	NUM
aiua-13880	82	123	40.8	40.8	NUM
aiua-13880	82	124	)	)	PUNCT
aiua-13880	82	125	7	7	NUM
aiua-13880	82	126	(	(	PUNCT
aiua-13880	82	127	16	16	NUM
aiua-13880	82	128	)	)	PUNCT
aiua-13880	82	129	utuc	utuc	NOUN
aiua-13880	82	130	:	:	PUNCT
aiua-13880	82	131	16	16	NUM
aiua-13880	82	132	(	(	PUNCT
aiua-13880	82	133	36	36	NUM
aiua-13880	82	134	)	)	PUNCT
aiua-13880	82	135	54.5	54.5	NUM
aiua-13880	82	136	nr	nr	PROPN
aiua-13880	82	137	nr	nr	PROPN
aiua-13880	82	138	bc	bc	PROPN
aiua-13880	82	139	:	:	PUNCT
aiua-13880	82	140	28	28	NUM
aiua-13880	82	141	(	(	PUNCT
aiua-13880	82	142	64	64	NUM
aiua-13880	82	143	)	)	PUNCT
aiua-13880	82	144	3	3	NUM
aiua-13880	82	145	furubayashi	furubayashi	NOUN
aiua-13880	82	146	;	;	PUNCT
aiua-13880	82	147	2021	2021	NUM
aiua-13880	82	148	(	(	PUNCT
aiua-13880	82	149	42	42	NUM
aiua-13880	82	150	)	)	PUNCT
aiua-13880	82	151	japan	japan	PROPN
aiua-13880	82	152	retrospective	retrospective	ADJ
aiua-13880	82	153	study	study	NOUN
aiua-13880	82	154	105	105	NUM
aiua-13880	82	155	72	72	NUM
aiua-13880	82	156	(	(	PUNCT
aiua-13880	82	157	67	67	NUM
aiua-13880	82	158	-	-	SYM
aiua-13880	82	159	77	77	NUM
aiua-13880	82	160	)	)	PUNCT
aiua-13880	82	161	75	75	NUM
aiua-13880	82	162	(	(	PUNCT
aiua-13880	82	163	71.4	71.4	NUM
aiua-13880	82	164	)	)	PUNCT
aiua-13880	82	165	8.4	8.4	NUM
aiua-13880	82	166	(	(	PUNCT
aiua-13880	82	167	4.1	4.1	NUM
aiua-13880	82	168	-	-	SYM
aiua-13880	82	169	15.7	15.7	NUM
aiua-13880	82	170	)	)	PUNCT
aiua-13880	82	171	10	10	NUM
aiua-13880	82	172	(	(	PUNCT
aiua-13880	82	173	9.5	9.5	NUM
aiua-13880	82	174	)	)	PUNCT
aiua-13880	82	175	utuc	utuc	NOUN
aiua-13880	82	176	:	:	PUNCT
aiua-13880	82	177	41	41	NUM
aiua-13880	82	178	(	(	PUNCT
aiua-13880	82	179	39	39	NUM
aiua-13880	82	180	)	)	PUNCT
aiua-13880	82	181	36.2	36.2	NUM
aiua-13880	82	182	nr	nr	PROPN
aiua-13880	82	183	nr	nr	PROPN
aiua-13880	82	184	bc	bc	PROPN
aiua-13880	82	185	:	:	PUNCT
aiua-13880	82	186	42	42	NUM
aiua-13880	82	187	(	(	PUNCT
aiua-13880	82	188	40	40	NUM
aiua-13880	82	189	)	)	PUNCT
aiua-13880	82	190	both	both	PRON
aiua-13880	82	191	:	:	PUNCT
aiua-13880	82	192	22	22	NUM
aiua-13880	82	193	(	(	PUNCT
aiua-13880	82	194	21	21	NUM
aiua-13880	82	195	)	)	PUNCT
aiua-13880	82	196	4	4	NUM
aiua-13880	82	197	ito	ito	X
aiua-13880	82	198	;	;	PUNCT
aiua-13880	82	199	2020	2020	NUM
aiua-13880	82	200	(	(	PUNCT
aiua-13880	82	201	43	43	NUM
aiua-13880	82	202	)	)	PUNCT
aiua-13880	82	203	japan	japan	PROPN
aiua-13880	82	204	retrospective	retrospective	ADJ
aiua-13880	82	205	study	study	NOUN
aiua-13880	82	206	755	755	NUM
aiua-13880	82	207	ecog	ecog	VERB
aiua-13880	82	208	0	0	NUM
aiua-13880	82	209	-	-	SYM
aiua-13880	82	210	1	1	NUM
aiua-13880	82	211	:	:	PUNCT
aiua-13880	82	212	72.09	72.09	NUM
aiua-13880	82	213	568	568	NUM
aiua-13880	82	214	(	(	PUNCT
aiua-13880	82	215	75.2	75.2	NUM
aiua-13880	82	216	)	)	PUNCT
aiua-13880	82	217	7.2	7.2	NUM
aiua-13880	82	218	153	153	NUM
aiua-13880	82	219	(	(	PUNCT
aiua-13880	82	220	20.26	20.26	NUM
aiua-13880	82	221	)	)	PUNCT
aiua-13880	82	222	utuc	utuc	NOUN
aiua-13880	82	223	:	:	PUNCT
aiua-13880	82	224	373	373	NUM
aiua-13880	82	225	(	(	PUNCT
aiua-13880	82	226	49.4	49.4	NUM
aiua-13880	82	227	)	)	PUNCT
aiua-13880	82	228	26.2	26.2	NUM
aiua-13880	82	229	nr	nr	PROPN
aiua-13880	82	230	nr	nr	PROPN
aiua-13880	82	231	(	(	PUNCT
aiua-13880	82	232	66.3	66.3	NUM
aiua-13880	82	233	-	-	PUNCT
aiua-13880	82	234	77.23	77.23	NUM
aiua-13880	82	235	)	)	PUNCT
aiua-13880	82	236	bc	bc	PROPN
aiua-13880	82	237	:	:	PUNCT
aiua-13880	82	238	382	382	NUM
aiua-13880	82	239	(	(	PUNCT
aiua-13880	82	240	50.6	50.6	NUM
aiua-13880	82	241	)	)	PUNCT
aiua-13880	82	242	ecog	ecog	VERB
aiua-13880	82	243	2	2	NUM
aiua-13880	82	244	:	:	PUNCT
aiua-13880	82	245	72.01	72.01	NUM
aiua-13880	82	246	(	(	PUNCT
aiua-13880	82	247	66.49	66.49	NUM
aiua-13880	82	248	-	-	SYM
aiua-13880	82	249	76.21	76.21	NUM
aiua-13880	82	250	)	)	PUNCT
aiua-13880	82	251	ecog	ecog	VERB
aiua-13880	82	252	3	3	NUM
aiua-13880	82	253	-	-	SYM
aiua-13880	82	254	4	4	NUM
aiua-13880	82	255	:	:	PUNCT
aiua-13880	82	256	70.18	70.18	NUM
aiua-13880	82	257	(	(	PUNCT
aiua-13880	82	258	63.5	63.5	NUM
aiua-13880	82	259	-	-	SYM
aiua-13880	82	260	75.72	75.72	NUM
aiua-13880	82	261	)	)	PUNCT
aiua-13880	82	262	5	5	NUM
aiua-13880	82	263	kawashima	kawashima	NOUN
aiua-13880	82	264	;	;	PUNCT
aiua-13880	82	265	2021(a	2021(a	NUM
aiua-13880	82	266	)	)	PUNCT
aiua-13880	82	267	(	(	PUNCT
aiua-13880	82	268	44	44	X
aiua-13880	82	269	)	)	PUNCT
aiua-13880	82	270	japan	japan	PROPN
aiua-13880	82	271	retrospective	retrospective	ADJ
aiua-13880	82	272	study	study	NOUN
aiua-13880	82	273	165	165	NUM
aiua-13880	82	274	73	73	NUM
aiua-13880	82	275	(	(	PUNCT
aiua-13880	82	276	28	28	NUM
aiua-13880	82	277	-	-	SYM
aiua-13880	82	278	93	93	NUM
aiua-13880	82	279	)	)	PUNCT
aiua-13880	82	280	117	117	NUM
aiua-13880	82	281	(	(	PUNCT
aiua-13880	82	282	70.9	70.9	NUM
aiua-13880	82	283	)	)	PUNCT
aiua-13880	82	284	6.71	6.71	NUM
aiua-13880	82	285	(	(	PUNCT
aiua-13880	82	286	0.26	0.26	NUM
aiua-13880	82	287	-	-	SYM
aiua-13880	82	288	37.0	37.0	NUM
aiua-13880	82	289	)	)	PUNCT
aiua-13880	82	290	27	27	NUM
aiua-13880	82	291	(	(	PUNCT
aiua-13880	82	292	16.3	16.3	NUM
aiua-13880	82	293	)	)	PUNCT
aiua-13880	82	294	utuc	utuc	NOUN
aiua-13880	82	295	:	:	PUNCT
aiua-13880	82	296	99	99	NUM
aiua-13880	82	297	(	(	PUNCT
aiua-13880	82	298	60	60	NUM
aiua-13880	82	299	)	)	PUNCT
aiua-13880	82	300	21.8	21.8	NUM
aiua-13880	82	301	(	(	PUNCT
aiua-13880	82	302	2.32	2.32	NUM
aiua-13880	82	303	-	-	SYM
aiua-13880	82	304	2.88	2.88	NUM
aiua-13880	82	305	)	)	PUNCT
aiua-13880	82	306	2.6	2.6	NUM
aiua-13880	82	307	nr	nr	PROPN
aiua-13880	82	308	bc	bc	PROPN
aiua-13880	82	309	:	:	PUNCT
aiua-13880	82	310	61	61	NUM
aiua-13880	82	311	(	(	PUNCT
aiua-13880	82	312	37	37	NUM
aiua-13880	82	313	)	)	PUNCT
aiua-13880	82	314	both	both	PRON
aiua-13880	82	315	:	:	PUNCT
aiua-13880	82	316	5	5	NUM
aiua-13880	82	317	(	(	PUNCT
aiua-13880	82	318	3.0	3.0	NUM
aiua-13880	82	319	)	)	PUNCT
aiua-13880	82	320	5	5	NUM
aiua-13880	82	321	kawashima	kawashima	NOUN
aiua-13880	82	322	;	;	PUNCT
aiua-13880	82	323	2021(b	2021(b	NUM
aiua-13880	82	324	)	)	PUNCT
aiua-13880	83	1	(	(	PUNCT
aiua-13880	83	2	45	45	NUM
aiua-13880	83	3	)	)	PUNCT
aiua-13880	83	4	japan	japan	PROPN
aiua-13880	83	5	retrospective	retrospective	PROPN
aiua-13880	83	6	study	study	NOUN
aiua-13880	83	7	103	103	NUM
aiua-13880	83	8	73	73	NUM
aiua-13880	83	9	(	(	PUNCT
aiua-13880	83	10	30	30	NUM
aiua-13880	83	11	-	-	SYM
aiua-13880	83	12	86	86	NUM
aiua-13880	83	13	)	)	PUNCT
aiua-13880	83	14	76	76	NUM
aiua-13880	83	15	(	(	PUNCT
aiua-13880	83	16	73.8	73.8	NUM
aiua-13880	83	17	)	)	PUNCT
aiua-13880	83	18	6.67	6.67	NUM
aiua-13880	83	19	(	(	PUNCT
aiua-13880	83	20	0.99	0.99	NUM
aiua-13880	83	21	-	-	SYM
aiua-13880	83	22	36.1	36.1	NUM
aiua-13880	83	23	)	)	PUNCT
aiua-13880	83	24	23	23	NUM
aiua-13880	83	25	(	(	PUNCT
aiua-13880	83	26	22.3	22.3	NUM
aiua-13880	83	27	)	)	PUNCT
aiua-13880	83	28	utuc	utuc	NOUN
aiua-13880	83	29	:	:	PUNCT
aiua-13880	83	30	58	58	NUM
aiua-13880	83	31	(	(	PUNCT
aiua-13880	83	32	56.3	56.3	NUM
aiua-13880	83	33	)	)	PUNCT
aiua-13880	83	34	30.1	30.1	NUM
aiua-13880	83	35	(	(	PUNCT
aiua-13880	83	36	1.79	1.79	NUM
aiua-13880	83	37	-	-	SYM
aiua-13880	83	38	5.31	5.31	NUM
aiua-13880	83	39	)	)	PUNCT
aiua-13880	83	40	3.55	3.55	NUM
aiua-13880	83	41	nr	nr	NOUN
aiua-13880	83	42	bc	bc	PROPN
aiua-13880	83	43	:	:	PUNCT
aiua-13880	83	44	45	45	NUM
aiua-13880	83	45	(	(	PUNCT
aiua-13880	83	46	43.7	43.7	NUM
aiua-13880	83	47	)	)	PUNCT
aiua-13880	83	48	6	6	NUM
aiua-13880	83	49	kita	kita	PROPN
aiua-13880	83	50	;	;	PUNCT
aiua-13880	83	51	2022	2022	NUM
aiua-13880	83	52	(	(	PUNCT
aiua-13880	83	53	45	45	NUM
aiua-13880	83	54	)	)	PUNCT
aiua-13880	83	55	japan	japan	PROPN
aiua-13880	83	56	retrospective	retrospective	ADJ
aiua-13880	83	57	study	study	NOUN
aiua-13880	83	58	739	739	NUM
aiua-13880	83	59	nr	nr	NOUN
aiua-13880	83	60	554	554	NUM
aiua-13880	83	61	(	(	PUNCT
aiua-13880	83	62	75	75	NUM
aiua-13880	83	63	)	)	PUNCT
aiua-13880	83	64	34	34	NUM
aiua-13880	83	65	150	150	NUM
aiua-13880	83	66	(	(	PUNCT
aiua-13880	83	67	20.3	20.3	NUM
aiua-13880	83	68	)	)	PUNCT
aiua-13880	83	69	utuc	utuc	NOUN
aiua-13880	83	70	:	:	PUNCT
aiua-13880	83	71	352	352	NUM
aiua-13880	83	72	(	(	PUNCT
aiua-13880	83	73	47.63	47.63	NUM
aiua-13880	83	74	)	)	PUNCT
aiua-13880	83	75	27.2	27.2	NUM
aiua-13880	83	76	3.5	3.5	NUM
aiua-13880	83	77	nr	nr	PRON
aiua-13880	83	78	bc	bc	PROPN
aiua-13880	83	79	:	:	PUNCT
aiua-13880	83	80	384	384	NUM
aiua-13880	83	81	(	(	PUNCT
aiua-13880	83	82	51.9	51.9	NUM
aiua-13880	83	83	)	)	PUNCT
aiua-13880	83	84	unknown	unknown	ADJ
aiua-13880	83	85	:	:	PUNCT
aiua-13880	83	86	4	4	NUM
aiua-13880	83	87	(	(	PUNCT
aiua-13880	83	88	0.4	0.4	NUM
aiua-13880	83	89	)	)	PUNCT
aiua-13880	83	90	7	7	NUM
aiua-13880	83	91	kobayashi	kobayashi	PROPN
aiua-13880	83	92	;	;	PUNCT
aiua-13880	83	93	2020	2020	NUM
aiua-13880	83	94	(	(	PUNCT
aiua-13880	83	95	46	46	NUM
aiua-13880	83	96	)	)	PUNCT
aiua-13880	83	97	japan	japan	PROPN
aiua-13880	83	98	retrospective	retrospective	ADJ
aiua-13880	83	99	study	study	NOUN
aiua-13880	83	100	463	463	NUM
aiua-13880	83	101	71	71	NUM
aiua-13880	83	102	(	(	PUNCT
aiua-13880	83	103	31	31	NUM
aiua-13880	83	104	-	-	SYM
aiua-13880	83	105	88	88	NUM
aiua-13880	83	106	)	)	PUNCT
aiua-13880	83	107	357	357	NUM
aiua-13880	83	108	(	(	PUNCT
aiua-13880	83	109	77.1	77.1	NUM
aiua-13880	83	110	)	)	PUNCT
aiua-13880	83	111	17.7	17.7	NUM
aiua-13880	83	112	(	(	PUNCT
aiua-13880	83	113	12.9	12.9	NUM
aiua-13880	83	114	-	-	SYM
aiua-13880	83	115	21.4	21.4	NUM
aiua-13880	83	116	)	)	PUNCT
aiua-13880	83	117	90	90	NUM
aiua-13880	83	118	(	(	PUNCT
aiua-13880	83	119	19.4	19.4	NUM
aiua-13880	83	120	)	)	PUNCT
aiua-13880	83	121	utuc	utuc	NOUN
aiua-13880	83	122	:	:	PUNCT
aiua-13880	83	123	179	179	NUM
aiua-13880	83	124	(	(	PUNCT
aiua-13880	83	125	38.7	38.7	NUM
aiua-13880	83	126	)	)	PUNCT
aiua-13880	83	127	30.5	30.5	NUM
aiua-13880	83	128	nr	nr	NOUN
aiua-13880	83	129	10.2	10.2	NUM
aiua-13880	83	130	(	(	PUNCT
aiua-13880	83	131	8.2	8.2	NUM
aiua-13880	83	132	-	-	SYM
aiua-13880	83	133	11.7	11.7	NUM
aiua-13880	83	134	)	)	PUNCT
aiua-13880	83	135	bc	bc	PROPN
aiua-13880	83	136	:	:	PUNCT
aiua-13880	83	137	230	230	NUM
aiua-13880	83	138	(	(	PUNCT
aiua-13880	83	139	49.7	49.7	NUM
aiua-13880	83	140	)	)	PUNCT
aiua-13880	83	141	both	both	PRON
aiua-13880	83	142	:	:	PUNCT
aiua-13880	83	143	27	27	NUM
aiua-13880	83	144	(	(	PUNCT
aiua-13880	83	145	5.8	5.8	NUM
aiua-13880	83	146	)	)	PUNCT
aiua-13880	83	147	unknown	unknown	ADJ
aiua-13880	83	148	:	:	PUNCT
aiua-13880	83	149	1	1	NUM
aiua-13880	83	150	(	(	PUNCT
aiua-13880	83	151	0.2	0.2	NUM
aiua-13880	83	152	)	)	PUNCT
aiua-13880	83	153	8	8	NUM
aiua-13880	83	154	komura	komura	NOUN
aiua-13880	83	155	;	;	PUNCT
aiua-13880	83	156	2023	2023	NUM
aiua-13880	83	157	(	(	PUNCT
aiua-13880	83	158	47	47	NUM
aiua-13880	83	159	)	)	PUNCT
aiua-13880	83	160	japan	japan	PROPN
aiua-13880	83	161	retrospective	retrospective	ADJ
aiua-13880	83	162	study	study	NOUN
aiua-13880	83	163	100	100	NUM
aiua-13880	83	164	70.30	70.30	NUM
aiua-13880	83	165	(	(	PUNCT
aiua-13880	83	166	9.03	9.03	NUM
aiua-13880	83	167	)	)	PUNCT
aiua-13880	83	168	78	78	NUM
aiua-13880	83	169	(	(	PUNCT
aiua-13880	83	170	78	78	NUM
aiua-13880	83	171	)	)	PUNCT
aiua-13880	83	172	nr	nr	PROPN
aiua-13880	83	173	nr	nr	PROPN
aiua-13880	83	174	utuc	utuc	NOUN
aiua-13880	83	175	:	:	PUNCT
aiua-13880	83	176	18	18	NUM
aiua-13880	83	177	(	(	PUNCT
aiua-13880	83	178	18	18	NUM
aiua-13880	83	179	)	)	PUNCT
aiua-13880	83	180	22	22	NUM
aiua-13880	83	181	nr	nr	PROPN
aiua-13880	83	182	nr	nr	PROPN
aiua-13880	83	183	bc	bc	PROPN
aiua-13880	83	184	:	:	PUNCT
aiua-13880	83	185	77	77	NUM
aiua-13880	83	186	(	(	PUNCT
aiua-13880	83	187	77	77	NUM
aiua-13880	83	188	)	)	PUNCT
aiua-13880	83	189	both	both	PRON
aiua-13880	83	190	:	:	PUNCT
aiua-13880	83	191	5	5	NUM
aiua-13880	83	192	(	(	PUNCT
aiua-13880	83	193	5	5	NUM
aiua-13880	83	194	)	)	PUNCT
aiua-13880	83	195	9	9	NUM
aiua-13880	83	196	kurashina	kurashina	NOUN
aiua-13880	83	197	;	;	PUNCT
aiua-13880	83	198	2023	2023	NUM
aiua-13880	83	199	(	(	PUNCT
aiua-13880	83	200	18	18	NUM
aiua-13880	83	201	)	)	PUNCT
aiua-13880	83	202	japan	japan	PROPN
aiua-13880	83	203	retrospective	retrospective	ADJ
aiua-13880	83	204	study	study	NOUN
aiua-13880	83	205	75	75	NUM
aiua-13880	83	206	nr	nr	PROPN
aiua-13880	83	207	nr	nr	PROPN
aiua-13880	83	208	7.3	7.3	NUM
aiua-13880	83	209	(	(	PUNCT
aiua-13880	83	210	0.47	0.47	NUM
aiua-13880	83	211	-	-	SYM
aiua-13880	83	212	47.6	47.6	NUM
aiua-13880	83	213	)	)	PUNCT
aiua-13880	83	214	nr	nr	PROPN
aiua-13880	83	215	nr	nr	PROPN
aiua-13880	83	216	21.3	21.3	NUM
aiua-13880	83	217	nr	nr	PROPN
aiua-13880	83	218	8.5	8.5	NUM
aiua-13880	83	219	(	(	PUNCT
aiua-13880	83	220	6.4	6.4	NUM
aiua-13880	83	221	-	-	SYM
aiua-13880	83	222	10.7	10.7	NUM
aiua-13880	83	223	)	)	PUNCT
aiua-13880	83	224	10	10	NUM
aiua-13880	83	225	miyama	miyama	NOUN
aiua-13880	83	226	;	;	PUNCT
aiua-13880	83	227	2022	2022	NUM
aiua-13880	83	228	(	(	PUNCT
aiua-13880	83	229	48	48	NUM
aiua-13880	83	230	)	)	PUNCT
aiua-13880	83	231	japan	japan	PROPN
aiua-13880	83	232	retrospective	retrospective	ADJ
aiua-13880	83	233	study	study	NOUN
aiua-13880	83	234	50	50	NUM
aiua-13880	83	235	71.9	71.9	NUM
aiua-13880	83	236	(	(	PUNCT
aiua-13880	83	237	1.69	1.69	NUM
aiua-13880	83	238	)	)	PUNCT
aiua-13880	83	239	31	31	NUM
aiua-13880	83	240	(	(	PUNCT
aiua-13880	83	241	62	62	NUM
aiua-13880	83	242	)	)	PUNCT
aiua-13880	83	243	nr	nr	PROPN
aiua-13880	83	244	nr	nr	PROPN
aiua-13880	83	245	utuc	utuc	NOUN
aiua-13880	83	246	:	:	PUNCT
aiua-13880	83	247	23	23	NUM
aiua-13880	83	248	(	(	PUNCT
aiua-13880	83	249	46	46	NUM
aiua-13880	83	250	)	)	PUNCT
aiua-13880	83	251	bc	bc	PROPN
aiua-13880	83	252	:	:	PUNCT
aiua-13880	83	253	27	27	NUM
aiua-13880	83	254	(	(	PUNCT
aiua-13880	83	255	54	54	NUM
aiua-13880	83	256	)	)	PUNCT
aiua-13880	83	257	30	30	NUM
aiua-13880	83	258	3.62	3.62	NUM
aiua-13880	83	259	10.97	10.97	NUM
aiua-13880	83	260	11	11	NUM
aiua-13880	83	261	nagasaka	nagasaka	ADV
aiua-13880	83	262	;	;	PUNCT
aiua-13880	83	263	2024	2024	NUM
aiua-13880	83	264	(	(	PUNCT
aiua-13880	83	265	49	49	NUM
aiua-13880	83	266	)	)	PUNCT
aiua-13880	83	267	japan	japan	PROPN
aiua-13880	83	268	retrospective	retrospective	ADJ
aiua-13880	83	269	study	study	NOUN
aiua-13880	83	270	48	48	NUM
aiua-13880	83	271	76	76	NUM
aiua-13880	83	272	(	(	PUNCT
aiua-13880	83	273	47	47	NUM
aiua-13880	83	274	-	-	SYM
aiua-13880	83	275	88	88	NUM
aiua-13880	83	276	)	)	PUNCT
aiua-13880	83	277	31	31	NUM
aiua-13880	83	278	(	(	PUNCT
aiua-13880	83	279	64.58	64.58	NUM
aiua-13880	83	280	)	)	PUNCT
aiua-13880	83	281	nr	nr	PROPN
aiua-13880	83	282	2	2	NUM
aiua-13880	83	283	(	(	PUNCT
aiua-13880	83	284	4.17	4.17	NUM
aiua-13880	83	285	)	)	PUNCT
aiua-13880	83	286	utuc	utuc	NOUN
aiua-13880	83	287	:	:	PUNCT
aiua-13880	83	288	48	48	NUM
aiua-13880	83	289	(	(	PUNCT
aiua-13880	83	290	100	100	NUM
aiua-13880	83	291	)	)	PUNCT
aiua-13880	83	292	27.1	27.1	NUM
aiua-13880	83	293	2.2	2.2	NUM
aiua-13880	83	294	5.47	5.47	NUM
aiua-13880	83	295	12	12	NUM
aiua-13880	83	296	nishio	nishio	NOUN
aiua-13880	83	297	;	;	PUNCT
aiua-13880	83	298	2024	2024	NUM
aiua-13880	83	299	(	(	PUNCT
aiua-13880	83	300	50	50	NUM
aiua-13880	83	301	)	)	PUNCT
aiua-13880	83	302	japan	japan	PROPN
aiua-13880	83	303	retrospective	retrospective	ADJ
aiua-13880	83	304	study	study	NOUN
aiua-13880	83	305	220	220	NUM
aiua-13880	83	306	nr	nr	PROPN
aiua-13880	83	307	154	154	NUM
aiua-13880	83	308	(	(	PUNCT
aiua-13880	83	309	70	70	NUM
aiua-13880	83	310	)	)	PUNCT
aiua-13880	83	311	7.3	7.3	NUM
aiua-13880	83	312	123	123	NUM
aiua-13880	83	313	(	(	PUNCT
aiua-13880	83	314	56	56	NUM
aiua-13880	83	315	)	)	PUNCT
aiua-13880	83	316	*	*	PUNCT
aiua-13880	83	317	utuc	utuc	NOUN
aiua-13880	83	318	:	:	PUNCT
aiua-13880	83	319	85	85	NUM
aiua-13880	83	320	(	(	PUNCT
aiua-13880	83	321	39	39	NUM
aiua-13880	83	322	)	)	PUNCT
aiua-13880	83	323	29.1	29.1	NUM
aiua-13880	83	324	nr	nr	PROPN
aiua-13880	83	325	nr	nr	PROPN
aiua-13880	83	326	bc	bc	PROPN
aiua-13880	83	327	:	:	PUNCT
aiua-13880	83	328	135	135	NUM
aiua-13880	83	329	(	(	PUNCT
aiua-13880	83	330	61	61	NUM
aiua-13880	83	331	)	)	PUNCT
aiua-13880	83	332	13	13	NUM
aiua-13880	83	333	ogihara	ogihara	NOUN
aiua-13880	83	334	;	;	PUNCT
aiua-13880	83	335	2020	2020	NUM
aiua-13880	83	336	(	(	PUNCT
aiua-13880	83	337	51	51	NUM
aiua-13880	83	338	)	)	PUNCT
aiua-13880	83	339	japan	japan	PROPN
aiua-13880	83	340	retrospective	retrospective	ADJ
aiua-13880	83	341	study	study	NOUN
aiua-13880	83	342	78	78	NUM
aiua-13880	83	343	72.16	72.16	NUM
aiua-13880	83	344	(	(	PUNCT
aiua-13880	83	345	9.29	9.29	NUM
aiua-13880	83	346	)	)	PUNCT
aiua-13880	83	347	54	54	NUM
aiua-13880	83	348	(	(	PUNCT
aiua-13880	83	349	69.23	69.23	NUM
aiua-13880	83	350	)	)	PUNCT
aiua-13880	83	351	7.42	7.42	NUM
aiua-13880	83	352	(	(	PUNCT
aiua-13880	83	353	0.9	0.9	NUM
aiua-13880	83	354	-	-	SYM
aiua-13880	83	355	17.9	17.9	NUM
aiua-13880	83	356	)	)	PUNCT
aiua-13880	83	357	18	18	NUM
aiua-13880	83	358	(	(	PUNCT
aiua-13880	83	359	23.07	23.07	NUM
aiua-13880	83	360	)	)	PUNCT
aiua-13880	83	361	*	*	PUNCT
aiua-13880	84	1	utuc	utuc	NOUN
aiua-13880	84	2	:	:	PUNCT
aiua-13880	84	3	35	35	NUM
aiua-13880	84	4	(	(	PUNCT
aiua-13880	84	5	44.9	44.9	NUM
aiua-13880	84	6	)	)	PUNCT
aiua-13880	84	7	29.5	29.5	NUM
aiua-13880	84	8	nr	nr	PROPN
aiua-13880	84	9	nr	nr	PROPN
aiua-13880	84	10	bc	bc	PROPN
aiua-13880	84	11	:	:	PUNCT
aiua-13880	84	12	43	43	NUM
aiua-13880	84	13	(	(	PUNCT
aiua-13880	84	14	55.1	55.1	NUM
aiua-13880	84	15	)	)	PUNCT
aiua-13880	84	16	14	14	NUM
aiua-13880	84	17	rijnders	rijnder	NOUN
aiua-13880	84	18	;	;	PUNCT
aiua-13880	84	19	2023	2023	NUM
aiua-13880	84	20	(	(	PUNCT
aiua-13880	84	21	52	52	NUM
aiua-13880	84	22	)	)	PUNCT
aiua-13880	84	23	netherlands	netherlands	PROPN
aiua-13880	84	24	retrospective	retrospective	ADJ
aiua-13880	84	25	study	study	NOUN
aiua-13880	84	26	71	71	NUM
aiua-13880	84	27	nr	nr	PRON
aiua-13880	84	28	51	51	NUM
aiua-13880	84	29	(	(	PUNCT
aiua-13880	84	30	71.8	71.8	NUM
aiua-13880	84	31	)	)	PUNCT
aiua-13880	84	32	nr	nr	PROPN
aiua-13880	84	33	nr	nr	PROPN
aiua-13880	84	34	utuc	utuc	NOUN
aiua-13880	84	35	:	:	PUNCT
aiua-13880	84	36	21	21	NUM
aiua-13880	84	37	(	(	PUNCT
aiua-13880	84	38	29.6	29.6	NUM
aiua-13880	84	39	)	)	PUNCT
aiua-13880	84	40	nr	nr	PROPN
aiua-13880	84	41	nr	nr	PROPN
aiua-13880	84	42	nr	nr	PROPN
aiua-13880	84	43	bc	bc	PROPN
aiua-13880	84	44	:	:	PUNCT
aiua-13880	84	45	44	44	NUM
aiua-13880	84	46	(	(	PUNCT
aiua-13880	84	47	61.9	61.9	NUM
aiua-13880	84	48	)	)	PUNCT
aiua-13880	84	49	both	both	PRON
aiua-13880	84	50	:	:	PUNCT
aiua-13880	84	51	6	6	NUM
aiua-13880	84	52	(	(	PUNCT
aiua-13880	84	53	8.5	8.5	NUM
aiua-13880	84	54	)	)	PUNCT
aiua-13880	84	55	15	15	NUM
aiua-13880	84	56	sato	sato	NOUN
aiua-13880	84	57	;	;	PUNCT
aiua-13880	84	58	202353	202353	NUM
aiua-13880	84	59	japan	japan	PROPN
aiua-13880	84	60	retrospective	retrospective	PROPN
aiua-13880	84	61	study	study	NOUN
aiua-13880	84	62	101	101	NUM
aiua-13880	84	63	71	71	NUM
aiua-13880	84	64	(	(	PUNCT
aiua-13880	84	65	33	33	NUM
aiua-13880	84	66	-	-	SYM
aiua-13880	84	67	85	85	NUM
aiua-13880	84	68	)	)	PUNCT
aiua-13880	84	69	71	71	NUM
aiua-13880	84	70	(	(	PUNCT
aiua-13880	84	71	70.3	70.3	NUM
aiua-13880	84	72	)	)	PUNCT
aiua-13880	84	73	19	19	NUM
aiua-13880	84	74	(	(	PUNCT
aiua-13880	84	75	3	3	NUM
aiua-13880	84	76	-	-	SYM
aiua-13880	84	77	54	54	NUM
aiua-13880	84	78	)	)	PUNCT
aiua-13880	84	79	17	17	NUM
aiua-13880	84	80	(	(	PUNCT
aiua-13880	84	81	16.8	16.8	NUM
aiua-13880	84	82	)	)	PUNCT
aiua-13880	84	83	utuc	utuc	NOUN
aiua-13880	84	84	:	:	PUNCT
aiua-13880	84	85	35	35	NUM
aiua-13880	84	86	(	(	PUNCT
aiua-13880	84	87	34.7	34.7	NUM
aiua-13880	84	88	)	)	PUNCT
aiua-13880	84	89	19.8	19.8	NUM
aiua-13880	84	90	nr	nr	PROPN
aiua-13880	84	91	13	13	NUM
aiua-13880	84	92	bc	bc	PROPN
aiua-13880	84	93	:	:	PUNCT
aiua-13880	84	94	66	66	NUM
aiua-13880	84	95	(	(	PUNCT
aiua-13880	84	96	65.3	65.3	NUM
aiua-13880	84	97	)	)	PUNCT
aiua-13880	84	98	16	16	NUM
aiua-13880	84	99	shimizu	shimizu	PROPN
aiua-13880	84	100	;	;	PUNCT
aiua-13880	84	101	202054	202054	NUM
aiua-13880	84	102	japan	japan	PROPN
aiua-13880	84	103	retrospective	retrospective	PROPN
aiua-13880	84	104	study	study	NOUN
aiua-13880	84	105	27	27	NUM
aiua-13880	84	106	71.48	71.48	NUM
aiua-13880	84	107	(	(	PUNCT
aiua-13880	84	108	7.51	7.51	NUM
aiua-13880	84	109	)	)	PUNCT
aiua-13880	84	110	23	23	NUM
aiua-13880	84	111	(	(	PUNCT
aiua-13880	84	112	85	85	NUM
aiua-13880	84	113	)	)	PUNCT
aiua-13880	84	114	7.88	7.88	NUM
aiua-13880	84	115	(	(	PUNCT
aiua-13880	84	116	4.76	4.76	NUM
aiua-13880	84	117	)	)	PUNCT
aiua-13880	84	118	12	12	NUM
aiua-13880	84	119	(	(	PUNCT
aiua-13880	84	120	44	44	NUM
aiua-13880	84	121	)	)	PUNCT
aiua-13880	84	122	utuc	utuc	NOUN
aiua-13880	84	123	:	:	PUNCT
aiua-13880	84	124	12	12	NUM
aiua-13880	84	125	(	(	PUNCT
aiua-13880	84	126	44	44	NUM
aiua-13880	84	127	)	)	PUNCT
aiua-13880	84	128	37.0	37.0	NUM
aiua-13880	84	129	4	4	NUM
aiua-13880	84	130	7	7	NUM
aiua-13880	84	131	bc	bc	PROPN
aiua-13880	84	132	:	:	PUNCT
aiua-13880	84	133	15	15	NUM
aiua-13880	84	134	(	(	PUNCT
aiua-13880	84	135	56	56	NUM
aiua-13880	84	136	)	)	PUNCT
aiua-13880	84	137	17	17	NUM
aiua-13880	84	138	tamura	tamura	NOUN
aiua-13880	84	139	;	;	PUNCT
aiua-13880	84	140	202055	202055	NUM
aiua-13880	84	141	japan	japan	PROPN
aiua-13880	84	142	retrospective	retrospective	ADJ
aiua-13880	84	143	study	study	NOUN
aiua-13880	84	144	41	41	NUM
aiua-13880	84	145	68.91	68.91	NUM
aiua-13880	84	146	±	±	NUM
aiua-13880	84	147	8.08	8.08	NUM
aiua-13880	84	148	29	29	NUM
aiua-13880	84	149	(	(	PUNCT
aiua-13880	84	150	70	70	NUM
aiua-13880	84	151	)	)	PUNCT
aiua-13880	84	152	6.2	6.2	NUM
aiua-13880	84	153	(	(	PUNCT
aiua-13880	84	154	4.4	4.4	NUM
aiua-13880	84	155	)	)	PUNCT
aiua-13880	84	156	6	6	NUM
aiua-13880	84	157	(	(	PUNCT
aiua-13880	84	158	15	15	NUM
aiua-13880	84	159	)	)	PUNCT
aiua-13880	84	160	utuc	utuc	NOUN
aiua-13880	84	161	:	:	PUNCT
aiua-13880	84	162	22	22	NUM
aiua-13880	84	163	(	(	PUNCT
aiua-13880	84	164	54	54	NUM
aiua-13880	84	165	)	)	PUNCT
aiua-13880	84	166	14.6	14.6	NUM
aiua-13880	84	167	2.5	2.5	NUM
aiua-13880	84	168	(	(	PUNCT
aiua-13880	84	169	1.4	1.4	NUM
aiua-13880	84	170	-	-	SYM
aiua-13880	84	171	6.2	6.2	NUM
aiua-13880	84	172	)	)	PUNCT
aiua-13880	84	173	11.9	11.9	NUM
aiua-13880	84	174	bc	bc	PROPN
aiua-13880	84	175	:	:	PUNCT
aiua-13880	84	176	19	19	NUM
aiua-13880	84	177	(	(	PUNCT
aiua-13880	84	178	46	46	NUM
aiua-13880	84	179	)	)	PUNCT
aiua-13880	84	180	18	18	NUM
aiua-13880	84	181	tanabe	tanabe	NOUN
aiua-13880	84	182	;	;	PUNCT
aiua-13880	84	183	202415	202415	NUM
aiua-13880	84	184	japan	japan	PROPN
aiua-13880	84	185	retrospective	retrospective	ADJ
aiua-13880	84	186	study	study	NOUN
aiua-13880	84	187	331	331	NUM
aiua-13880	84	188	73	73	NUM
aiua-13880	84	189	(	(	PUNCT
aiua-13880	84	190	68	68	NUM
aiua-13880	84	191	-	-	SYM
aiua-13880	84	192	78	78	NUM
aiua-13880	84	193	)	)	PUNCT
aiua-13880	84	194	241	241	NUM
aiua-13880	84	195	(	(	PUNCT
aiua-13880	84	196	73	73	NUM
aiua-13880	84	197	)	)	PUNCT
aiua-13880	84	198	7.3	7.3	NUM
aiua-13880	84	199	(	(	PUNCT
aiua-13880	84	200	3.4	3.4	NUM
aiua-13880	84	201	-	-	SYM
aiua-13880	84	202	16.5	16.5	NUM
aiua-13880	84	203	)	)	PUNCT
aiua-13880	84	204	57	57	NUM
aiua-13880	84	205	(	(	PUNCT
aiua-13880	84	206	17	17	NUM
aiua-13880	84	207	)	)	PUNCT
aiua-13880	84	208	utuc	utuc	NOUN
aiua-13880	84	209	:	:	PUNCT
aiua-13880	84	210	154	154	NUM
aiua-13880	84	211	(	(	PUNCT
aiua-13880	84	212	47	47	NUM
aiua-13880	84	213	)	)	PUNCT
aiua-13880	84	214	32.3	32.3	NUM
aiua-13880	84	215	3.3	3.3	NUM
aiua-13880	84	216	(	(	PUNCT
aiua-13880	84	217	2.6	2.6	NUM
aiua-13880	84	218	-	-	SYM
aiua-13880	84	219	4.3	4.3	NUM
aiua-13880	84	220	)	)	PUNCT
aiua-13880	84	221	9.6	9.6	NUM
aiua-13880	84	222	(	(	PUNCT
aiua-13880	84	223	7.3	7.3	NUM
aiua-13880	84	224	-	-	SYM
aiua-13880	84	225	13.2	13.2	NUM
aiua-13880	84	226	)	)	PUNCT
aiua-13880	84	227	bc	bc	PROPN
aiua-13880	84	228	:	:	PUNCT
aiua-13880	84	229	177	177	NUM
aiua-13880	84	230	(	(	PUNCT
aiua-13880	84	231	53	53	NUM
aiua-13880	84	232	)	)	PUNCT
aiua-13880	84	233	19	19	NUM
aiua-13880	84	234	tomioka	tomioka	NOUN
aiua-13880	84	235	-	-	PUNCT
aiua-13880	84	236	inagawa	inagawa	NOUN
aiua-13880	84	237	;	;	PUNCT
aiua-13880	84	238	202216	202216	NUM
aiua-13880	84	239	japan	japan	PROPN
aiua-13880	84	240	retrospective	retrospective	ADJ
aiua-13880	84	241	study	study	NOUN
aiua-13880	84	242	211	211	NUM
aiua-13880	84	243	72.1	72.1	NUM
aiua-13880	84	244	(	(	PUNCT
aiua-13880	84	245	1.63	1.63	NUM
aiua-13880	84	246	)	)	PUNCT
aiua-13880	84	247	121	121	NUM
aiua-13880	84	248	(	(	PUNCT
aiua-13880	84	249	57.3	57.3	NUM
aiua-13880	84	250	)	)	PUNCT
aiua-13880	84	251	10	10	NUM
aiua-13880	84	252	28	28	NUM
aiua-13880	84	253	(	(	PUNCT
aiua-13880	84	254	13.4	13.4	NUM
aiua-13880	84	255	)	)	PUNCT
aiua-13880	84	256	utuc	utuc	NOUN
aiua-13880	84	257	:	:	PUNCT
aiua-13880	84	258	49	49	NUM
aiua-13880	84	259	(	(	PUNCT
aiua-13880	84	260	23.2	23.2	NUM
aiua-13880	84	261	)	)	PUNCT
aiua-13880	84	262	25.1	25.1	NUM
aiua-13880	84	263	5	5	NUM
aiua-13880	84	264	(	(	PUNCT
aiua-13880	84	265	3	3	NUM
aiua-13880	84	266	-	-	SYM
aiua-13880	84	267	5	5	NUM
aiua-13880	84	268	)	)	PUNCT
aiua-13880	84	269	17	17	NUM
aiua-13880	84	270	(	(	PUNCT
aiua-13880	84	271	15	15	NUM
aiua-13880	84	272	-	-	SYM
aiua-13880	84	273	26	26	NUM
aiua-13880	84	274	)	)	PUNCT
aiua-13880	84	275	bc	bc	PROPN
aiua-13880	84	276	:	:	PUNCT
aiua-13880	84	277	89	89	NUM
aiua-13880	84	278	(	(	PUNCT
aiua-13880	84	279	42.2	42.2	NUM
aiua-13880	84	280	)	)	PUNCT
aiua-13880	84	281	archivio	archivio	NOUN
aiua-13880	84	282	italiano	italiano	NOUN
aiua-13880	84	283	di	di	X
aiua-13880	84	284	urologia	urologia	PROPN
aiua-13880	84	285	e	e	PROPN
aiua-13880	84	286	andrologia	andrologia	NOUN
aiua-13880	84	287	2025	2025	NUM
aiua-13880	84	288	;	;	PUNCT
aiua-13880	84	289	97(2):13880	97(2):13880	NUM
aiua-13880	84	290	5	5	NUM
aiua-13880	84	291	pembrolizumab	pembrolizumab	NOUN
aiua-13880	84	292	in	in	ADP
aiua-13880	84	293	advanced	advanced	ADJ
aiua-13880	84	294	/	/	SYM
aiua-13880	84	295	metastatic	metastatic	ADJ
aiua-13880	84	296	urothelial	urothelial	ADJ
aiua-13880	84	297	carcinoma	carcinoma	NOUN
aiua-13880	84	298	were	be	AUX
aiua-13880	84	299	included	include	VERB
aiua-13880	84	300	for	for	ADP
aiua-13880	84	301	meta	meta	ADJ
aiua-13880	84	302	-	-	PUNCT
aiua-13880	84	303	analysis	analysis	NOUN
aiua-13880	84	304	.	.	PUNCT
aiua-13880	85	1	pooled	pool	VERB
aiua-13880	85	2	pfs	pfs	PROPN
aiua-13880	85	3	and	and	CCONJ
aiua-13880	85	4	os	os	NOUN
aiua-13880	85	5	were	be	AUX
aiua-13880	85	6	measured	measure	VERB
aiua-13880	85	7	using	use	VERB
aiua-13880	85	8	hazard	hazard	NOUN
aiua-13880	85	9	ratios	ratio	NOUN
aiua-13880	85	10	(	(	PUNCT
aiua-13880	85	11	hrs	hrs	NOUN
aiua-13880	85	12	)	)	PUNCT
aiua-13880	85	13	.	.	PUNCT
aiua-13880	86	1	demographic	demographic	ADJ
aiua-13880	86	2	factors	factor	NOUN
aiua-13880	86	3	the	the	DET
aiua-13880	86	4	demographic	demographic	ADJ
aiua-13880	86	5	factors	factor	NOUN
aiua-13880	86	6	chosen	choose	VERB
aiua-13880	86	7	for	for	ADP
aiua-13880	86	8	this	this	DET
aiua-13880	86	9	analysis	analysis	NOUN
aiua-13880	86	10	are	be	AUX
aiua-13880	86	11	age	age	NOUN
aiua-13880	86	12	and	and	CCONJ
aiua-13880	86	13	gender	gender	NOUN
aiua-13880	86	14	.	.	PUNCT
aiua-13880	87	1	among	among	ADP
aiua-13880	87	2	these	these	DET
aiua-13880	87	3	factors	factor	NOUN
aiua-13880	87	4	,	,	PUNCT
aiua-13880	87	5	age	age	NOUN
aiua-13880	87	6	≥	≥	NUM
aiua-13880	87	7	70	70	NUM
aiua-13880	87	8	-	-	SYM
aiua-13880	87	9	75	75	NUM
aiua-13880	87	10	years	year	NOUN
aiua-13880	87	11	old	old	ADJ
aiua-13880	87	12	are	be	AUX
aiua-13880	87	13	found	find	VERB
aiua-13880	87	14	to	to	PART
aiua-13880	87	15	be	be	AUX
aiua-13880	87	16	associated	associate	VERB
aiua-13880	87	17	with	with	ADP
aiua-13880	87	18	worse	bad	ADJ
aiua-13880	87	19	progression	progression	NOUN
aiua-13880	87	20	free	free	ADJ
aiua-13880	87	21	survival	survival	NOUN
aiua-13880	87	22	(	(	PUNCT
aiua-13880	87	23	hr	hr	NOUN
aiua-13880	87	24	1.21	1.21	NUM
aiua-13880	87	25	,	,	PUNCT
aiua-13880	87	26	95%ci	95%ci	NUM
aiua-13880	87	27	1.04	1.04	NUM
aiua-13880	87	28	-	-	SYM
aiua-13880	87	29	1.41	1.41	NUM
aiua-13880	87	30	,	,	PUNCT
aiua-13880	87	31	n	n	NOUN
aiua-13880	87	32	=	=	SYM
aiua-13880	87	33	8	8	NUM
aiua-13880	87	34	studies	study	NOUN
aiua-13880	87	35	)	)	PUNCT
aiua-13880	87	36	.	.	PUNCT
aiua-13880	88	1	furthermore	furthermore	ADV
aiua-13880	88	2	,	,	PUNCT
aiua-13880	88	3	our	our	PRON
aiua-13880	88	4	investigation	investigation	NOUN
aiua-13880	88	5	revealed	reveal	VERB
aiua-13880	88	6	a	a	DET
aiua-13880	88	7	lack	lack	NOUN
aiua-13880	88	8	of	of	ADP
aiua-13880	88	9	significant	significant	ADJ
aiua-13880	88	10	heterogeneity	heterogeneity	NOUN
aiua-13880	88	11	regarding	regard	VERB
aiua-13880	88	12	these	these	DET
aiua-13880	88	13	outcomes	outcome	NOUN
aiua-13880	88	14	.	.	PUNCT
aiua-13880	89	1	clinical	clinical	ADJ
aiua-13880	89	2	factors	factor	NOUN
aiua-13880	89	3	ten	ten	NUM
aiua-13880	89	4	clinical	clinical	ADJ
aiua-13880	89	5	factors	factor	NOUN
aiua-13880	89	6	are	be	AUX
aiua-13880	89	7	included	include	VERB
aiua-13880	89	8	in	in	ADP
aiua-13880	89	9	this	this	DET
aiua-13880	89	10	analysis	analysis	NOUN
aiua-13880	89	11	,	,	PUNCT
aiua-13880	89	12	consisting	consist	VERB
aiua-13880	89	13	of	of	ADP
aiua-13880	89	14	metastasis	metastasis	NOUN
aiua-13880	89	15	sites	site	NOUN
aiua-13880	89	16	(	(	PUNCT
aiua-13880	89	17	bone	bone	NOUN
aiua-13880	89	18	,	,	PUNCT
aiua-13880	89	19	liver	liver	NOUN
aiua-13880	89	20	,	,	PUNCT
aiua-13880	89	21	lung	lung	NOUN
aiua-13880	89	22	,	,	PUNCT
aiua-13880	89	23	and	and	CCONJ
aiua-13880	89	24	lymph	lymph	NOUN
aiua-13880	89	25	node	node	PROPN
aiua-13880	89	26	)	)	PUNCT
aiua-13880	89	27	,	,	PUNCT
aiua-13880	89	28	ecog	ecog	VERB
aiua-13880	89	29	-	-	PUNCT
aiua-13880	89	30	ps	ps	NOUN
aiua-13880	89	31	≥	≥	NOUN
aiua-13880	89	32	2	2	NUM
aiua-13880	89	33	,	,	PUNCT
aiua-13880	89	34	utuc	utuc	ADJ
aiua-13880	89	35	primary	primary	NOUN
aiua-13880	89	36	site	site	NOUN
aiua-13880	89	37	,	,	PUNCT
aiua-13880	89	38	prior	prior	ADJ
aiua-13880	89	39	surgical	surgical	ADJ
aiua-13880	89	40	removal	removal	NOUN
aiua-13880	89	41	for	for	ADP
aiua-13880	89	42	primary	primary	ADJ
aiua-13880	89	43	site	site	NOUN
aiua-13880	89	44	,	,	PUNCT
aiua-13880	89	45	pure	pure	ADJ
aiua-13880	89	46	uc	uc	ADJ
aiua-13880	89	47	pathological	pathological	ADJ
aiua-13880	89	48	type	type	NOUN
aiua-13880	89	49	,	,	PUNCT
aiua-13880	89	50	smoking	smoking	NOUN
aiua-13880	89	51	,	,	PUNCT
aiua-13880	89	52	<	<	X
aiua-13880	89	53	90	90	NUM
aiua-13880	89	54	days	day	NOUN
aiua-13880	89	55	from	from	ADP
aiua-13880	89	56	previous	previous	ADJ
aiua-13880	89	57	chemotherapy	chemotherapy	NOUN
aiua-13880	89	58	(	(	PUNCT
aiua-13880	89	59	table	table	NOUN
aiua-13880	89	60	2	2	NUM
aiua-13880	89	61	)	)	PUNCT
aiua-13880	89	62	.	.	PUNCT
aiua-13880	90	1	for	for	ADP
aiua-13880	90	2	pfs	pfs	PROPN
aiua-13880	90	3	,	,	PUNCT
aiua-13880	90	4	we	we	PRON
aiua-13880	90	5	detected	detect	VERB
aiua-13880	90	6	one	one	NUM
aiua-13880	90	7	factor	factor	NOUN
aiua-13880	90	8	with	with	ADP
aiua-13880	90	9	moderate	moderate	ADJ
aiua-13880	90	10	amount	amount	NOUN
aiua-13880	90	11	of	of	ADP
aiua-13880	90	12	heterogeneity	heterogeneity	NOUN
aiua-13880	90	13	,	,	PUNCT
aiua-13880	90	14	which	which	PRON
aiua-13880	90	15	is	be	AUX
aiua-13880	90	16	utuc	utuc	ADJ
aiua-13880	90	17	primary	primary	ADJ
aiua-13880	90	18	site	site	NOUN
aiua-13880	90	19	(	(	PUNCT
aiua-13880	90	20	i2	i2	PROPN
aiua-13880	90	21	=	=	PUNCT
aiua-13880	90	22	58	58	NUM
aiua-13880	90	23	%	%	NOUN
aiua-13880	90	24	)	)	PUNCT
aiua-13880	90	25	.	.	PUNCT
aiua-13880	91	1	for	for	ADP
aiua-13880	91	2	os	os	NOUN
aiua-13880	91	3	,	,	PUNCT
aiua-13880	91	4	we	we	PRON
aiua-13880	91	5	detected	detect	VERB
aiua-13880	91	6	three	three	NUM
aiua-13880	91	7	factors	factor	NOUN
aiua-13880	91	8	with	with	ADP
aiua-13880	91	9	moderate	moderate	ADJ
aiua-13880	91	10	to	to	PART
aiua-13880	91	11	high	high	ADJ
aiua-13880	91	12	amounts	amount	NOUN
aiua-13880	91	13	of	of	ADP
aiua-13880	91	14	heterogeneity	heterogeneity	NOUN
aiua-13880	91	15	,	,	PUNCT
aiua-13880	91	16	including	include	VERB
aiua-13880	91	17	presence	presence	NOUN
aiua-13880	91	18	of	of	ADP
aiua-13880	91	19	bone	bone	NOUN
aiua-13880	91	20	(	(	PUNCT
aiua-13880	91	21	i2	i2	NOUN
aiua-13880	91	22	=	=	PUNCT
aiua-13880	91	23	64	64	NUM
aiua-13880	91	24	%	%	NOUN
aiua-13880	91	25	)	)	PUNCT
aiua-13880	91	26	or	or	CCONJ
aiua-13880	91	27	lymph	lymph	NOUN
aiua-13880	91	28	node	node	NOUN
aiua-13880	91	29	metastasis	metastasis	NOUN
aiua-13880	91	30	(	(	PUNCT
aiua-13880	91	31	i2	i2	NOUN
aiua-13880	91	32	=	=	PUNCT
aiua-13880	91	33	73	73	NUM
aiua-13880	91	34	%	%	NOUN
aiua-13880	91	35	)	)	PUNCT
aiua-13880	91	36	,	,	PUNCT
aiua-13880	91	37	and	and	CCONJ
aiua-13880	91	38	ecog	ecog	VERB
aiua-13880	91	39	-	-	PUNCT
aiua-13880	91	40	ps	ps	NOUN
aiua-13880	91	41	≥	≥	NOUN
aiua-13880	91	42	2	2	NUM
aiua-13880	91	43	(	(	PUNCT
aiua-13880	91	44	i2	i2	NOUN
aiua-13880	91	45	=	=	PUNCT
aiua-13880	91	46	86	86	NUM
aiua-13880	91	47	%	%	NOUN
aiua-13880	91	48	)	)	PUNCT
aiua-13880	91	49	.	.	PUNCT
aiua-13880	92	1	all	all	DET
aiua-13880	92	2	heterogeneity	heterogeneity	NOUN
aiua-13880	92	3	tests	test	NOUN
aiua-13880	92	4	are	be	AUX
aiua-13880	92	5	performed	perform	VERB
aiua-13880	92	6	using	use	VERB
aiua-13880	92	7	rem	rem	PROPN
aiua-13880	92	8	.	.	PROPN
aiua-13880	92	9	based	base	VERB
aiua-13880	92	10	on	on	ADP
aiua-13880	92	11	the	the	DET
aiua-13880	92	12	hrs	hrs	NOUN
aiua-13880	92	13	,	,	PUNCT
aiua-13880	92	14	there	there	PRON
aiua-13880	92	15	are	be	VERB
aiua-13880	92	16	six	six	NUM
aiua-13880	92	17	clinical	clinical	ADJ
aiua-13880	92	18	factors	factor	NOUN
aiua-13880	92	19	that	that	PRON
aiua-13880	92	20	can	can	AUX
aiua-13880	92	21	be	be	AUX
aiua-13880	92	22	considered	consider	VERB
aiua-13880	92	23	as	as	ADP
aiua-13880	92	24	prognostic	prognostic	ADJ
aiua-13880	92	25	factors	factor	NOUN
aiua-13880	92	26	.	.	PUNCT
aiua-13880	93	1	for	for	ADP
aiua-13880	93	2	pfs	pfs	PROPN
aiua-13880	93	3	,	,	PUNCT
aiua-13880	93	4	five	five	NUM
aiua-13880	93	5	factors	factor	NOUN
aiua-13880	93	6	are	be	AUX
aiua-13880	93	7	linked	link	VERB
aiua-13880	93	8	with	with	ADP
aiua-13880	93	9	worse	bad	ADJ
aiua-13880	93	10	survival	survival	NOUN
aiua-13880	93	11	are	be	AUX
aiua-13880	93	12	as	as	SCONJ
aiua-13880	93	13	follows	follow	VERB
aiua-13880	93	14	:	:	PUNCT
aiua-13880	93	15	(	(	PUNCT
aiua-13880	93	16	1	1	X
aiua-13880	93	17	)	)	PUNCT
aiua-13880	93	18	ecog	ecog	NOUN
aiua-13880	93	19	-	-	PUNCT
aiua-13880	93	20	ps	ps	NOUN
aiua-13880	93	21	≥	≥	NOUN
aiua-13880	93	22	2	2	NUM
aiua-13880	93	23	(	(	PUNCT
aiua-13880	93	24	hr	hr	NOUN
aiua-13880	93	25	2.30	2.30	NUM
aiua-13880	93	26	,	,	PUNCT
aiua-13880	93	27	95%ci	95%ci	NUM
aiua-13880	93	28	1.91	1.91	NUM
aiua-13880	93	29	-	-	SYM
aiua-13880	93	30	2.76	2.76	NUM
aiua-13880	93	31	)	)	PUNCT
aiua-13880	93	32	;	;	PUNCT
aiua-13880	93	33	(	(	PUNCT
aiua-13880	93	34	2	2	X
aiua-13880	93	35	)	)	PUNCT
aiua-13880	93	36	pure	pure	ADJ
aiua-13880	93	37	uc	uc	ADJ
aiua-13880	93	38	pathological	pathological	ADJ
aiua-13880	93	39	type	type	NOUN
aiua-13880	93	40	(	(	PUNCT
aiua-13880	93	41	hr	hr	NOUN
aiua-13880	93	42	2.33	2.33	NUM
aiua-13880	93	43	,	,	PUNCT
aiua-13880	93	44	95%ci	95%ci	NUM
aiua-13880	93	45	1.20	1.20	NUM
aiua-13880	93	46	-	-	SYM
aiua-13880	93	47	4.54	4.54	NUM
aiua-13880	93	48	)	)	PUNCT
aiua-13880	93	49	;	;	PUNCT
aiua-13880	93	50	(	(	PUNCT
aiua-13880	93	51	3	3	X
aiua-13880	93	52	)	)	PUNCT
aiua-13880	93	53	presence	presence	NOUN
aiua-13880	93	54	of	of	ADP
aiua-13880	93	55	liver	liver	NOUN
aiua-13880	93	56	metastasis	metastasis	NOUN
aiua-13880	93	57	(	(	PUNCT
aiua-13880	93	58	hr	hr	NOUN
aiua-13880	93	59	1.70	1.70	NUM
aiua-13880	93	60	,	,	PUNCT
aiua-13880	93	61	95%ci	95%ci	NUM
aiua-13880	93	62	1.35	1.35	NUM
aiua-13880	93	63	-	-	SYM
aiua-13880	93	64	2.14	2.14	NUM
aiua-13880	93	65	)	)	PUNCT
aiua-13880	93	66	;	;	PUNCT
aiua-13880	93	67	(	(	PUNCT
aiua-13880	93	68	4	4	X
aiua-13880	93	69	)	)	PUNCT
aiua-13880	93	70	lung	lung	NOUN
aiua-13880	93	71	metastasis	metastasis	NOUN
aiua-13880	93	72	(	(	PUNCT
aiua-13880	93	73	hr	hr	NOUN
aiua-13880	93	74	1.34	1.34	NUM
aiua-13880	93	75	,	,	PUNCT
aiua-13880	93	76	95%ci	95%ci	NUM
aiua-13880	93	77	1.10	1.10	NUM
aiua-13880	93	78	-	-	SYM
aiua-13880	93	79	1.64	1.64	NUM
aiua-13880	93	80	)	)	PUNCT
aiua-13880	93	81	;	;	PUNCT
aiua-13880	93	82	and	and	CCONJ
aiua-13880	93	83	(	(	PUNCT
aiua-13880	93	84	5	5	X
aiua-13880	93	85	)	)	PUNCT
aiua-13880	93	86	bone	bone	NOUN
aiua-13880	93	87	metastasis	metastasis	NOUN
aiua-13880	93	88	(	(	PUNCT
aiua-13880	93	89	hr	hr	NOUN
aiua-13880	93	90	1.29	1.29	NUM
aiua-13880	93	91	,	,	PUNCT
aiua-13880	93	92	95%ci	95%ci	NUM
aiua-13880	93	93	1.02	1.02	NUM
aiua-13880	93	94	-	-	SYM
aiua-13880	93	95	1.64	1.64	NUM
aiua-13880	93	96	)	)	PUNCT
aiua-13880	93	97	.	.	PUNCT
aiua-13880	94	1	on	on	ADP
aiua-13880	94	2	the	the	DET
aiua-13880	94	3	contrary	contrary	NOUN
aiua-13880	94	4	,	,	PUNCT
aiua-13880	94	5	surgical	surgical	ADJ
aiua-13880	94	6	removal	removal	NOUN
aiua-13880	94	7	of	of	ADP
aiua-13880	94	8	primary	primary	ADJ
aiua-13880	94	9	site	site	NOUN
aiua-13880	94	10	(	(	PUNCT
aiua-13880	94	11	hr	hr	PROPN
aiua-13880	94	12	0.80	0.80	NUM
aiua-13880	94	13	,	,	PUNCT
aiua-13880	94	14	95%ci	95%ci	NUM
aiua-13880	94	15	0.65	0.65	NUM
aiua-13880	94	16	-	-	PUNCT
aiua-13880	94	17	0.99	0.99	NUM
aiua-13880	94	18	)	)	PUNCT
aiua-13880	94	19	is	be	AUX
aiua-13880	94	20	associated	associate	VERB
aiua-13880	94	21	with	with	ADP
aiua-13880	94	22	better	well	ADJ
aiua-13880	94	23	survival	survival	NOUN
aiua-13880	94	24	.	.	PUNCT
aiua-13880	95	1	sensitivity	sensitivity	NOUN
aiua-13880	95	2	analysis	analysis	NOUN
aiua-13880	95	3	of	of	ADP
aiua-13880	95	4	pfs	pfs	PROPN
aiua-13880	95	5	factors	factor	NOUN
aiua-13880	95	6	suggest	suggest	VERB
aiua-13880	95	7	that	that	SCONJ
aiua-13880	95	8	the	the	DET
aiua-13880	95	9	provided	provide	VERB
aiua-13880	95	10	overall	overall	ADJ
aiua-13880	95	11	effects	effect	NOUN
aiua-13880	95	12	are	be	AUX
aiua-13880	95	13	robust	robust	ADJ
aiua-13880	95	14	and	and	CCONJ
aiua-13880	95	15	not	not	PART
aiua-13880	95	16	affected	affect	VERB
aiua-13880	95	17	by	by	ADP
aiua-13880	95	18	any	any	DET
aiua-13880	95	19	single	single	ADJ
aiua-13880	95	20	study	study	NOUN
aiua-13880	95	21	.	.	PUNCT
aiua-13880	96	1	for	for	ADP
aiua-13880	96	2	os	os	NOUN
aiua-13880	96	3	,	,	PUNCT
aiua-13880	96	4	five	five	NUM
aiua-13880	96	5	factors	factor	NOUN
aiua-13880	96	6	are	be	AUX
aiua-13880	96	7	also	also	ADV
aiua-13880	96	8	associated	associate	VERB
aiua-13880	96	9	with	with	ADP
aiua-13880	96	10	worse	bad	ADJ
aiua-13880	96	11	survival	survival	NOUN
aiua-13880	96	12	:	:	PUNCT
aiua-13880	96	13	(	(	PUNCT
aiua-13880	96	14	1	1	X
aiua-13880	96	15	)	)	PUNCT
aiua-13880	96	16	presence	presence	NOUN
aiua-13880	96	17	of	of	ADP
aiua-13880	96	18	bone	bone	NOUN
aiua-13880	96	19	metastasis	metastasis	NOUN
aiua-13880	96	20	(	(	PUNCT
aiua-13880	96	21	hr	hr	NOUN
aiua-13880	96	22	1.94	1.94	NUM
aiua-13880	96	23	,	,	PUNCT
aiua-13880	96	24	95%ci	95%ci	NUM
aiua-13880	96	25	1.253.0	1.253.0	NUM
aiua-13880	96	26	)	)	PUNCT
aiua-13880	96	27	;	;	PUNCT
aiua-13880	96	28	(	(	PUNCT
aiua-13880	96	29	2	2	X
aiua-13880	96	30	)	)	PUNCT
aiua-13880	96	31	liver	liver	NOUN
aiua-13880	96	32	metastasis	metastasis	NOUN
aiua-13880	96	33	(	(	PUNCT
aiua-13880	96	34	hr	hr	NOUN
aiua-13880	96	35	2.44	2.44	NUM
aiua-13880	96	36	,	,	PUNCT
aiua-13880	96	37	95%ci	95%ci	NUM
aiua-13880	96	38	2.16	2.16	NUM
aiua-13880	96	39	-	-	SYM
aiua-13880	96	40	2.76	2.76	NUM
aiua-13880	96	41	)	)	PUNCT
aiua-13880	96	42	;	;	PUNCT
aiua-13880	96	43	(	(	PUNCT
aiua-13880	96	44	3	3	X
aiua-13880	96	45	)	)	PUNCT
aiua-13880	96	46	lung	lung	NOUN
aiua-13880	96	47	metastasis	metastasis	NOUN
aiua-13880	96	48	(	(	PUNCT
aiua-13880	96	49	hr	hr	NOUN
aiua-13880	96	50	1.35	1.35	NUM
aiua-13880	96	51	,	,	PUNCT
aiua-13880	96	52	95%ci	95%ci	NUM
aiua-13880	96	53	1.18	1.18	NUM
aiua-13880	96	54	-	-	SYM
aiua-13880	96	55	1.56	1.56	NUM
aiua-13880	96	56	)	)	PUNCT
aiua-13880	96	57	;	;	PUNCT
aiua-13880	96	58	(	(	PUNCT
aiua-13880	96	59	4	4	X
aiua-13880	96	60	)	)	PUNCT
aiua-13880	96	61	ecogps	ecogps	X
aiua-13880	96	62	≥	≥	NOUN
aiua-13880	96	63	2	2	NUM
aiua-13880	96	64	(	(	PUNCT
aiua-13880	96	65	hr	hr	NOUN
aiua-13880	96	66	3.38	3.38	NUM
aiua-13880	96	67	,	,	PUNCT
aiua-13880	96	68	95%ci	95%ci	NUM
aiua-13880	96	69	2.17	2.17	NUM
aiua-13880	96	70	-	-	SYM
aiua-13880	96	71	5.28	5.28	NUM
aiua-13880	96	72	)	)	PUNCT
aiua-13880	96	73	;	;	PUNCT
aiua-13880	96	74	(	(	PUNCT
aiua-13880	96	75	5	5	X
aiua-13880	96	76	)	)	PUNCT
aiua-13880	96	77	time	time	NOUN
aiua-13880	96	78	from	from	ADP
aiua-13880	96	79	previous	previous	ADJ
aiua-13880	96	80	chemotherapy	chemotherapy	NOUN
aiua-13880	96	81	<	<	X
aiua-13880	96	82	90	90	NUM
aiua-13880	96	83	days	day	NOUN
aiua-13880	96	84	(	(	PUNCT
aiua-13880	96	85	hr	hr	NOUN
aiua-13880	96	86	1.42	1.42	NUM
aiua-13880	96	87	,	,	PUNCT
aiua-13880	96	88	95%ci	95%ci	NUM
aiua-13880	96	89	1.221.64	1.221.64	NUM
aiua-13880	96	90	)	)	PUNCT
aiua-13880	96	91	.	.	PUNCT
aiua-13880	97	1	a	a	DET
aiua-13880	97	2	leave	leave	VERB
aiua-13880	97	3	-	-	PUNCT
aiua-13880	97	4	one	one	NUM
aiua-13880	97	5	-	-	PUNCT
aiua-13880	97	6	out	out	NOUN
aiua-13880	97	7	sensitivity	sensitivity	NOUN
aiua-13880	97	8	analysis	analysis	NOUN
aiua-13880	97	9	was	be	AUX
aiua-13880	97	10	conducted	conduct	VERB
aiua-13880	97	11	for	for	ADP
aiua-13880	97	12	all	all	DET
aiua-13880	97	13	prognostic	prognostic	ADJ
aiua-13880	97	14	factors	factor	NOUN
aiua-13880	97	15	showing	show	VERB
aiua-13880	97	16	significant	significant	ADJ
aiua-13880	97	17	heterogeneity	heterogeneity	NOUN
aiua-13880	97	18	.	.	PUNCT
aiua-13880	98	1	the	the	DET
aiua-13880	98	2	analysis	analysis	NOUN
aiua-13880	98	3	revealed	reveal	VERB
aiua-13880	98	4	that	that	SCONJ
aiua-13880	98	5	the	the	DET
aiua-13880	98	6	presence	presence	NOUN
aiua-13880	98	7	of	of	ADP
aiua-13880	98	8	bone	bone	NOUN
aiua-13880	98	9	metastasis	metastasis	NOUN
aiua-13880	98	10	,	,	PUNCT
aiua-13880	98	11	upon	upon	SCONJ
aiua-13880	98	12	removal	removal	NOUN
aiua-13880	98	13	of	of	ADP
aiua-13880	98	14	one	one	NUM
aiua-13880	98	15	study	study	NOUN
aiua-13880	98	16	by	by	ADP
aiua-13880	98	17	tanabe	tanabe	PROPN
aiua-13880	98	18	et	et	PROPN
aiua-13880	98	19	al	al	PROPN
aiua-13880	98	20	.	.	PROPN
aiua-13880	99	1	(	(	PUNCT
aiua-13880	99	2	15	15	NUM
aiua-13880	99	3	)	)	PUNCT
aiua-13880	99	4	resulted	result	VERB
aiua-13880	99	5	in	in	ADP
aiua-13880	99	6	a	a	DET
aiua-13880	99	7	shift	shift	NOUN
aiua-13880	99	8	of	of	ADP
aiua-13880	99	9	the	the	DET
aiua-13880	99	10	pooled	pooled	ADJ
aiua-13880	99	11	effect	effect	NOUN
aiua-13880	99	12	from	from	ADP
aiua-13880	99	13	significant	significant	ADJ
aiua-13880	99	14	to	to	ADP
aiua-13880	99	15	nonsignificant	nonsignificant	ADJ
aiua-13880	99	16	,	,	PUNCT
aiua-13880	99	17	and	and	CCONJ
aiua-13880	99	18	significant	significant	ADJ
aiua-13880	99	19	reduction	reduction	NOUN
aiua-13880	99	20	of	of	ADP
aiua-13880	99	21	heterogeneity	heterogeneity	NOUN
aiua-13880	99	22	.	.	PUNCT
aiua-13880	100	1	the	the	DET
aiua-13880	100	2	same	same	ADJ
aiua-13880	100	3	result	result	NOUN
aiua-13880	100	4	is	be	AUX
aiua-13880	100	5	found	find	VERB
aiua-13880	100	6	for	for	ADP
aiua-13880	100	7	c	c	NOUN
aiua-13880	100	8	-	-	PUNCT
aiua-13880	100	9	reactive	reactive	ADJ
aiua-13880	100	10	protein	protein	NOUN
aiua-13880	100	11	level	level	NOUN
aiua-13880	100	12	.	.	PUNCT
aiua-13880	101	1	in	in	ADP
aiua-13880	101	2	contrast	contrast	NOUN
aiua-13880	101	3	,	,	PUNCT
aiua-13880	101	4	the	the	DET
aiua-13880	101	5	effects	effect	NOUN
aiua-13880	101	6	of	of	ADP
aiua-13880	101	7	all	all	DET
aiua-13880	101	8	other	other	ADJ
aiua-13880	101	9	clinical	clinical	ADJ
aiua-13880	101	10	factors	factor	NOUN
aiua-13880	101	11	remained	remain	VERB
aiua-13880	101	12	robust	robust	ADJ
aiua-13880	101	13	(	(	PUNCT
aiua-13880	101	14	supplementary	supplementary	ADJ
aiua-13880	101	15	figures	figure	NOUN
aiua-13880	101	16	s2b	s2b	PROPN
aiua-13880	101	17	,	,	PUNCT
aiua-13880	101	18	s2d	s2d	PROPN
aiua-13880	101	19	)	)	PUNCT
aiua-13880	101	20	.	.	PUNCT
aiua-13880	102	1	hematological	hematological	ADJ
aiua-13880	102	2	factors	factor	NOUN
aiua-13880	102	3	we	we	PRON
aiua-13880	102	4	identified	identify	VERB
aiua-13880	102	5	four	four	NUM
aiua-13880	102	6	potential	potential	ADJ
aiua-13880	102	7	hematological	hematological	ADJ
aiua-13880	102	8	markers	marker	NOUN
aiua-13880	102	9	as	as	ADP
aiua-13880	102	10	prognostic	prognostic	ADJ
aiua-13880	102	11	factors	factor	NOUN
aiua-13880	102	12	:	:	PUNCT
aiua-13880	102	13	albumin	albumin	PROPN
aiua-13880	102	14	,	,	PUNCT
aiua-13880	102	15	crp	crp	PROPN
aiua-13880	102	16	,	,	PUNCT
aiua-13880	102	17	hemoglobin	hemoglobin	NOUN
aiua-13880	102	18	,	,	PUNCT
aiua-13880	102	19	and	and	CCONJ
aiua-13880	102	20	nlr	nlr	PROPN
aiua-13880	102	21	.	.	PUNCT
aiua-13880	103	1	most	most	ADJ
aiua-13880	103	2	outcome	outcome	NOUN
aiua-13880	103	3	analyses	analysis	NOUN
aiua-13880	103	4	demonstrated	demonstrate	VERB
aiua-13880	103	5	nonsignificant	nonsignificant	ADJ
aiua-13880	103	6	heterogeneity	heterogeneity	NOUN
aiua-13880	103	7	,	,	PUNCT
aiua-13880	103	8	except	except	SCONJ
aiua-13880	103	9	for	for	ADP
aiua-13880	103	10	crp	crp	PROPN
aiua-13880	103	11	’s	’s	PART
aiua-13880	103	12	association	association	NOUN
aiua-13880	103	13	with	with	ADP
aiua-13880	103	14	os	os	NOUN
aiua-13880	103	15	,	,	PUNCT
aiua-13880	103	16	which	which	PRON
aiua-13880	103	17	exhibited	exhibit	VERB
aiua-13880	103	18	high	high	ADJ
aiua-13880	103	19	heterogeneity	heterogeneity	NOUN
aiua-13880	103	20	(	(	PUNCT
aiua-13880	103	21	i²	i²	NOUN
aiua-13880	103	22	=	=	PUNCT
aiua-13880	103	23	94	94	NUM
aiua-13880	103	24	%	%	NOUN
aiua-13880	103	25	)	)	PUNCT
aiua-13880	103	26	.	.	PUNCT
aiua-13880	104	1	for	for	ADP
aiua-13880	104	2	pfs	pfs	PROPN
aiua-13880	104	3	,	,	PUNCT
aiua-13880	104	4	three	three	NUM
aiua-13880	104	5	markers	marker	NOUN
aiua-13880	104	6	showed	show	VERB
aiua-13880	104	7	a	a	DET
aiua-13880	104	8	significant	significant	ADJ
aiua-13880	104	9	effect	effect	NOUN
aiua-13880	104	10	:	:	PUNCT
aiua-13880	104	11	elevated	elevated	ADJ
aiua-13880	104	12	crp	crp	NOUN
aiua-13880	104	13	(	(	PUNCT
aiua-13880	104	14	hr	hr	NOUN
aiua-13880	104	15	1.94	1.94	NUM
aiua-13880	104	16	,	,	PUNCT
aiua-13880	104	17	95%ci	95%ci	NUM
aiua-13880	104	18	1.54	1.54	NUM
aiua-13880	104	19	-	-	SYM
aiua-13880	104	20	2.45	2.45	NUM
aiua-13880	104	21	)	)	PUNCT
aiua-13880	104	22	,	,	PUNCT
aiua-13880	104	23	low	low	ADJ
aiua-13880	104	24	hemoglobin	hemoglobin	NOUN
aiua-13880	104	25	(	(	PUNCT
aiua-13880	104	26	hr	hr	NOUN
aiua-13880	104	27	1.80	1.80	NUM
aiua-13880	104	28	,	,	PUNCT
aiua-13880	104	29	95%ci	95%ci	NUM
aiua-13880	104	30	1.51	1.51	NUM
aiua-13880	104	31	-	-	SYM
aiua-13880	104	32	2.14	2.14	NUM
aiua-13880	104	33	)	)	PUNCT
aiua-13880	104	34	,	,	PUNCT
aiua-13880	104	35	and	and	CCONJ
aiua-13880	104	36	high	high	ADJ
aiua-13880	104	37	nlr	nlr	PROPN
aiua-13880	104	38	(	(	PUNCT
aiua-13880	104	39	hr	hr	PROPN
aiua-13880	104	40	1.65	1.65	NUM
aiua-13880	104	41	,	,	PUNCT
aiua-13880	104	42	95%ci	95%ci	NUM
aiua-13880	104	43	1.441.89	1.441.89	NUM
aiua-13880	104	44	)	)	PUNCT
aiua-13880	104	45	.	.	PUNCT
aiua-13880	105	1	for	for	ADP
aiua-13880	105	2	os	os	NOUN
aiua-13880	105	3	,	,	PUNCT
aiua-13880	105	4	we	we	PRON
aiua-13880	105	5	found	find	VERB
aiua-13880	105	6	four	four	NUM
aiua-13880	105	7	markers	marker	NOUN
aiua-13880	105	8	associated	associate	VERB
aiua-13880	105	9	with	with	ADP
aiua-13880	105	10	poorer	poor	ADJ
aiua-13880	105	11	survival	survival	NOUN
aiua-13880	105	12	:	:	PUNCT
aiua-13880	105	13	hypoalbuminemia	hypoalbuminemia	PROPN
aiua-13880	105	14	(	(	PUNCT
aiua-13880	105	15	hr	hr	NOUN
aiua-13880	105	16	3.13	3.13	NUM
aiua-13880	105	17	,	,	PUNCT
aiua-13880	105	18	95%ci	95%ci	NUM
aiua-13880	105	19	2.52	2.52	NUM
aiua-13880	105	20	-	-	SYM
aiua-13880	105	21	3.88	3.88	NUM
aiua-13880	105	22	)	)	PUNCT
aiua-13880	105	23	,	,	PUNCT
aiua-13880	105	24	high	high	ADJ
aiua-13880	105	25	crp	crp	PROPN
aiua-13880	105	26	(	(	PUNCT
aiua-13880	105	27	hr	hr	NOUN
aiua-13880	105	28	2.18	2.18	NUM
aiua-13880	105	29	,	,	PUNCT
aiua-13880	105	30	95%ci	95%ci	NUM
aiua-13880	105	31	1.07	1.07	NUM
aiua-13880	105	32	-	-	SYM
aiua-13880	105	33	4.42	4.42	NUM
aiua-13880	105	34	)	)	PUNCT
aiua-13880	105	35	,	,	PUNCT
aiua-13880	105	36	low	low	ADJ
aiua-13880	105	37	hemoglobin	hemoglobin	NOUN
aiua-13880	105	38	(	(	PUNCT
aiua-13880	105	39	hr	hr	NOUN
aiua-13880	105	40	2.08	2.08	NUM
aiua-13880	105	41	,	,	PUNCT
aiua-13880	105	42	95%ci	95%ci	NUM
aiua-13880	105	43	1.85	1.85	NUM
aiua-13880	105	44	-	-	PUNCT
aiua-13880	105	45	2.35	2.35	NUM
aiua-13880	105	46	)	)	PUNCT
aiua-13880	105	47	,	,	PUNCT
aiua-13880	105	48	and	and	CCONJ
aiua-13880	105	49	high	high	ADJ
aiua-13880	105	50	nlr	nlr	PROPN
aiua-13880	105	51	(	(	PUNCT
aiua-13880	105	52	hr	hr	PROPN
aiua-13880	105	53	1.93	1.93	NUM
aiua-13880	105	54	,	,	PUNCT
aiua-13880	105	55	95%ci	95%ci	NUM
aiua-13880	105	56	1.71	1.71	NUM
aiua-13880	105	57	-	-	SYM
aiua-13880	105	58	2.18	2.18	NUM
aiua-13880	105	59	)	)	PUNCT
aiua-13880	105	60	.	.	PUNCT
aiua-13880	106	1	sensitivity	sensitivity	NOUN
aiua-13880	106	2	analysis	analysis	NOUN
aiua-13880	106	3	was	be	AUX
aiua-13880	106	4	performed	perform	VERB
aiua-13880	106	5	for	for	ADP
aiua-13880	106	6	all	all	DET
aiua-13880	106	7	outcomes	outcome	NOUN
aiua-13880	106	8	.	.	PUNCT
aiua-13880	107	1	for	for	ADP
aiua-13880	107	2	crp	crp	PROPN
aiua-13880	107	3	,	,	PUNCT
aiua-13880	107	4	removing	remove	VERB
aiua-13880	107	5	one	one	NUM
aiua-13880	107	6	study	study	NOUN
aiua-13880	107	7	by	by	ADP
aiua-13880	107	8	tomioka	tomioka	NOUN
aiua-13880	107	9	-	-	PUNCT
aiua-13880	107	10	inagawa	inagawa	NOUN
aiua-13880	107	11	significantly	significantly	ADV
aiua-13880	107	12	reduced	reduce	VERB
aiua-13880	107	13	heterogeneity	heterogeneity	NOUN
aiua-13880	107	14	(	(	PUNCT
aiua-13880	107	15	16	16	NUM
aiua-13880	107	16	)	)	PUNCT
aiua-13880	107	17	,	,	PUNCT
aiua-13880	107	18	while	while	SCONJ
aiua-13880	107	19	excluding	exclude	VERB
aiua-13880	107	20	a	a	DET
aiua-13880	107	21	study	study	NOUN
aiua-13880	107	22	by	by	ADP
aiua-13880	107	23	tanabe	tanabe	PROPN
aiua-13880	107	24	et	et	PROPN
aiua-13880	107	25	al	al	PROPN
aiua-13880	107	26	.	.	PROPN
aiua-13880	107	27	made	make	VERB
aiua-13880	107	28	the	the	DET
aiua-13880	107	29	effect	effect	NOUN
aiua-13880	107	30	size	size	NOUN
aiua-13880	107	31	nonsignificant	nonsignificant	ADJ
aiua-13880	107	32	(	(	PUNCT
aiua-13880	107	33	15	15	NUM
aiua-13880	107	34	)	)	PUNCT
aiua-13880	107	35	.	.	PUNCT
aiua-13880	108	1	given	give	VERB
aiua-13880	108	2	this	this	PRON
aiua-13880	108	3	,	,	PUNCT
aiua-13880	108	4	we	we	PRON
aiua-13880	108	5	advise	advise	VERB
aiua-13880	108	6	interpreting	interpret	VERB
aiua-13880	108	7	these	these	DET
aiua-13880	108	8	results	result	NOUN
aiua-13880	108	9	with	with	ADP
aiua-13880	108	10	caution	caution	NOUN
aiua-13880	108	11	,	,	PUNCT
aiua-13880	108	12	while	while	SCONJ
aiua-13880	108	13	all	all	DET
aiua-13880	108	14	other	other	ADJ
aiua-13880	108	15	hematological	hematological	ADJ
aiua-13880	108	16	markers	marker	NOUN
aiua-13880	108	17	showed	show	VERB
aiua-13880	108	18	stable	stable	ADJ
aiua-13880	108	19	outcomes	outcome	NOUN
aiua-13880	108	20	.	.	PUNCT
aiua-13880	109	1	subgroup	subgroup	NOUN
aiua-13880	109	2	and	and	CCONJ
aiua-13880	109	3	meta	meta	ADJ
aiua-13880	109	4	-	-	PUNCT
aiua-13880	109	5	regression	regression	NOUN
aiua-13880	109	6	analyses	analysis	NOUN
aiua-13880	109	7	we	we	PRON
aiua-13880	109	8	performed	perform	VERB
aiua-13880	109	9	subgroup	subgroup	NOUN
aiua-13880	109	10	and	and	CCONJ
aiua-13880	109	11	meta	meta	ADJ
aiua-13880	109	12	-	-	PUNCT
aiua-13880	109	13	regression	regression	NOUN
aiua-13880	109	14	analyses	analysis	NOUN
aiua-13880	109	15	for	for	ADP
aiua-13880	109	16	prognostic	prognostic	ADJ
aiua-13880	109	17	factors	factor	NOUN
aiua-13880	109	18	with	with	ADP
aiua-13880	109	19	a	a	DET
aiua-13880	109	20	sufficient	sufficient	ADJ
aiua-13880	109	21	number	number	NOUN
aiua-13880	109	22	of	of	ADP
aiua-13880	109	23	studies	study	NOUN
aiua-13880	109	24	:	:	PUNCT
aiua-13880	109	25	(	(	PUNCT
aiua-13880	109	26	1	1	X
aiua-13880	109	27	)	)	PUNCT
aiua-13880	109	28	age	age	NOUN
aiua-13880	109	29	,	,	PUNCT
aiua-13880	109	30	(	(	PUNCT
aiua-13880	109	31	2	2	NUM
aiua-13880	109	32	)	)	PUNCT
aiua-13880	109	33	gender	gender	NOUN
aiua-13880	109	34	,	,	PUNCT
aiua-13880	109	35	(	(	PUNCT
aiua-13880	109	36	3	3	X
aiua-13880	109	37	)	)	PUNCT
aiua-13880	109	38	presence	presence	NOUN
aiua-13880	109	39	of	of	ADP
aiua-13880	109	40	liver	liver	NOUN
aiua-13880	109	41	metastasis	metastasis	NOUN
aiua-13880	109	42	,	,	PUNCT
aiua-13880	109	43	(	(	PUNCT
aiua-13880	109	44	4	4	X
aiua-13880	109	45	)	)	PUNCT
aiua-13880	109	46	ecog	ecog	NOUN
aiua-13880	109	47	-	-	PUNCT
aiua-13880	109	48	ps	ps	NOUN
aiua-13880	109	49	≥	≥	NOUN
aiua-13880	109	50	2	2	NUM
aiua-13880	109	51	,	,	PUNCT
aiua-13880	109	52	and	and	CCONJ
aiua-13880	109	53	(	(	PUNCT
aiua-13880	109	54	5	5	X
aiua-13880	109	55	)	)	PUNCT
aiua-13880	109	56	utuc	utuc	NOUN
aiua-13880	109	57	primary	primary	ADJ
aiua-13880	109	58	site	site	NOUN
aiua-13880	109	59	associated	associate	VERB
aiua-13880	109	60	with	with	ADP
aiua-13880	109	61	os	os	NOUN
aiua-13880	109	62	.	.	PUNCT
aiua-13880	110	1	for	for	ADP
aiua-13880	110	2	most	most	ADJ
aiua-13880	110	3	factors	factor	NOUN
aiua-13880	110	4	,	,	PUNCT
aiua-13880	110	5	we	we	PRON
aiua-13880	110	6	found	find	VERB
aiua-13880	110	7	no	no	DET
aiua-13880	110	8	significant	significant	ADJ
aiua-13880	110	9	differences	difference	NOUN
aiua-13880	110	10	between	between	ADP
aiua-13880	110	11	subgroups	subgroup	NOUN
aiua-13880	110	12	.	.	PUNCT
aiua-13880	111	1	for	for	ADP
aiua-13880	111	2	ecog	ecog	NOUN
aiua-13880	111	3	-	-	PUNCT
aiua-13880	111	4	ps	ps	NOUN
aiua-13880	111	5	,	,	PUNCT
aiua-13880	111	6	results	result	NOUN
aiua-13880	111	7	of	of	ADP
aiua-13880	111	8	the	the	DET
aiua-13880	111	9	subgroup	subgroup	NOUN
aiua-13880	111	10	analysis	analysis	NOUN
aiua-13880	111	11	of	of	ADP
aiua-13880	111	12	risk	risk	NOUN
aiua-13880	111	13	of	of	ADP
aiua-13880	111	14	bias	bias	NOUN
aiua-13880	111	15	are	be	AUX
aiua-13880	111	16	presented	present	VERB
aiua-13880	111	17	in	in	ADP
aiua-13880	111	18	the	the	DET
aiua-13880	111	19	supplementary	supplementary	ADJ
aiua-13880	111	20	materials	material	NOUN
aiua-13880	111	21	.	.	PUNCT
aiua-13880	112	1	meta	meta	ADJ
aiua-13880	112	2	-	-	PUNCT
aiua-13880	112	3	regression	regression	NOUN
aiua-13880	112	4	analyses	analysis	NOUN
aiua-13880	112	5	on	on	ADP
aiua-13880	112	6	the	the	DET
aiua-13880	112	7	percentage	percentage	NOUN
aiua-13880	112	8	of	of	ADP
aiua-13880	112	9	male	male	NOUN
aiua-13880	112	10	(	(	PUNCT
aiua-13880	112	11	p	p	X
aiua-13880	112	12	=	=	NOUN
aiua-13880	112	13	0.01	0.01	NUM
aiua-13880	112	14	)	)	PUNCT
aiua-13880	112	15	suggest	suggest	VERB
aiua-13880	112	16	that	that	SCONJ
aiua-13880	112	17	this	this	DET
aiua-13880	112	18	factor	factor	NOUN
aiua-13880	112	19	influenced	influence	VERB
aiua-13880	112	20	the	the	DET
aiua-13880	112	21	effect	effect	NOUN
aiua-13880	112	22	of	of	ADP
aiua-13880	112	23	ecog	ecog	NOUN
aiua-13880	112	24	-	-	PUNCT
aiua-13880	112	25	ps	ps	NOUN
aiua-13880	112	26	≥	≥	NOUN
aiua-13880	112	27	2	2	NUM
aiua-13880	112	28	on	on	ADP
aiua-13880	112	29	overall	overall	ADJ
aiua-13880	112	30	survival	survival	NOUN
aiua-13880	112	31	(	(	PUNCT
aiua-13880	112	32	supplementary	supplementary	ADJ
aiua-13880	112	33	table	table	NOUN
aiua-13880	112	34	s3	s3	PROPN
aiua-13880	112	35	and	and	CCONJ
aiua-13880	112	36	figure	figure	NOUN
aiua-13880	112	37	s4	s4	PROPN
aiua-13880	112	38	)	)	PUNCT
aiua-13880	112	39	.	.	PUNCT
aiua-13880	113	1	additionally	additionally	ADV
aiua-13880	113	2	,	,	PUNCT
aiua-13880	113	3	subgroup	subgroup	NOUN
aiua-13880	113	4	comparisons	comparison	NOUN
aiua-13880	113	5	based	base	VERB
aiua-13880	113	6	on	on	ADP
aiua-13880	113	7	risk	risk	NOUN
aiua-13880	113	8	of	of	ADP
aiua-13880	113	9	bias	bias	NOUN
aiua-13880	113	10	revealed	reveal	VERB
aiua-13880	113	11	no	no	DET
aiua-13880	113	12	statistically	statistically	ADV
aiua-13880	113	13	significant	significant	ADJ
aiua-13880	113	14	differences	difference	NOUN
aiua-13880	113	15	in	in	ADP
aiua-13880	113	16	effect	effect	NOUN
aiua-13880	113	17	sizes	size	NOUN
aiua-13880	113	18	between	between	ADP
aiua-13880	113	19	20	20	NUM
aiua-13880	113	20	uchimoto	uchimoto	NOUN
aiua-13880	113	21	;	;	PUNCT
aiua-13880	113	22	202156	202156	NUM
aiua-13880	113	23	japan	japan	PROPN
aiua-13880	113	24	retrospective	retrospective	ADJ
aiua-13880	113	25	study	study	NOUN
aiua-13880	113	26	212	212	NUM
aiua-13880	113	27	72	72	NUM
aiua-13880	113	28	(	(	PUNCT
aiua-13880	113	29	8.95	8.95	NUM
aiua-13880	113	30	)	)	SYM
aiua-13880	113	31	151	151	NUM
aiua-13880	113	32	(	(	PUNCT
aiua-13880	113	33	71.2	71.2	NUM
aiua-13880	113	34	)	)	PUNCT
aiua-13880	113	35	8	8	NUM
aiua-13880	113	36	120	120	NUM
aiua-13880	113	37	(	(	PUNCT
aiua-13880	113	38	56.6	56.6	NUM
aiua-13880	113	39	)	)	PUNCT
aiua-13880	113	40	*	*	PUNCT
aiua-13880	114	1	utuc	utuc	NOUN
aiua-13880	114	2	:	:	PUNCT
aiua-13880	114	3	82	82	NUM
aiua-13880	114	4	(	(	PUNCT
aiua-13880	114	5	38.7	38.7	NUM
aiua-13880	114	6	)	)	PUNCT
aiua-13880	114	7	26.4	26.4	NUM
aiua-13880	114	8	nr	nr	PROPN
aiua-13880	114	9	11.7	11.7	NUM
aiua-13880	114	10	bc	bc	PROPN
aiua-13880	114	11	:	:	PUNCT
aiua-13880	114	12	130	130	NUM
aiua-13880	114	13	(	(	PUNCT
aiua-13880	114	14	61.3	61.3	NUM
aiua-13880	114	15	)	)	PUNCT
aiua-13880	114	16	21	21	NUM
aiua-13880	114	17	uchimoto	uchimoto	NOUN
aiua-13880	114	18	;	;	PUNCT
aiua-13880	114	19	202257	202257	NUM
aiua-13880	114	20	japan	japan	PROPN
aiua-13880	114	21	retrospective	retrospective	ADJ
aiua-13880	114	22	study	study	NOUN
aiua-13880	114	23	177	177	NUM
aiua-13880	114	24	72	72	NUM
aiua-13880	114	25	(	(	PUNCT
aiua-13880	114	26	66	66	NUM
aiua-13880	114	27	-	-	SYM
aiua-13880	114	28	78	78	NUM
aiua-13880	114	29	)	)	PUNCT
aiua-13880	114	30	125	125	NUM
aiua-13880	114	31	(	(	PUNCT
aiua-13880	114	32	70.6	70.6	NUM
aiua-13880	114	33	)	)	PUNCT
aiua-13880	114	34	6	6	NUM
aiua-13880	114	35	100	100	NUM
aiua-13880	114	36	(	(	PUNCT
aiua-13880	114	37	56.5	56.5	NUM
aiua-13880	114	38	)	)	PUNCT
aiua-13880	114	39	*	*	PUNCT
aiua-13880	115	1	utuc	utuc	NOUN
aiua-13880	115	2	:	:	PUNCT
aiua-13880	115	3	68	68	NUM
aiua-13880	115	4	(	(	PUNCT
aiua-13880	115	5	38.4	38.4	NUM
aiua-13880	115	6	)	)	PUNCT
aiua-13880	115	7	26.6	26.6	NUM
aiua-13880	115	8	nr	nr	PROPN
aiua-13880	115	9	14	14	NUM
aiua-13880	115	10	bc	bc	PROPN
aiua-13880	115	11	:	:	PUNCT
aiua-13880	115	12	109	109	NUM
aiua-13880	115	13	(	(	PUNCT
aiua-13880	115	14	61.6	61.6	NUM
aiua-13880	115	15	)	)	PUNCT
aiua-13880	115	16	22	22	NUM
aiua-13880	115	17	umeda	umeda	PROPN
aiua-13880	115	18	;	;	PUNCT
aiua-13880	115	19	202258	202258	NUM
aiua-13880	115	20	japan	japan	PROPN
aiua-13880	115	21	retrospective	retrospective	ADJ
aiua-13880	115	22	study	study	NOUN
aiua-13880	115	23	115	115	NUM
aiua-13880	115	24	75	75	NUM
aiua-13880	115	25	(	(	PUNCT
aiua-13880	115	26	70	70	NUM
aiua-13880	115	27	-	-	SYM
aiua-13880	115	28	79	79	NUM
aiua-13880	115	29	)	)	PUNCT
aiua-13880	115	30	29	29	NUM
aiua-13880	115	31	(	(	PUNCT
aiua-13880	115	32	65.9	65.9	NUM
aiua-13880	115	33	)	)	PUNCT
aiua-13880	115	34	7.4	7.4	NUM
aiua-13880	115	35	(	(	PUNCT
aiua-13880	115	36	4.6	4.6	NUM
aiua-13880	115	37	-	-	SYM
aiua-13880	115	38	16.4	16.4	NUM
aiua-13880	115	39	)	)	PUNCT
aiua-13880	115	40	nr	nr	NOUN
aiua-13880	115	41	utuc	utuc	NOUN
aiua-13880	115	42	:	:	PUNCT
aiua-13880	115	43	22	22	NUM
aiua-13880	115	44	(	(	PUNCT
aiua-13880	115	45	50	50	NUM
aiua-13880	115	46	)	)	PUNCT
aiua-13880	115	47	25.2	25.2	NUM
aiua-13880	115	48	nr	nr	PROPN
aiua-13880	115	49	nr	nr	PROPN
aiua-13880	115	50	bc	bc	PROPN
aiua-13880	115	51	:	:	PUNCT
aiua-13880	115	52	21	21	NUM
aiua-13880	115	53	(	(	PUNCT
aiua-13880	115	54	47.7	47.7	NUM
aiua-13880	115	55	)	)	PUNCT
aiua-13880	115	56	both	both	PRON
aiua-13880	115	57	:	:	PUNCT
aiua-13880	115	58	1	1	NUM
aiua-13880	115	59	(	(	PUNCT
aiua-13880	115	60	2.3	2.3	NUM
aiua-13880	115	61	)	)	PUNCT
aiua-13880	115	62	23	23	NUM
aiua-13880	115	63	yamamoto	yamamoto	NOUN
aiua-13880	115	64	;	;	PUNCT
aiua-13880	115	65	202259	202259	NUM
aiua-13880	115	66	japan	japan	PROPN
aiua-13880	115	67	retrospective	retrospective	ADJ
aiua-13880	115	68	study	study	NOUN
aiua-13880	115	69	31	31	NUM
aiua-13880	115	70	74	74	NUM
aiua-13880	115	71	(	(	PUNCT
aiua-13880	115	72	70	70	NUM
aiua-13880	115	73	-	-	SYM
aiua-13880	115	74	82	82	NUM
aiua-13880	115	75	)	)	PUNCT
aiua-13880	115	76	22	22	NUM
aiua-13880	115	77	(	(	PUNCT
aiua-13880	115	78	71	71	NUM
aiua-13880	115	79	)	)	PUNCT
aiua-13880	115	80	5.7	5.7	NUM
aiua-13880	115	81	(	(	PUNCT
aiua-13880	115	82	3.4	3.4	NUM
aiua-13880	115	83	-	-	SYM
aiua-13880	115	84	16.3	16.3	NUM
aiua-13880	115	85	)	)	PUNCT
aiua-13880	115	86	3	3	NUM
aiua-13880	115	87	(	(	PUNCT
aiua-13880	115	88	10	10	NUM
aiua-13880	115	89	)	)	PUNCT
aiua-13880	115	90	utuc	utuc	NOUN
aiua-13880	115	91	:	:	PUNCT
aiua-13880	115	92	9	9	NUM
aiua-13880	115	93	(	(	PUNCT
aiua-13880	115	94	29	29	NUM
aiua-13880	115	95	)	)	PUNCT
aiua-13880	115	96	35.5	35.5	NUM
aiua-13880	115	97	nr	nr	PROPN
aiua-13880	115	98	nr	nr	PROPN
aiua-13880	115	99	bc	bc	PROPN
aiua-13880	115	100	:	:	PUNCT
aiua-13880	115	101	22	22	NUM
aiua-13880	115	102	(	(	PUNCT
aiua-13880	115	103	71	71	NUM
aiua-13880	115	104	)	)	PUNCT
aiua-13880	115	105	24	24	NUM
aiua-13880	115	106	yamashita	yamashita	PROPN
aiua-13880	115	107	;	;	PUNCT
aiua-13880	115	108	202360	202360	NUM
aiua-13880	115	109	japan	japan	PROPN
aiua-13880	115	110	retrospective	retrospective	ADJ
aiua-13880	115	111	study	study	NOUN
aiua-13880	115	112	96	96	NUM
aiua-13880	115	113	74	74	NUM
aiua-13880	115	114	(	(	PUNCT
aiua-13880	115	115	70	70	NUM
aiua-13880	115	116	-	-	SYM
aiua-13880	115	117	79	79	NUM
aiua-13880	115	118	)	)	PUNCT
aiua-13880	115	119	69	69	NUM
aiua-13880	115	120	(	(	PUNCT
aiua-13880	115	121	72	72	NUM
aiua-13880	115	122	)	)	PUNCT
aiua-13880	115	123	7	7	NUM
aiua-13880	115	124	(	(	PUNCT
aiua-13880	115	125	4	4	NUM
aiua-13880	115	126	-	-	SYM
aiua-13880	115	127	17	17	NUM
aiua-13880	115	128	)	)	PUNCT
aiua-13880	115	129	15	15	NUM
aiua-13880	115	130	(	(	PUNCT
aiua-13880	115	131	15.6	15.6	NUM
aiua-13880	115	132	)	)	PUNCT
aiua-13880	115	133	utuc	utuc	NOUN
aiua-13880	115	134	:	:	PUNCT
aiua-13880	115	135	46	46	NUM
aiua-13880	115	136	(	(	PUNCT
aiua-13880	115	137	48	48	NUM
aiua-13880	115	138	)	)	PUNCT
aiua-13880	115	139	23	23	NUM
aiua-13880	115	140	2	2	NUM
aiua-13880	115	141	nr	nr	PRON
aiua-13880	115	142	bc	bc	PROPN
aiua-13880	115	143	:	:	PUNCT
aiua-13880	115	144	41	41	NUM
aiua-13880	115	145	(	(	PUNCT
aiua-13880	115	146	43	43	NUM
aiua-13880	115	147	)	)	PUNCT
aiua-13880	115	148	both	both	PRON
aiua-13880	115	149	:	:	PUNCT
aiua-13880	115	150	9	9	NUM
aiua-13880	115	151	(	(	PUNCT
aiua-13880	115	152	9	9	NUM
aiua-13880	115	153	)	)	PUNCT
aiua-13880	115	154	categorical	categorical	ADJ
aiua-13880	115	155	data	datum	NOUN
aiua-13880	115	156	are	be	AUX
aiua-13880	115	157	shown	show	VERB
aiua-13880	115	158	as	as	ADP
aiua-13880	115	159	n	n	PROPN
aiua-13880	115	160	(	(	PUNCT
aiua-13880	115	161	%	%	NOUN
aiua-13880	115	162	)	)	PUNCT
aiua-13880	115	163	,	,	PUNCT
aiua-13880	115	164	while	while	SCONJ
aiua-13880	115	165	numerical	numerical	ADJ
aiua-13880	115	166	data	datum	NOUN
aiua-13880	115	167	are	be	AUX
aiua-13880	115	168	presented	present	VERB
aiua-13880	115	169	as	as	ADP
aiua-13880	115	170	mean	mean	NOUN
aiua-13880	115	171	(	(	PUNCT
aiua-13880	115	172	sd	sd	NOUN
aiua-13880	115	173	)	)	PUNCT
aiua-13880	115	174	or	or	CCONJ
aiua-13880	115	175	median	median	ADJ
aiua-13880	115	176	(	(	PUNCT
aiua-13880	115	177	iqr	iqr	NOUN
aiua-13880	115	178	)	)	PUNCT
aiua-13880	115	179	.	.	PUNCT
aiua-13880	116	1	nr	nr	PROPN
aiua-13880	116	2	:	:	PUNCT
aiua-13880	116	3	not	not	PART
aiua-13880	116	4	reported	report	VERB
aiua-13880	116	5	;	;	PUNCT
aiua-13880	116	6	ecog	ecog	VERB
aiua-13880	116	7	-	-	PUNCT
aiua-13880	116	8	ps	ps	NOUN
aiua-13880	116	9	:	:	PUNCT
aiua-13880	116	10	eastern	eastern	ADJ
aiua-13880	116	11	cooperative	cooperative	ADJ
aiua-13880	116	12	oncology	oncology	NOUN
aiua-13880	116	13	group	group	NOUN
aiua-13880	116	14	performance	performance	NOUN
aiua-13880	116	15	status	status	NOUN
aiua-13880	116	16	scale	scale	NOUN
aiua-13880	116	17	;	;	PUNCT
aiua-13880	116	18	utuc	utuc	NOUN
aiua-13880	116	19	:	:	PUNCT
aiua-13880	116	20	upper	upper	ADJ
aiua-13880	116	21	urinary	urinary	ADJ
aiua-13880	116	22	tract	tract	NOUN
aiua-13880	116	23	urothelial	urothelial	ADJ
aiua-13880	116	24	carcinoma	carcinoma	NOUN
aiua-13880	116	25	;	;	PUNCT
aiua-13880	116	26	bc	bc	ADJ
aiua-13880	116	27	:	:	PUNCT
aiua-13880	116	28	bladder	bladder	NOUN
aiua-13880	116	29	urothelial	urothelial	ADJ
aiua-13880	116	30	carcinoma	carcinoma	NOUN
aiua-13880	116	31	.	.	PUNCT
aiua-13880	117	1	*	*	PUNCT
aiua-13880	117	2	ecog	ecog	VERB
aiua-13880	117	3	ps	ps	PROPN
aiua-13880	117	4	>	>	PUNCT
aiua-13880	117	5	=	=	PROPN
aiua-13880	117	6	1	1	X
aiua-13880	117	7	.	.	X
aiua-13880	117	8	archivio	archivio	NOUN
aiua-13880	117	9	italiano	italiano	X
aiua-13880	117	10	di	di	PROPN
aiua-13880	117	11	urologia	urologia	PROPN
aiua-13880	117	12	e	e	PROPN
aiua-13880	117	13	andrologia	andrologia	NOUN
aiua-13880	117	14	2025	2025	NUM
aiua-13880	117	15	;	;	PUNCT
aiua-13880	117	16	97(2):13880	97(2):13880	NUM
aiua-13880	117	17	k	k	PROPN
aiua-13880	117	18	..	..	PUNCT
aiua-13880	117	19	yuwono	yuwono	PROPN
aiua-13880	117	20	,	,	PUNCT
aiua-13880	117	21	j.	j.	PROPN
aiua-13880	117	22	nimasratu	nimasratu	PROPN
aiua-13880	117	23	rahmatsani	rahmatsani	PROPN
aiua-13880	117	24	,	,	PUNCT
aiua-13880	117	25	nadhifah	nadhifah	VERB
aiua-13880	117	26	,	,	PUNCT
aiua-13880	117	27	et	et	PROPN
aiua-13880	117	28	al	al	PROPN
aiua-13880	117	29	.	.	PROPN
aiua-13880	118	1	6	6	NUM
aiua-13880	118	2	studies	study	NOUN
aiua-13880	118	3	classified	classify	VERB
aiua-13880	118	4	as	as	ADP
aiua-13880	118	5	low	low	ADJ
aiua-13880	118	6	risk	risk	NOUN
aiua-13880	118	7	versus	versus	ADP
aiua-13880	118	8	moderate	moderate	ADJ
aiua-13880	118	9	-	-	PUNCT
aiua-13880	118	10	high	high	ADJ
aiua-13880	118	11	risk	risk	NOUN
aiua-13880	118	12	(	(	PUNCT
aiua-13880	118	13	supplementary	supplementary	ADJ
aiua-13880	118	14	figure	figure	NOUN
aiua-13880	118	15	s5	s5	PROPN
aiua-13880	118	16	)	)	PUNCT
aiua-13880	118	17	.	.	PUNCT
aiua-13880	119	1	publication	publication	NOUN
aiua-13880	119	2	bias	bias	NOUN
aiua-13880	119	3	and	and	CCONJ
aiua-13880	119	4	quality	quality	NOUN
aiua-13880	119	5	assessment	assessment	NOUN
aiua-13880	119	6	of	of	ADP
aiua-13880	119	7	included	include	VERB
aiua-13880	119	8	studies	study	NOUN
aiua-13880	119	9	for	for	ADP
aiua-13880	119	10	outcomes	outcome	NOUN
aiua-13880	119	11	with	with	ADP
aiua-13880	119	12	included	include	VERB
aiua-13880	119	13	studies	study	NOUN
aiua-13880	119	14	≥	≥	NOUN
aiua-13880	119	15	10	10	NUM
aiua-13880	119	16	,	,	PUNCT
aiua-13880	119	17	we	we	PRON
aiua-13880	119	18	performed	perform	VERB
aiua-13880	119	19	publication	publication	NOUN
aiua-13880	119	20	bias	bias	NOUN
aiua-13880	119	21	assessment	assessment	NOUN
aiua-13880	119	22	by	by	ADP
aiua-13880	119	23	generating	generate	VERB
aiua-13880	119	24	funnel	funnel	NOUN
aiua-13880	119	25	plots	plot	NOUN
aiua-13880	119	26	.	.	PUNCT
aiua-13880	120	1	for	for	ADP
aiua-13880	120	2	overall	overall	ADJ
aiua-13880	120	3	survival	survival	NOUN
aiua-13880	120	4	,	,	PUNCT
aiua-13880	120	5	one	one	NUM
aiua-13880	120	6	study	study	NOUN
aiua-13880	120	7	each	each	PRON
aiua-13880	120	8	by	by	ADP
aiua-13880	120	9	tanabe	tanabe	PROPN
aiua-13880	120	10	et	et	PROPN
aiua-13880	120	11	al	al	PROPN
aiua-13880	120	12	.	.	PROPN
aiua-13880	121	1	(	(	PUNCT
aiua-13880	121	2	15	15	NUM
aiua-13880	121	3	)	)	PUNCT
aiua-13880	121	4	,	,	PUNCT
aiua-13880	121	5	kobayashi	kobayashi	PROPN
aiua-13880	121	6	et	et	PROPN
aiua-13880	121	7	al	al	PROPN
aiua-13880	121	8	.	.	PROPN
aiua-13880	122	1	(	(	PUNCT
aiua-13880	122	2	17	17	NUM
aiua-13880	122	3	)	)	PUNCT
aiua-13880	122	4	,	,	PUNCT
aiua-13880	122	5	and	and	CCONJ
aiua-13880	122	6	kurashina	kurashina	VERB
aiua-13880	122	7	et	et	PROPN
aiua-13880	122	8	al	al	PROPN
aiua-13880	122	9	.	.	PROPN
aiua-13880	123	1	(	(	PUNCT
aiua-13880	123	2	18	18	NUM
aiua-13880	123	3	)	)	PUNCT
aiua-13880	123	4	appeared	appear	VERB
aiua-13880	123	5	as	as	ADP
aiua-13880	123	6	outliers	outlier	NOUN
aiua-13880	123	7	in	in	ADP
aiua-13880	123	8	the	the	DET
aiua-13880	123	9	funnel	funnel	NOUN
aiua-13880	123	10	plots	plot	NOUN
aiua-13880	123	11	for	for	ADP
aiua-13880	123	12	age	age	NOUN
aiua-13880	123	13	,	,	PUNCT
aiua-13880	123	14	gender	gender	NOUN
aiua-13880	123	15	,	,	PUNCT
aiua-13880	123	16	and	and	CCONJ
aiua-13880	123	17	liver	liver	NOUN
aiua-13880	123	18	metastasis	metastasis	NOUN
aiua-13880	123	19	,	,	PUNCT
aiua-13880	123	20	respectively	respectively	ADV
aiua-13880	123	21	.	.	PUNCT
aiua-13880	124	1	in	in	ADP
aiua-13880	124	2	contrast	contrast	NOUN
aiua-13880	124	3	,	,	PUNCT
aiua-13880	124	4	a	a	DET
aiua-13880	124	5	total	total	NOUN
aiua-13880	124	6	of	of	ADP
aiua-13880	124	7	three	three	NUM
aiua-13880	124	8	studies	study	NOUN
aiua-13880	124	9	assessing	assess	VERB
aiua-13880	124	10	ecog	ecog	NOUN
aiua-13880	124	11	-	-	PUNCT
aiua-13880	124	12	ps	ps	NOUN
aiua-13880	124	13	fell	fall	VERB
aiua-13880	124	14	outside	outside	ADP
aiua-13880	124	15	the	the	DET
aiua-13880	124	16	funnel	funnel	NOUN
aiua-13880	124	17	plot	plot	NOUN
aiua-13880	124	18	,	,	PUNCT
aiua-13880	124	19	suggesting	suggest	VERB
aiua-13880	124	20	that	that	SCONJ
aiua-13880	124	21	ecog	ecog	NOUN
aiua-13880	124	22	-	-	PUNCT
aiua-13880	124	23	ps	ps	NOUN
aiua-13880	124	24	results	result	NOUN
aiua-13880	124	25	may	may	AUX
aiua-13880	124	26	be	be	AUX
aiua-13880	124	27	particularly	particularly	ADV
aiua-13880	124	28	affected	affect	VERB
aiua-13880	124	29	by	by	ADP
aiua-13880	124	30	publication	publication	NOUN
aiua-13880	124	31	bias	bias	NOUN
aiua-13880	124	32	.	.	PUNCT
aiua-13880	125	1	nonetheless	nonetheless	ADV
aiua-13880	125	2	,	,	PUNCT
aiua-13880	125	3	egger	egger	NOUN
aiua-13880	125	4	’s	’s	PART
aiua-13880	125	5	test	test	NOUN
aiua-13880	125	6	did	do	AUX
aiua-13880	125	7	not	not	PART
aiua-13880	125	8	show	show	VERB
aiua-13880	125	9	statistically	statistically	ADV
aiua-13880	125	10	significant	significant	ADJ
aiua-13880	125	11	bias	bias	NOUN
aiua-13880	125	12	for	for	ADP
aiua-13880	125	13	any	any	PRON
aiua-13880	125	14	of	of	ADP
aiua-13880	125	15	the	the	DET
aiua-13880	125	16	evaluated	evaluated	ADJ
aiua-13880	125	17	risk	risk	NOUN
aiua-13880	125	18	factors	factor	NOUN
aiua-13880	125	19	(	(	PUNCT
aiua-13880	125	20	supplementary	supplementary	ADJ
aiua-13880	125	21	table	table	NOUN
aiua-13880	125	22	s2	s2	NOUN
aiua-13880	125	23	and	and	CCONJ
aiua-13880	125	24	figure	figure	NOUN
aiua-13880	125	25	s3	s3	PROPN
aiua-13880	125	26	)	)	PUNCT
aiua-13880	125	27	.	.	PUNCT
aiua-13880	126	1	three	three	NUM
aiua-13880	126	2	reviewers	reviewer	NOUN
aiua-13880	126	3	assessed	assess	VERB
aiua-13880	126	4	the	the	DET
aiua-13880	126	5	risk	risk	NOUN
aiua-13880	126	6	of	of	ADP
aiua-13880	126	7	bias	bias	NOUN
aiua-13880	126	8	within	within	ADP
aiua-13880	126	9	individual	individual	ADJ
aiua-13880	126	10	studies	study	NOUN
aiua-13880	126	11	using	use	VERB
aiua-13880	126	12	the	the	DET
aiua-13880	126	13	quips	quip	NOUN
aiua-13880	126	14	tool	tool	NOUN
aiua-13880	126	15	,	,	PUNCT
aiua-13880	126	16	given	give	VERB
aiua-13880	126	17	that	that	SCONJ
aiua-13880	126	18	all	all	DET
aiua-13880	126	19	the	the	DET
aiua-13880	126	20	included	include	VERB
aiua-13880	126	21	studies	study	NOUN
aiua-13880	126	22	were	be	AUX
aiua-13880	126	23	studies	study	NOUN
aiua-13880	126	24	evaluating	evaluate	VERB
aiua-13880	126	25	prognostic	prognostic	ADJ
aiua-13880	126	26	factors	factor	NOUN
aiua-13880	126	27	(	(	PUNCT
aiua-13880	126	28	figure	figure	NOUN
aiua-13880	126	29	2	2	NUM
aiua-13880	126	30	)	)	PUNCT
aiua-13880	126	31	.	.	PUNCT
aiua-13880	127	1	among	among	ADP
aiua-13880	127	2	the	the	DET
aiua-13880	127	3	studies	study	NOUN
aiua-13880	127	4	reviewed	review	VERB
aiua-13880	127	5	,	,	PUNCT
aiua-13880	127	6	six	six	NUM
aiua-13880	127	7	were	be	AUX
aiua-13880	127	8	identified	identify	VERB
aiua-13880	127	9	as	as	ADP
aiua-13880	127	10	having	have	VERB
aiua-13880	127	11	a	a	DET
aiua-13880	127	12	high	high	ADJ
aiua-13880	127	13	risk	risk	NOUN
aiua-13880	127	14	of	of	ADP
aiua-13880	127	15	bias	bias	NOUN
aiua-13880	127	16	due	due	ADP
aiua-13880	127	17	to	to	ADP
aiua-13880	127	18	attrition	attrition	NOUN
aiua-13880	127	19	.	.	PUNCT
aiua-13880	128	1	all	all	DET
aiua-13880	128	2	the	the	DET
aiua-13880	128	3	included	include	VERB
aiua-13880	128	4	studies	study	NOUN
aiua-13880	128	5	were	be	AUX
aiua-13880	128	6	retrospective	retrospective	ADJ
aiua-13880	128	7	in	in	ADP
aiua-13880	128	8	nature	nature	NOUN
aiua-13880	128	9	,	,	PUNCT
aiua-13880	128	10	and	and	CCONJ
aiua-13880	128	11	the	the	DET
aiua-13880	128	12	high	high	ADJ
aiua-13880	128	13	risk	risk	NOUN
aiua-13880	128	14	of	of	ADP
aiua-13880	128	15	attrition	attrition	NOUN
aiua-13880	128	16	bias	bias	NOUN
aiua-13880	128	17	stemmed	stem	VERB
aiua-13880	128	18	from	from	ADP
aiua-13880	128	19	either	either	CCONJ
aiua-13880	128	20	a	a	DET
aiua-13880	128	21	lack	lack	NOUN
aiua-13880	128	22	of	of	ADP
aiua-13880	128	23	reporting	report	VERB
aiua-13880	128	24	on	on	ADP
aiua-13880	128	25	missing	miss	VERB
aiua-13880	128	26	data	datum	NOUN
aiua-13880	128	27	or	or	CCONJ
aiua-13880	128	28	the	the	DET
aiua-13880	128	29	exclusion	exclusion	NOUN
aiua-13880	128	30	of	of	ADP
aiua-13880	128	31	a	a	DET
aiua-13880	128	32	significant	significant	ADJ
aiua-13880	128	33	portion	portion	NOUN
aiua-13880	128	34	of	of	ADP
aiua-13880	128	35	data	datum	NOUN
aiua-13880	128	36	(	(	PUNCT
aiua-13880	128	37	>	>	X
aiua-13880	128	38	10	10	NUM
aiua-13880	128	39	%	%	NOUN
aiua-13880	128	40	)	)	PUNCT
aiua-13880	128	41	from	from	ADP
aiua-13880	128	42	the	the	DET
aiua-13880	128	43	final	final	ADJ
aiua-13880	128	44	analysis	analysis	NOUN
aiua-13880	128	45	.	.	PUNCT
aiua-13880	129	1	we	we	PRON
aiua-13880	129	2	identified	identify	VERB
aiua-13880	129	3	three	three	NUM
aiua-13880	129	4	studies	study	NOUN
aiua-13880	129	5	with	with	ADP
aiua-13880	129	6	a	a	DET
aiua-13880	129	7	moderate	moderate	ADJ
aiua-13880	129	8	risk	risk	NOUN
aiua-13880	129	9	of	of	ADP
aiua-13880	129	10	bias	bias	NOUN
aiua-13880	129	11	,	,	PUNCT
aiua-13880	129	12	while	while	SCONJ
aiua-13880	129	13	the	the	DET
aiua-13880	129	14	remaining	remain	VERB
aiua-13880	129	15	studies	study	NOUN
aiua-13880	129	16	had	have	VERB
aiua-13880	129	17	a	a	DET
aiua-13880	129	18	low	low	ADJ
aiua-13880	129	19	risk	risk	NOUN
aiua-13880	129	20	of	of	ADP
aiua-13880	129	21	bias	bias	NOUN
aiua-13880	129	22	.	.	PUNCT
aiua-13880	130	1	some	some	DET
aiua-13880	130	2	studies	study	NOUN
aiua-13880	130	3	were	be	AUX
aiua-13880	130	4	rated	rate	VERB
aiua-13880	130	5	as	as	ADP
aiua-13880	130	6	having	have	VERB
aiua-13880	130	7	a	a	DET
aiua-13880	130	8	moderate	moderate	ADJ
aiua-13880	130	9	risk	risk	NOUN
aiua-13880	130	10	of	of	ADP
aiua-13880	130	11	bias	bias	NOUN
aiua-13880	130	12	related	relate	VERB
aiua-13880	130	13	to	to	ADP
aiua-13880	130	14	participation	participation	NOUN
aiua-13880	130	15	,	,	PUNCT
aiua-13880	130	16	primarily	primarily	ADV
aiua-13880	130	17	because	because	SCONJ
aiua-13880	130	18	they	they	PRON
aiua-13880	130	19	failed	fail	VERB
aiua-13880	130	20	to	to	PART
aiua-13880	130	21	report	report	VERB
aiua-13880	130	22	details	detail	NOUN
aiua-13880	130	23	such	such	ADJ
aiua-13880	130	24	as	as	ADP
aiua-13880	130	25	the	the	DET
aiua-13880	130	26	study	study	NOUN
aiua-13880	130	27	location	location	NOUN
aiua-13880	130	28	or	or	CCONJ
aiua-13880	130	29	the	the	DET
aiua-13880	130	30	recruitment	recruitment	NOUN
aiua-13880	130	31	period	period	NOUN
aiua-13880	130	32	.	.	PUNCT
aiua-13880	131	1	additionally	additionally	ADV
aiua-13880	131	2	,	,	PUNCT
aiua-13880	131	3	a	a	DET
aiua-13880	131	4	few	few	ADJ
aiua-13880	131	5	studies	study	NOUN
aiua-13880	131	6	exhibited	exhibit	VERB
aiua-13880	131	7	a	a	DET
aiua-13880	131	8	moderate	moderate	ADJ
aiua-13880	131	9	risk	risk	NOUN
aiua-13880	131	10	of	of	ADP
aiua-13880	131	11	bias	bias	NOUN
aiua-13880	131	12	due	due	ADP
aiua-13880	131	13	to	to	ADP
aiua-13880	131	14	confounding	confound	VERB
aiua-13880	131	15	,	,	PUNCT
aiua-13880	131	16	as	as	SCONJ
aiua-13880	131	17	significant	significant	ADJ
aiua-13880	131	18	confounders	confounder	NOUN
aiua-13880	131	19	were	be	AUX
aiua-13880	131	20	neither	neither	CCONJ
aiua-13880	131	21	addressed	address	VERB
aiua-13880	131	22	in	in	ADP
aiua-13880	131	23	the	the	DET
aiua-13880	131	24	study	study	NOUN
aiua-13880	131	25	design	design	NOUN
aiua-13880	131	26	nor	nor	CCONJ
aiua-13880	131	27	adjusted	adjust	VERB
aiua-13880	131	28	for	for	ADP
aiua-13880	131	29	in	in	ADP
aiua-13880	131	30	the	the	DET
aiua-13880	131	31	statistical	statistical	ADJ
aiua-13880	131	32	analysis	analysis	NOUN
aiua-13880	131	33	.	.	PUNCT
aiua-13880	132	1	figure	figure	NOUN
aiua-13880	132	2	2	2	NUM
aiua-13880	132	3	and	and	CCONJ
aiua-13880	132	4	3	3	NUM
aiua-13880	132	5	provides	provide	VERB
aiua-13880	132	6	an	an	DET
aiua-13880	132	7	in	in	ADP
aiua-13880	132	8	-	-	PUNCT
aiua-13880	132	9	depth	depth	NOUN
aiua-13880	132	10	visualization	visualization	NOUN
aiua-13880	132	11	of	of	ADP
aiua-13880	132	12	the	the	DET
aiua-13880	132	13	risk	risk	NOUN
aiua-13880	132	14	of	of	ADP
aiua-13880	132	15	bias	bias	NOUN
aiua-13880	132	16	assessment	assessment	NOUN
aiua-13880	132	17	for	for	ADP
aiua-13880	132	18	each	each	DET
aiua-13880	132	19	study	study	NOUN
aiua-13880	132	20	.	.	PUNCT
aiua-13880	133	1	table	table	NOUN
aiua-13880	133	2	2	2	NUM
aiua-13880	133	3	.	.	PUNCT
aiua-13880	133	4	pooled	pool	VERB
aiua-13880	133	5	hazard	hazard	NOUN
aiua-13880	133	6	ratios	ratio	NOUN
aiua-13880	133	7	of	of	ADP
aiua-13880	133	8	demographical	demographical	ADJ
aiua-13880	133	9	,	,	PUNCT
aiua-13880	133	10	clinical	clinical	ADJ
aiua-13880	133	11	,	,	PUNCT
aiua-13880	133	12	and	and	CCONJ
aiua-13880	133	13	hematological	hematological	ADJ
aiua-13880	133	14	factors	factor	NOUN
aiua-13880	133	15	associated	associate	VERB
aiua-13880	133	16	with	with	ADP
aiua-13880	133	17	pfs	pfs	PROPN
aiua-13880	133	18	and	and	CCONJ
aiua-13880	133	19	os	os	NOUN
aiua-13880	133	20	.	.	PUNCT
aiua-13880	134	1	factors	factor	VERB
aiua-13880	134	2	definition	definition	NOUN
aiua-13880	134	3	number	number	NOUN
aiua-13880	134	4	hazard	hazard	NOUN
aiua-13880	134	5	ratio	ratio	NOUN
aiua-13880	134	6	heterogeneity	heterogeneity	NOUN
aiua-13880	134	7	overall	overall	ADJ
aiua-13880	134	8	effect	effect	NOUN
aiua-13880	134	9	of	of	ADP
aiua-13880	134	10	studies	study	NOUN
aiua-13880	134	11	(	(	PUNCT
aiua-13880	134	12	95%ci	95%ci	NUM
aiua-13880	134	13	)	)	PUNCT
aiua-13880	134	14	i2	i2	PROPN
aiua-13880	134	15	p	p	NOUN
aiua-13880	134	16	-	-	PUNCT
aiua-13880	134	17	value	value	NOUN
aiua-13880	134	18	z	z	NOUN
aiua-13880	134	19	-	-	PUNCT
aiua-13880	134	20	score	score	NOUN
aiua-13880	134	21	p	p	NOUN
aiua-13880	134	22	-	-	PUNCT
aiua-13880	134	23	value	value	NOUN
aiua-13880	134	24	progression	progression	NOUN
aiua-13880	134	25	free	free	ADJ
aiua-13880	134	26	survival	survival	NOUN
aiua-13880	134	27	demographic	demographic	ADJ
aiua-13880	134	28	factors	factor	NOUN
aiua-13880	134	29	age	age	VERB
aiua-13880	134	30	≥	≥	NUM
aiua-13880	134	31	70	70	NUM
aiua-13880	134	32	-	-	SYM
aiua-13880	134	33	75	75	NUM
aiua-13880	134	34	years	year	NOUN
aiua-13880	134	35	old	old	ADJ
aiua-13880	134	36	8	8	NUM
aiua-13880	134	37	1.21	1.21	NUM
aiua-13880	134	38	(	(	PUNCT
aiua-13880	134	39	1.04	1.04	NUM
aiua-13880	134	40	-	-	NUM
aiua-13880	134	41	1.41	1.41	NUM
aiua-13880	134	42	)	)	PUNCT
aiua-13880	134	43	0	0	NUM
aiua-13880	134	44	0.84	0.84	NUM
aiua-13880	134	45	2.44	2.44	NUM
aiua-13880	134	46	0.01	0.01	NUM
aiua-13880	134	47	gender	gender	NOUN
aiua-13880	134	48	male	male	NOUN
aiua-13880	134	49	vs.	vs.	ADP
aiua-13880	134	50	female	female	ADJ
aiua-13880	134	51	8	8	NUM
aiua-13880	134	52	0.99	0.99	NUM
aiua-13880	134	53	(	(	PUNCT
aiua-13880	134	54	0.84	0.84	NUM
aiua-13880	134	55	-	-	SYM
aiua-13880	134	56	1.17	1.17	NUM
aiua-13880	134	57	)	)	PUNCT
aiua-13880	134	58	1	1	NUM
aiua-13880	134	59	0.42	0.42	NUM
aiua-13880	134	60	-0.14	-0.14	NUM
aiua-13880	134	61	0.89	0.89	NUM
aiua-13880	134	62	clinical	clinical	ADJ
aiua-13880	134	63	factors	factor	NOUN
aiua-13880	134	64	ecog	ecog	VERB
aiua-13880	134	65	-	-	PUNCT
aiua-13880	134	66	ps	ps	NOUN
aiua-13880	134	67	≥	≥	NOUN
aiua-13880	134	68	2	2	NUM
aiua-13880	134	69	vs.	vs.	ADP
aiua-13880	134	70	<	<	X
aiua-13880	134	71	2	2	NUM
aiua-13880	134	72	8	8	NUM
aiua-13880	134	73	2.30	2.30	NUM
aiua-13880	134	74	(	(	PUNCT
aiua-13880	134	75	1.91	1.91	NUM
aiua-13880	134	76	-	-	SYM
aiua-13880	134	77	2.76	2.76	NUM
aiua-13880	134	78	)	)	PUNCT
aiua-13880	134	79	39	39	NUM
aiua-13880	134	80	0.12	0.12	NUM
aiua-13880	134	81	8.9	8.9	NUM
aiua-13880	134	82	<	<	X
aiua-13880	134	83	0.01	0.01	NUM
aiua-13880	134	84	pathological	pathological	ADJ
aiua-13880	134	85	type	type	NOUN
aiua-13880	134	86	pure	pure	ADJ
aiua-13880	134	87	vs	vs	ADP
aiua-13880	134	88	mixed	mixed	ADJ
aiua-13880	134	89	uc	uc	PROPN
aiua-13880	134	90	3	3	NUM
aiua-13880	134	91	2.33	2.33	NUM
aiua-13880	134	92	(	(	PUNCT
aiua-13880	134	93	1.20	1.20	NUM
aiua-13880	134	94	-	-	SYM
aiua-13880	134	95	4.54	4.54	NUM
aiua-13880	134	96	)	)	PUNCT
aiua-13880	134	97	3	3	NUM
aiua-13880	134	98	0.36	0.36	NUM
aiua-13880	134	99	2.49	2.49	NUM
aiua-13880	134	100	0.01	0.01	NUM
aiua-13880	134	101	liver	liver	NOUN
aiua-13880	134	102	metastasis	metastasis	PRON
aiua-13880	135	1	yes	yes	INTJ
aiua-13880	135	2	vs.	vs.	NOUN
aiua-13880	135	3	no	no	DET
aiua-13880	135	4	5	5	NUM
aiua-13880	135	5	1.70	1.70	NUM
aiua-13880	135	6	(	(	PUNCT
aiua-13880	135	7	1.35	1.35	NUM
aiua-13880	135	8	-	-	SYM
aiua-13880	135	9	2.14	2.14	NUM
aiua-13880	135	10	)	)	PUNCT
aiua-13880	135	11	13	13	NUM
aiua-13880	135	12	0.33	0.33	NUM
aiua-13880	135	13	4.52	4.52	NUM
aiua-13880	135	14	<	<	X
aiua-13880	135	15	0.01	0.01	NUM
aiua-13880	135	16	lung	lung	NOUN
aiua-13880	135	17	metastasis	metastasis	PRON
aiua-13880	135	18	yes	yes	INTJ
aiua-13880	135	19	vs.	vs.	ADP
aiua-13880	135	20	no	no	DET
aiua-13880	135	21	4	4	NUM
aiua-13880	135	22	1.34	1.34	NUM
aiua-13880	135	23	(	(	PUNCT
aiua-13880	135	24	1.10	1.10	NUM
aiua-13880	135	25	-	-	SYM
aiua-13880	135	26	1.64	1.64	NUM
aiua-13880	135	27	)	)	PUNCT
aiua-13880	135	28	0	0	NUM
aiua-13880	136	1	0.73	0.73	NUM
aiua-13880	136	2	2.93	2.93	NUM
aiua-13880	136	3	<	<	SYM
aiua-13880	136	4	0.01	0.01	NUM
aiua-13880	136	5	lymph	lymph	NOUN
aiua-13880	136	6	node	node	NOUN
aiua-13880	136	7	metastasis	metastasis	PRON
aiua-13880	137	1	yes	yes	INTJ
aiua-13880	137	2	vs.	vs.	NOUN
aiua-13880	137	3	no	no	DET
aiua-13880	137	4	5	5	NUM
aiua-13880	137	5	0.84	0.84	NUM
aiua-13880	137	6	(	(	PUNCT
aiua-13880	137	7	0.70	0.70	NUM
aiua-13880	137	8	-	-	SYM
aiua-13880	137	9	1.01	1.01	NUM
aiua-13880	137	10	)	)	PUNCT
aiua-13880	137	11	0	0	NUM
aiua-13880	138	1	0.78	0.78	NUM
aiua-13880	138	2	-1.82	-1.82	NUM
aiua-13880	138	3	0.07	0.07	NUM
aiua-13880	138	4	bone	bone	NOUN
aiua-13880	138	5	metastasis	metastasis	NOUN
aiua-13880	138	6	yes	yes	INTJ
aiua-13880	138	7	vs.	vs.	ADP
aiua-13880	138	8	no	no	DET
aiua-13880	138	9	3	3	NUM
aiua-13880	138	10	1.29	1.29	NUM
aiua-13880	138	11	(	(	PUNCT
aiua-13880	138	12	1.02	1.02	NUM
aiua-13880	138	13	-	-	SYM
aiua-13880	138	14	1.64	1.64	NUM
aiua-13880	138	15	)	)	PUNCT
aiua-13880	138	16	0	0	NUM
aiua-13880	138	17	0.89	0.89	NUM
aiua-13880	138	18	2.12	2.12	NUM
aiua-13880	138	19	0.03	0.03	NUM
aiua-13880	138	20	primary	primary	ADJ
aiua-13880	138	21	site	site	NOUN
aiua-13880	138	22	utuc	utuc	NOUN
aiua-13880	138	23	vs	vs	ADP
aiua-13880	138	24	bc	bc	PROPN
aiua-13880	138	25	8	8	NUM
aiua-13880	138	26	1.05	1.05	NUM
aiua-13880	138	27	(	(	PUNCT
aiua-13880	138	28	0.73	0.73	NUM
aiua-13880	138	29	-	-	SYM
aiua-13880	138	30	1.52	1.52	NUM
aiua-13880	138	31	)	)	PUNCT
aiua-13880	138	32	58	58	NUM
aiua-13880	138	33	0.02	0.02	NUM
aiua-13880	138	34	0.32	0.32	NUM
aiua-13880	138	35	0.76	0.76	NUM
aiua-13880	138	36	surgical	surgical	ADJ
aiua-13880	138	37	removal	removal	NOUN
aiua-13880	138	38	of	of	ADP
aiua-13880	138	39	primary	primary	ADJ
aiua-13880	138	40	site	site	NOUN
aiua-13880	139	1	yes	yes	INTJ
aiua-13880	139	2	vs.	vs.	ADP
aiua-13880	139	3	no	no	DET
aiua-13880	139	4	5	5	NUM
aiua-13880	139	5	0.80	0.80	NUM
aiua-13880	139	6	(	(	PUNCT
aiua-13880	139	7	0.65	0.65	NUM
aiua-13880	139	8	-	-	PUNCT
aiua-13880	139	9	0.99	0.99	NUM
aiua-13880	139	10	)	)	PUNCT
aiua-13880	139	11	5	5	NUM
aiua-13880	139	12	0.38	0.38	NUM
aiua-13880	139	13	-2.07	-2.07	NUM
aiua-13880	139	14	0.04	0.04	NUM
aiua-13880	139	15	hematological	hematological	ADJ
aiua-13880	139	16	parameters	parameter	NOUN
aiua-13880	139	17	crp	crp	PROPN
aiua-13880	139	18	high	high	ADJ
aiua-13880	139	19	vs.	vs.	ADP
aiua-13880	139	20	low	low	ADJ
aiua-13880	139	21	4	4	NUM
aiua-13880	139	22	1.94	1.94	NUM
aiua-13880	139	23	(	(	PUNCT
aiua-13880	139	24	1.54	1.54	NUM
aiua-13880	139	25	-	-	SYM
aiua-13880	139	26	2.45	2.45	NUM
aiua-13880	139	27	)	)	PUNCT
aiua-13880	139	28	21	21	NUM
aiua-13880	139	29	0.28	0.28	NUM
aiua-13880	139	30	5.62	5.62	NUM
aiua-13880	139	31	<	<	X
aiua-13880	139	32	0.01	0.01	NUM
aiua-13880	139	33	hemoglobin	hemoglobin	NOUN
aiua-13880	139	34	low	low	ADJ
aiua-13880	139	35	vs.	vs.	ADP
aiua-13880	139	36	high	high	ADJ
aiua-13880	139	37	5	5	NUM
aiua-13880	139	38	1.80	1.80	NUM
aiua-13880	139	39	(	(	PUNCT
aiua-13880	139	40	1.51	1.51	NUM
aiua-13880	139	41	-	-	SYM
aiua-13880	139	42	2.14	2.14	NUM
aiua-13880	139	43	)	)	PUNCT
aiua-13880	139	44	0	0	NUM
aiua-13880	139	45	0.69	0.69	NUM
aiua-13880	139	46	6.52	6.52	NUM
aiua-13880	139	47	<	<	X
aiua-13880	139	48	0.01	0.01	NUM
aiua-13880	139	49	nlr	nlr	PROPN
aiua-13880	139	50	high	high	ADJ
aiua-13880	139	51	vs.	vs.	ADP
aiua-13880	139	52	low	low	ADJ
aiua-13880	139	53	6	6	NUM
aiua-13880	139	54	1.65	1.65	NUM
aiua-13880	139	55	(	(	PUNCT
aiua-13880	139	56	1.44	1.44	NUM
aiua-13880	139	57	-	-	SYM
aiua-13880	139	58	1.89	1.89	NUM
aiua-13880	139	59	)	)	PUNCT
aiua-13880	139	60	13	13	NUM
aiua-13880	139	61	0.33	0.33	NUM
aiua-13880	139	62	7.22	7.22	NUM
aiua-13880	139	63	<	<	X
aiua-13880	139	64	0.01	0.01	NUM
aiua-13880	139	65	overall	overall	ADJ
aiua-13880	139	66	survival	survival	NOUN
aiua-13880	139	67	demographic	demographic	ADJ
aiua-13880	139	68	factors	factor	NOUN
aiua-13880	139	69	age	age	VERB
aiua-13880	139	70	≥	≥	NUM
aiua-13880	139	71	70	70	NUM
aiua-13880	139	72	-	-	SYM
aiua-13880	139	73	75	75	NUM
aiua-13880	139	74	years	year	NOUN
aiua-13880	139	75	old	old	ADJ
aiua-13880	139	76	10	10	NUM
aiua-13880	139	77	1.00	1.00	NUM
aiua-13880	139	78	(	(	PUNCT
aiua-13880	139	79	0.99	0.99	NUM
aiua-13880	139	80	-	-	SYM
aiua-13880	139	81	1.01	1.01	NUM
aiua-13880	139	82	)	)	PUNCT
aiua-13880	139	83	43	43	NUM
aiua-13880	139	84	0.07	0.07	NUM
aiua-13880	139	85	0.16	0.16	NUM
aiua-13880	139	86	0.87	0.87	NUM
aiua-13880	139	87	gender	gender	NOUN
aiua-13880	139	88	male	male	NOUN
aiua-13880	139	89	vs.	vs.	ADP
aiua-13880	139	90	female	female	ADJ
aiua-13880	139	91	10	10	NUM
aiua-13880	139	92	0.97	0.97	NUM
aiua-13880	139	93	(	(	PUNCT
aiua-13880	139	94	0.87	0.87	NUM
aiua-13880	139	95	-	-	SYM
aiua-13880	139	96	1.08	1.08	NUM
aiua-13880	139	97	)	)	PUNCT
aiua-13880	139	98	30	30	NUM
aiua-13880	139	99	0.17	0.17	NUM
aiua-13880	139	100	-0.58	-0.58	NUM
aiua-13880	139	101	0.57	0.57	NUM
aiua-13880	139	102	clinical	clinical	ADJ
aiua-13880	139	103	factors	factor	NOUN
aiua-13880	139	104	bone	bone	NOUN
aiua-13880	139	105	metastasis	metastasis	PRON
aiua-13880	139	106	yes	yes	INTJ
aiua-13880	139	107	vs.	vs.	ADP
aiua-13880	139	108	no	no	DET
aiua-13880	139	109	5	5	NUM
aiua-13880	139	110	1.94	1.94	NUM
aiua-13880	139	111	(	(	PUNCT
aiua-13880	139	112	1.25	1.25	NUM
aiua-13880	139	113	-	-	SYM
aiua-13880	139	114	3.00	3.00	NUM
aiua-13880	139	115	)	)	PUNCT
aiua-13880	139	116	64	64	NUM
aiua-13880	139	117	0.03	0.03	NUM
aiua-13880	139	118	4.2	4.2	NUM
aiua-13880	139	119	0.01	0.01	NUM
aiua-13880	139	120	liver	liver	NOUN
aiua-13880	139	121	metastasis	metastasis	PRON
aiua-13880	139	122	yes	yes	INTJ
aiua-13880	139	123	vs.	vs.	ADP
aiua-13880	139	124	no	no	DET
aiua-13880	139	125	10	10	NUM
aiua-13880	139	126	2.44	2.44	NUM
aiua-13880	139	127	(	(	PUNCT
aiua-13880	139	128	2.16	2.16	NUM
aiua-13880	139	129	-	-	SYM
aiua-13880	139	130	2.76	2.76	NUM
aiua-13880	139	131	)	)	PUNCT
aiua-13880	139	132	31	31	NUM
aiua-13880	139	133	0.16	0.16	NUM
aiua-13880	139	134	14.39	14.39	NUM
aiua-13880	139	135	<	<	X
aiua-13880	139	136	0.01	0.01	NUM
aiua-13880	139	137	lung	lung	NOUN
aiua-13880	139	138	metastasis	metastasis	PRON
aiua-13880	139	139	yes	yes	INTJ
aiua-13880	139	140	vs.	vs.	ADP
aiua-13880	139	141	no	no	DET
aiua-13880	139	142	7	7	NUM
aiua-13880	139	143	1.35	1.35	NUM
aiua-13880	139	144	(	(	PUNCT
aiua-13880	139	145	1.18	1.18	NUM
aiua-13880	139	146	-	-	SYM
aiua-13880	139	147	1.56	1.56	NUM
aiua-13880	139	148	)	)	PUNCT
aiua-13880	139	149	34	34	NUM
aiua-13880	139	150	0.17	0.17	NUM
aiua-13880	139	151	4.29	4.29	NUM
aiua-13880	139	152	<	<	X
aiua-13880	139	153	0.01	0.01	NUM
aiua-13880	139	154	lymph	lymph	NOUN
aiua-13880	139	155	node	node	NOUN
aiua-13880	139	156	metastasis	metastasis	PRON
aiua-13880	139	157	yes	yes	INTJ
aiua-13880	139	158	vs.	vs.	ADP
aiua-13880	139	159	no	no	DET
aiua-13880	139	160	7	7	NUM
aiua-13880	139	161	0.94	0.94	NUM
aiua-13880	139	162	(	(	PUNCT
aiua-13880	139	163	0.67	0.67	NUM
aiua-13880	139	164	-	-	SYM
aiua-13880	139	165	1.33	1.33	NUM
aiua-13880	139	166	)	)	PUNCT
aiua-13880	139	167	73	73	NUM
aiua-13880	139	168	<	<	X
aiua-13880	139	169	0.01	0.01	NUM
aiua-13880	139	170	-0.4	-0.4	NUM
aiua-13880	139	171	0.7	0.7	NUM
aiua-13880	139	172	ecog	ecog	NOUN
aiua-13880	139	173	-	-	PUNCT
aiua-13880	139	174	ps	ps	NOUN
aiua-13880	139	175	≥	≥	NOUN
aiua-13880	139	176	2	2	NUM
aiua-13880	139	177	vs.	vs.	ADP
aiua-13880	139	178	<	<	X
aiua-13880	139	179	2	2	NUM
aiua-13880	139	180	10	10	NUM
aiua-13880	139	181	3.38	3.38	NUM
aiua-13880	139	182	(	(	PUNCT
aiua-13880	139	183	2.17	2.17	NUM
aiua-13880	139	184	-	-	SYM
aiua-13880	139	185	5.28	5.28	NUM
aiua-13880	139	186	)	)	PUNCT
aiua-13880	139	187	86	86	NUM
aiua-13880	139	188	<	<	X
aiua-13880	139	189	0.01	0.01	NUM
aiua-13880	139	190	6.68	6.68	NUM
aiua-13880	139	191	<	<	X
aiua-13880	139	192	0.01	0.01	NUM
aiua-13880	139	193	pathological	pathological	ADJ
aiua-13880	139	194	type	type	NOUN
aiua-13880	139	195	pure	pure	ADJ
aiua-13880	139	196	vs.	vs.	ADP
aiua-13880	139	197	mixed	mixed	ADJ
aiua-13880	139	198	uc	uc	PROPN
aiua-13880	139	199	5	5	NUM
aiua-13880	139	200	1.17	1.17	NUM
aiua-13880	139	201	(	(	PUNCT
aiua-13880	139	202	0.88	0.88	NUM
aiua-13880	139	203	-	-	SYM
aiua-13880	139	204	1.55	1.55	NUM
aiua-13880	139	205	)	)	PUNCT
aiua-13880	139	206	21	21	NUM
aiua-13880	139	207	0.28	0.28	NUM
aiua-13880	139	208	1.07	1.07	NUM
aiua-13880	139	209	0.29	0.29	NUM
aiua-13880	139	210	primary	primary	ADJ
aiua-13880	139	211	site	site	NOUN
aiua-13880	139	212	utuc	utuc	NOUN
aiua-13880	139	213	vs	vs	ADP
aiua-13880	139	214	bc	bc	PROPN
aiua-13880	139	215	10	10	NUM
aiua-13880	139	216	1.07	1.07	NUM
aiua-13880	139	217	(	(	PUNCT
aiua-13880	139	218	0.97	0.97	NUM
aiua-13880	139	219	-	-	SYM
aiua-13880	139	220	1.18	1.18	NUM
aiua-13880	139	221	)	)	PUNCT
aiua-13880	139	222	7	7	NUM
aiua-13880	139	223	0.38	0.38	NUM
aiua-13880	139	224	1.36	1.36	NUM
aiua-13880	139	225	0.17	0.17	NUM
aiua-13880	139	226	smoking	smoking	NOUN
aiua-13880	139	227	yes	yes	INTJ
aiua-13880	139	228	vs.	vs.	ADP
aiua-13880	139	229	no	no	DET
aiua-13880	139	230	6	6	NUM
aiua-13880	139	231	1.03	1.03	NUM
aiua-13880	139	232	(	(	PUNCT
aiua-13880	139	233	0.93	0.93	NUM
aiua-13880	139	234	-	-	SYM
aiua-13880	139	235	1.14	1.14	NUM
aiua-13880	139	236	)	)	PUNCT
aiua-13880	139	237	0	0	NUM
aiua-13880	140	1	0.44	0.44	NUM
aiua-13880	140	2	0.57	0.57	NUM
aiua-13880	140	3	0.57	0.57	NUM
aiua-13880	140	4	surgical	surgical	ADJ
aiua-13880	140	5	removal	removal	NOUN
aiua-13880	140	6	of	of	ADP
aiua-13880	140	7	primary	primary	ADJ
aiua-13880	140	8	site	site	NOUN
aiua-13880	141	1	yes	yes	INTJ
aiua-13880	141	2	vs.	vs.	ADP
aiua-13880	141	3	no	no	DET
aiua-13880	141	4	4	4	NUM
aiua-13880	141	5	0.71	0.71	NUM
aiua-13880	141	6	(	(	PUNCT
aiua-13880	141	7	0.58	0.58	NUM
aiua-13880	141	8	-	-	SYM
aiua-13880	141	9	0.88	0.88	NUM
aiua-13880	141	10	)	)	PUNCT
aiua-13880	141	11	0	0	NUM
aiua-13880	141	12	0.6	0.6	NUM
aiua-13880	141	13	-3.21	-3.21	NOUN
aiua-13880	141	14	<	<	X
aiua-13880	141	15	0.01	0.01	NUM
aiua-13880	141	16	time	time	NOUN
aiua-13880	141	17	from	from	ADP
aiua-13880	141	18	previous	previous	ADJ
aiua-13880	141	19	chemotherapy	chemotherapy	NOUN
aiua-13880	141	20	<	<	X
aiua-13880	141	21	90d	90d	NOUN
aiua-13880	141	22	vs.	vs.	ADP
aiua-13880	141	23	≥	≥	NOUN
aiua-13880	141	24	90d	90d	NOUN
aiua-13880	141	25	4	4	NUM
aiua-13880	141	26	1.42	1.42	NUM
aiua-13880	141	27	(	(	PUNCT
aiua-13880	141	28	1.22	1.22	NUM
aiua-13880	141	29	-	-	SYM
aiua-13880	141	30	1.64	1.64	NUM
aiua-13880	141	31	)	)	PUNCT
aiua-13880	141	32	0	0	NUM
aiua-13880	141	33	0.66	0.66	NUM
aiua-13880	141	34	4.66	4.66	NUM
aiua-13880	141	35	<	<	X
aiua-13880	141	36	0.01	0.01	NUM
aiua-13880	141	37	hematological	hematological	ADJ
aiua-13880	141	38	parameters	parameter	NOUN
aiua-13880	141	39	albumin	albumin	VERB
aiua-13880	141	40	<	<	X
aiua-13880	141	41	3.5	3.5	NUM
aiua-13880	141	42	-	-	SYM
aiua-13880	141	43	3.7	3.7	NUM
aiua-13880	141	44	3	3	NUM
aiua-13880	141	45	3.13	3.13	NUM
aiua-13880	141	46	(	(	PUNCT
aiua-13880	141	47	2.52	2.52	NUM
aiua-13880	141	48	-	-	SYM
aiua-13880	141	49	3.88	3.88	NUM
aiua-13880	141	50	)	)	PUNCT
aiua-13880	141	51	0	0	NUM
aiua-13880	142	1	0.7	0.7	NUM
aiua-13880	142	2	10.4	10.4	NUM
aiua-13880	142	3	<	<	X
aiua-13880	142	4	0.01	0.01	NUM
aiua-13880	142	5	crp	crp	NOUN
aiua-13880	142	6	high	high	ADJ
aiua-13880	142	7	vs.	vs.	ADP
aiua-13880	142	8	low	low	ADJ
aiua-13880	142	9	5	5	NUM
aiua-13880	142	10	2.18	2.18	NUM
aiua-13880	142	11	(	(	PUNCT
aiua-13880	142	12	1.07	1.07	NUM
aiua-13880	142	13	-	-	SYM
aiua-13880	142	14	4.42	4.42	NUM
aiua-13880	142	15	)	)	PUNCT
aiua-13880	142	16	94	94	NUM
aiua-13880	142	17	<	<	NOUN
aiua-13880	142	18	0.01	0.01	NUM
aiua-13880	142	19	3.05	3.05	NUM
aiua-13880	142	20	0.04	0.04	NUM
aiua-13880	142	21	hemoglobin	hemoglobin	NOUN
aiua-13880	142	22	low	low	ADJ
aiua-13880	142	23	vs.	vs.	X
aiua-13880	142	24	high	high	ADJ
aiua-13880	142	25	8	8	NUM
aiua-13880	142	26	2.08	2.08	NUM
aiua-13880	142	27	(	(	PUNCT
aiua-13880	142	28	1.85	1.85	NUM
aiua-13880	142	29	-	-	NUM
aiua-13880	142	30	2.35	2.35	NUM
aiua-13880	142	31	)	)	PUNCT
aiua-13880	142	32	23	23	NUM
aiua-13880	142	33	0.24	0.24	NUM
aiua-13880	142	34	12.05	12.05	NUM
aiua-13880	142	35	<	<	X
aiua-13880	142	36	0.01	0.01	NUM
aiua-13880	142	37	nlr	nlr	PROPN
aiua-13880	142	38	high	high	ADJ
aiua-13880	142	39	vs.	vs.	X
aiua-13880	142	40	low	low	ADJ
aiua-13880	142	41	8	8	NUM
aiua-13880	142	42	1.93	1.93	NUM
aiua-13880	142	43	(	(	PUNCT
aiua-13880	142	44	1.71	1.71	NUM
aiua-13880	142	45	-	-	SYM
aiua-13880	142	46	2.18	2.18	NUM
aiua-13880	142	47	)	)	PUNCT
aiua-13880	142	48	46	46	NUM
aiua-13880	142	49	0.07	0.07	NUM
aiua-13880	142	50	10.52	10.52	NUM
aiua-13880	142	51	<	<	X
aiua-13880	142	52	0.01	0.01	NUM
aiua-13880	142	53	ecog	ecog	NOUN
aiua-13880	142	54	-	-	PUNCT
aiua-13880	142	55	ps	ps	NOUN
aiua-13880	142	56	:	:	PUNCT
aiua-13880	142	57	eastern	eastern	ADJ
aiua-13880	142	58	cooperative	cooperative	ADJ
aiua-13880	142	59	oncology	oncology	NOUN
aiua-13880	142	60	group	group	NOUN
aiua-13880	142	61	performance	performance	NOUN
aiua-13880	142	62	status	status	NOUN
aiua-13880	142	63	scale	scale	NOUN
aiua-13880	142	64	;	;	PUNCT
aiua-13880	142	65	uc	uc	ADJ
aiua-13880	142	66	:	:	PUNCT
aiua-13880	142	67	urothelial	urothelial	ADJ
aiua-13880	142	68	carcinoma	carcinoma	NOUN
aiua-13880	142	69	;	;	PUNCT
aiua-13880	142	70	utuc	utuc	NOUN
aiua-13880	142	71	:	:	PUNCT
aiua-13880	142	72	upper	upper	ADJ
aiua-13880	142	73	urinary	urinary	ADJ
aiua-13880	142	74	tract	tract	NOUN
aiua-13880	142	75	urothelial	urothelial	ADJ
aiua-13880	142	76	carcinoma	carcinoma	NOUN
aiua-13880	142	77	;	;	PUNCT
aiua-13880	142	78	bc	bc	ADJ
aiua-13880	142	79	:	:	PUNCT
aiua-13880	142	80	bladder	bladder	NOUN
aiua-13880	142	81	urothelial	urothelial	ADJ
aiua-13880	142	82	carcinoma	carcinoma	NOUN
aiua-13880	142	83	;	;	PUNCT
aiua-13880	142	84	crp	crp	NOUN
aiua-13880	142	85	:	:	PUNCT
aiua-13880	142	86	c	c	X
aiua-13880	142	87	-	-	PUNCT
aiua-13880	142	88	reactive	reactive	ADJ
aiua-13880	142	89	protein	protein	NOUN
aiua-13880	142	90	.	.	PUNCT
aiua-13880	143	1	archivio	archivio	NOUN
aiua-13880	143	2	italiano	italiano	PROPN
aiua-13880	143	3	di	di	PROPN
aiua-13880	143	4	urologia	urologia	PROPN
aiua-13880	143	5	e	e	PROPN
aiua-13880	143	6	andrologia	andrologia	NOUN
aiua-13880	143	7	2025	2025	NUM
aiua-13880	143	8	;	;	PUNCT
aiua-13880	143	9	97(2):13880	97(2):13880	NUM
aiua-13880	143	10	7	7	NUM
aiua-13880	143	11	pembrolizumab	pembrolizumab	NOUN
aiua-13880	143	12	in	in	ADP
aiua-13880	143	13	advanced	advanced	ADJ
aiua-13880	143	14	/	/	SYM
aiua-13880	143	15	metastatic	metastatic	ADJ
aiua-13880	143	16	urothelial	urothelial	ADJ
aiua-13880	143	17	carcinoma	carcinoma	NOUN
aiua-13880	143	18	figure	figure	NOUN
aiua-13880	143	19	2	2	NUM
aiua-13880	143	20	.	.	PUNCT
aiua-13880	143	21	traffic	traffic	NOUN
aiua-13880	143	22	plot	plot	NOUN
aiua-13880	143	23	of	of	ADP
aiua-13880	143	24	the	the	DET
aiua-13880	143	25	included	include	VERB
aiua-13880	143	26	studies	study	NOUN
aiua-13880	143	27	risk	risk	NOUN
aiua-13880	143	28	of	of	ADP
aiua-13880	143	29	bias	bias	NOUN
aiua-13880	143	30	assessed	assess	VERB
aiua-13880	143	31	by	by	ADP
aiua-13880	143	32	quips	quip	NOUN
aiua-13880	143	33	tool	tool	NOUN
aiua-13880	143	34	.	.	PUNCT
aiua-13880	144	1	archivio	archivio	NOUN
aiua-13880	144	2	italiano	italiano	PROPN
aiua-13880	144	3	di	di	PROPN
aiua-13880	144	4	urologia	urologia	PROPN
aiua-13880	144	5	e	e	PROPN
aiua-13880	144	6	andrologia	andrologia	NOUN
aiua-13880	144	7	2025	2025	NUM
aiua-13880	144	8	;	;	PUNCT
aiua-13880	144	9	97(2):13880	97(2):13880	NUM
aiua-13880	144	10	k	k	PROPN
aiua-13880	144	11	..	..	PUNCT
aiua-13880	144	12	yuwono	yuwono	PROPN
aiua-13880	144	13	,	,	PUNCT
aiua-13880	144	14	j.	j.	PROPN
aiua-13880	144	15	nimasratu	nimasratu	PROPN
aiua-13880	144	16	rahmatsani	rahmatsani	PROPN
aiua-13880	144	17	,	,	PUNCT
aiua-13880	144	18	nadhifah	nadhifah	VERB
aiua-13880	144	19	,	,	PUNCT
aiua-13880	144	20	et	et	PROPN
aiua-13880	144	21	al	al	PROPN
aiua-13880	144	22	.	.	PROPN
aiua-13880	144	23	8	8	NUM
aiua-13880	144	24	discussion	discussion	NOUN
aiua-13880	144	25	given	give	VERB
aiua-13880	144	26	that	that	SCONJ
aiua-13880	144	27	only	only	ADV
aiua-13880	144	28	a	a	DET
aiua-13880	144	29	small	small	ADJ
aiua-13880	144	30	percentage	percentage	NOUN
aiua-13880	144	31	of	of	ADP
aiua-13880	144	32	patients	patient	NOUN
aiua-13880	144	33	derive	derive	VERB
aiua-13880	144	34	benefits	benefit	NOUN
aiua-13880	144	35	from	from	ADP
aiua-13880	144	36	immunotherapy	immunotherapy	NOUN
aiua-13880	144	37	,	,	PUNCT
aiua-13880	144	38	numerous	numerous	ADJ
aiua-13880	144	39	predictive	predictive	ADJ
aiua-13880	144	40	biomarkers	biomarker	NOUN
aiua-13880	144	41	have	have	AUX
aiua-13880	144	42	been	be	AUX
aiua-13880	144	43	developed	develop	VERB
aiua-13880	144	44	to	to	PART
aiua-13880	144	45	improve	improve	VERB
aiua-13880	144	46	outcome	outcome	NOUN
aiua-13880	144	47	predictions	prediction	NOUN
aiua-13880	144	48	.	.	PUNCT
aiua-13880	145	1	current	current	ADJ
aiua-13880	145	2	evidence	evidence	NOUN
aiua-13880	145	3	indicates	indicate	VERB
aiua-13880	145	4	that	that	SCONJ
aiua-13880	145	5	pd	pd	PROPN
aiua-13880	145	6	-	-	PUNCT
aiua-13880	145	7	l1	l1	PROPN
aiua-13880	145	8	expression	expression	NOUN
aiua-13880	145	9	serves	serve	VERB
aiua-13880	145	10	as	as	ADP
aiua-13880	145	11	the	the	DET
aiua-13880	145	12	most	most	ADV
aiua-13880	145	13	reliable	reliable	ADJ
aiua-13880	145	14	biomarker	biomarker	NOUN
aiua-13880	145	15	for	for	ADP
aiua-13880	145	16	predicting	predict	VERB
aiua-13880	145	17	which	which	PRON
aiua-13880	145	18	patients	patient	NOUN
aiua-13880	145	19	with	with	ADP
aiua-13880	145	20	advanced	advanced	ADJ
aiua-13880	145	21	uc	uc	NOUN
aiua-13880	145	22	are	be	AUX
aiua-13880	145	23	likely	likely	ADJ
aiua-13880	145	24	to	to	PART
aiua-13880	145	25	respond	respond	VERB
aiua-13880	145	26	to	to	ADP
aiua-13880	145	27	anti	anti	ADJ
aiua-13880	145	28	-	-	ADJ
aiua-13880	145	29	pd-1	pd-1	ADJ
aiua-13880	145	30	or	or	CCONJ
aiua-13880	145	31	anti	anti	ADJ
aiua-13880	145	32	-	-	ADJ
aiua-13880	145	33	pd	pd	ADJ
aiua-13880	145	34	-	-	PUNCT
aiua-13880	145	35	l1	l1	PROPN
aiua-13880	145	36	therapies	therapy	NOUN
aiua-13880	145	37	(	(	PUNCT
aiua-13880	145	38	19	19	NUM
aiua-13880	145	39	-	-	SYM
aiua-13880	145	40	21	21	NUM
aiua-13880	145	41	)	)	PUNCT
aiua-13880	145	42	.	.	PUNCT
aiua-13880	146	1	however	however	ADV
aiua-13880	146	2	,	,	PUNCT
aiua-13880	146	3	pembrolizumab	pembrolizumab	NOUN
aiua-13880	146	4	monotherapy	monotherapy	NOUN
aiua-13880	146	5	showed	show	VERB
aiua-13880	146	6	comparable	comparable	ADJ
aiua-13880	146	7	survival	survival	NOUN
aiua-13880	146	8	to	to	ADP
aiua-13880	146	9	platinumbased	platinumbase	VERB
aiua-13880	146	10	chemotherapy	chemotherapy	NOUN
aiua-13880	146	11	regardless	regardless	ADV
aiua-13880	146	12	of	of	ADP
aiua-13880	146	13	pd	pd	PROPN
aiua-13880	146	14	-	-	PROPN
aiua-13880	146	15	l1	l1	PROPN
aiua-13880	146	16	combined	combine	VERB
aiua-13880	146	17	positive	positive	ADJ
aiua-13880	146	18	score	score	NOUN
aiua-13880	146	19	(	(	PUNCT
aiua-13880	146	20	cps	cps	PROPN
aiua-13880	146	21	)	)	PUNCT
aiua-13880	146	22	(	(	PUNCT
aiua-13880	146	23	22	22	NUM
aiua-13880	146	24	)	)	PUNCT
aiua-13880	146	25	.	.	PUNCT
aiua-13880	147	1	that	that	PRON
aiua-13880	147	2	is	be	AUX
aiua-13880	147	3	why	why	SCONJ
aiua-13880	147	4	in	in	ADP
aiua-13880	147	5	this	this	DET
aiua-13880	147	6	study	study	NOUN
aiua-13880	147	7	,	,	PUNCT
aiua-13880	147	8	we	we	PRON
aiua-13880	147	9	identified	identify	VERB
aiua-13880	147	10	several	several	ADJ
aiua-13880	147	11	potential	potential	ADJ
aiua-13880	147	12	hematological	hematological	ADJ
aiua-13880	147	13	and	and	CCONJ
aiua-13880	147	14	clinical	clinical	ADJ
aiua-13880	147	15	risk	risk	NOUN
aiua-13880	147	16	factors	factor	NOUN
aiua-13880	147	17	linked	link	VERB
aiua-13880	147	18	to	to	ADP
aiua-13880	147	19	unfavorable	unfavorable	ADJ
aiua-13880	147	20	outcomes	outcome	NOUN
aiua-13880	147	21	in	in	ADP
aiua-13880	147	22	patients	patient	NOUN
aiua-13880	147	23	with	with	ADP
aiua-13880	147	24	advanced	advanced	ADJ
aiua-13880	148	1	uc	uc	INTJ
aiua-13880	148	2	receiving	receive	VERB
aiua-13880	148	3	pembrolizumab	pembrolizumab	NOUN
aiua-13880	148	4	monotherapy	monotherapy	NOUN
aiua-13880	148	5	.	.	PUNCT
aiua-13880	149	1	the	the	DET
aiua-13880	149	2	metastatic	metastatic	ADJ
aiua-13880	149	3	sites	site	NOUN
aiua-13880	149	4	significantly	significantly	ADV
aiua-13880	149	5	associated	associate	VERB
aiua-13880	149	6	with	with	ADP
aiua-13880	149	7	worse	bad	ADJ
aiua-13880	149	8	progression	progression	NOUN
aiua-13880	149	9	free	free	ADJ
aiua-13880	149	10	survival	survival	NOUN
aiua-13880	149	11	and	and	CCONJ
aiua-13880	149	12	overall	overall	ADJ
aiua-13880	149	13	survival	survival	NOUN
aiua-13880	149	14	are	be	AUX
aiua-13880	149	15	the	the	DET
aiua-13880	149	16	liver	liver	NOUN
aiua-13880	149	17	,	,	PUNCT
aiua-13880	149	18	lung	lung	NOUN
aiua-13880	149	19	,	,	PUNCT
aiua-13880	149	20	and	and	CCONJ
aiua-13880	149	21	bone	bone	NOUN
aiua-13880	149	22	.	.	PUNCT
aiua-13880	150	1	lymph	lymph	NOUN
aiua-13880	150	2	nodes	node	NOUN
aiua-13880	150	3	are	be	AUX
aiua-13880	150	4	the	the	DET
aiua-13880	150	5	most	most	ADV
aiua-13880	150	6	common	common	ADJ
aiua-13880	150	7	site	site	NOUN
aiua-13880	150	8	of	of	ADP
aiua-13880	150	9	metastasis	metastasis	NOUN
aiua-13880	150	10	in	in	ADP
aiua-13880	150	11	urothelial	urothelial	ADJ
aiua-13880	150	12	carcinoma	carcinoma	NOUN
aiua-13880	150	13	,	,	PUNCT
aiua-13880	150	14	with	with	ADP
aiua-13880	150	15	other	other	ADJ
aiua-13880	150	16	studies	study	NOUN
aiua-13880	150	17	reporting	report	VERB
aiua-13880	150	18	an	an	DET
aiua-13880	150	19	incidence	incidence	NOUN
aiua-13880	150	20	of	of	ADP
aiua-13880	150	21	69%-90	69%-90	NUM
aiua-13880	150	22	%	%	NOUN
aiua-13880	150	23	(	(	PUNCT
aiua-13880	150	24	23	23	NUM
aiua-13880	150	25	)	)	PUNCT
aiua-13880	150	26	.	.	PUNCT
aiua-13880	151	1	in	in	ADP
aiua-13880	151	2	accordance	accordance	NOUN
aiua-13880	151	3	with	with	ADP
aiua-13880	151	4	this	this	DET
aiua-13880	151	5	study	study	NOUN
aiua-13880	151	6	,	,	PUNCT
aiua-13880	151	7	patients	patient	NOUN
aiua-13880	151	8	with	with	ADP
aiua-13880	151	9	lymph	lymph	NOUN
aiua-13880	151	10	-	-	PUNCT
aiua-13880	151	11	node	node	NOUN
aiua-13880	151	12	-	-	PUNCT
aiua-13880	151	13	only	only	ADV
aiua-13880	151	14	metastasis	metastasis	NOUN
aiua-13880	151	15	tend	tend	VERB
aiua-13880	151	16	to	to	PART
aiua-13880	151	17	have	have	VERB
aiua-13880	151	18	better	well	ADJ
aiua-13880	151	19	pfs	pf	VERB
aiua-13880	151	20	and	and	CCONJ
aiua-13880	151	21	os	os	NOUN
aiua-13880	151	22	compared	compare	VERB
aiua-13880	151	23	to	to	ADP
aiua-13880	151	24	those	those	PRON
aiua-13880	151	25	with	with	ADP
aiua-13880	151	26	visceral	visceral	ADJ
aiua-13880	151	27	metastases	metastasis	NOUN
aiua-13880	151	28	.	.	PUNCT
aiua-13880	152	1	this	this	DET
aiua-13880	152	2	better	well	ADJ
aiua-13880	152	3	prognosis	prognosis	NOUN
aiua-13880	152	4	may	may	AUX
aiua-13880	152	5	be	be	AUX
aiua-13880	152	6	explained	explain	VERB
aiua-13880	152	7	by	by	ADP
aiua-13880	152	8	the	the	DET
aiua-13880	152	9	presence	presence	NOUN
aiua-13880	152	10	of	of	ADP
aiua-13880	152	11	immune	immune	ADJ
aiua-13880	152	12	cells	cell	NOUN
aiua-13880	152	13	within	within	ADP
aiua-13880	152	14	the	the	DET
aiua-13880	152	15	lymph	lymph	NOUN
aiua-13880	152	16	nodes	node	NOUN
aiua-13880	152	17	,	,	PUNCT
aiua-13880	152	18	which	which	PRON
aiua-13880	152	19	may	may	AUX
aiua-13880	152	20	enhance	enhance	VERB
aiua-13880	152	21	the	the	DET
aiua-13880	152	22	efficacy	efficacy	NOUN
aiua-13880	152	23	of	of	ADP
aiua-13880	152	24	immune	immune	ADJ
aiua-13880	152	25	checkpoint	checkpoint	NOUN
aiua-13880	152	26	inhibitors	inhibitor	NOUN
aiua-13880	152	27	(	(	PUNCT
aiua-13880	152	28	icis	icis	NOUN
aiua-13880	152	29	)	)	PUNCT
aiua-13880	152	30	and	and	CCONJ
aiua-13880	152	31	other	other	ADJ
aiua-13880	152	32	therapies	therapy	NOUN
aiua-13880	152	33	.	.	PUNCT
aiua-13880	153	1	additionally	additionally	ADV
aiua-13880	153	2	,	,	PUNCT
aiua-13880	153	3	lymph	lymph	NOUN
aiua-13880	153	4	-	-	PUNCT
aiua-13880	153	5	node	node	NOUN
aiua-13880	153	6	-	-	PUNCT
aiua-13880	153	7	only	only	ADJ
aiua-13880	153	8	metastasis	metastasis	NOUN
aiua-13880	153	9	may	may	AUX
aiua-13880	153	10	represent	represent	VERB
aiua-13880	153	11	an	an	DET
aiua-13880	153	12	earlier	early	ADJ
aiua-13880	153	13	stage	stage	NOUN
aiua-13880	153	14	of	of	ADP
aiua-13880	153	15	cancer	cancer	NOUN
aiua-13880	153	16	progression	progression	NOUN
aiua-13880	153	17	,	,	PUNCT
aiua-13880	153	18	with	with	ADP
aiua-13880	153	19	less	less	ADJ
aiua-13880	153	20	tumor	tumor	NOUN
aiua-13880	153	21	heterogeneity	heterogeneity	NOUN
aiua-13880	153	22	or	or	CCONJ
aiua-13880	153	23	clonal	clonal	ADJ
aiua-13880	153	24	evolution	evolution	NOUN
aiua-13880	153	25	compared	compare	VERB
aiua-13880	153	26	to	to	ADP
aiua-13880	153	27	visceral	visceral	ADJ
aiua-13880	153	28	metastasis	metastasis	NOUN
aiua-13880	153	29	(	(	PUNCT
aiua-13880	153	30	24	24	NUM
aiua-13880	153	31	)	)	PUNCT
aiua-13880	153	32	.	.	PUNCT
aiua-13880	154	1	in	in	ADP
aiua-13880	154	2	contrast	contrast	NOUN
aiua-13880	154	3	,	,	PUNCT
aiua-13880	154	4	liver	liver	NOUN
aiua-13880	154	5	metastasis	metastasis	NOUN
aiua-13880	154	6	occurs	occur	VERB
aiua-13880	154	7	less	less	ADV
aiua-13880	154	8	frequently	frequently	ADV
aiua-13880	154	9	,	,	PUNCT
aiua-13880	154	10	with	with	ADP
aiua-13880	154	11	an	an	DET
aiua-13880	154	12	incidence	incidence	NOUN
aiua-13880	154	13	ranging	range	VERB
aiua-13880	154	14	from	from	ADP
aiua-13880	154	15	19	19	NUM
aiua-13880	154	16	%	%	NOUN
aiua-13880	154	17	up	up	ADP
aiua-13880	154	18	to	to	PART
aiua-13880	154	19	47	47	NUM
aiua-13880	154	20	%	%	NOUN
aiua-13880	154	21	,	,	PUNCT
aiua-13880	154	22	but	but	CCONJ
aiua-13880	154	23	is	be	AUX
aiua-13880	154	24	associated	associate	VERB
aiua-13880	154	25	with	with	ADP
aiua-13880	154	26	the	the	DET
aiua-13880	154	27	worst	bad	ADJ
aiua-13880	154	28	survival	survival	NOUN
aiua-13880	154	29	outcomes	outcome	NOUN
aiua-13880	154	30	among	among	ADP
aiua-13880	154	31	metastatic	metastatic	ADJ
aiua-13880	154	32	sites	site	NOUN
aiua-13880	154	33	,	,	PUNCT
aiua-13880	154	34	as	as	SCONJ
aiua-13880	154	35	this	this	DET
aiua-13880	154	36	research	research	NOUN
aiua-13880	154	37	demonstrates	demonstrate	VERB
aiua-13880	154	38	(	(	PUNCT
aiua-13880	154	39	25	25	NUM
aiua-13880	154	40	)	)	PUNCT
aiua-13880	154	41	.	.	PUNCT
aiua-13880	155	1	patients	patient	NOUN
aiua-13880	155	2	with	with	ADP
aiua-13880	155	3	liver	liver	NOUN
aiua-13880	155	4	metastases	metastasis	NOUN
aiua-13880	155	5	have	have	VERB
aiua-13880	155	6	a	a	DET
aiua-13880	155	7	median	median	ADJ
aiua-13880	155	8	overall	overall	ADJ
aiua-13880	155	9	survival	survival	NOUN
aiua-13880	155	10	of	of	ADP
aiua-13880	155	11	only	only	ADV
aiua-13880	155	12	seven	seven	NUM
aiua-13880	155	13	months	month	NOUN
aiua-13880	155	14	,	,	PUNCT
aiua-13880	155	15	highlighting	highlight	VERB
aiua-13880	155	16	its	its	PRON
aiua-13880	155	17	poor	poor	ADJ
aiua-13880	155	18	prognosis	prognosis	NOUN
aiua-13880	155	19	compared	compare	VERB
aiua-13880	155	20	to	to	ADP
aiua-13880	155	21	other	other	ADJ
aiua-13880	155	22	metastatic	metastatic	ADJ
aiua-13880	155	23	patterns	pattern	NOUN
aiua-13880	155	24	(	(	PUNCT
aiua-13880	155	25	26	26	NUM
aiua-13880	155	26	)	)	PUNCT
aiua-13880	155	27	.	.	PUNCT
aiua-13880	156	1	liver	liver	NOUN
aiua-13880	156	2	metastases	metastasis	NOUN
aiua-13880	156	3	are	be	AUX
aiua-13880	156	4	often	often	ADV
aiua-13880	156	5	multiple	multiple	ADJ
aiua-13880	156	6	and	and	CCONJ
aiua-13880	156	7	diffuse	diffuse	ADJ
aiua-13880	156	8	,	,	PUNCT
aiua-13880	156	9	indicating	indicate	VERB
aiua-13880	156	10	systemic	systemic	ADJ
aiua-13880	156	11	disease	disease	NOUN
aiua-13880	156	12	with	with	ADP
aiua-13880	156	13	high	high	ADJ
aiua-13880	156	14	tumor	tumor	NOUN
aiua-13880	156	15	burden	burden	NOUN
aiua-13880	156	16	hypotheses	hypothesis	NOUN
aiua-13880	156	17	for	for	ADP
aiua-13880	156	18	the	the	DET
aiua-13880	156	19	poor	poor	ADJ
aiua-13880	156	20	prognosis	prognosis	NOUN
aiua-13880	156	21	of	of	ADP
aiua-13880	156	22	liver	liver	NOUN
aiua-13880	156	23	metastases	metastasis	NOUN
aiua-13880	156	24	include	include	VERB
aiua-13880	156	25	the	the	DET
aiua-13880	156	26	immunosuppressive	immunosuppressive	ADJ
aiua-13880	156	27	microenvironment	microenvironment	NOUN
aiua-13880	156	28	of	of	ADP
aiua-13880	156	29	the	the	DET
aiua-13880	156	30	liver	liver	NOUN
aiua-13880	156	31	,	,	PUNCT
aiua-13880	156	32	increased	increase	VERB
aiua-13880	156	33	tumor	tumor	NOUN
aiua-13880	156	34	mutation	mutation	NOUN
aiua-13880	156	35	burden	burden	NOUN
aiua-13880	156	36	,	,	PUNCT
aiua-13880	156	37	clonal	clonal	ADJ
aiua-13880	156	38	evolution	evolution	NOUN
aiua-13880	156	39	,	,	PUNCT
aiua-13880	156	40	and	and	CCONJ
aiua-13880	156	41	poor	poor	ADJ
aiua-13880	156	42	response	response	NOUN
aiua-13880	156	43	to	to	ADP
aiua-13880	156	44	chemotherapy	chemotherapy	NOUN
aiua-13880	156	45	and	and	CCONJ
aiua-13880	156	46	icis	icis	PROPN
aiua-13880	156	47	(	(	PUNCT
aiua-13880	156	48	24	24	NUM
aiua-13880	156	49	,	,	PUNCT
aiua-13880	156	50	25	25	NUM
aiua-13880	156	51	)	)	PUNCT
aiua-13880	156	52	.	.	PUNCT
aiua-13880	157	1	furthermore	furthermore	ADV
aiua-13880	157	2	,	,	PUNCT
aiua-13880	157	3	small	small	ADJ
aiua-13880	157	4	metastases	metastasis	NOUN
aiua-13880	157	5	in	in	ADP
aiua-13880	157	6	the	the	DET
aiua-13880	157	7	liver	liver	NOUN
aiua-13880	157	8	might	might	AUX
aiua-13880	157	9	not	not	PART
aiua-13880	157	10	be	be	AUX
aiua-13880	157	11	detected	detect	VERB
aiua-13880	157	12	by	by	ADP
aiua-13880	157	13	imaging	image	VERB
aiua-13880	157	14	techniques	technique	NOUN
aiua-13880	157	15	and	and	CCONJ
aiua-13880	157	16	are	be	AUX
aiua-13880	157	17	only	only	ADV
aiua-13880	157	18	revealed	reveal	VERB
aiua-13880	157	19	later	later	ADV
aiua-13880	157	20	on	on	ADV
aiua-13880	157	21	during	during	ADP
aiua-13880	157	22	autopsy	autopsy	ADJ
aiua-13880	157	23	,	,	PUNCT
aiua-13880	157	24	such	such	ADJ
aiua-13880	157	25	as	as	ADP
aiua-13880	157	26	in	in	ADP
aiua-13880	157	27	the	the	DET
aiua-13880	157	28	study	study	NOUN
aiua-13880	157	29	performed	perform	VERB
aiua-13880	157	30	by	by	ADP
aiua-13880	157	31	wallmeroth	wallmeroth	NOUN
aiua-13880	157	32	(	(	PUNCT
aiua-13880	157	33	27	27	NUM
aiua-13880	157	34	)	)	PUNCT
aiua-13880	157	35	.	.	PUNCT
aiua-13880	158	1	liver	liver	NOUN
aiua-13880	158	2	-	-	PUNCT
aiua-13880	158	3	directed	direct	VERB
aiua-13880	158	4	therapies	therapy	NOUN
aiua-13880	158	5	such	such	ADJ
aiua-13880	158	6	as	as	ADP
aiua-13880	158	7	radiofrequency	radiofrequency	NOUN
aiua-13880	158	8	ablation	ablation	NOUN
aiua-13880	158	9	may	may	AUX
aiua-13880	158	10	offer	offer	VERB
aiua-13880	158	11	some	some	DET
aiua-13880	158	12	survival	survival	NOUN
aiua-13880	158	13	benefit	benefit	NOUN
aiua-13880	158	14	on	on	ADP
aiua-13880	158	15	top	top	NOUN
aiua-13880	158	16	of	of	ADP
aiua-13880	158	17	systemic	systemic	ADJ
aiua-13880	158	18	chemotherapy	chemotherapy	NOUN
aiua-13880	158	19	(	(	PUNCT
aiua-13880	158	20	26	26	NUM
aiua-13880	158	21	)	)	PUNCT
aiua-13880	158	22	.	.	PUNCT
aiua-13880	159	1	bone	bone	NOUN
aiua-13880	159	2	metastases	metastasis	NOUN
aiua-13880	159	3	are	be	AUX
aiua-13880	159	4	reported	report	VERB
aiua-13880	159	5	in	in	ADP
aiua-13880	159	6	32%-47	32%-47	NUM
aiua-13880	159	7	%	%	NOUN
aiua-13880	159	8	of	of	ADP
aiua-13880	159	9	patients	patient	NOUN
aiua-13880	159	10	with	with	ADP
aiua-13880	159	11	muc	muc	PROPN
aiua-13880	159	12	(	(	PUNCT
aiua-13880	159	13	23	23	NUM
aiua-13880	159	14	,	,	PUNCT
aiua-13880	159	15	27	27	NUM
aiua-13880	159	16	)	)	PUNCT
aiua-13880	159	17	.	.	PUNCT
aiua-13880	160	1	recent	recent	ADJ
aiua-13880	160	2	studies	study	NOUN
aiua-13880	160	3	have	have	AUX
aiua-13880	160	4	reported	report	VERB
aiua-13880	160	5	a	a	DET
aiua-13880	160	6	higher	high	ADJ
aiua-13880	160	7	incidence	incidence	NOUN
aiua-13880	160	8	of	of	ADP
aiua-13880	160	9	bone	bone	NOUN
aiua-13880	160	10	metastases	metastasis	NOUN
aiua-13880	160	11	,	,	PUNCT
aiua-13880	160	12	potentially	potentially	ADV
aiua-13880	160	13	due	due	ADJ
aiua-13880	160	14	to	to	ADP
aiua-13880	160	15	advanced	advanced	ADJ
aiua-13880	160	16	imaging	imaging	NOUN
aiua-13880	160	17	techniques	technique	NOUN
aiua-13880	160	18	like	like	ADP
aiua-13880	160	19	bone	bone	NOUN
aiua-13880	160	20	scintigraphy	scintigraphy	NOUN
aiua-13880	160	21	and	and	CCONJ
aiua-13880	160	22	mri	mri	NOUN
aiua-13880	160	23	,	,	PUNCT
aiua-13880	160	24	which	which	PRON
aiua-13880	160	25	have	have	AUX
aiua-13880	160	26	improved	improve	VERB
aiua-13880	160	27	the	the	DET
aiua-13880	160	28	detection	detection	NOUN
aiua-13880	160	29	of	of	ADP
aiua-13880	160	30	osseous	osseous	ADJ
aiua-13880	160	31	lesions	lesion	NOUN
aiua-13880	160	32	.	.	PUNCT
aiua-13880	161	1	bone	bone	NOUN
aiua-13880	161	2	metastases	metastasis	NOUN
aiua-13880	161	3	often	often	ADV
aiua-13880	161	4	coexist	coexist	VERB
aiua-13880	161	5	with	with	ADP
aiua-13880	161	6	other	other	ADJ
aiua-13880	161	7	metastatic	metastatic	ADJ
aiua-13880	161	8	sites	site	NOUN
aiua-13880	161	9	and	and	CCONJ
aiua-13880	161	10	contribute	contribute	VERB
aiua-13880	161	11	to	to	ADP
aiua-13880	161	12	significant	significant	ADJ
aiua-13880	161	13	morbidity	morbidity	NOUN
aiua-13880	161	14	,	,	PUNCT
aiua-13880	161	15	including	include	VERB
aiua-13880	161	16	pain	pain	NOUN
aiua-13880	161	17	and	and	CCONJ
aiua-13880	161	18	fractures	fracture	NOUN
aiua-13880	161	19	,	,	PUNCT
aiua-13880	161	20	further	far	ADV
aiua-13880	161	21	complicating	complicate	VERB
aiua-13880	161	22	the	the	DET
aiua-13880	161	23	disease	disease	NOUN
aiua-13880	161	24	course	course	NOUN
aiua-13880	161	25	(	(	PUNCT
aiua-13880	161	26	23	23	NUM
aiua-13880	161	27	)	)	PUNCT
aiua-13880	161	28	.	.	PUNCT
aiua-13880	162	1	lung	lung	NOUN
aiua-13880	162	2	metastases	metastasis	NOUN
aiua-13880	162	3	,	,	PUNCT
aiua-13880	162	4	present	present	ADJ
aiua-13880	162	5	in	in	ADP
aiua-13880	162	6	37%-45	37%-45	NUM
aiua-13880	162	7	%	%	NOUN
aiua-13880	162	8	of	of	ADP
aiua-13880	162	9	cases	case	NOUN
aiua-13880	162	10	,	,	PUNCT
aiua-13880	162	11	are	be	AUX
aiua-13880	162	12	another	another	DET
aiua-13880	162	13	common	common	ADJ
aiua-13880	162	14	manifestation	manifestation	NOUN
aiua-13880	162	15	of	of	ADP
aiua-13880	162	16	advanced	advanced	ADJ
aiua-13880	162	17	urothelial	urothelial	ADJ
aiua-13880	162	18	carcinoma	carcinoma	NOUN
aiua-13880	162	19	(	(	PUNCT
aiua-13880	162	20	25	25	NUM
aiua-13880	162	21	)	)	PUNCT
aiua-13880	162	22	.	.	PUNCT
aiua-13880	163	1	these	these	DET
aiua-13880	163	2	metastases	metastasis	NOUN
aiua-13880	163	3	typically	typically	ADV
aiua-13880	163	4	appear	appear	VERB
aiua-13880	163	5	as	as	ADP
aiua-13880	163	6	pulmonary	pulmonary	ADJ
aiua-13880	163	7	nodules	nodule	NOUN
aiua-13880	163	8	,	,	PUNCT
aiua-13880	163	9	consolidation	consolidation	NOUN
aiua-13880	163	10	,	,	PUNCT
aiua-13880	163	11	or	or	CCONJ
aiua-13880	163	12	lymphangitic	lymphangitic	ADJ
aiua-13880	163	13	spread	spread	NOUN
aiua-13880	163	14	.	.	PUNCT
aiua-13880	164	1	although	although	SCONJ
aiua-13880	164	2	lung	lung	NOUN
aiua-13880	164	3	metastases	metastasis	NOUN
aiua-13880	164	4	are	be	AUX
aiua-13880	164	5	less	less	ADV
aiua-13880	164	6	associated	associate	VERB
aiua-13880	164	7	with	with	ADP
aiua-13880	164	8	poor	poor	ADJ
aiua-13880	164	9	survival	survival	NOUN
aiua-13880	164	10	outcomes	outcome	NOUN
aiua-13880	164	11	than	than	ADP
aiua-13880	164	12	liver	liver	NOUN
aiua-13880	164	13	metastases	metastasis	NOUN
aiua-13880	164	14	,	,	PUNCT
aiua-13880	164	15	their	their	PRON
aiua-13880	164	16	presence	presence	NOUN
aiua-13880	164	17	often	often	ADV
aiua-13880	164	18	indicates	indicate	VERB
aiua-13880	164	19	advanced	advanced	ADJ
aiua-13880	164	20	disease	disease	NOUN
aiua-13880	164	21	progression	progression	NOUN
aiua-13880	164	22	(	(	PUNCT
aiua-13880	164	23	25	25	NUM
aiua-13880	164	24	)	)	PUNCT
aiua-13880	164	25	.	.	PUNCT
aiua-13880	165	1	the	the	DET
aiua-13880	165	2	differences	difference	NOUN
aiua-13880	165	3	in	in	ADP
aiua-13880	165	4	prognosis	prognosis	NOUN
aiua-13880	165	5	among	among	ADP
aiua-13880	165	6	metastatic	metastatic	ADJ
aiua-13880	165	7	sites	site	NOUN
aiua-13880	165	8	may	may	AUX
aiua-13880	165	9	be	be	AUX
aiua-13880	165	10	attributed	attribute	VERB
aiua-13880	165	11	to	to	ADP
aiua-13880	165	12	several	several	ADJ
aiua-13880	165	13	factors	factor	NOUN
aiua-13880	165	14	.	.	PUNCT
aiua-13880	166	1	organotropism	organotropism	NOUN
aiua-13880	166	2	and	and	CCONJ
aiua-13880	166	3	tumor	tumor	NOUN
aiua-13880	166	4	biology	biology	NOUN
aiua-13880	166	5	likely	likely	ADV
aiua-13880	166	6	play	play	VERB
aiua-13880	166	7	significant	significant	ADJ
aiua-13880	166	8	roles	role	NOUN
aiua-13880	166	9	,	,	PUNCT
aiua-13880	166	10	as	as	SCONJ
aiua-13880	166	11	metastases	metastasis	NOUN
aiua-13880	166	12	to	to	ADP
aiua-13880	166	13	organs	organ	NOUN
aiua-13880	166	14	like	like	ADP
aiua-13880	166	15	the	the	DET
aiua-13880	166	16	liver	liver	NOUN
aiua-13880	166	17	may	may	AUX
aiua-13880	166	18	reflect	reflect	VERB
aiua-13880	166	19	advanced	advanced	ADJ
aiua-13880	166	20	clonal	clonal	ADJ
aiua-13880	166	21	evolution	evolution	NOUN
aiua-13880	166	22	,	,	PUNCT
aiua-13880	166	23	greater	great	ADJ
aiua-13880	166	24	tumor	tumor	NOUN
aiua-13880	166	25	heterogeneity	heterogeneity	NOUN
aiua-13880	166	26	,	,	PUNCT
aiua-13880	166	27	and	and	CCONJ
aiua-13880	166	28	a	a	DET
aiua-13880	166	29	more	more	ADV
aiua-13880	166	30	unfavorable	unfavorable	ADJ
aiua-13880	166	31	tumor	tumor	NOUN
aiua-13880	166	32	microenvironment	microenvironment	NOUN
aiua-13880	166	33	(	(	PUNCT
aiua-13880	166	34	24	24	NUM
aiua-13880	166	35	,	,	PUNCT
aiua-13880	166	36	25	25	NUM
aiua-13880	166	37	)	)	PUNCT
aiua-13880	166	38	.	.	PUNCT
aiua-13880	167	1	immune	immune	ADJ
aiua-13880	167	2	heterogeneity	heterogeneity	NOUN
aiua-13880	167	3	across	across	ADP
aiua-13880	167	4	metastatic	metastatic	ADJ
aiua-13880	167	5	sites	site	NOUN
aiua-13880	167	6	,	,	PUNCT
aiua-13880	167	7	such	such	ADJ
aiua-13880	167	8	as	as	ADP
aiua-13880	167	9	variations	variation	NOUN
aiua-13880	167	10	in	in	ADP
aiua-13880	167	11	tumor	tumor	NOUN
aiua-13880	167	12	-	-	PUNCT
aiua-13880	167	13	infiltrating	infiltrate	VERB
aiua-13880	167	14	lymphocytes	lymphocyte	NOUN
aiua-13880	167	15	,	,	PUNCT
aiua-13880	167	16	pdl1	pdl1	NOUN
aiua-13880	167	17	expression	expression	NOUN
aiua-13880	167	18	,	,	PUNCT
aiua-13880	167	19	and	and	CCONJ
aiua-13880	167	20	immune	immune	ADJ
aiua-13880	167	21	response	response	NOUN
aiua-13880	167	22	,	,	PUNCT
aiua-13880	167	23	can	can	AUX
aiua-13880	167	24	further	far	ADV
aiua-13880	167	25	influence	influence	VERB
aiua-13880	167	26	prognosis	prognosis	NOUN
aiua-13880	167	27	and	and	CCONJ
aiua-13880	167	28	treatment	treatment	NOUN
aiua-13880	167	29	outcomes	outcome	NOUN
aiua-13880	167	30	.	.	PUNCT
aiua-13880	168	1	additionally	additionally	ADV
aiua-13880	168	2	,	,	PUNCT
aiua-13880	168	3	molecular	molecular	ADJ
aiua-13880	168	4	factors	factor	NOUN
aiua-13880	168	5	,	,	PUNCT
aiua-13880	168	6	such	such	ADJ
aiua-13880	168	7	as	as	ADP
aiua-13880	168	8	mtap	mtap	ADJ
aiua-13880	168	9	-	-	PUNCT
aiua-13880	168	10	deficient	deficient	ADJ
aiua-13880	168	11	tumors	tumor	NOUN
aiua-13880	168	12	,	,	PUNCT
aiua-13880	168	13	have	have	AUX
aiua-13880	168	14	been	be	AUX
aiua-13880	168	15	associated	associate	VERB
aiua-13880	168	16	with	with	ADP
aiua-13880	168	17	an	an	DET
aiua-13880	168	18	increased	increase	VERB
aiua-13880	168	19	likelihood	likelihood	NOUN
aiua-13880	168	20	of	of	ADP
aiua-13880	168	21	visceral	visceral	ADJ
aiua-13880	168	22	metastases	metastasis	NOUN
aiua-13880	168	23	and	and	CCONJ
aiua-13880	168	24	worse	bad	ADJ
aiua-13880	168	25	outcomes	outcome	NOUN
aiua-13880	168	26	with	with	ADP
aiua-13880	168	27	icis	icis	PROPN
aiua-13880	168	28	(	(	PUNCT
aiua-13880	168	29	28	28	NUM
aiua-13880	168	30	)	)	PUNCT
aiua-13880	168	31	.	.	PUNCT
aiua-13880	169	1	patients	patient	NOUN
aiua-13880	169	2	with	with	ADP
aiua-13880	169	3	an	an	DET
aiua-13880	169	4	ecog	ecog	PROPN
aiua-13880	169	5	ps	ps	PROPN
aiua-13880	169	6	of	of	ADP
aiua-13880	169	7	≥	≥	NOUN
aiua-13880	169	8	2	2	NUM
aiua-13880	169	9	are	be	AUX
aiua-13880	169	10	clearly	clearly	ADV
aiua-13880	169	11	at	at	ADP
aiua-13880	169	12	a	a	DET
aiua-13880	169	13	higher	high	ADJ
aiua-13880	169	14	risk	risk	NOUN
aiua-13880	169	15	of	of	ADP
aiua-13880	169	16	poor	poor	ADJ
aiua-13880	169	17	outcomes	outcome	NOUN
aiua-13880	169	18	.	.	PUNCT
aiua-13880	170	1	this	this	PRON
aiua-13880	170	2	is	be	AUX
aiua-13880	170	3	particularly	particularly	ADV
aiua-13880	170	4	significant	significant	ADJ
aiua-13880	170	5	as	as	SCONJ
aiua-13880	170	6	patients	patient	NOUN
aiua-13880	170	7	with	with	ADP
aiua-13880	170	8	a	a	DET
aiua-13880	170	9	ps	ps	NOUN
aiua-13880	170	10	>	>	SYM
aiua-13880	170	11	2	2	NUM
aiua-13880	170	12	are	be	AUX
aiua-13880	170	13	typically	typically	ADV
aiua-13880	170	14	considered	consider	VERB
aiua-13880	170	15	unfit	unfit	ADJ
aiua-13880	170	16	for	for	ADP
aiua-13880	170	17	platinum	platinum	NOUN
aiua-13880	170	18	-	-	PUNCT
aiua-13880	170	19	based	base	VERB
aiua-13880	170	20	chemotherapy	chemotherapy	NOUN
aiua-13880	170	21	.	.	PUNCT
aiua-13880	171	1	in	in	ADP
aiua-13880	171	2	such	such	ADJ
aiua-13880	171	3	cases	case	NOUN
aiua-13880	171	4	,	,	PUNCT
aiua-13880	171	5	the	the	DET
aiua-13880	171	6	european	european	PROPN
aiua-13880	171	7	association	association	PROPN
aiua-13880	171	8	of	of	ADP
aiua-13880	171	9	urology	urology	NOUN
aiua-13880	171	10	suggests	suggest	VERB
aiua-13880	171	11	that	that	SCONJ
aiua-13880	171	12	best	good	ADJ
aiua-13880	171	13	supportive	supportive	ADJ
aiua-13880	171	14	care	care	NOUN
aiua-13880	171	15	may	may	AUX
aiua-13880	171	16	be	be	AUX
aiua-13880	171	17	the	the	DET
aiua-13880	171	18	most	most	ADV
aiua-13880	171	19	appropriate	appropriate	ADJ
aiua-13880	171	20	approach	approach	NOUN
aiua-13880	171	21	to	to	PART
aiua-13880	171	22	optimize	optimize	VERB
aiua-13880	171	23	quality	quality	NOUN
aiua-13880	171	24	of	of	ADP
aiua-13880	171	25	life	life	NOUN
aiua-13880	171	26	and	and	CCONJ
aiua-13880	171	27	minimize	minimize	VERB
aiua-13880	171	28	treatment	treatment	NOUN
aiua-13880	171	29	-	-	PUNCT
aiua-13880	171	30	related	relate	VERB
aiua-13880	171	31	harm	harm	NOUN
aiua-13880	171	32	(	(	PUNCT
aiua-13880	171	33	3	3	NUM
aiua-13880	171	34	)	)	PUNCT
aiua-13880	171	35	.	.	PUNCT
aiua-13880	172	1	for	for	ADP
aiua-13880	172	2	patients	patient	NOUN
aiua-13880	172	3	with	with	ADP
aiua-13880	172	4	a	a	DET
aiua-13880	172	5	ps	ps	NOUN
aiua-13880	172	6	of	of	ADP
aiua-13880	172	7	2	2	NUM
aiua-13880	172	8	,	,	PUNCT
aiua-13880	172	9	careful	careful	ADJ
aiua-13880	172	10	consideration	consideration	NOUN
aiua-13880	172	11	of	of	ADP
aiua-13880	172	12	additional	additional	ADJ
aiua-13880	172	13	risk	risk	NOUN
aiua-13880	172	14	factors	factor	NOUN
aiua-13880	172	15	and	and	CCONJ
aiua-13880	172	16	overall	overall	ADJ
aiua-13880	172	17	organ	organ	NOUN
aiua-13880	172	18	function	function	NOUN
aiua-13880	172	19	is	be	AUX
aiua-13880	172	20	essential	essential	ADJ
aiua-13880	172	21	,	,	PUNCT
aiua-13880	172	22	e.g.	e.g.	ADV
aiua-13880	172	23	glomerular	glomerular	ADJ
aiua-13880	172	24	filtration	filtration	NOUN
aiua-13880	172	25	rate	rate	NOUN
aiua-13880	172	26	(	(	PUNCT
aiua-13880	172	27	gfr	gfr	NOUN
aiua-13880	172	28	)	)	PUNCT
aiua-13880	172	29	of	of	ADP
aiua-13880	172	30	less	less	ADJ
aiua-13880	172	31	than	than	ADP
aiua-13880	172	32	60ml	60ml	NOUN
aiua-13880	172	33	/	/	SYM
aiua-13880	172	34	min	min	NOUN
aiua-13880	172	35	.	.	PUNCT
aiua-13880	173	1	this	this	DET
aiua-13880	173	2	decision	decision	NOUN
aiua-13880	173	3	should	should	AUX
aiua-13880	173	4	be	be	AUX
aiua-13880	173	5	made	make	VERB
aiua-13880	173	6	in	in	ADP
aiua-13880	173	7	close	close	ADJ
aiua-13880	173	8	collaboration	collaboration	NOUN
aiua-13880	173	9	with	with	ADP
aiua-13880	173	10	experts	expert	NOUN
aiua-13880	173	11	to	to	PART
aiua-13880	173	12	ensure	ensure	VERB
aiua-13880	173	13	a	a	DET
aiua-13880	173	14	tailored	tailor	VERB
aiua-13880	173	15	and	and	CCONJ
aiua-13880	173	16	balfigure	balfigure	NOUN
aiua-13880	173	17	3	3	NUM
aiua-13880	173	18	.	.	PUNCT
aiua-13880	173	19	summary	summary	NOUN
aiua-13880	173	20	plot	plot	NOUN
aiua-13880	173	21	of	of	ADP
aiua-13880	173	22	the	the	DET
aiua-13880	173	23	included	include	VERB
aiua-13880	173	24	studies	study	NOUN
aiua-13880	173	25	risk	risk	NOUN
aiua-13880	173	26	of	of	ADP
aiua-13880	173	27	bias	bias	NOUN
aiua-13880	173	28	assessed	assess	VERB
aiua-13880	173	29	by	by	ADP
aiua-13880	173	30	quips	quip	NOUN
aiua-13880	173	31	tool	tool	NOUN
aiua-13880	173	32	.	.	PUNCT
aiua-13880	174	1	archivio	archivio	NOUN
aiua-13880	174	2	italiano	italiano	PROPN
aiua-13880	174	3	di	di	PROPN
aiua-13880	174	4	urologia	urologia	PROPN
aiua-13880	174	5	e	e	PROPN
aiua-13880	174	6	andrologia	andrologia	NOUN
aiua-13880	174	7	2025	2025	NUM
aiua-13880	174	8	;	;	PUNCT
aiua-13880	174	9	97(2):13880	97(2):13880	NUM
aiua-13880	174	10	9	9	NUM
aiua-13880	174	11	pembrolizumab	pembrolizumab	NOUN
aiua-13880	174	12	in	in	ADP
aiua-13880	174	13	advanced	advanced	ADJ
aiua-13880	174	14	/	/	SYM
aiua-13880	174	15	metastatic	metastatic	ADJ
aiua-13880	174	16	urothelial	urothelial	ADJ
aiua-13880	174	17	carcinoma	carcinoma	NOUN
aiua-13880	174	18	anced	ance	VERB
aiua-13880	174	19	approach	approach	NOUN
aiua-13880	174	20	that	that	PRON
aiua-13880	174	21	takes	take	VERB
aiua-13880	174	22	into	into	ADP
aiua-13880	174	23	account	account	NOUN
aiua-13880	174	24	the	the	DET
aiua-13880	174	25	patient	patient	NOUN
aiua-13880	174	26	’s	’s	PART
aiua-13880	174	27	comorbidities	comorbiditie	NOUN
aiua-13880	174	28	,	,	PUNCT
aiua-13880	174	29	disease	disease	NOUN
aiua-13880	174	30	burden	burden	NOUN
aiua-13880	174	31	,	,	PUNCT
aiua-13880	174	32	and	and	CCONJ
aiua-13880	174	33	treatment	treatment	NOUN
aiua-13880	174	34	goals	goal	NOUN
aiua-13880	174	35	.	.	PUNCT
aiua-13880	175	1	in	in	ADP
aiua-13880	175	2	contrast	contrast	NOUN
aiua-13880	175	3	,	,	PUNCT
aiua-13880	175	4	patients	patient	NOUN
aiua-13880	175	5	with	with	ADP
aiua-13880	175	6	a	a	DET
aiua-13880	175	7	ps	ps	NOUN
aiua-13880	175	8	of	of	ADP
aiua-13880	175	9	0	0	NUM
aiua-13880	175	10	-	-	SYM
aiua-13880	175	11	1	1	NUM
aiua-13880	175	12	represent	represent	VERB
aiua-13880	175	13	a	a	DET
aiua-13880	175	14	subgroup	subgroup	NOUN
aiua-13880	175	15	that	that	PRON
aiua-13880	175	16	may	may	AUX
aiua-13880	175	17	be	be	AUX
aiua-13880	175	18	better	well	ADV
aiua-13880	175	19	suited	suit	VERB
aiua-13880	175	20	for	for	ADP
aiua-13880	175	21	more	more	ADV
aiua-13880	175	22	active	active	ADJ
aiua-13880	175	23	treatment	treatment	NOUN
aiua-13880	175	24	strategies	strategy	NOUN
aiua-13880	175	25	.	.	PUNCT
aiua-13880	176	1	for	for	ADP
aiua-13880	176	2	these	these	DET
aiua-13880	176	3	individuals	individual	NOUN
aiua-13880	176	4	,	,	PUNCT
aiua-13880	176	5	pembrolizumab	pembrolizumab	NOUN
aiua-13880	176	6	monotherapy	monotherapy	NOUN
aiua-13880	176	7	could	could	AUX
aiua-13880	176	8	be	be	AUX
aiua-13880	176	9	considered	consider	VERB
aiua-13880	176	10	in	in	ADP
aiua-13880	176	11	two	two	NUM
aiua-13880	176	12	specific	specific	ADJ
aiua-13880	176	13	scenarios	scenario	NOUN
aiua-13880	176	14	:	:	PUNCT
aiua-13880	176	15	(	(	PUNCT
aiua-13880	176	16	1	1	X
aiua-13880	176	17	)	)	PUNCT
aiua-13880	176	18	when	when	SCONJ
aiua-13880	176	19	enfortumab	enfortumab	ADV
aiua-13880	176	20	-	-	PUNCT
aiua-13880	176	21	vedotin	vedotin	ADJ
aiua-13880	176	22	(	(	PUNCT
aiua-13880	176	23	efv	efv	ADJ
aiua-13880	176	24	)	)	PUNCT
aiua-13880	176	25	and	and	CCONJ
aiua-13880	176	26	platinum	platinum	NOUN
aiua-13880	176	27	-	-	PUNCT
aiua-13880	176	28	based	base	VERB
aiua-13880	176	29	chemotherapy	chemotherapy	NOUN
aiua-13880	176	30	are	be	AUX
aiua-13880	176	31	unavailable	unavailable	ADJ
aiua-13880	176	32	,	,	PUNCT
aiua-13880	176	33	or	or	CCONJ
aiua-13880	176	34	(	(	PUNCT
aiua-13880	176	35	2	2	X
aiua-13880	176	36	)	)	PUNCT
aiua-13880	176	37	when	when	SCONJ
aiua-13880	176	38	the	the	DET
aiua-13880	176	39	patient	patient	NOUN
aiua-13880	176	40	is	be	AUX
aiua-13880	176	41	deemed	deem	VERB
aiua-13880	176	42	ineligible	ineligible	ADJ
aiua-13880	176	43	for	for	ADP
aiua-13880	176	44	platinum	platinum	NOUN
aiua-13880	176	45	-	-	PUNCT
aiua-13880	176	46	based	base	VERB
aiua-13880	176	47	chemotherapy	chemotherapy	NOUN
aiua-13880	176	48	due	due	ADP
aiua-13880	176	49	to	to	ADP
aiua-13880	176	50	other	other	ADJ
aiua-13880	176	51	contraindications	contraindication	NOUN
aiua-13880	176	52	.	.	PUNCT
aiua-13880	177	1	while	while	SCONJ
aiua-13880	177	2	pembrolizumab	pembrolizumab	NOUN
aiua-13880	177	3	monotherapy	monotherapy	NOUN
aiua-13880	177	4	may	may	AUX
aiua-13880	177	5	not	not	PART
aiua-13880	177	6	be	be	AUX
aiua-13880	177	7	the	the	DET
aiua-13880	177	8	first	first	ADJ
aiua-13880	177	9	-	-	PUNCT
aiua-13880	177	10	line	line	NOUN
aiua-13880	177	11	option	option	NOUN
aiua-13880	177	12	in	in	ADP
aiua-13880	177	13	many	many	ADJ
aiua-13880	177	14	cases	case	NOUN
aiua-13880	177	15	,	,	PUNCT
aiua-13880	177	16	its	its	PRON
aiua-13880	177	17	role	role	NOUN
aiua-13880	177	18	as	as	ADP
aiua-13880	177	19	an	an	DET
aiua-13880	177	20	alternative	alternative	NOUN
aiua-13880	177	21	should	should	AUX
aiua-13880	177	22	be	be	AUX
aiua-13880	177	23	weighed	weigh	VERB
aiua-13880	177	24	carefully	carefully	ADV
aiua-13880	177	25	,	,	PUNCT
aiua-13880	177	26	particularly	particularly	ADV
aiua-13880	177	27	in	in	ADP
aiua-13880	177	28	light	light	NOUN
aiua-13880	177	29	of	of	ADP
aiua-13880	177	30	emerging	emerge	VERB
aiua-13880	177	31	evidence	evidence	NOUN
aiua-13880	177	32	supporting	support	VERB
aiua-13880	177	33	its	its	PRON
aiua-13880	177	34	efficacy	efficacy	NOUN
aiua-13880	177	35	and	and	CCONJ
aiua-13880	177	36	safety	safety	NOUN
aiua-13880	177	37	in	in	ADP
aiua-13880	177	38	select	select	ADJ
aiua-13880	177	39	patient	patient	ADJ
aiua-13880	177	40	populations	population	NOUN
aiua-13880	177	41	.	.	PUNCT
aiua-13880	178	1	in	in	ADP
aiua-13880	178	2	a	a	DET
aiua-13880	178	3	phase	phase	NOUN
aiua-13880	178	4	ii	ii	NOUN
aiua-13880	178	5	single	single	ADJ
aiua-13880	178	6	-	-	PUNCT
aiua-13880	178	7	arm	arm	NOUN
aiua-13880	178	8	trial	trial	NOUN
aiua-13880	178	9	involving	involve	VERB
aiua-13880	178	10	370	370	NUM
aiua-13880	178	11	participants	participant	NOUN
aiua-13880	178	12	with	with	ADP
aiua-13880	178	13	cisplatin	cisplatin	NOUN
aiua-13880	178	14	-	-	PUNCT
aiua-13880	178	15	ineligible	ineligible	ADJ
aiua-13880	178	16	urothelial	urothelial	ADJ
aiua-13880	178	17	carcinoma	carcinoma	NOUN
aiua-13880	178	18	,	,	PUNCT
aiua-13880	178	19	pembrolizumab	pembrolizumab	NOUN
aiua-13880	178	20	monotherapy	monotherapy	NOUN
aiua-13880	178	21	achieved	achieve	VERB
aiua-13880	178	22	an	an	DET
aiua-13880	178	23	objective	objective	ADJ
aiua-13880	178	24	response	response	NOUN
aiua-13880	178	25	rate	rate	NOUN
aiua-13880	178	26	of	of	ADP
aiua-13880	178	27	26	26	NUM
aiua-13880	178	28	%	%	NOUN
aiua-13880	178	29	among	among	ADP
aiua-13880	178	30	69	69	NUM
aiua-13880	178	31	patients	patient	NOUN
aiua-13880	178	32	with	with	ADP
aiua-13880	178	33	metastatic	metastatic	ADJ
aiua-13880	178	34	utuc	utuc	NOUN
aiua-13880	178	35	(	(	PUNCT
aiua-13880	178	36	29	29	NUM
aiua-13880	178	37	)	)	PUNCT
aiua-13880	178	38	.	.	PUNCT
aiua-13880	179	1	several	several	ADJ
aiua-13880	179	2	prognostic	prognostic	ADJ
aiua-13880	179	3	bloodor	bloodor	NOUN
aiua-13880	179	4	serum	serum	NOUN
aiua-13880	179	5	-	-	PUNCT
aiua-13880	179	6	based	base	VERB
aiua-13880	179	7	parameters	parameter	NOUN
aiua-13880	179	8	have	have	AUX
aiua-13880	179	9	been	be	AUX
aiua-13880	179	10	reported	report	VERB
aiua-13880	179	11	in	in	ADP
aiua-13880	179	12	advanced	advanced	ADJ
aiua-13880	179	13	ucs	ucs	NOUN
aiua-13880	179	14	,	,	PUNCT
aiua-13880	179	15	including	include	VERB
aiua-13880	179	16	crp	crp	PROPN
aiua-13880	179	17	,	,	PUNCT
aiua-13880	179	18	ldh	ldh	PROPN
aiua-13880	179	19	,	,	PUNCT
aiua-13880	179	20	platelet	platelet	NOUN
aiua-13880	179	21	-	-	PUNCT
aiua-13880	179	22	to	to	ADP
aiua-13880	179	23	-	-	PUNCT
aiua-13880	179	24	lymphocyte	lymphocyte	ADJ
aiua-13880	179	25	ratio	ratio	NOUN
aiua-13880	179	26	(	(	PUNCT
aiua-13880	179	27	plr	plr	NOUN
aiua-13880	179	28	)	)	PUNCT
aiua-13880	179	29	,	,	PUNCT
aiua-13880	179	30	and	and	CCONJ
aiua-13880	179	31	neutrophil	neutrophil	ADJ
aiua-13880	179	32	-	-	PUNCT
aiua-13880	179	33	tolymphocyte	tolymphocyte	NOUN
aiua-13880	179	34	ratio	ratio	NOUN
aiua-13880	179	35	(	(	PUNCT
aiua-13880	179	36	nlr	nlr	PROPN
aiua-13880	179	37	)	)	PUNCT
aiua-13880	179	38	.	.	PUNCT
aiua-13880	180	1	in	in	ADP
aiua-13880	180	2	our	our	PRON
aiua-13880	180	3	study	study	NOUN
aiua-13880	180	4	,	,	PUNCT
aiua-13880	180	5	low	low	ADJ
aiua-13880	180	6	hemoglobin	hemoglobin	NOUN
aiua-13880	180	7	and	and	CCONJ
aiua-13880	180	8	high	high	ADJ
aiua-13880	180	9	nlr	nlr	PROPN
aiua-13880	180	10	consistently	consistently	ADV
aiua-13880	180	11	demonstrated	demonstrate	VERB
aiua-13880	180	12	worse	bad	ADJ
aiua-13880	180	13	pfs	pfs	PROPN
aiua-13880	180	14	and	and	CCONJ
aiua-13880	180	15	os	os	NOUN
aiua-13880	180	16	.	.	PUNCT
aiua-13880	181	1	hemoglobin	hemoglobin	PROPN
aiua-13880	181	2	(	(	PUNCT
aiua-13880	181	3	hgb	hgb	NOUN
aiua-13880	181	4	)	)	PUNCT
aiua-13880	181	5	level	level	NOUN
aiua-13880	181	6	is	be	AUX
aiua-13880	181	7	one	one	NUM
aiua-13880	181	8	of	of	ADP
aiua-13880	181	9	the	the	DET
aiua-13880	181	10	parameters	parameter	NOUN
aiua-13880	181	11	that	that	PRON
aiua-13880	181	12	has	have	AUX
aiua-13880	181	13	been	be	AUX
aiua-13880	181	14	used	use	VERB
aiua-13880	181	15	as	as	ADP
aiua-13880	181	16	inclusion	inclusion	NOUN
aiua-13880	181	17	criteria	criterion	NOUN
aiua-13880	181	18	in	in	ADP
aiua-13880	181	19	the	the	DET
aiua-13880	181	20	original	original	ADJ
aiua-13880	181	21	trials	trial	NOUN
aiua-13880	181	22	assessing	assess	VERB
aiua-13880	181	23	pembrolizumab	pembrolizumab	NOUN
aiua-13880	181	24	for	for	ADP
aiua-13880	181	25	advanced	advanced	ADJ
aiua-13880	181	26	urothelial	urothelial	ADJ
aiua-13880	181	27	carcinoma	carcinoma	NOUN
aiua-13880	181	28	(	(	PUNCT
aiua-13880	181	29	20	20	NUM
aiua-13880	181	30	)	)	PUNCT
aiua-13880	181	31	.	.	PUNCT
aiua-13880	182	1	several	several	ADJ
aiua-13880	182	2	studies	study	NOUN
aiua-13880	182	3	of	of	ADP
aiua-13880	182	4	other	other	ADJ
aiua-13880	182	5	types	type	NOUN
aiua-13880	182	6	of	of	ADP
aiua-13880	182	7	cancers	cancer	NOUN
aiua-13880	182	8	have	have	AUX
aiua-13880	182	9	shown	show	VERB
aiua-13880	182	10	significantly	significantly	ADV
aiua-13880	182	11	longer	long	ADV
aiua-13880	182	12	os	os	NOUN
aiua-13880	182	13	and	and	CCONJ
aiua-13880	182	14	pfs	pf	VERB
aiua-13880	182	15	in	in	ADP
aiua-13880	182	16	patients	patient	NOUN
aiua-13880	182	17	with	with	ADP
aiua-13880	182	18	higher	high	ADJ
aiua-13880	182	19	hgb	hgb	PROPN
aiua-13880	182	20	levels	level	NOUN
aiua-13880	182	21	undergoing	undergo	VERB
aiua-13880	182	22	immunotherapy	immunotherapy	NOUN
aiua-13880	182	23	(	(	PUNCT
aiua-13880	182	24	30	30	NUM
aiua-13880	182	25	,	,	PUNCT
aiua-13880	182	26	31	31	NUM
aiua-13880	182	27	)	)	PUNCT
aiua-13880	182	28	.	.	PUNCT
aiua-13880	183	1	in	in	ADP
aiua-13880	183	2	one	one	NUM
aiua-13880	183	3	study	study	NOUN
aiua-13880	183	4	,	,	PUNCT
aiua-13880	183	5	hgb	hgb	PROPN
aiua-13880	183	6	levels	level	NOUN
aiua-13880	183	7	were	be	AUX
aiua-13880	183	8	positively	positively	ADV
aiua-13880	183	9	correlated	correlate	VERB
aiua-13880	183	10	with	with	ADP
aiua-13880	183	11	clinical	clinical	ADJ
aiua-13880	183	12	outcomes	outcome	NOUN
aiua-13880	183	13	in	in	ADP
aiua-13880	183	14	cancer	cancer	NOUN
aiua-13880	183	15	patients	patient	NOUN
aiua-13880	183	16	receiving	receive	VERB
aiua-13880	183	17	immunotherapy	immunotherapy	NOUN
aiua-13880	183	18	,	,	PUNCT
aiua-13880	183	19	but	but	CCONJ
aiua-13880	183	20	not	not	PART
aiua-13880	183	21	in	in	ADP
aiua-13880	183	22	those	those	PRON
aiua-13880	183	23	not	not	PART
aiua-13880	183	24	undergoing	undergo	VERB
aiua-13880	183	25	such	such	ADJ
aiua-13880	183	26	treatment	treatment	NOUN
aiua-13880	183	27	,	,	PUNCT
aiua-13880	183	28	suggesting	suggest	VERB
aiua-13880	183	29	a	a	DET
aiua-13880	183	30	positive	positive	ADJ
aiua-13880	183	31	association	association	NOUN
aiua-13880	183	32	between	between	ADP
aiua-13880	183	33	hgb	hgb	PROPN
aiua-13880	183	34	levels	level	NOUN
aiua-13880	183	35	and	and	CCONJ
aiua-13880	183	36	response	response	NOUN
aiua-13880	183	37	to	to	ADP
aiua-13880	183	38	immunotherapy	immunotherapy	NOUN
aiua-13880	183	39	.	.	PUNCT
aiua-13880	184	1	additionally	additionally	ADV
aiua-13880	184	2	,	,	PUNCT
aiua-13880	184	3	it	it	PRON
aiua-13880	184	4	was	be	AUX
aiua-13880	184	5	found	find	VERB
aiua-13880	184	6	that	that	SCONJ
aiua-13880	184	7	this	this	DET
aiua-13880	184	8	effect	effect	NOUN
aiua-13880	184	9	was	be	AUX
aiua-13880	184	10	independent	independent	ADJ
aiua-13880	184	11	of	of	ADP
aiua-13880	184	12	other	other	ADJ
aiua-13880	184	13	clinicopathological	clinicopathological	ADJ
aiua-13880	184	14	factors	factor	NOUN
aiua-13880	184	15	,	,	PUNCT
aiua-13880	184	16	including	include	VERB
aiua-13880	184	17	sex	sex	NOUN
aiua-13880	184	18	,	,	PUNCT
aiua-13880	184	19	age	age	NOUN
aiua-13880	184	20	,	,	PUNCT
aiua-13880	184	21	tumor	tumor	NOUN
aiua-13880	184	22	stage	stage	NOUN
aiua-13880	184	23	,	,	PUNCT
aiua-13880	184	24	and	and	CCONJ
aiua-13880	184	25	tumor	tumor	NOUN
aiua-13880	184	26	mutational	mutational	ADJ
aiua-13880	184	27	burden	burden	NOUN
aiua-13880	184	28	(	(	PUNCT
aiua-13880	184	29	tmb	tmb	NOUN
aiua-13880	184	30	)	)	PUNCT
aiua-13880	184	31	,	,	PUNCT
aiua-13880	184	32	as	as	ADV
aiua-13880	184	33	well	well	ADV
aiua-13880	184	34	as	as	ADP
aiua-13880	184	35	established	establish	VERB
aiua-13880	184	36	biomarkers	biomarker	NOUN
aiua-13880	184	37	like	like	ADP
aiua-13880	184	38	pd	pd	PROPN
aiua-13880	184	39	-	-	PROPN
aiua-13880	184	40	l1	l1	PROPN
aiua-13880	184	41	expression	expression	NOUN
aiua-13880	184	42	and	and	CCONJ
aiua-13880	184	43	microsatellite	microsatellite	ADJ
aiua-13880	184	44	instability	instability	NOUN
aiua-13880	184	45	(	(	PUNCT
aiua-13880	184	46	msi	msi	PROPN
aiua-13880	184	47	)	)	PUNCT
aiua-13880	184	48	(	(	PUNCT
aiua-13880	184	49	32	32	NUM
aiua-13880	184	50	)	)	PUNCT
aiua-13880	184	51	.	.	PUNCT
aiua-13880	185	1	it	it	PRON
aiua-13880	185	2	is	be	AUX
aiua-13880	185	3	thought	think	VERB
aiua-13880	185	4	that	that	DET
aiua-13880	185	5	hypoxia	hypoxia	NOUN
aiua-13880	185	6	induced	induce	VERB
aiua-13880	185	7	by	by	ADP
aiua-13880	185	8	hgb	hgb	PROPN
aiua-13880	185	9	reduction	reduction	NOUN
aiua-13880	185	10	stimulates	stimulate	VERB
aiua-13880	185	11	tumor	tumor	NOUN
aiua-13880	185	12	growth	growth	NOUN
aiua-13880	185	13	and	and	CCONJ
aiua-13880	185	14	progression	progression	NOUN
aiua-13880	185	15	and	and	CCONJ
aiua-13880	185	16	decreases	decrease	VERB
aiua-13880	185	17	their	their	PRON
aiua-13880	185	18	sensitivity	sensitivity	NOUN
aiua-13880	185	19	to	to	PART
aiua-13880	185	20	anticancer	anticancer	NOUN
aiua-13880	185	21	treatments	treatment	NOUN
aiua-13880	185	22	,	,	PUNCT
aiua-13880	185	23	eventually	eventually	ADV
aiua-13880	185	24	contributing	contribute	VERB
aiua-13880	185	25	to	to	ADP
aiua-13880	185	26	poor	poor	ADJ
aiua-13880	185	27	patient	patient	ADJ
aiua-13880	185	28	outcomes	outcome	NOUN
aiua-13880	185	29	(	(	PUNCT
aiua-13880	185	30	33	33	NUM
aiua-13880	185	31	)	)	PUNCT
aiua-13880	185	32	.	.	PUNCT
aiua-13880	186	1	pretreatment	pretreatment	NOUN
aiua-13880	186	2	nlr	nlr	PROPN
aiua-13880	186	3	and	and	CCONJ
aiua-13880	186	4	lymphocytopenia	lymphocytopenia	NOUN
aiua-13880	186	5	have	have	AUX
aiua-13880	186	6	been	be	AUX
aiua-13880	186	7	linked	link	VERB
aiua-13880	186	8	to	to	ADP
aiua-13880	186	9	increased	increase	VERB
aiua-13880	186	10	mortality	mortality	NOUN
aiua-13880	186	11	rates	rate	NOUN
aiua-13880	186	12	in	in	ADP
aiua-13880	186	13	patients	patient	NOUN
aiua-13880	186	14	with	with	ADP
aiua-13880	186	15	solid	solid	ADJ
aiua-13880	186	16	tumors	tumor	NOUN
aiua-13880	186	17	,	,	PUNCT
aiua-13880	186	18	as	as	ADV
aiua-13880	186	19	well	well	ADV
aiua-13880	186	20	as	as	ADP
aiua-13880	186	21	in	in	ADP
aiua-13880	186	22	the	the	DET
aiua-13880	186	23	general	general	ADJ
aiua-13880	186	24	population	population	NOUN
aiua-13880	186	25	(	(	PUNCT
aiua-13880	186	26	34	34	NUM
aiua-13880	186	27	,	,	PUNCT
aiua-13880	186	28	35	35	NUM
aiua-13880	186	29	)	)	PUNCT
aiua-13880	186	30	.	.	PUNCT
aiua-13880	187	1	this	this	PRON
aiua-13880	187	2	suggests	suggest	VERB
aiua-13880	187	3	that	that	SCONJ
aiua-13880	187	4	nlr	nlr	PROPN
aiua-13880	187	5	is	be	AUX
aiua-13880	187	6	not	not	PART
aiua-13880	187	7	a	a	DET
aiua-13880	187	8	specific	specific	ADJ
aiua-13880	187	9	biomarker	biomarker	NOUN
aiua-13880	187	10	for	for	ADP
aiua-13880	187	11	patients	patient	NOUN
aiua-13880	187	12	with	with	ADP
aiua-13880	187	13	ucs	ucs	PROPN
aiua-13880	187	14	.	.	PUNCT
aiua-13880	188	1	one	one	NUM
aiua-13880	188	2	study	study	NOUN
aiua-13880	188	3	found	find	VERB
aiua-13880	188	4	that	that	SCONJ
aiua-13880	188	5	after	after	ADP
aiua-13880	188	6	adjusting	adjust	VERB
aiua-13880	188	7	for	for	ADP
aiua-13880	188	8	other	other	ADJ
aiua-13880	188	9	prognostic	prognostic	ADJ
aiua-13880	188	10	factors	factor	NOUN
aiua-13880	188	11	,	,	PUNCT
aiua-13880	188	12	patients	patient	NOUN
aiua-13880	188	13	with	with	ADP
aiua-13880	188	14	a	a	DET
aiua-13880	188	15	decrease	decrease	NOUN
aiua-13880	188	16	in	in	ADP
aiua-13880	188	17	post	post	ADJ
aiua-13880	188	18	-	-	ADJ
aiua-13880	188	19	chemotherapy	chemotherapy	ADJ
aiua-13880	188	20	nlr	nlr	PROPN
aiua-13880	188	21	experienced	experience	VERB
aiua-13880	188	22	longer	long	ADV
aiua-13880	188	23	os	os	NOUN
aiua-13880	188	24	compared	compare	VERB
aiua-13880	188	25	to	to	ADP
aiua-13880	188	26	those	those	PRON
aiua-13880	188	27	with	with	ADP
aiua-13880	188	28	merely	merely	ADV
aiua-13880	188	29	low	low	ADJ
aiua-13880	188	30	pretreatment	pretreatment	NOUN
aiua-13880	188	31	nlr	nlr	PROPN
aiua-13880	188	32	levels	level	NOUN
aiua-13880	188	33	.	.	PUNCT
aiua-13880	189	1	these	these	DET
aiua-13880	189	2	findings	finding	NOUN
aiua-13880	189	3	suggest	suggest	VERB
aiua-13880	189	4	a	a	DET
aiua-13880	189	5	unique	unique	ADJ
aiua-13880	189	6	association	association	NOUN
aiua-13880	189	7	between	between	ADP
aiua-13880	189	8	response	response	NOUN
aiua-13880	189	9	to	to	ADP
aiua-13880	189	10	1st	1st	ADJ
aiua-13880	189	11	-	-	PUNCT
aiua-13880	189	12	line	line	NOUN
aiua-13880	189	13	chemotherapy	chemotherapy	NOUN
aiua-13880	189	14	with	with	ADP
aiua-13880	189	15	efficacy	efficacy	NOUN
aiua-13880	189	16	of	of	ADP
aiua-13880	189	17	pembrolizumab	pembrolizumab	NOUN
aiua-13880	189	18	treatment	treatment	NOUN
aiua-13880	189	19	(	(	PUNCT
aiua-13880	189	20	17	17	NUM
aiua-13880	189	21	)	)	PUNCT
aiua-13880	189	22	.	.	PUNCT
aiua-13880	190	1	furthermore	furthermore	ADV
aiua-13880	190	2	,	,	PUNCT
aiua-13880	190	3	a	a	DET
aiua-13880	190	4	trend	trend	NOUN
aiua-13880	190	5	was	be	AUX
aiua-13880	190	6	observed	observe	VERB
aiua-13880	190	7	suggesting	suggest	VERB
aiua-13880	190	8	that	that	SCONJ
aiua-13880	190	9	high	high	ADJ
aiua-13880	190	10	nlr	nlr	PROPN
aiua-13880	190	11	is	be	AUX
aiua-13880	190	12	associated	associate	VERB
aiua-13880	190	13	with	with	ADP
aiua-13880	190	14	worse	bad	ADJ
aiua-13880	190	15	os	os	NOUN
aiua-13880	190	16	,	,	PUNCT
aiua-13880	190	17	particularly	particularly	ADV
aiua-13880	190	18	in	in	ADP
aiua-13880	190	19	metastatic	metastatic	ADJ
aiua-13880	190	20	diseases	disease	NOUN
aiua-13880	190	21	.	.	PUNCT
aiua-13880	191	1	this	this	PRON
aiua-13880	191	2	suggests	suggest	VERB
aiua-13880	191	3	either	either	CCONJ
aiua-13880	191	4	a	a	DET
aiua-13880	191	5	greater	great	ADJ
aiua-13880	191	6	tumor	tumor	NOUN
aiua-13880	191	7	burden	burden	NOUN
aiua-13880	191	8	or	or	CCONJ
aiua-13880	191	9	more	more	ADV
aiua-13880	191	10	prolonged	prolonged	ADJ
aiua-13880	191	11	chronic	chronic	ADJ
aiua-13880	191	12	inflammatory	inflammatory	ADJ
aiua-13880	191	13	process	process	NOUN
aiua-13880	191	14	(	(	PUNCT
aiua-13880	191	15	36	36	NUM
aiua-13880	191	16	)	)	PUNCT
aiua-13880	191	17	.	.	PUNCT
aiua-13880	192	1	the	the	DET
aiua-13880	192	2	mechanisms	mechanism	NOUN
aiua-13880	192	3	linking	link	VERB
aiua-13880	192	4	high	high	ADJ
aiua-13880	192	5	nlr	nlr	PROPN
aiua-13880	192	6	to	to	ADP
aiua-13880	192	7	poor	poor	ADJ
aiua-13880	192	8	outcomes	outcome	NOUN
aiua-13880	192	9	in	in	ADP
aiua-13880	192	10	cancer	cancer	NOUN
aiua-13880	192	11	patients	patient	NOUN
aiua-13880	192	12	remain	remain	VERB
aiua-13880	192	13	poorly	poorly	ADV
aiua-13880	192	14	understood	understand	VERB
aiua-13880	192	15	.	.	PUNCT
aiua-13880	193	1	research	research	NOUN
aiua-13880	193	2	has	have	AUX
aiua-13880	193	3	indicated	indicate	VERB
aiua-13880	193	4	that	that	SCONJ
aiua-13880	193	5	neutrophils	neutrophil	NOUN
aiua-13880	193	6	,	,	PUNCT
aiua-13880	193	7	along	along	ADP
aiua-13880	193	8	with	with	ADP
aiua-13880	193	9	other	other	ADJ
aiua-13880	193	10	cells	cell	NOUN
aiua-13880	193	11	like	like	ADP
aiua-13880	193	12	macrophages	macrophage	NOUN
aiua-13880	193	13	,	,	PUNCT
aiua-13880	193	14	secrete	secrete	VERB
aiua-13880	193	15	various	various	ADJ
aiua-13880	193	16	factors	factor	NOUN
aiua-13880	193	17	that	that	PRON
aiua-13880	193	18	promote	promote	VERB
aiua-13880	193	19	tumor	tumor	NOUN
aiua-13880	193	20	growth	growth	NOUN
aiua-13880	193	21	,	,	PUNCT
aiua-13880	193	22	likely	likely	ADV
aiua-13880	193	23	contributing	contribute	VERB
aiua-13880	193	24	to	to	ADP
aiua-13880	193	25	an	an	DET
aiua-13880	193	26	environment	environment	NOUN
aiua-13880	193	27	that	that	PRON
aiua-13880	193	28	stimulates	stimulate	VERB
aiua-13880	193	29	tumor	tumor	NOUN
aiua-13880	193	30	progression	progression	NOUN
aiua-13880	193	31	(	(	PUNCT
aiua-13880	193	32	34	34	NUM
aiua-13880	193	33	)	)	PUNCT
aiua-13880	193	34	.	.	PUNCT
aiua-13880	194	1	a	a	DET
aiua-13880	194	2	range	range	NOUN
aiua-13880	194	3	of	of	ADP
aiua-13880	194	4	inflammatory	inflammatory	ADJ
aiua-13880	194	5	cytokines	cytokine	NOUN
aiua-13880	194	6	play	play	VERB
aiua-13880	194	7	a	a	DET
aiua-13880	194	8	role	role	NOUN
aiua-13880	194	9	in	in	ADP
aiua-13880	194	10	the	the	DET
aiua-13880	194	11	systemic	systemic	ADJ
aiua-13880	194	12	inflammatory	inflammatory	ADJ
aiua-13880	194	13	response	response	NOUN
aiua-13880	194	14	.	.	PUNCT
aiua-13880	195	1	notably	notably	ADV
aiua-13880	195	2	,	,	PUNCT
aiua-13880	195	3	il-6	il-6	PRON
aiua-13880	195	4	specifically	specifically	ADV
aiua-13880	195	5	enhances	enhance	VERB
aiua-13880	195	6	the	the	DET
aiua-13880	195	7	production	production	NOUN
aiua-13880	195	8	of	of	ADP
aiua-13880	195	9	acute	acute	ADJ
aiua-13880	195	10	-	-	PUNCT
aiua-13880	195	11	phase	phase	NOUN
aiua-13880	195	12	proteins	protein	NOUN
aiua-13880	195	13	,	,	PUNCT
aiua-13880	195	14	such	such	ADJ
aiua-13880	195	15	as	as	ADP
aiua-13880	195	16	c	c	NOUN
aiua-13880	195	17	-	-	PUNCT
aiua-13880	195	18	reactive	reactive	ADJ
aiua-13880	195	19	protein	protein	NOUN
aiua-13880	195	20	,	,	PUNCT
aiua-13880	195	21	while	while	SCONJ
aiua-13880	195	22	simultaneously	simultaneously	ADV
aiua-13880	195	23	reducing	reduce	VERB
aiua-13880	195	24	albumin	albumin	ADJ
aiua-13880	195	25	synthesis	synthesis	NOUN
aiua-13880	195	26	in	in	ADP
aiua-13880	195	27	the	the	DET
aiua-13880	195	28	liver	liver	NOUN
aiua-13880	195	29	(	(	PUNCT
aiua-13880	195	30	37	37	NUM
aiua-13880	195	31	)	)	PUNCT
aiua-13880	195	32	.	.	PUNCT
aiua-13880	196	1	in	in	ADP
aiua-13880	196	2	this	this	DET
aiua-13880	196	3	review	review	NOUN
aiua-13880	196	4	,	,	PUNCT
aiua-13880	196	5	we	we	PRON
aiua-13880	196	6	also	also	ADV
aiua-13880	196	7	identified	identify	VERB
aiua-13880	196	8	an	an	DET
aiua-13880	196	9	association	association	NOUN
aiua-13880	196	10	between	between	ADP
aiua-13880	196	11	high	high	ADJ
aiua-13880	196	12	crp	crp	PROPN
aiua-13880	196	13	levels	level	NOUN
aiua-13880	196	14	and	and	CCONJ
aiua-13880	196	15	hypoalbuminemia	hypoalbuminemia	ADV
aiua-13880	196	16	with	with	ADP
aiua-13880	196	17	poor	poor	ADJ
aiua-13880	196	18	os	os	NOUN
aiua-13880	196	19	,	,	PUNCT
aiua-13880	196	20	although	although	SCONJ
aiua-13880	196	21	this	this	PRON
aiua-13880	196	22	was	be	AUX
aiua-13880	196	23	supported	support	VERB
aiua-13880	196	24	by	by	ADP
aiua-13880	196	25	fewer	few	ADJ
aiua-13880	196	26	studies	study	NOUN
aiua-13880	196	27	and	and	CCONJ
aiua-13880	196	28	significant	significant	ADJ
aiua-13880	196	29	heterogeneity	heterogeneity	NOUN
aiua-13880	196	30	.	.	PUNCT
aiua-13880	197	1	interestingly	interestingly	ADV
aiua-13880	197	2	,	,	PUNCT
aiua-13880	197	3	varying	vary	VERB
aiua-13880	197	4	cutoff	cutoff	NOUN
aiua-13880	197	5	points	point	NOUN
aiua-13880	197	6	for	for	ADP
aiua-13880	197	7	both	both	DET
aiua-13880	197	8	hemoglobin	hemoglobin	NOUN
aiua-13880	197	9	and	and	CCONJ
aiua-13880	197	10	nlr	nlr	PROPN
aiua-13880	197	11	across	across	ADP
aiua-13880	197	12	studies	study	NOUN
aiua-13880	197	13	were	be	AUX
aiua-13880	197	14	documented	document	VERB
aiua-13880	197	15	.	.	PUNCT
aiua-13880	198	1	despite	despite	SCONJ
aiua-13880	198	2	these	these	DET
aiua-13880	198	3	differences	difference	NOUN
aiua-13880	198	4	,	,	PUNCT
aiua-13880	198	5	given	give	VERB
aiua-13880	198	6	the	the	DET
aiua-13880	198	7	relatively	relatively	ADV
aiua-13880	198	8	narrow	narrow	ADJ
aiua-13880	198	9	range	range	NOUN
aiua-13880	198	10	of	of	ADP
aiua-13880	198	11	hemoglobin	hemoglobin	NOUN
aiua-13880	198	12	and	and	CCONJ
aiua-13880	198	13	nlr	nlr	PROPN
aiua-13880	198	14	cutoffs	cutoff	NOUN
aiua-13880	198	15	used	use	VERB
aiua-13880	198	16	in	in	ADP
aiua-13880	198	17	our	our	PRON
aiua-13880	198	18	analysis	analysis	NOUN
aiua-13880	198	19	,	,	PUNCT
aiua-13880	198	20	we	we	PRON
aiua-13880	198	21	do	do	AUX
aiua-13880	198	22	not	not	PART
aiua-13880	198	23	expect	expect	VERB
aiua-13880	198	24	this	this	DET
aiua-13880	198	25	variability	variability	NOUN
aiua-13880	198	26	to	to	PART
aiua-13880	198	27	significantly	significantly	ADV
aiua-13880	198	28	affect	affect	VERB
aiua-13880	198	29	the	the	DET
aiua-13880	198	30	interpretation	interpretation	NOUN
aiua-13880	198	31	of	of	ADP
aiua-13880	198	32	our	our	PRON
aiua-13880	198	33	findings	finding	NOUN
aiua-13880	198	34	.	.	PUNCT
aiua-13880	199	1	in	in	ADP
aiua-13880	199	2	our	our	PRON
aiua-13880	199	3	study	study	NOUN
aiua-13880	199	4	,	,	PUNCT
aiua-13880	199	5	we	we	PRON
aiua-13880	199	6	found	find	VERB
aiua-13880	199	7	that	that	SCONJ
aiua-13880	199	8	higher	high	ADJ
aiua-13880	199	9	crp	crp	PROPN
aiua-13880	199	10	levels	level	NOUN
aiua-13880	199	11	are	be	AUX
aiua-13880	199	12	associated	associate	VERB
aiua-13880	199	13	with	with	ADP
aiua-13880	199	14	worse	bad	ADJ
aiua-13880	199	15	outcomes	outcome	NOUN
aiua-13880	199	16	,	,	PUNCT
aiua-13880	199	17	although	although	SCONJ
aiua-13880	199	18	there	there	PRON
aiua-13880	199	19	is	be	VERB
aiua-13880	199	20	considerable	considerable	ADJ
aiua-13880	199	21	heterogeneity	heterogeneity	NOUN
aiua-13880	199	22	.	.	PUNCT
aiua-13880	200	1	this	this	DET
aiua-13880	200	2	variability	variability	NOUN
aiua-13880	200	3	may	may	AUX
aiua-13880	200	4	be	be	AUX
aiua-13880	200	5	attributed	attribute	VERB
aiua-13880	200	6	to	to	ADP
aiua-13880	200	7	the	the	DET
aiua-13880	200	8	different	different	ADJ
aiua-13880	200	9	cutoff	cutoff	NOUN
aiua-13880	200	10	values	value	NOUN
aiua-13880	200	11	used	use	VERB
aiua-13880	200	12	in	in	ADP
aiua-13880	200	13	the	the	DET
aiua-13880	200	14	studies	study	NOUN
aiua-13880	200	15	included	include	VERB
aiua-13880	200	16	.	.	PUNCT
aiua-13880	201	1	the	the	DET
aiua-13880	201	2	relationship	relationship	NOUN
aiua-13880	201	3	between	between	ADP
aiua-13880	201	4	crp	crp	PROPN
aiua-13880	201	5	and	and	CCONJ
aiua-13880	201	6	cancer	cancer	NOUN
aiua-13880	201	7	prognosis	prognosis	NOUN
aiua-13880	201	8	is	be	AUX
aiua-13880	201	9	a	a	DET
aiua-13880	201	10	complex	complex	ADJ
aiua-13880	201	11	interplay	interplay	NOUN
aiua-13880	201	12	of	of	ADP
aiua-13880	201	13	cytokines	cytokine	NOUN
aiua-13880	201	14	.	.	PUNCT
aiua-13880	202	1	tumor	tumor	NOUN
aiua-13880	202	2	cells	cell	NOUN
aiua-13880	202	3	release	release	VERB
aiua-13880	202	4	cytokines	cytokine	NOUN
aiua-13880	202	5	and	and	CCONJ
aiua-13880	202	6	chemokines	chemokine	NOUN
aiua-13880	202	7	such	such	ADJ
aiua-13880	202	8	as	as	ADP
aiua-13880	202	9	il-6	il-6	NUM
aiua-13880	202	10	and	and	CCONJ
aiua-13880	202	11	il-8	il-8	NOUN
aiua-13880	202	12	,	,	PUNCT
aiua-13880	202	13	which	which	PRON
aiua-13880	202	14	result	result	VERB
aiua-13880	202	15	in	in	ADP
aiua-13880	202	16	elevated	elevated	ADJ
aiua-13880	202	17	serum	serum	NOUN
aiua-13880	202	18	crp	crp	PROPN
aiua-13880	202	19	levels	level	NOUN
aiua-13880	202	20	.	.	PUNCT
aiua-13880	203	1	moreover	moreover	ADV
aiua-13880	203	2	,	,	PUNCT
aiua-13880	203	3	tumor	tumor	NOUN
aiua-13880	203	4	growth	growth	NOUN
aiua-13880	203	5	and	and	CCONJ
aiua-13880	203	6	invasion	invasion	NOUN
aiua-13880	203	7	can	can	AUX
aiua-13880	203	8	cause	cause	VERB
aiua-13880	203	9	inflammation	inflammation	NOUN
aiua-13880	203	10	,	,	PUNCT
aiua-13880	203	11	contributing	contribute	VERB
aiua-13880	203	12	to	to	PART
aiua-13880	203	13	further	far	ADV
aiua-13880	203	14	rise	rise	VERB
aiua-13880	203	15	in	in	ADP
aiua-13880	203	16	crp	crp	PROPN
aiua-13880	203	17	(	(	PUNCT
aiua-13880	203	18	38	38	NUM
aiua-13880	203	19	)	)	PUNCT
aiua-13880	203	20	.	.	PUNCT
aiua-13880	204	1	high	high	PROPN
aiua-13880	204	2	crp	crp	PROPN
aiua-13880	204	3	levels	level	NOUN
aiua-13880	204	4	have	have	AUX
aiua-13880	204	5	also	also	ADV
aiua-13880	204	6	been	be	AUX
aiua-13880	204	7	demonstrated	demonstrate	VERB
aiua-13880	204	8	to	to	PART
aiua-13880	204	9	cause	cause	VERB
aiua-13880	204	10	dna	dna	NOUN
aiua-13880	204	11	damage	damage	NOUN
aiua-13880	204	12	and	and	CCONJ
aiua-13880	204	13	weaken	weaken	VERB
aiua-13880	204	14	immune	immune	ADJ
aiua-13880	204	15	function	function	NOUN
aiua-13880	204	16	,	,	PUNCT
aiua-13880	204	17	further	far	ADV
aiua-13880	204	18	facilitating	facilitate	VERB
aiua-13880	204	19	carcinogenesis	carcinogenesis	NOUN
aiua-13880	204	20	and	and	CCONJ
aiua-13880	204	21	tumor	tumor	NOUN
aiua-13880	204	22	progression	progression	NOUN
aiua-13880	204	23	(	(	PUNCT
aiua-13880	204	24	39	39	NUM
aiua-13880	204	25	)	)	PUNCT
aiua-13880	204	26	.	.	PUNCT
aiua-13880	205	1	to	to	ADP
aiua-13880	205	2	our	our	PRON
aiua-13880	205	3	knowledge	knowledge	NOUN
aiua-13880	205	4	,	,	PUNCT
aiua-13880	205	5	this	this	PRON
aiua-13880	205	6	is	be	AUX
aiua-13880	205	7	the	the	DET
aiua-13880	205	8	first	first	ADJ
aiua-13880	205	9	systematic	systematic	ADJ
aiua-13880	205	10	review	review	NOUN
aiua-13880	205	11	and	and	CCONJ
aiua-13880	205	12	meta	meta	NOUN
aiua-13880	205	13	-	-	PUNCT
aiua-13880	205	14	analysis	analysis	NOUN
aiua-13880	205	15	that	that	PRON
aiua-13880	205	16	comprehensively	comprehensively	ADV
aiua-13880	205	17	assess	assess	VERB
aiua-13880	205	18	prognostic	prognostic	ADJ
aiua-13880	205	19	value	value	NOUN
aiua-13880	205	20	of	of	ADP
aiua-13880	205	21	pre	pre	ADJ
aiua-13880	205	22	-	-	ADJ
aiua-13880	205	23	treatment	treatment	ADJ
aiua-13880	205	24	hematologic	hematologic	NOUN
aiua-13880	205	25	and	and	CCONJ
aiua-13880	205	26	clinical	clinical	ADJ
aiua-13880	205	27	parameters	parameter	NOUN
aiua-13880	205	28	in	in	ADP
aiua-13880	205	29	predicting	predict	VERB
aiua-13880	205	30	outcomes	outcome	NOUN
aiua-13880	205	31	of	of	ADP
aiua-13880	205	32	patients	patient	NOUN
aiua-13880	205	33	with	with	ADP
aiua-13880	205	34	locally	locally	ADV
aiua-13880	205	35	advanced	advanced	ADJ
aiua-13880	205	36	or	or	CCONJ
aiua-13880	205	37	metastatic	metastatic	ADJ
aiua-13880	205	38	urothelial	urothelial	ADJ
aiua-13880	205	39	carcinoma	carcinoma	NOUN
aiua-13880	205	40	.	.	PUNCT
aiua-13880	206	1	while	while	SCONJ
aiua-13880	206	2	we	we	PRON
aiua-13880	206	3	have	have	AUX
aiua-13880	206	4	made	make	VERB
aiua-13880	206	5	every	every	DET
aiua-13880	206	6	effort	effort	NOUN
aiua-13880	206	7	to	to	PART
aiua-13880	206	8	ensure	ensure	VERB
aiua-13880	206	9	the	the	DET
aiua-13880	206	10	highest	high	ADJ
aiua-13880	206	11	quality	quality	NOUN
aiua-13880	206	12	in	in	ADP
aiua-13880	206	13	this	this	DET
aiua-13880	206	14	study	study	NOUN
aiua-13880	206	15	,	,	PUNCT
aiua-13880	206	16	we	we	PRON
aiua-13880	206	17	recognize	recognize	VERB
aiua-13880	206	18	several	several	ADJ
aiua-13880	206	19	limitations	limitation	NOUN
aiua-13880	206	20	.	.	PUNCT
aiua-13880	207	1	first	first	ADV
aiua-13880	207	2	,	,	PUNCT
aiua-13880	207	3	the	the	DET
aiua-13880	207	4	studies	study	NOUN
aiua-13880	207	5	included	include	VERB
aiua-13880	207	6	in	in	ADP
aiua-13880	207	7	this	this	DET
aiua-13880	207	8	review	review	NOUN
aiua-13880	207	9	were	be	AUX
aiua-13880	207	10	quite	quite	ADV
aiua-13880	207	11	heterogeneous	heterogeneous	ADJ
aiua-13880	207	12	,	,	PUNCT
aiua-13880	207	13	as	as	SCONJ
aiua-13880	207	14	they	they	PRON
aiua-13880	207	15	encompassed	encompass	VERB
aiua-13880	207	16	patients	patient	NOUN
aiua-13880	207	17	with	with	ADP
aiua-13880	207	18	different	different	ADJ
aiua-13880	207	19	lines	line	NOUN
aiua-13880	207	20	of	of	ADP
aiua-13880	207	21	chemotherapy	chemotherapy	NOUN
aiua-13880	207	22	.	.	PUNCT
aiua-13880	208	1	second	second	ADJ
aiua-13880	208	2	,	,	PUNCT
aiua-13880	208	3	most	most	ADJ
aiua-13880	208	4	of	of	ADP
aiua-13880	208	5	the	the	DET
aiua-13880	208	6	studies	study	NOUN
aiua-13880	208	7	that	that	PRON
aiua-13880	208	8	met	meet	VERB
aiua-13880	208	9	our	our	PRON
aiua-13880	208	10	inclusion	inclusion	NOUN
aiua-13880	208	11	criteria	criterion	NOUN
aiua-13880	208	12	originated	originate	VERB
aiua-13880	208	13	from	from	ADP
aiua-13880	208	14	japan	japan	PROPN
aiua-13880	208	15	.	.	PUNCT
aiua-13880	209	1	these	these	DET
aiua-13880	209	2	limitations	limitation	NOUN
aiua-13880	209	3	underscore	underscore	VERB
aiua-13880	209	4	the	the	DET
aiua-13880	209	5	necessity	necessity	NOUN
aiua-13880	209	6	for	for	ADP
aiua-13880	209	7	standardized	standardized	ADJ
aiua-13880	209	8	protocols	protocol	NOUN
aiua-13880	209	9	and	and	CCONJ
aiua-13880	209	10	more	more	ADV
aiua-13880	209	11	rigorous	rigorous	ADJ
aiua-13880	209	12	studies	study	NOUN
aiua-13880	209	13	to	to	PART
aiua-13880	209	14	enhance	enhance	VERB
aiua-13880	209	15	our	our	PRON
aiua-13880	209	16	understanding	understanding	NOUN
aiua-13880	209	17	of	of	ADP
aiua-13880	209	18	the	the	DET
aiua-13880	209	19	predictive	predictive	ADJ
aiua-13880	209	20	value	value	NOUN
aiua-13880	209	21	of	of	ADP
aiua-13880	209	22	these	these	DET
aiua-13880	209	23	prognostic	prognostic	ADJ
aiua-13880	209	24	factors	factor	NOUN
aiua-13880	209	25	in	in	ADP
aiua-13880	209	26	immunotherapy	immunotherapy	NOUN
aiua-13880	209	27	.	.	PUNCT
aiua-13880	210	1	conclusions	conclusion	NOUN
aiua-13880	210	2	our	our	PRON
aiua-13880	210	3	research	research	NOUN
aiua-13880	210	4	revealed	reveal	VERB
aiua-13880	210	5	a	a	DET
aiua-13880	210	6	number	number	NOUN
aiua-13880	210	7	of	of	ADP
aiua-13880	210	8	important	important	ADJ
aiua-13880	210	9	prognostic	prognostic	ADJ
aiua-13880	210	10	variables	variable	NOUN
aiua-13880	210	11	linked	link	VERB
aiua-13880	210	12	to	to	ADP
aiua-13880	210	13	survival	survival	NOUN
aiua-13880	210	14	in	in	ADP
aiua-13880	210	15	pembrolizumab	pembrolizumab	NOUN
aiua-13880	210	16	-	-	PUNCT
aiua-13880	210	17	treated	treat	VERB
aiua-13880	210	18	muc	muc	ADJ
aiua-13880	210	19	patients	patient	NOUN
aiua-13880	210	20	.	.	PUNCT
aiua-13880	211	1	the	the	DET
aiua-13880	211	2	occurrence	occurrence	NOUN
aiua-13880	211	3	of	of	ADP
aiua-13880	211	4	liver	liver	NOUN
aiua-13880	211	5	,	,	PUNCT
aiua-13880	211	6	lung	lung	NOUN
aiua-13880	211	7	,	,	PUNCT
aiua-13880	211	8	or	or	CCONJ
aiua-13880	211	9	bone	bone	NOUN
aiua-13880	211	10	metastases	metastasis	NOUN
aiua-13880	211	11	,	,	PUNCT
aiua-13880	211	12	low	low	ADJ
aiua-13880	211	13	hemoglobin	hemoglobin	NOUN
aiua-13880	211	14	levels	level	NOUN
aiua-13880	211	15	,	,	PUNCT
aiua-13880	211	16	high	high	ADJ
aiua-13880	211	17	neutrophil	neutrophil	ADJ
aiua-13880	211	18	-	-	PUNCT
aiua-13880	211	19	tolymphocyte	tolymphocyte	NOUN
aiua-13880	211	20	ratio	ratio	NOUN
aiua-13880	211	21	(	(	PUNCT
aiua-13880	211	22	nlr	nlr	PROPN
aiua-13880	211	23	)	)	PUNCT
aiua-13880	211	24	,	,	PUNCT
aiua-13880	211	25	higher	high	ADJ
aiua-13880	211	26	c	c	NOUN
aiua-13880	211	27	-	-	ADJ
aiua-13880	211	28	reactive	reactive	ADJ
aiua-13880	211	29	protein	protein	NOUN
aiua-13880	211	30	(	(	PUNCT
aiua-13880	211	31	crp	crp	NOUN
aiua-13880	211	32	)	)	PUNCT
aiua-13880	211	33	levels	level	NOUN
aiua-13880	211	34	,	,	PUNCT
aiua-13880	211	35	and	and	CCONJ
aiua-13880	211	36	poor	poor	ADJ
aiua-13880	211	37	performance	performance	NOUN
aiua-13880	211	38	status	status	NOUN
aiua-13880	211	39	(	(	PUNCT
aiua-13880	211	40	ecog	ecog	VERB
aiua-13880	211	41	-	-	PUNCT
aiua-13880	211	42	ps	ps	NOUN
aiua-13880	211	43	≥	≥	NOUN
aiua-13880	211	44	2	2	NUM
aiua-13880	211	45	)	)	PUNCT
aiua-13880	211	46	were	be	AUX
aiua-13880	211	47	all	all	PRON
aiua-13880	211	48	consistently	consistently	ADV
aiua-13880	211	49	associated	associate	VERB
aiua-13880	211	50	with	with	ADP
aiua-13880	211	51	poorer	poor	ADJ
aiua-13880	211	52	outcomes	outcome	NOUN
aiua-13880	211	53	.	.	PUNCT
aiua-13880	212	1	although	although	SCONJ
aiua-13880	212	2	the	the	DET
aiua-13880	212	3	analysis	analysis	NOUN
aiua-13880	212	4	offers	offer	VERB
aiua-13880	212	5	insightful	insightful	ADJ
aiua-13880	212	6	information	information	NOUN
aiua-13880	212	7	,	,	PUNCT
aiua-13880	212	8	the	the	DET
aiua-13880	212	9	variety	variety	NOUN
aiua-13880	212	10	of	of	ADP
aiua-13880	212	11	included	include	VERB
aiua-13880	212	12	studies	study	NOUN
aiua-13880	212	13	and	and	CCONJ
aiua-13880	212	14	the	the	DET
aiua-13880	212	15	majority	majority	NOUN
aiua-13880	212	16	of	of	ADP
aiua-13880	212	17	data	datum	NOUN
aiua-13880	212	18	from	from	ADP
aiua-13880	212	19	japan	japan	PROPN
aiua-13880	212	20	highlight	highlight	VERB
aiua-13880	212	21	the	the	DET
aiua-13880	212	22	need	need	NOUN
aiua-13880	212	23	for	for	ADP
aiua-13880	212	24	further	further	ADJ
aiua-13880	212	25	systematic	systematic	ADJ
aiua-13880	212	26	research	research	NOUN
aiua-13880	212	27	to	to	PART
aiua-13880	212	28	confirm	confirm	VERB
aiua-13880	212	29	these	these	DET
aiua-13880	212	30	predictive	predictive	ADJ
aiua-13880	212	31	markers	marker	NOUN
aiua-13880	212	32	and	and	CCONJ
aiua-13880	212	33	enhance	enhance	VERB
aiua-13880	212	34	clinical	clinical	ADJ
aiua-13880	212	35	judgment	judgment	NOUN
aiua-13880	212	36	for	for	ADP
aiua-13880	212	37	patients	patient	NOUN
aiua-13880	212	38	with	with	ADP
aiua-13880	212	39	muc	muc	X
aiua-13880	212	40	.	.	PUNCT
aiua-13880	213	1	references	reference	NOUN
aiua-13880	213	2	1	1	NUM
aiua-13880	213	3	.	.	PUNCT
aiua-13880	214	1	lenis	lenis	PROPN
aiua-13880	214	2	at	at	ADP
aiua-13880	214	3	,	,	PUNCT
aiua-13880	214	4	lec	lec	PROPN
aiua-13880	214	5	pm	pm	PROPN
aiua-13880	214	6	,	,	PUNCT
aiua-13880	214	7	chamie	chamie	VERB
aiua-13880	214	8	k	k	PROPN
aiua-13880	214	9	,	,	PUNCT
aiua-13880	214	10	mshs	mshs	PROPN
aiua-13880	214	11	md	md	PROPN
aiua-13880	214	12	.	.	PROPN
aiua-13880	214	13	bladder	bladder	NOUN
aiua-13880	214	14	cancer	cancer	NOUN
aiua-13880	214	15	:	:	PUNCT
aiua-13880	214	16	a	a	DET
aiua-13880	214	17	review	review	NOUN
aiua-13880	214	18	.	.	PUNCT
aiua-13880	215	1	jama	jama	PROPN
aiua-13880	215	2	.	.	PUNCT
aiua-13880	216	1	2020	2020	NUM
aiua-13880	216	2	;	;	PUNCT
aiua-13880	216	3	324:1980	324:1980	NUM
aiua-13880	216	4	-	-	SYM
aiua-13880	216	5	91	91	NUM
aiua-13880	216	6	.	.	PUNCT
aiua-13880	217	1	2	2	X
aiua-13880	217	2	.	.	X
aiua-13880	217	3	sung	sung	PROPN
aiua-13880	217	4	h	h	NOUN
aiua-13880	217	5	,	,	PUNCT
aiua-13880	217	6	ferlay	ferlay	PROPN
aiua-13880	217	7	j	j	PROPN
aiua-13880	217	8	,	,	PUNCT
aiua-13880	217	9	siegel	siegel	PROPN
aiua-13880	217	10	rl	rl	PROPN
aiua-13880	217	11	,	,	PUNCT
aiua-13880	217	12	et	et	PROPN
aiua-13880	217	13	al	al	PROPN
aiua-13880	217	14	.	.	PUNCT
aiua-13880	218	1	global	global	ADJ
aiua-13880	218	2	cancer	cancer	NOUN
aiua-13880	218	3	statistics	statistic	NOUN
aiua-13880	218	4	2020	2020	NUM
aiua-13880	218	5	:	:	PUNCT
aiua-13880	218	6	archivio	archivio	NOUN
aiua-13880	218	7	italiano	italiano	X
aiua-13880	218	8	di	di	X
aiua-13880	218	9	urologia	urologia	PROPN
aiua-13880	218	10	e	e	PROPN
aiua-13880	218	11	andrologia	andrologia	NOUN
aiua-13880	218	12	2025	2025	NUM
aiua-13880	218	13	;	;	PUNCT
aiua-13880	218	14	97(2):13880	97(2):13880	NUM
aiua-13880	218	15	k	k	PROPN
aiua-13880	218	16	..	..	PUNCT
aiua-13880	218	17	yuwono	yuwono	PROPN
aiua-13880	218	18	,	,	PUNCT
aiua-13880	218	19	j.	j.	PROPN
aiua-13880	218	20	nimasratu	nimasratu	PROPN
aiua-13880	218	21	rahmatsani	rahmatsani	PROPN
aiua-13880	218	22	,	,	PUNCT
aiua-13880	218	23	nadhifah	nadhifah	VERB
aiua-13880	218	24	,	,	PUNCT
aiua-13880	218	25	et	et	PROPN
aiua-13880	218	26	al	al	PROPN
aiua-13880	218	27	.	.	PROPN
aiua-13880	219	1	10	10	NUM
aiua-13880	219	2	globocan	globocan	PROPN
aiua-13880	219	3	estimates	estimate	NOUN
aiua-13880	219	4	of	of	ADP
aiua-13880	219	5	incidence	incidence	NOUN
aiua-13880	219	6	and	and	CCONJ
aiua-13880	219	7	mortality	mortality	NOUN
aiua-13880	219	8	worldwide	worldwide	ADV
aiua-13880	219	9	for	for	ADP
aiua-13880	219	10	36	36	NUM
aiua-13880	219	11	cancers	cancer	NOUN
aiua-13880	219	12	in	in	ADP
aiua-13880	219	13	185	185	NUM
aiua-13880	219	14	countries	country	NOUN
aiua-13880	219	15	.	.	PUNCT
aiua-13880	220	1	ca	can	AUX
aiua-13880	220	2	cancer	cancer	PROPN
aiua-13880	220	3	j	j	PROPN
aiua-13880	220	4	clin	clin	PROPN
aiua-13880	220	5	.	.	PUNCT
aiua-13880	221	1	2021	2021	NUM
aiua-13880	221	2	;	;	PUNCT
aiua-13880	221	3	71:209	71:209	NUM
aiua-13880	221	4	-	-	SYM
aiua-13880	221	5	49	49	NUM
aiua-13880	221	6	.	.	PUNCT
aiua-13880	222	1	3	3	X
aiua-13880	222	2	.	.	X
aiua-13880	222	3	heijden	heijden	PROPN
aiua-13880	222	4	ag	ag	PROPN
aiua-13880	222	5	van	van	PROPN
aiua-13880	222	6	der	der	PROPN
aiua-13880	222	7	,	,	PUNCT
aiua-13880	222	8	bruins	bruin	VERB
aiua-13880	222	9	hm	hm	INTJ
aiua-13880	222	10	,	,	PUNCT
aiua-13880	222	11	carrion	carrion	NOUN
aiua-13880	222	12	a	a	PRON
aiua-13880	222	13	,	,	PUNCT
aiua-13880	222	14	et	et	PROPN
aiua-13880	222	15	al	al	PROPN
aiua-13880	222	16	.	.	PUNCT
aiua-13880	223	1	eau	eau	PROPN
aiua-13880	223	2	guidelines	guideline	NOUN
aiua-13880	223	3	on	on	ADP
aiua-13880	223	4	muscle	muscle	NOUN
aiua-13880	223	5	-	-	PUNCT
aiua-13880	223	6	invasive	invasive	ADJ
aiua-13880	223	7	and	and	CCONJ
aiua-13880	223	8	metastatic	metastatic	ADJ
aiua-13880	223	9	bladder	bladder	NOUN
aiua-13880	223	10	cancer	cancer	NOUN
aiua-13880	223	11	.	.	PUNCT
aiua-13880	224	1	in	in	ADP
aiua-13880	224	2	arnhem	arnhem	PROPN
aiua-13880	224	3	,	,	PUNCT
aiua-13880	224	4	the	the	DET
aiua-13880	224	5	netherlands	netherlands	PROPN
aiua-13880	224	6	:	:	PUNCT
aiua-13880	224	7	eau	eau	PROPN
aiua-13880	224	8	guidelines	guideline	VERB
aiua-13880	224	9	office	office	NOUN
aiua-13880	224	10	;	;	PUNCT
aiua-13880	224	11	2025	2025	NUM
aiua-13880	224	12	.	.	PUNCT
aiua-13880	225	1	available	available	ADJ
aiua-13880	225	2	from	from	ADP
aiua-13880	225	3	:	:	PUNCT
aiua-13880	225	4	https://uroweb.org/guidelines/muscle-invasive-and-metastatic-bladder-cancer/	https://uroweb.org/guidelines/muscle-invasive-and-metastatic-bladder-cancer/	PROPN
aiua-13880	225	5	4	4	X
aiua-13880	225	6	.	.	NOUN
aiua-13880	225	7	dash	dash	NOUN
aiua-13880	225	8	a	a	DET
aiua-13880	225	9	,	,	PUNCT
aiua-13880	225	10	galsky	galsky	PROPN
aiua-13880	225	11	md	md	PROPN
aiua-13880	225	12	,	,	PUNCT
aiua-13880	225	13	vickers	vickers	PROPN
aiua-13880	225	14	aj	aj	PROPN
aiua-13880	225	15	,	,	PUNCT
aiua-13880	225	16	et	et	PROPN
aiua-13880	225	17	al	al	PROPN
aiua-13880	225	18	.	.	PROPN
aiua-13880	225	19	impact	impact	NOUN
aiua-13880	225	20	of	of	ADP
aiua-13880	225	21	renal	renal	ADJ
aiua-13880	225	22	impairment	impairment	NOUN
aiua-13880	225	23	on	on	ADP
aiua-13880	225	24	eligibility	eligibility	NOUN
aiua-13880	225	25	for	for	ADP
aiua-13880	225	26	adjuvant	adjuvant	ADJ
aiua-13880	225	27	cisplatin	cisplatin	NOUN
aiua-13880	225	28	-	-	PUNCT
aiua-13880	225	29	based	base	VERB
aiua-13880	225	30	chemotherapy	chemotherapy	NOUN
aiua-13880	225	31	in	in	ADP
aiua-13880	225	32	patients	patient	NOUN
aiua-13880	225	33	with	with	ADP
aiua-13880	225	34	urothelial	urothelial	ADJ
aiua-13880	225	35	carcinoma	carcinoma	NOUN
aiua-13880	225	36	of	of	ADP
aiua-13880	225	37	the	the	DET
aiua-13880	225	38	bladder	bladder	NOUN
aiua-13880	225	39	.	.	PUNCT
aiua-13880	226	1	cancer	cancer	NOUN
aiua-13880	226	2	.	.	PUNCT
aiua-13880	227	1	2006	2006	NUM
aiua-13880	227	2	;	;	PUNCT
aiua-13880	227	3	107:506	107:506	NOUN
aiua-13880	227	4	-	-	SYM
aiua-13880	227	5	13	13	NUM
aiua-13880	227	6	.	.	PUNCT
aiua-13880	228	1	5	5	NUM
aiua-13880	228	2	.	.	X
aiua-13880	228	3	balar	balar	PROPN
aiua-13880	228	4	av	av	PROPN
aiua-13880	228	5	,	,	PUNCT
aiua-13880	228	6	galsky	galsky	PROPN
aiua-13880	228	7	md	md	PROPN
aiua-13880	228	8	,	,	PUNCT
aiua-13880	228	9	rosenberg	rosenberg	PROPN
aiua-13880	228	10	je	je	PROPN
aiua-13880	228	11	,	,	PUNCT
aiua-13880	228	12	et	et	PROPN
aiua-13880	228	13	al	al	PROPN
aiua-13880	228	14	.	.	PROPN
aiua-13880	228	15	atezolizumab	atezolizumab	PROPN
aiua-13880	228	16	as	as	ADP
aiua-13880	228	17	firstline	firstline	ADJ
aiua-13880	228	18	treatment	treatment	NOUN
aiua-13880	228	19	in	in	ADP
aiua-13880	228	20	cisplatin	cisplatin	NOUN
aiua-13880	228	21	-	-	PUNCT
aiua-13880	228	22	ineligible	ineligible	ADJ
aiua-13880	228	23	patients	patient	NOUN
aiua-13880	228	24	with	with	ADP
aiua-13880	228	25	locally	locally	ADV
aiua-13880	228	26	advanced	advanced	ADJ
aiua-13880	228	27	and	and	CCONJ
aiua-13880	228	28	metastatic	metastatic	ADJ
aiua-13880	228	29	urothelial	urothelial	ADJ
aiua-13880	228	30	carcinoma	carcinoma	NOUN
aiua-13880	228	31	:	:	PUNCT
aiua-13880	228	32	a	a	DET
aiua-13880	228	33	single	single	ADJ
aiua-13880	228	34	-	-	PUNCT
aiua-13880	228	35	arm	arm	NOUN
aiua-13880	228	36	,	,	PUNCT
aiua-13880	228	37	multicentre	multicentre	NOUN
aiua-13880	228	38	,	,	PUNCT
aiua-13880	228	39	phase	phase	NOUN
aiua-13880	228	40	2	2	NUM
aiua-13880	228	41	trial	trial	NOUN
aiua-13880	228	42	.	.	PUNCT
aiua-13880	229	1	lancet	lancet	NOUN
aiua-13880	229	2	.	.	PUNCT
aiua-13880	230	1	2017	2017	NUM
aiua-13880	230	2	;	;	PUNCT
aiua-13880	231	1	389:67	389:67	NUM
aiua-13880	231	2	-	-	SYM
aiua-13880	231	3	76	76	NUM
aiua-13880	231	4	.	.	PUNCT
aiua-13880	232	1	6	6	X
aiua-13880	232	2	.	.	X
aiua-13880	232	3	balar	balar	PROPN
aiua-13880	232	4	av	av	PROPN
aiua-13880	232	5	,	,	PUNCT
aiua-13880	232	6	castellano	castellano	PROPN
aiua-13880	232	7	d	d	PROPN
aiua-13880	232	8	,	,	PUNCT
aiua-13880	232	9	o’donnell	o’donnell	PROPN
aiua-13880	232	10	ph	ph	VERB
aiua-13880	232	11	,	,	PUNCT
aiua-13880	232	12	et	et	PROPN
aiua-13880	232	13	al	al	PROPN
aiua-13880	232	14	.	.	PUNCT
aiua-13880	233	1	first	first	ADJ
aiua-13880	233	2	-	-	PUNCT
aiua-13880	233	3	line	line	NOUN
aiua-13880	233	4	pembrolizumab	pembrolizumab	NOUN
aiua-13880	233	5	in	in	ADP
aiua-13880	233	6	cisplatin	cisplatin	NOUN
aiua-13880	233	7	-	-	PUNCT
aiua-13880	233	8	ineligible	ineligible	ADJ
aiua-13880	233	9	patients	patient	NOUN
aiua-13880	233	10	with	with	ADP
aiua-13880	233	11	locally	locally	ADV
aiua-13880	233	12	advanced	advanced	ADJ
aiua-13880	233	13	and	and	CCONJ
aiua-13880	233	14	unresectable	unresectable	ADJ
aiua-13880	233	15	or	or	CCONJ
aiua-13880	233	16	metastatic	metastatic	ADJ
aiua-13880	233	17	urothelial	urothelial	ADJ
aiua-13880	233	18	cancer	cancer	NOUN
aiua-13880	233	19	(	(	PUNCT
aiua-13880	233	20	keynote-052	keynote-052	NOUN
aiua-13880	233	21	):	):	PUNCT
aiua-13880	233	22	a	a	DET
aiua-13880	233	23	multicentre	multicentre	NOUN
aiua-13880	233	24	,	,	PUNCT
aiua-13880	233	25	single	single	ADJ
aiua-13880	233	26	-	-	PUNCT
aiua-13880	233	27	arm	arm	NOUN
aiua-13880	233	28	,	,	PUNCT
aiua-13880	233	29	phase	phase	NOUN
aiua-13880	233	30	2	2	NUM
aiua-13880	233	31	study	study	NOUN
aiua-13880	233	32	.	.	PUNCT
aiua-13880	234	1	lancet	lancet	PROPN
aiua-13880	234	2	oncol	oncol	PROPN
aiua-13880	234	3	.	.	PUNCT
aiua-13880	235	1	2017	2017	NUM
aiua-13880	235	2	;	;	PUNCT
aiua-13880	235	3	18:1483	18:1483	NUM
aiua-13880	235	4	-	-	SYM
aiua-13880	235	5	92	92	NUM
aiua-13880	235	6	.	.	PUNCT
aiua-13880	236	1	7	7	X
aiua-13880	236	2	.	.	X
aiua-13880	236	3	merck	merck	PROPN
aiua-13880	236	4	sharp	sharp	PROPN
aiua-13880	236	5	&	&	CCONJ
aiua-13880	236	6	dohme	dohme	PROPN
aiua-13880	236	7	llc	llc	PROPN
aiua-13880	236	8	.	.	PUNCT
aiua-13880	237	1	a	a	DET
aiua-13880	237	2	study	study	NOUN
aiua-13880	237	3	of	of	ADP
aiua-13880	237	4	efficacy	efficacy	NOUN
aiua-13880	237	5	and	and	CCONJ
aiua-13880	237	6	safety	safety	NOUN
aiua-13880	237	7	of	of	ADP
aiua-13880	237	8	pembrolizumab	pembrolizumab	NOUN
aiua-13880	237	9	plus	plus	CCONJ
aiua-13880	237	10	enfortumab	enfortumab	X
aiua-13880	237	11	vedotin	vedotin	ADJ
aiua-13880	237	12	(	(	PUNCT
aiua-13880	237	13	ev	ev	ADJ
aiua-13880	237	14	)	)	PUNCT
aiua-13880	237	15	+	+	ADJ
aiua-13880	237	16	/investigational	/investigational	ADJ
aiua-13880	237	17	agents	agent	NOUN
aiua-13880	237	18	in	in	ADP
aiua-13880	237	19	first	first	ADJ
aiua-13880	237	20	-	-	PUNCT
aiua-13880	237	21	line	line	NOUN
aiua-13880	237	22	metastatic	metastatic	ADJ
aiua-13880	237	23	urothelial	urothelial	ADJ
aiua-13880	237	24	carcinoma	carcinoma	NOUN
aiua-13880	237	25	(	(	PUNCT
aiua-13880	237	26	muc	muc	X
aiua-13880	237	27	)	)	PUNCT
aiua-13880	237	28	(	(	PUNCT
aiua-13880	237	29	mk3475	mk3475	PROPN
aiua-13880	237	30	-	-	PUNCT
aiua-13880	237	31	04b	04b	NOUN
aiua-13880	237	32	/	/	SYM
aiua-13880	237	33	keymaker	keymaker	NOUN
aiua-13880	237	34	-	-	PUNCT
aiua-13880	237	35	u04	u04	NOUN
aiua-13880	238	1	[	[	X
aiua-13880	238	2	internet	internet	NOUN
aiua-13880	238	3	]	]	PUNCT
aiua-13880	238	4	.	.	PUNCT
aiua-13880	239	1	2025	2025	NUM
aiua-13880	239	2	feb	feb	NOUN
aiua-13880	239	3	[	[	X
aiua-13880	239	4	cited	cite	VERB
aiua-13880	239	5	2025	2025	NUM
aiua-13880	239	6	mar	mar	PROPN
aiua-13880	239	7	1	1	NUM
aiua-13880	239	8	]	]	PUNCT
aiua-13880	239	9	.	.	PUNCT
aiua-13880	240	1	report	report	VERB
aiua-13880	240	2	no	no	INTJ
aiua-13880	240	3	.	.	PUNCT
aiua-13880	240	4	:	:	PUNCT
aiua-13880	241	1	nct05845814	nct05845814	PROPN
aiua-13880	241	2	.	.	PUNCT
aiua-13880	242	1	available	available	ADJ
aiua-13880	242	2	from	from	ADP
aiua-13880	242	3	:	:	PUNCT
aiua-13880	242	4	https://clinicaltrials.gov/study/nct05845814	https://clinicaltrials.gov/study/nct05845814	PROPN
aiua-13880	242	5	.	.	PUNCT
aiua-13880	243	1	8	8	NUM
aiua-13880	243	2	.	.	PUNCT
aiua-13880	243	3	powles	powles	PROPN
aiua-13880	243	4	t	t	PROPN
aiua-13880	243	5	,	,	PUNCT
aiua-13880	243	6	valderrama	valderrama	PROPN
aiua-13880	243	7	bp	bp	PROPN
aiua-13880	243	8	,	,	PUNCT
aiua-13880	243	9	gupta	gupta	PROPN
aiua-13880	243	10	s	s	PART
aiua-13880	243	11	,	,	PUNCT
aiua-13880	243	12	et	et	PROPN
aiua-13880	243	13	al	al	PROPN
aiua-13880	243	14	.	.	PROPN
aiua-13880	243	15	enfortumab	enfortumab	PROPN
aiua-13880	243	16	vedotin	vedotin	ADJ
aiua-13880	243	17	and	and	CCONJ
aiua-13880	243	18	pembrolizumab	pembrolizumab	NOUN
aiua-13880	243	19	in	in	ADP
aiua-13880	243	20	untreated	untreated	ADJ
aiua-13880	243	21	advanced	advanced	ADJ
aiua-13880	243	22	urothelial	urothelial	ADJ
aiua-13880	243	23	cancer	cancer	NOUN
aiua-13880	243	24	.	.	PUNCT
aiua-13880	244	1	n	n	PROPN
aiua-13880	244	2	engl	engl	PROPN
aiua-13880	244	3	j	j	PROPN
aiua-13880	244	4	med	med	PROPN
aiua-13880	244	5	.	.	PUNCT
aiua-13880	244	6	2024	2024	NUM
aiua-13880	244	7	;	;	PUNCT
aiua-13880	244	8	390:875	390:875	NUM
aiua-13880	244	9	-	-	SYM
aiua-13880	244	10	88	88	NUM
aiua-13880	244	11	.	.	PUNCT
aiua-13880	245	1	9	9	NUM
aiua-13880	245	2	.	.	X
aiua-13880	245	3	rosenberg	rosenberg	PROPN
aiua-13880	245	4	je	je	PROPN
aiua-13880	245	5	,	,	PUNCT
aiua-13880	245	6	o’donnell	o’donnell	PROPN
aiua-13880	245	7	ph	ph	VERB
aiua-13880	245	8	,	,	PUNCT
aiua-13880	245	9	balar	balar	PROPN
aiua-13880	245	10	av	av	PROPN
aiua-13880	245	11	,	,	PUNCT
aiua-13880	245	12	et	et	PROPN
aiua-13880	245	13	al	al	PROPN
aiua-13880	245	14	.	.	PUNCT
aiua-13880	246	1	pivotal	pivotal	ADJ
aiua-13880	246	2	trial	trial	NOUN
aiua-13880	246	3	of	of	ADP
aiua-13880	246	4	enfortumab	enfortumab	NOUN
aiua-13880	246	5	vedotin	vedotin	ADJ
aiua-13880	246	6	in	in	ADP
aiua-13880	246	7	urothelial	urothelial	ADJ
aiua-13880	246	8	carcinoma	carcinoma	NOUN
aiua-13880	246	9	after	after	ADP
aiua-13880	246	10	platinum	platinum	NOUN
aiua-13880	246	11	and	and	CCONJ
aiua-13880	246	12	anti	anti	ADJ
aiua-13880	246	13	-	-	ADJ
aiua-13880	246	14	programmed	programmed	ADJ
aiua-13880	246	15	death	death	NOUN
aiua-13880	246	16	1	1	NUM
aiua-13880	246	17	/	/	SYM
aiua-13880	246	18	programmed	program	VERB
aiua-13880	246	19	death	death	NOUN
aiua-13880	246	20	ligand	ligand	NOUN
aiua-13880	246	21	1	1	NUM
aiua-13880	246	22	therapy	therapy	NOUN
aiua-13880	246	23	.	.	PUNCT
aiua-13880	247	1	j	j	PROPN
aiua-13880	247	2	clin	clin	PROPN
aiua-13880	247	3	oncol	oncol	PROPN
aiua-13880	247	4	.	.	PUNCT
aiua-13880	248	1	2019	2019	NUM
aiua-13880	248	2	;	;	PUNCT
aiua-13880	248	3	37:2592	37:2592	X
aiua-13880	248	4	-	-	SYM
aiua-13880	248	5	600	600	NUM
aiua-13880	248	6	.	.	NOUN
aiua-13880	249	1	10	10	NUM
aiua-13880	249	2	.	.	PUNCT
aiua-13880	250	1	khunger	khunger	PROPN
aiua-13880	250	2	m	m	PROPN
aiua-13880	250	3	,	,	PUNCT
aiua-13880	250	4	hernandez	hernandez	PROPN
aiua-13880	250	5	av	av	PROPN
aiua-13880	250	6	,	,	PUNCT
aiua-13880	250	7	pasupuleti	pasupuleti	PROPN
aiua-13880	250	8	v	v	NOUN
aiua-13880	250	9	,	,	PUNCT
aiua-13880	250	10	et	et	PROPN
aiua-13880	250	11	al	al	PROPN
aiua-13880	250	12	.	.	PROPN
aiua-13880	251	1	programmed	program	VERB
aiua-13880	251	2	cell	cell	NOUN
aiua-13880	251	3	death	death	NOUN
aiua-13880	251	4	1	1	NUM
aiua-13880	251	5	(	(	PUNCT
aiua-13880	251	6	pd-1	pd-1	NOUN
aiua-13880	251	7	)	)	PUNCT
aiua-13880	251	8	ligand	ligand	NOUN
aiua-13880	251	9	(	(	PUNCT
aiua-13880	251	10	pd	pd	NOUN
aiua-13880	251	11	-	-	PUNCT
aiua-13880	251	12	l1	l1	NOUN
aiua-13880	251	13	)	)	PUNCT
aiua-13880	251	14	expression	expression	NOUN
aiua-13880	251	15	in	in	ADP
aiua-13880	251	16	solid	solid	ADJ
aiua-13880	251	17	tumors	tumor	NOUN
aiua-13880	251	18	as	as	ADP
aiua-13880	251	19	a	a	DET
aiua-13880	251	20	predictive	predictive	ADJ
aiua-13880	251	21	biomarker	biomarker	NOUN
aiua-13880	251	22	of	of	ADP
aiua-13880	251	23	benefit	benefit	NOUN
aiua-13880	251	24	from	from	ADP
aiua-13880	251	25	pd-1	pd-1	ADP
aiua-13880	251	26	/	/	SYM
aiua-13880	251	27	pd	pd	ADJ
aiua-13880	251	28	-	-	PUNCT
aiua-13880	251	29	l1	l1	PROPN
aiua-13880	251	30	axis	axis	NOUN
aiua-13880	251	31	inhibitors	inhibitor	NOUN
aiua-13880	251	32	:	:	PUNCT
aiua-13880	251	33	a	a	DET
aiua-13880	251	34	systematic	systematic	ADJ
aiua-13880	251	35	review	review	NOUN
aiua-13880	251	36	and	and	CCONJ
aiua-13880	251	37	meta	meta	ADJ
aiua-13880	251	38	-	-	PUNCT
aiua-13880	251	39	analysis	analysis	NOUN
aiua-13880	251	40	.	.	PUNCT
aiua-13880	252	1	jco	jco	PROPN
aiua-13880	252	2	precis	precis	PROPN
aiua-13880	252	3	oncol	oncol	PROPN
aiua-13880	252	4	.	.	PUNCT
aiua-13880	253	1	2017	2017	NUM
aiua-13880	253	2	;	;	PUNCT
aiua-13880	253	3	1:1	1:1	NUM
aiua-13880	253	4	-	-	SYM
aiua-13880	253	5	15	15	NUM
aiua-13880	253	6	.	.	NOUN
aiua-13880	254	1	11	11	NUM
aiua-13880	254	2	.	.	X
aiua-13880	254	3	le	le	PUNCT
aiua-13880	255	1	dt	dt	PROPN
aiua-13880	255	2	,	,	PUNCT
aiua-13880	255	3	uram	uram	PROPN
aiua-13880	255	4	jn	jn	PROPN
aiua-13880	255	5	,	,	PUNCT
aiua-13880	255	6	wang	wang	PROPN
aiua-13880	255	7	h	h	PROPN
aiua-13880	255	8	,	,	PUNCT
aiua-13880	255	9	et	et	PROPN
aiua-13880	255	10	al	al	PROPN
aiua-13880	255	11	.	.	PROPN
aiua-13880	255	12	pd-1	pd-1	ADP
aiua-13880	255	13	blockade	blockade	NOUN
aiua-13880	255	14	in	in	ADP
aiua-13880	255	15	tumors	tumor	NOUN
aiua-13880	255	16	with	with	ADP
aiua-13880	255	17	mismatch	mismatch	ADJ
aiua-13880	255	18	-	-	PUNCT
aiua-13880	255	19	repair	repair	NOUN
aiua-13880	255	20	deficiency	deficiency	NOUN
aiua-13880	255	21	.	.	PUNCT
aiua-13880	256	1	n	n	CCONJ
aiua-13880	256	2	engl	engl	PROPN
aiua-13880	256	3	j	j	PROPN
aiua-13880	256	4	med	med	PROPN
aiua-13880	256	5	.	.	PROPN
aiua-13880	256	6	2015	2015	NUM
aiua-13880	256	7	;	;	PUNCT
aiua-13880	256	8	372:2509	372:2509	NUM
aiua-13880	256	9	-	-	SYM
aiua-13880	256	10	20	20	NUM
aiua-13880	256	11	.	.	PUNCT
aiua-13880	257	1	12	12	NUM
aiua-13880	257	2	.	.	PUNCT
aiua-13880	258	1	hayden	hayden	PROPN
aiua-13880	258	2	ja	ja	PROPN
aiua-13880	258	3	,	,	PUNCT
aiua-13880	258	4	côté	côté	PROPN
aiua-13880	258	5	p	p	PROPN
aiua-13880	258	6	,	,	PUNCT
aiua-13880	258	7	bombardier	bombardier	PROPN
aiua-13880	258	8	c.	c.	NOUN
aiua-13880	258	9	evaluation	evaluation	NOUN
aiua-13880	258	10	of	of	ADP
aiua-13880	258	11	the	the	DET
aiua-13880	258	12	quality	quality	NOUN
aiua-13880	258	13	of	of	ADP
aiua-13880	258	14	prognosis	prognosis	NOUN
aiua-13880	258	15	studies	study	NOUN
aiua-13880	258	16	in	in	ADP
aiua-13880	258	17	systematic	systematic	ADJ
aiua-13880	258	18	reviews	review	NOUN
aiua-13880	258	19	.	.	PUNCT
aiua-13880	259	1	ann	ann	PROPN
aiua-13880	259	2	intern	intern	PROPN
aiua-13880	259	3	med	me	VERB
aiua-13880	259	4	.	.	PUNCT
aiua-13880	260	1	2006	2006	NUM
aiua-13880	260	2	;	;	PUNCT
aiua-13880	261	1	144:427	144:427	X
aiua-13880	261	2	-	-	SYM
aiua-13880	261	3	37	37	NUM
aiua-13880	261	4	.	.	NOUN
aiua-13880	261	5	13	13	NUM
aiua-13880	261	6	.	.	PUNCT
aiua-13880	261	7	mcguinness	mcguinness	PROPN
aiua-13880	261	8	la	la	PROPN
aiua-13880	261	9	,	,	PUNCT
aiua-13880	261	10	higgins	higgins	PROPN
aiua-13880	261	11	jpt	jpt	PROPN
aiua-13880	261	12	.	.	PUNCT
aiua-13880	261	13	risk	risk	NOUN
aiua-13880	261	14	-	-	PUNCT
aiua-13880	261	15	of	of	ADP
aiua-13880	261	16	-	-	PUNCT
aiua-13880	261	17	bias	bias	NOUN
aiua-13880	261	18	visualization	visualization	NOUN
aiua-13880	261	19	(	(	PUNCT
aiua-13880	261	20	robvis	robvi	VERB
aiua-13880	261	21	):	):	PUNCT
aiua-13880	261	22	an	an	DET
aiua-13880	261	23	r	r	NOUN
aiua-13880	261	24	package	package	NOUN
aiua-13880	261	25	and	and	CCONJ
aiua-13880	261	26	shiny	shiny	ADJ
aiua-13880	261	27	web	web	NOUN
aiua-13880	261	28	app	app	NOUN
aiua-13880	261	29	for	for	ADP
aiua-13880	261	30	visualizing	visualize	VERB
aiua-13880	261	31	risk	risk	NOUN
aiua-13880	261	32	-	-	PUNCT
aiua-13880	261	33	of	of	ADP
aiua-13880	261	34	-	-	PUNCT
aiua-13880	261	35	bias	bias	NOUN
aiua-13880	261	36	assessments	assessment	NOUN
aiua-13880	261	37	.	.	PUNCT
aiua-13880	262	1	res	re	NOUN
aiua-13880	262	2	synth	synth	ADJ
aiua-13880	262	3	methods	method	NOUN
aiua-13880	262	4	.	.	PUNCT
aiua-13880	262	5	2021	2021	NUM
aiua-13880	262	6	;	;	PUNCT
aiua-13880	262	7	12:55	12:55	NUM
aiua-13880	262	8	-	-	SYM
aiua-13880	262	9	61	61	NUM
aiua-13880	262	10	.	.	PUNCT
aiua-13880	262	11	14	14	NUM
aiua-13880	262	12	.	.	PUNCT
aiua-13880	263	1	higgins	higgins	PROPN
aiua-13880	263	2	jpt	jpt	PROPN
aiua-13880	263	3	.	.	PUNCT
aiua-13880	264	1	measuring	measure	VERB
aiua-13880	264	2	inconsistency	inconsistency	NOUN
aiua-13880	264	3	in	in	ADP
aiua-13880	264	4	meta	meta	NOUN
aiua-13880	264	5	-	-	PUNCT
aiua-13880	264	6	analyses	analysis	NOUN
aiua-13880	264	7	.	.	PUNCT
aiua-13880	265	1	bmj	bmj	PROPN
aiua-13880	265	2	.	.	PUNCT
aiua-13880	265	3	2003	2003	NUM
aiua-13880	265	4	;	;	PUNCT
aiua-13880	265	5	327:557	327:557	PROPN
aiua-13880	265	6	-	-	SYM
aiua-13880	265	7	60	60	NUM
aiua-13880	265	8	.	.	PUNCT
aiua-13880	265	9	15	15	NUM
aiua-13880	265	10	.	.	PUNCT
aiua-13880	266	1	tanabe	tanabe	PROPN
aiua-13880	266	2	k	k	PROPN
aiua-13880	266	3	,	,	PUNCT
aiua-13880	266	4	kobayashi	kobayashi	PROPN
aiua-13880	266	5	s	s	PROPN
aiua-13880	266	6	,	,	PUNCT
aiua-13880	266	7	maezawa	maezawa	PROPN
aiua-13880	266	8	y	y	PROPN
aiua-13880	266	9	,	,	PUNCT
aiua-13880	266	10	et	et	PROPN
aiua-13880	266	11	al	al	PROPN
aiua-13880	266	12	.	.	PUNCT
aiua-13880	267	1	gustave	gustave	PROPN
aiua-13880	267	2	roussy	roussy	ADJ
aiua-13880	267	3	immune	immune	ADJ
aiua-13880	267	4	score	score	NOUN
aiua-13880	267	5	as	as	ADP
aiua-13880	267	6	a	a	DET
aiua-13880	267	7	prognostic	prognostic	ADJ
aiua-13880	267	8	biomarker	biomarker	NOUN
aiua-13880	267	9	in	in	ADP
aiua-13880	267	10	patients	patient	NOUN
aiua-13880	267	11	with	with	ADP
aiua-13880	267	12	platinumrefractory	platinumrefractory	PROPN
aiua-13880	267	13	metastatic	metastatic	ADJ
aiua-13880	267	14	urothelial	urothelial	ADJ
aiua-13880	267	15	carcinoma	carcinoma	NOUN
aiua-13880	267	16	treated	treat	VERB
aiua-13880	267	17	with	with	ADP
aiua-13880	267	18	pembrolizumab	pembrolizumab	NOUN
aiua-13880	267	19	:	:	PUNCT
aiua-13880	267	20	yushima	yushima	PROPN
aiua-13880	267	21	study	study	PROPN
aiua-13880	267	22	.	.	PUNCT
aiua-13880	268	1	int	int	PROPN
aiua-13880	269	1	j	j	PROPN
aiua-13880	269	2	clin	clin	PROPN
aiua-13880	269	3	oncol	oncol	PROPN
aiua-13880	269	4	.	.	PUNCT
aiua-13880	270	1	2024	2024	NUM
aiua-13880	270	2	;	;	PUNCT
aiua-13880	270	3	29:1302	29:1302	NUM
aiua-13880	270	4	-	-	SYM
aiua-13880	270	5	10	10	NUM
aiua-13880	270	6	.	.	PUNCT
aiua-13880	271	1	16	16	NUM
aiua-13880	271	2	.	.	PUNCT
aiua-13880	272	1	tomioka	tomioka	NOUN
aiua-13880	272	2	-	-	PUNCT
aiua-13880	272	3	inagawa	inagawa	NOUN
aiua-13880	272	4	r	r	NOUN
aiua-13880	272	5	,	,	PUNCT
aiua-13880	272	6	nakane	nakane	PROPN
aiua-13880	272	7	k	k	NOUN
aiua-13880	272	8	,	,	PUNCT
aiua-13880	272	9	enomoto	enomoto	PROPN
aiua-13880	272	10	t	t	PROPN
aiua-13880	272	11	,	,	PUNCT
aiua-13880	272	12	et	et	PROPN
aiua-13880	272	13	al	al	PROPN
aiua-13880	272	14	.	.	PUNCT
aiua-13880	273	1	the	the	DET
aiua-13880	273	2	impact	impact	NOUN
aiua-13880	273	3	of	of	ADP
aiua-13880	273	4	neutrophil	neutrophil	ADJ
aiua-13880	273	5	-	-	PUNCT
aiua-13880	273	6	to	to	ADP
aiua-13880	273	7	-	-	PUNCT
aiua-13880	273	8	lymphocyte	lymphocyte	NOUN
aiua-13880	273	9	ratio	ratio	NOUN
aiua-13880	273	10	after	after	ADP
aiua-13880	273	11	two	two	NUM
aiua-13880	273	12	courses	course	NOUN
aiua-13880	273	13	of	of	ADP
aiua-13880	273	14	pembrolizumab	pembrolizumab	NOUN
aiua-13880	273	15	for	for	ADP
aiua-13880	273	16	oncological	oncological	ADJ
aiua-13880	273	17	outcomes	outcome	NOUN
aiua-13880	273	18	in	in	ADP
aiua-13880	273	19	patients	patient	NOUN
aiua-13880	273	20	with	with	ADP
aiua-13880	273	21	metastatic	metastatic	ADJ
aiua-13880	273	22	urothelial	urothelial	ADJ
aiua-13880	273	23	carcinoma	carcinoma	NOUN
aiua-13880	273	24	.	.	PUNCT
aiua-13880	274	1	biomedicines	biomedicine	NOUN
aiua-13880	274	2	.	.	PUNCT
aiua-13880	275	1	2022	2022	NUM
aiua-13880	275	2	;	;	PUNCT
aiua-13880	275	3	10:1609	10:1609	X
aiua-13880	275	4	.	.	PUNCT
aiua-13880	276	1	17	17	NUM
aiua-13880	276	2	.	.	PUNCT
aiua-13880	277	1	kobayashi	kobayashi	PROPN
aiua-13880	277	2	t	t	PROPN
aiua-13880	277	3	,	,	PUNCT
aiua-13880	277	4	ito	ito	PROPN
aiua-13880	277	5	k	k	PROPN
aiua-13880	277	6	,	,	PUNCT
aiua-13880	277	7	kojima	kojima	PROPN
aiua-13880	277	8	t	t	PROPN
aiua-13880	277	9	,	,	PUNCT
aiua-13880	277	10	et	et	PROPN
aiua-13880	277	11	al	al	PROPN
aiua-13880	277	12	.	.	PUNCT
aiua-13880	278	1	pre	pre	ADJ
aiua-13880	278	2	-	-	ADJ
aiua-13880	278	3	pembrolizumab	pembrolizumab	ADJ
aiua-13880	278	4	neutrophil	neutrophil	NOUN
aiua-13880	278	5	-	-	PUNCT
aiua-13880	278	6	to	to	ADP
aiua-13880	278	7	-	-	PUNCT
aiua-13880	278	8	lymphocyte	lymphocyte	NOUN
aiua-13880	278	9	ratio	ratio	NOUN
aiua-13880	278	10	(	(	PUNCT
aiua-13880	278	11	nlr	nlr	PROPN
aiua-13880	278	12	)	)	PUNCT
aiua-13880	278	13	predicts	predict	VERB
aiua-13880	278	14	the	the	DET
aiua-13880	278	15	efficacy	efficacy	NOUN
aiua-13880	278	16	of	of	ADP
aiua-13880	278	17	second	second	ADJ
aiua-13880	278	18	-	-	PUNCT
aiua-13880	278	19	line	line	NOUN
aiua-13880	278	20	pembrolizumab	pembrolizumab	NOUN
aiua-13880	278	21	treatment	treatment	NOUN
aiua-13880	278	22	in	in	ADP
aiua-13880	278	23	urothelial	urothelial	ADJ
aiua-13880	278	24	cancer	cancer	NOUN
aiua-13880	278	25	regardless	regardless	ADV
aiua-13880	278	26	of	of	ADP
aiua-13880	278	27	the	the	DET
aiua-13880	278	28	prechemo	prechemo	PROPN
aiua-13880	278	29	nlr	nlr	PROPN
aiua-13880	278	30	.	.	PUNCT
aiua-13880	279	1	cancer	cancer	PROPN
aiua-13880	279	2	immunol	immunol	PROPN
aiua-13880	279	3	immunother	immunother	PROPN
aiua-13880	279	4	.	.	PUNCT
aiua-13880	280	1	2022	2022	NUM
aiua-13880	280	2	;	;	PUNCT
aiua-13880	280	3	71:461	71:461	NUM
aiua-13880	280	4	-	-	SYM
aiua-13880	280	5	71	71	NUM
aiua-13880	280	6	.	.	PUNCT
aiua-13880	280	7	18	18	NUM
aiua-13880	280	8	.	.	X
aiua-13880	281	1	kurashina	kurashina	PROPN
aiua-13880	281	2	r	r	PROPN
aiua-13880	281	3	,	,	PUNCT
aiua-13880	281	4	ando	ando	PROPN
aiua-13880	281	5	k	k	PROPN
aiua-13880	281	6	,	,	PUNCT
aiua-13880	281	7	inoue	inoue	PROPN
aiua-13880	281	8	m	m	PROPN
aiua-13880	281	9	,	,	PUNCT
aiua-13880	281	10	et	et	PROPN
aiua-13880	281	11	al	al	PROPN
aiua-13880	281	12	.	.	PROPN
aiua-13880	281	13	pretreatment	pretreatment	NOUN
aiua-13880	281	14	hemoglobin	hemoglobin	NOUN
aiua-13880	281	15	levels	level	NOUN
aiua-13880	281	16	and	and	CCONJ
aiua-13880	281	17	platelet	platelet	NOUN
aiua-13880	281	18	-	-	PUNCT
aiua-13880	281	19	to	to	ADP
aiua-13880	281	20	-	-	PUNCT
aiua-13880	281	21	lymphocyte	lymphocyte	NOUN
aiua-13880	281	22	ratio	ratio	NOUN
aiua-13880	281	23	predict	predict	VERB
aiua-13880	281	24	survival	survival	NOUN
aiua-13880	281	25	benefit	benefit	VERB
aiua-13880	281	26	from	from	ADP
aiua-13880	281	27	pembrolizumab	pembrolizumab	NOUN
aiua-13880	281	28	in	in	ADP
aiua-13880	281	29	advanced	advanced	ADJ
aiua-13880	281	30	urothelial	urothelial	ADJ
aiua-13880	281	31	carcinoma	carcinoma	NOUN
aiua-13880	281	32	.	.	PUNCT
aiua-13880	282	1	cancer	cancer	NOUN
aiua-13880	282	2	diagn	diagn	PROPN
aiua-13880	282	3	progn	progn	PROPN
aiua-13880	282	4	.	.	PUNCT
aiua-13880	283	1	2023	2023	NUM
aiua-13880	283	2	;	;	PUNCT
aiua-13880	283	3	3:230	3:230	NUM
aiua-13880	283	4	-	-	SYM
aiua-13880	283	5	5	5	NUM
aiua-13880	283	6	.	.	NOUN
aiua-13880	283	7	19	19	NUM
aiua-13880	283	8	.	.	PUNCT
aiua-13880	283	9	plimack	plimack	PROPN
aiua-13880	283	10	er	er	INTJ
aiua-13880	283	11	,	,	PUNCT
aiua-13880	283	12	bellmunt	bellmunt	PROPN
aiua-13880	283	13	j	j	PROPN
aiua-13880	283	14	,	,	PUNCT
aiua-13880	283	15	gupta	gupta	PROPN
aiua-13880	283	16	s	s	PART
aiua-13880	283	17	,	,	PUNCT
aiua-13880	283	18	et	et	PROPN
aiua-13880	283	19	al	al	PROPN
aiua-13880	283	20	.	.	PROPN
aiua-13880	283	21	safety	safety	NOUN
aiua-13880	283	22	and	and	CCONJ
aiua-13880	283	23	activity	activity	NOUN
aiua-13880	283	24	of	of	ADP
aiua-13880	283	25	pembrolizumab	pembrolizumab	NOUN
aiua-13880	283	26	in	in	ADP
aiua-13880	283	27	patients	patient	NOUN
aiua-13880	283	28	with	with	ADP
aiua-13880	283	29	locally	locally	ADV
aiua-13880	283	30	advanced	advanced	ADJ
aiua-13880	283	31	or	or	CCONJ
aiua-13880	283	32	metastatic	metastatic	ADJ
aiua-13880	283	33	urothelial	urothelial	ADJ
aiua-13880	283	34	cancer	cancer	NOUN
aiua-13880	283	35	(	(	PUNCT
aiua-13880	283	36	keynote-012	keynote-012	NOUN
aiua-13880	283	37	):	):	PUNCT
aiua-13880	283	38	a	a	DET
aiua-13880	283	39	non	non	ADJ
aiua-13880	283	40	-	-	ADJ
aiua-13880	283	41	randomised	randomised	ADJ
aiua-13880	283	42	,	,	PUNCT
aiua-13880	283	43	open	open	ADJ
aiua-13880	283	44	-	-	PUNCT
aiua-13880	283	45	label	label	NOUN
aiua-13880	283	46	,	,	PUNCT
aiua-13880	283	47	phase	phase	NOUN
aiua-13880	283	48	1b	1b	NUM
aiua-13880	283	49	study	study	NOUN
aiua-13880	283	50	.	.	PUNCT
aiua-13880	284	1	lancet	lancet	PROPN
aiua-13880	284	2	oncol	oncol	PROPN
aiua-13880	284	3	.	.	PUNCT
aiua-13880	285	1	2017	2017	NUM
aiua-13880	285	2	;	;	PUNCT
aiua-13880	285	3	18:212	18:212	NUM
aiua-13880	285	4	-	-	SYM
aiua-13880	285	5	20	20	NUM
aiua-13880	285	6	.	.	NOUN
aiua-13880	286	1	20	20	NUM
aiua-13880	286	2	.	.	PUNCT
aiua-13880	287	1	bellmunt	bellmunt	PROPN
aiua-13880	287	2	j	j	PROPN
aiua-13880	287	3	,	,	PUNCT
aiua-13880	287	4	de	de	X
aiua-13880	287	5	wit	wit	ADJ
aiua-13880	287	6	r	r	PROPN
aiua-13880	287	7	,	,	PUNCT
aiua-13880	287	8	vaughn	vaughn	PROPN
aiua-13880	287	9	dj	dj	PROPN
aiua-13880	287	10	,	,	PUNCT
aiua-13880	287	11	et	et	PROPN
aiua-13880	287	12	al	al	PROPN
aiua-13880	287	13	.	.	PROPN
aiua-13880	287	14	pembrolizumab	pembrolizumab	NOUN
aiua-13880	287	15	as	as	ADP
aiua-13880	287	16	second	second	ADJ
aiua-13880	287	17	-	-	PUNCT
aiua-13880	287	18	line	line	NOUN
aiua-13880	287	19	therapy	therapy	NOUN
aiua-13880	287	20	for	for	ADP
aiua-13880	287	21	advanced	advanced	ADJ
aiua-13880	287	22	urothelial	urothelial	ADJ
aiua-13880	287	23	carcinoma	carcinoma	NOUN
aiua-13880	287	24	.	.	PUNCT
aiua-13880	288	1	n	n	CCONJ
aiua-13880	288	2	engl	engl	PROPN
aiua-13880	288	3	j	j	PROPN
aiua-13880	288	4	med	med	PROPN
aiua-13880	288	5	.	.	PROPN
aiua-13880	288	6	2017	2017	NUM
aiua-13880	288	7	;	;	PUNCT
aiua-13880	288	8	376:1015	376:1015	X
aiua-13880	288	9	-	-	SYM
aiua-13880	288	10	26	26	NUM
aiua-13880	288	11	.	.	PUNCT
aiua-13880	289	1	21	21	NUM
aiua-13880	289	2	.	.	PUNCT
aiua-13880	290	1	huang	huang	PROPN
aiua-13880	290	2	j	j	PROPN
aiua-13880	290	3	,	,	PUNCT
aiua-13880	290	4	teng	teng	PROPN
aiua-13880	290	5	x.	x.	NOUN
aiua-13880	290	6	expression	expression	NOUN
aiua-13880	290	7	of	of	ADP
aiua-13880	290	8	pd	pd	PROPN
aiua-13880	290	9	-	-	PROPN
aiua-13880	290	10	l1	l1	PROPN
aiua-13880	290	11	for	for	ADP
aiua-13880	290	12	predicting	predict	VERB
aiua-13880	290	13	response	response	NOUN
aiua-13880	290	14	to	to	ADP
aiua-13880	290	15	immune	immune	ADJ
aiua-13880	290	16	checkpoint	checkpoint	NOUN
aiua-13880	290	17	inhibitors	inhibitor	NOUN
aiua-13880	290	18	in	in	ADP
aiua-13880	290	19	metastatic	metastatic	ADJ
aiua-13880	290	20	urothelial	urothelial	ADJ
aiua-13880	290	21	carcinoma	carcinoma	NOUN
aiua-13880	290	22	:	:	PUNCT
aiua-13880	290	23	a	a	DET
aiua-13880	290	24	systematic	systematic	ADJ
aiua-13880	290	25	review	review	NOUN
aiua-13880	290	26	and	and	CCONJ
aiua-13880	290	27	meta	meta	ADJ
aiua-13880	290	28	-	-	PUNCT
aiua-13880	290	29	analysis	analysis	NOUN
aiua-13880	290	30	.	.	PUNCT
aiua-13880	291	1	curr	curr	PROPN
aiua-13880	291	2	oncol	oncol	PROPN
aiua-13880	291	3	.	.	PUNCT
aiua-13880	292	1	2020	2020	NUM
aiua-13880	292	2	;	;	PUNCT
aiua-13880	292	3	27:65663	27:65663	NUM
aiua-13880	292	4	.	.	NOUN
aiua-13880	292	5	22	22	NUM
aiua-13880	292	6	.	.	PUNCT
aiua-13880	293	1	powles	powle	NOUN
aiua-13880	293	2	t	t	PROPN
aiua-13880	293	3	,	,	PUNCT
aiua-13880	293	4	csoszi	csoszi	PROPN
aiua-13880	293	5	t	t	PROPN
aiua-13880	293	6	,	,	PUNCT
aiua-13880	293	7	özgüroglu	özgüroglu	NOUN
aiua-13880	293	8	m	m	PROPN
aiua-13880	293	9	,	,	PUNCT
aiua-13880	293	10	et	et	PROPN
aiua-13880	293	11	al	al	PROPN
aiua-13880	293	12	.	.	PROPN
aiua-13880	293	13	pembrolizumab	pembrolizumab	NOUN
aiua-13880	293	14	alone	alone	ADV
aiua-13880	293	15	or	or	CCONJ
aiua-13880	293	16	combined	combine	VERB
aiua-13880	293	17	with	with	ADP
aiua-13880	293	18	chemotherapy	chemotherapy	NOUN
aiua-13880	293	19	versus	versus	ADP
aiua-13880	293	20	chemotherapy	chemotherapy	NOUN
aiua-13880	293	21	as	as	ADP
aiua-13880	293	22	first	first	ADJ
aiua-13880	293	23	-	-	PUNCT
aiua-13880	293	24	line	line	NOUN
aiua-13880	293	25	therapy	therapy	NOUN
aiua-13880	293	26	for	for	ADP
aiua-13880	293	27	advanced	advanced	ADJ
aiua-13880	293	28	urothelial	urothelial	ADJ
aiua-13880	293	29	carcinoma	carcinoma	NOUN
aiua-13880	293	30	(	(	PUNCT
aiua-13880	293	31	keynote-361	keynote-361	NOUN
aiua-13880	293	32	):	):	PUNCT
aiua-13880	293	33	a	a	DET
aiua-13880	293	34	randomised	randomised	ADJ
aiua-13880	293	35	,	,	PUNCT
aiua-13880	293	36	open	open	ADJ
aiua-13880	293	37	-	-	PUNCT
aiua-13880	293	38	label	label	NOUN
aiua-13880	293	39	,	,	PUNCT
aiua-13880	293	40	phase	phase	NOUN
aiua-13880	293	41	3	3	NUM
aiua-13880	293	42	trial	trial	NOUN
aiua-13880	293	43	.	.	PUNCT
aiua-13880	294	1	lancet	lancet	PROPN
aiua-13880	294	2	oncol	oncol	PROPN
aiua-13880	294	3	.	.	PUNCT
aiua-13880	295	1	2021	2021	NUM
aiua-13880	295	2	;	;	PUNCT
aiua-13880	295	3	22:931	22:931	NUM
aiua-13880	295	4	-	-	SYM
aiua-13880	295	5	45	45	NUM
aiua-13880	295	6	.	.	NOUN
aiua-13880	296	1	23	23	NUM
aiua-13880	296	2	.	.	PUNCT
aiua-13880	297	1	shinagare	shinagare	PROPN
aiua-13880	297	2	ab	ab	PROPN
aiua-13880	297	3	,	,	PUNCT
aiua-13880	297	4	ramaiya	ramaiya	PROPN
aiua-13880	297	5	nh	nh	PROPN
aiua-13880	297	6	,	,	PUNCT
aiua-13880	297	7	jagannathan	jagannathan	PROPN
aiua-13880	297	8	jp	jp	PROPN
aiua-13880	297	9	,	,	PUNCT
aiua-13880	297	10	et	et	PROPN
aiua-13880	297	11	al	al	PROPN
aiua-13880	297	12	.	.	PUNCT
aiua-13880	298	1	metastatic	metastatic	ADJ
aiua-13880	298	2	pattern	pattern	NOUN
aiua-13880	298	3	of	of	ADP
aiua-13880	298	4	bladder	bladder	NOUN
aiua-13880	298	5	cancer	cancer	NOUN
aiua-13880	298	6	:	:	PUNCT
aiua-13880	298	7	correlation	correlation	NOUN
aiua-13880	298	8	with	with	ADP
aiua-13880	298	9	the	the	DET
aiua-13880	298	10	characteristics	characteristic	NOUN
aiua-13880	298	11	of	of	ADP
aiua-13880	298	12	the	the	DET
aiua-13880	298	13	primary	primary	ADJ
aiua-13880	298	14	tumor	tumor	NOUN
aiua-13880	298	15	.	.	PUNCT
aiua-13880	298	16	am	be	AUX
aiua-13880	298	17	j	j	PROPN
aiua-13880	298	18	roentgenol	roentgenol	NOUN
aiua-13880	298	19	.	.	PUNCT
aiua-13880	299	1	2011	2011	NUM
aiua-13880	299	2	;	;	PUNCT
aiua-13880	299	3	196:117	196:117	NUM
aiua-13880	299	4	-	-	SYM
aiua-13880	299	5	22	22	NUM
aiua-13880	299	6	.	.	PUNCT
aiua-13880	300	1	24	24	NUM
aiua-13880	300	2	.	.	PUNCT
aiua-13880	301	1	hsieh	hsieh	PROPN
aiua-13880	301	2	m	m	PROPN
aiua-13880	301	3	-	-	PUNCT
aiua-13880	301	4	c	c	PROPN
aiua-13880	301	5	,	,	PUNCT
aiua-13880	301	6	chiang	chiang	PROPN
aiua-13880	301	7	p	p	PROPN
aiua-13880	301	8	-	-	PUNCT
aiua-13880	301	9	h	h	PROPN
aiua-13880	301	10	,	,	PUNCT
aiua-13880	301	11	rau	rau	PROPN
aiua-13880	301	12	k	k	PROPN
aiua-13880	301	13	-	-	PROPN
aiua-13880	301	14	m	m	PROPN
aiua-13880	301	15	,	,	PUNCT
aiua-13880	301	16	et	et	PROPN
aiua-13880	301	17	al	al	PROPN
aiua-13880	301	18	.	.	PUNCT
aiua-13880	302	1	metastatic	metastatic	ADJ
aiua-13880	302	2	urothelial	urothelial	ADJ
aiua-13880	302	3	carcinoma	carcinoma	NOUN
aiua-13880	302	4	of	of	ADP
aiua-13880	302	5	the	the	DET
aiua-13880	302	6	bladder	bladder	NOUN
aiua-13880	302	7	with	with	ADP
aiua-13880	302	8	lymph	lymph	NOUN
aiua-13880	302	9	node	node	NOUN
aiua-13880	302	10	-	-	PUNCT
aiua-13880	302	11	only	only	ADV
aiua-13880	302	12	metastasis	metastasis	NOUN
aiua-13880	302	13	treated	treat	VERB
aiua-13880	302	14	with	with	ADP
aiua-13880	302	15	m	m	NOUN
aiua-13880	302	16	-	-	ADJ
aiua-13880	302	17	vac	vac	NOUN
aiua-13880	302	18	(	(	PUNCT
aiua-13880	302	19	methotrexate	methotrexate	NOUN
aiua-13880	302	20	,	,	PUNCT
aiua-13880	302	21	vinblastine	vinblastine	NOUN
aiua-13880	302	22	,	,	PUNCT
aiua-13880	302	23	doxorubicin	doxorubicin	PROPN
aiua-13880	302	24	and	and	CCONJ
aiua-13880	302	25	cisplatin	cisplatin	NOUN
aiua-13880	302	26	)	)	PUNCT
aiua-13880	302	27	has	have	VERB
aiua-13880	302	28	a	a	DET
aiua-13880	302	29	better	well	ADJ
aiua-13880	302	30	survival	survival	NOUN
aiua-13880	302	31	than	than	ADP
aiua-13880	302	32	gc	gc	PROPN
aiua-13880	302	33	(	(	PUNCT
aiua-13880	302	34	gemcitabine	gemcitabine	NOUN
aiua-13880	302	35	and	and	CCONJ
aiua-13880	302	36	cisplatin	cisplatin	NOUN
aiua-13880	302	37	)	)	PUNCT
aiua-13880	302	38	.	.	PUNCT
aiua-13880	303	1	journal	journal	PROPN
aiua-13880	303	2	of	of	ADP
aiua-13880	303	3	cancer	cancer	NOUN
aiua-13880	303	4	research	research	NOUN
aiua-13880	303	5	and	and	CCONJ
aiua-13880	303	6	practice	practice	NOUN
aiua-13880	303	7	2014	2014	NUM
aiua-13880	303	8	;	;	PUNCT
aiua-13880	303	9	1	1	NUM
aiua-13880	303	10	;	;	PUNCT
aiua-13880	303	11	197	197	NUM
aiua-13880	303	12	-	-	SYM
aiua-13880	303	13	207	207	NUM
aiua-13880	303	14	.	.	PUNCT
aiua-13880	304	1	25	25	NUM
aiua-13880	304	2	.	.	PUNCT
aiua-13880	305	1	shou	shou	PROPN
aiua-13880	305	2	j	j	PROPN
aiua-13880	305	3	,	,	PUNCT
aiua-13880	305	4	zhang	zhang	PROPN
aiua-13880	305	5	q	q	PROPN
aiua-13880	305	6	,	,	PUNCT
aiua-13880	305	7	zhang	zhang	PROPN
aiua-13880	305	8	d.	d.	PROPN
aiua-13880	305	9	the	the	DET
aiua-13880	305	10	prognostic	prognostic	ADJ
aiua-13880	305	11	effect	effect	NOUN
aiua-13880	305	12	of	of	ADP
aiua-13880	305	13	metastasis	metastasis	NOUN
aiua-13880	305	14	patterns	pattern	NOUN
aiua-13880	305	15	on	on	ADP
aiua-13880	305	16	overall	overall	ADJ
aiua-13880	305	17	survival	survival	NOUN
aiua-13880	305	18	in	in	ADP
aiua-13880	305	19	patients	patient	NOUN
aiua-13880	305	20	with	with	ADP
aiua-13880	305	21	distant	distant	ADJ
aiua-13880	305	22	metastatic	metastatic	ADJ
aiua-13880	305	23	bladder	bladder	NOUN
aiua-13880	305	24	cancer	cancer	NOUN
aiua-13880	305	25	:	:	PUNCT
aiua-13880	305	26	a	a	DET
aiua-13880	305	27	seer	seer	NOUN
aiua-13880	305	28	population	population	NOUN
aiua-13880	305	29	-	-	PUNCT
aiua-13880	305	30	based	base	VERB
aiua-13880	305	31	analysis	analysis	NOUN
aiua-13880	305	32	.	.	PUNCT
aiua-13880	306	1	world	world	PROPN
aiua-13880	306	2	j	j	PROPN
aiua-13880	306	3	urol	urol	PROPN
aiua-13880	306	4	.	.	PUNCT
aiua-13880	306	5	2021	2021	NUM
aiua-13880	306	6	;	;	PUNCT
aiua-13880	306	7	39:4151	39:4151	X
aiua-13880	306	8	-	-	SYM
aiua-13880	306	9	8	8	NUM
aiua-13880	306	10	.	.	NOUN
aiua-13880	306	11	26	26	NUM
aiua-13880	306	12	.	.	X
aiua-13880	307	1	tatokoro	tatokoro	PROPN
aiua-13880	307	2	m	m	PROPN
aiua-13880	307	3	,	,	PUNCT
aiua-13880	307	4	kihara	kihara	PROPN
aiua-13880	307	5	k.	k.	PROPN
aiua-13880	307	6	liver	liver	NOUN
aiua-13880	307	7	metastases	metastasis	NOUN
aiua-13880	307	8	from	from	ADP
aiua-13880	307	9	ureteral	ureteral	ADJ
aiua-13880	307	10	and	and	CCONJ
aiua-13880	307	11	bladder	bladder	NOUN
aiua-13880	307	12	cancer	cancer	NOUN
aiua-13880	307	13	.	.	PUNCT
aiua-13880	308	1	in	in	ADP
aiua-13880	308	2	:	:	PUNCT
aiua-13880	308	3	di	di	PROPN
aiua-13880	308	4	carlo	carlo	PROPN
aiua-13880	308	5	i	i	PROPN
aiua-13880	308	6	,	,	PUNCT
aiua-13880	308	7	editor	editor	NOUN
aiua-13880	308	8	.	.	PUNCT
aiua-13880	309	1	noncolorectal	noncolorectal	ADJ
aiua-13880	309	2	,	,	PUNCT
aiua-13880	309	3	nonneuroendocrine	nonneuroendocrine	NOUN
aiua-13880	309	4	liver	liver	NOUN
aiua-13880	309	5	metastases	metastasis	NOUN
aiua-13880	309	6	[	[	X
aiua-13880	309	7	internet	internet	NOUN
aiua-13880	309	8	]	]	PUNCT
aiua-13880	309	9	.	.	PUNCT
aiua-13880	310	1	cham	cham	PROPN
aiua-13880	310	2	:	:	PUNCT
aiua-13880	310	3	springer	springer	NOUN
aiua-13880	310	4	international	international	ADJ
aiua-13880	310	5	publishing	publishing	NOUN
aiua-13880	310	6	;	;	PUNCT
aiua-13880	310	7	2015	2015	NUM
aiua-13880	311	1	[	[	X
aiua-13880	311	2	cited	cite	VERB
aiua-13880	311	3	2025	2025	NUM
aiua-13880	311	4	jan	jan	PROPN
aiua-13880	311	5	21	21	NUM
aiua-13880	311	6	]	]	PUNCT
aiua-13880	311	7	.	.	PUNCT
aiua-13880	312	1	p.	p.	NOUN
aiua-13880	312	2	175	175	NUM
aiua-13880	313	1	-	-	SYM
aiua-13880	313	2	82	82	NUM
aiua-13880	313	3	.	.	PUNCT
aiua-13880	314	1	available	available	ADJ
aiua-13880	314	2	from	from	ADP
aiua-13880	314	3	:	:	PUNCT
aiua-13880	314	4	https://link.springer.com/10.1007/978-3-31909293-5_14	https://link.springer.com/10.1007/978-3-31909293-5_14	NOUN
aiua-13880	314	5	.	.	PUNCT
aiua-13880	314	6	27	27	NUM
aiua-13880	314	7	.	.	X
aiua-13880	315	1	wallmeroth	wallmeroth	NOUN
aiua-13880	315	2	a	a	PRON
aiua-13880	315	3	,	,	PUNCT
aiua-13880	315	4	wagner	wagner	PROPN
aiua-13880	315	5	u	u	PROPN
aiua-13880	315	6	,	,	PUNCT
aiua-13880	315	7	moch	moch	PROPN
aiua-13880	315	8	h	h	PROPN
aiua-13880	315	9	,	,	PUNCT
aiua-13880	315	10	et	et	PROPN
aiua-13880	315	11	al	al	PROPN
aiua-13880	315	12	.	.	PUNCT
aiua-13880	316	1	patterns	pattern	NOUN
aiua-13880	316	2	of	of	ADP
aiua-13880	316	3	metastasis	metastasis	NOUN
aiua-13880	316	4	in	in	ADP
aiua-13880	316	5	muscle	muscle	NOUN
aiua-13880	316	6	-	-	PUNCT
aiua-13880	316	7	invasive	invasive	ADJ
aiua-13880	316	8	bladder	bladder	NOUN
aiua-13880	316	9	cancer	cancer	NOUN
aiua-13880	316	10	(	(	PUNCT
aiua-13880	316	11	pt2	pt2	NOUN
aiua-13880	316	12	-	-	PUNCT
aiua-13880	316	13	4	4	NUM
aiua-13880	316	14	):	):	PUNCT
aiua-13880	316	15	an	an	DET
aiua-13880	316	16	autopsy	autopsy	ADJ
aiua-13880	316	17	study	study	NOUN
aiua-13880	316	18	on	on	ADP
aiua-13880	316	19	367	367	NUM
aiua-13880	316	20	patients	patient	NOUN
aiua-13880	316	21	.	.	PUNCT
aiua-13880	317	1	urol	urol	PROPN
aiua-13880	317	2	int	int	PROPN
aiua-13880	317	3	.	.	PUNCT
aiua-13880	317	4	1999	1999	NUM
aiua-13880	317	5	;	;	PUNCT
aiua-13880	317	6	62:69	62:69	NUM
aiua-13880	317	7	-	-	SYM
aiua-13880	317	8	75	75	NUM
aiua-13880	317	9	.	.	PUNCT
aiua-13880	318	1	28	28	NUM
aiua-13880	318	2	.	.	PUNCT
aiua-13880	319	1	makrakis	makraki	NOUN
aiua-13880	320	1	d	d	NOUN
aiua-13880	320	2	,	,	PUNCT
aiua-13880	320	3	talukder	talukder	NOUN
aiua-13880	320	4	r	r	NOUN
aiua-13880	320	5	,	,	PUNCT
aiua-13880	320	6	lin	lin	PROPN
aiua-13880	320	7	gi	gi	PROPN
aiua-13880	320	8	,	,	PUNCT
aiua-13880	320	9	et	et	PROPN
aiua-13880	320	10	al	al	PROPN
aiua-13880	320	11	.	.	PROPN
aiua-13880	320	12	association	association	PROPN
aiua-13880	320	13	between	between	ADP
aiua-13880	320	14	sites	site	NOUN
aiua-13880	320	15	of	of	ADP
aiua-13880	320	16	metastasis	metastasis	NOUN
aiua-13880	320	17	and	and	CCONJ
aiua-13880	320	18	outcomes	outcome	NOUN
aiua-13880	320	19	with	with	ADP
aiua-13880	320	20	immune	immune	ADJ
aiua-13880	320	21	checkpoint	checkpoint	NOUN
aiua-13880	320	22	inhibitors	inhibitor	NOUN
aiua-13880	320	23	in	in	ADP
aiua-13880	320	24	advanced	advanced	ADJ
aiua-13880	320	25	urothelial	urothelial	ADJ
aiua-13880	320	26	carcinoma	carcinoma	NOUN
aiua-13880	320	27	.	.	PUNCT
aiua-13880	321	1	clin	clin	PROPN
aiua-13880	321	2	genitourin	genitourin	NOUN
aiua-13880	321	3	cancer	cancer	NOUN
aiua-13880	321	4	.	.	PUNCT
aiua-13880	322	1	2022	2022	NUM
aiua-13880	322	2	;	;	PUNCT
aiua-13880	322	3	20	20	NUM
aiua-13880	322	4	:	:	PUNCT
aiua-13880	322	5	e440	e440	NOUN
aiua-13880	322	6	-	-	SYM
aiua-13880	322	7	52	52	NUM
aiua-13880	322	8	.	.	PUNCT
aiua-13880	323	1	29	29	NUM
aiua-13880	323	2	.	.	PUNCT
aiua-13880	324	1	vuky	vuky	PROPN
aiua-13880	324	2	j	j	PROPN
aiua-13880	324	3	,	,	PUNCT
aiua-13880	324	4	balar	balar	PROPN
aiua-13880	324	5	av	av	PROPN
aiua-13880	324	6	,	,	PUNCT
aiua-13880	324	7	castellano	castellano	PROPN
aiua-13880	324	8	d	d	PROPN
aiua-13880	324	9	,	,	PUNCT
aiua-13880	324	10	et	et	PROPN
aiua-13880	324	11	al	al	PROPN
aiua-13880	324	12	.	.	PUNCT
aiua-13880	325	1	long	long	ADJ
aiua-13880	325	2	-	-	PUNCT
aiua-13880	325	3	term	term	NOUN
aiua-13880	325	4	outcomes	outcome	NOUN
aiua-13880	325	5	in	in	ADP
aiua-13880	325	6	keynote-052	keynote-052	NOUN
aiua-13880	325	7	:	:	PUNCT
aiua-13880	325	8	phase	phase	NOUN
aiua-13880	325	9	ii	ii	PROPN
aiua-13880	325	10	study	study	NOUN
aiua-13880	325	11	investigating	investigate	VERB
aiua-13880	325	12	first	first	ADJ
aiua-13880	325	13	-	-	PUNCT
aiua-13880	325	14	line	line	NOUN
aiua-13880	325	15	pembrolizumab	pembrolizumab	NOUN
aiua-13880	325	16	in	in	ADP
aiua-13880	325	17	cisplatin	cisplatin	NOUN
aiua-13880	325	18	-	-	PUNCT
aiua-13880	325	19	ineligible	ineligible	ADJ
aiua-13880	325	20	patients	patient	NOUN
aiua-13880	325	21	with	with	ADP
aiua-13880	325	22	locally	locally	ADV
aiua-13880	325	23	advanced	advanced	ADJ
aiua-13880	325	24	or	or	CCONJ
aiua-13880	325	25	metastatic	metastatic	ADJ
aiua-13880	325	26	urothelial	urothelial	ADJ
aiua-13880	325	27	cancer	cancer	NOUN
aiua-13880	325	28	.	.	PUNCT
aiua-13880	326	1	j	j	PROPN
aiua-13880	326	2	clin	clin	PROPN
aiua-13880	326	3	oncol	oncol	PROPN
aiua-13880	326	4	.	.	PUNCT
aiua-13880	327	1	2020	2020	NUM
aiua-13880	327	2	;	;	PUNCT
aiua-13880	327	3	38:2658	38:2658	NUM
aiua-13880	327	4	-	-	SYM
aiua-13880	327	5	66	66	NUM
aiua-13880	327	6	.	.	PUNCT
aiua-13880	328	1	30	30	NUM
aiua-13880	328	2	.	.	PUNCT
aiua-13880	329	1	gou	gou	PROPN
aiua-13880	329	2	m	m	PROPN
aiua-13880	329	3	,	,	PUNCT
aiua-13880	329	4	zhang	zhang	PROPN
aiua-13880	329	5	y	y	PROPN
aiua-13880	329	6	,	,	PUNCT
aiua-13880	329	7	liu	liu	PROPN
aiua-13880	329	8	t	t	PROPN
aiua-13880	329	9	,	,	PUNCT
aiua-13880	329	10	et	et	PROPN
aiua-13880	329	11	al	al	PROPN
aiua-13880	329	12	.	.	PUNCT
aiua-13880	330	1	the	the	DET
aiua-13880	330	2	prognostic	prognostic	ADJ
aiua-13880	330	3	value	value	NOUN
aiua-13880	330	4	of	of	ADP
aiua-13880	330	5	pre	pre	ADJ
aiua-13880	330	6	-	-	ADJ
aiua-13880	330	7	treatment	treatment	ADJ
aiua-13880	330	8	hemoglobin	hemoglobin	NOUN
aiua-13880	330	9	(	(	PUNCT
aiua-13880	330	10	hb	hb	X
aiua-13880	330	11	)	)	PUNCT
aiua-13880	330	12	in	in	ADP
aiua-13880	330	13	patients	patient	NOUN
aiua-13880	330	14	with	with	ADP
aiua-13880	330	15	advanced	advanced	ADJ
aiua-13880	330	16	or	or	CCONJ
aiua-13880	330	17	metastatic	metastatic	ADJ
aiua-13880	330	18	gastric	gastric	ADJ
aiua-13880	330	19	cancer	cancer	NOUN
aiua-13880	330	20	treated	treat	VERB
aiua-13880	330	21	with	with	ADP
aiua-13880	330	22	immunotherapy	immunotherapy	NOUN
aiua-13880	330	23	.	.	PUNCT
aiua-13880	331	1	front	front	ADJ
aiua-13880	331	2	oncol	oncol	ADJ
aiua-13880	331	3	.	.	PUNCT
aiua-13880	332	1	2021	2021	NUM
aiua-13880	332	2	;	;	PUNCT
aiua-13880	332	3	11:655716	11:655716	PROPN
aiua-13880	332	4	.	.	X
aiua-13880	333	1	31	31	NUM
aiua-13880	333	2	.	.	PUNCT
aiua-13880	334	1	zhang	zhang	PROPN
aiua-13880	334	2	z	z	PROPN
aiua-13880	334	3	,	,	PUNCT
aiua-13880	334	4	zhang	zhang	PROPN
aiua-13880	334	5	f	f	PROPN
aiua-13880	334	6	,	,	PUNCT
aiua-13880	334	7	yuan	yuan	PROPN
aiua-13880	334	8	f	f	X
aiua-13880	334	9	,	,	PUNCT
aiua-13880	334	10	et	et	PROPN
aiua-13880	334	11	al	al	PROPN
aiua-13880	334	12	.	.	PROPN
aiua-13880	334	13	pretreatment	pretreatment	NOUN
aiua-13880	334	14	hemoglobin	hemoglobin	NOUN
aiua-13880	334	15	level	level	NOUN
aiua-13880	334	16	as	as	ADP
aiua-13880	334	17	a	a	DET
aiua-13880	334	18	predictor	predictor	NOUN
aiua-13880	334	19	to	to	PART
aiua-13880	334	20	evaluate	evaluate	VERB
aiua-13880	334	21	the	the	DET
aiua-13880	334	22	efficacy	efficacy	NOUN
aiua-13880	334	23	of	of	ADP
aiua-13880	334	24	immune	immune	ADJ
aiua-13880	334	25	checkpoint	checkpoint	NOUN
aiua-13880	334	26	inhibitors	inhibitor	NOUN
aiua-13880	334	27	in	in	ADP
aiua-13880	334	28	patients	patient	NOUN
aiua-13880	334	29	with	with	ADP
aiua-13880	334	30	advanced	advanced	ADJ
aiua-13880	334	31	non	non	ADJ
aiua-13880	334	32	-	-	ADJ
aiua-13880	334	33	small	small	ADJ
aiua-13880	334	34	cell	cell	NOUN
aiua-13880	334	35	lung	lung	NOUN
aiua-13880	334	36	cancer	cancer	NOUN
aiua-13880	334	37	.	.	PUNCT
aiua-13880	335	1	ther	ther	PROPN
aiua-13880	335	2	adv	adv	PROPN
aiua-13880	335	3	med	med	PROPN
aiua-13880	335	4	oncol	oncol	ADJ
aiua-13880	335	5	.	.	PUNCT
aiua-13880	336	1	2020	2020	NUM
aiua-13880	336	2	;	;	PUNCT
aiua-13880	336	3	12:1758835920970049	12:1758835920970049	X
aiua-13880	336	4	.	.	NOUN
aiua-13880	336	5	32	32	NUM
aiua-13880	336	6	.	.	PUNCT
aiua-13880	337	1	he	he	PRON
aiua-13880	337	2	y	y	PROPN
aiua-13880	337	3	,	,	PUNCT
aiua-13880	337	4	ren	ren	PROPN
aiua-13880	337	5	t	t	PROPN
aiua-13880	337	6	,	,	PUNCT
aiua-13880	337	7	ji	ji	PROPN
aiua-13880	337	8	c	c	PROPN
aiua-13880	337	9	,	,	PUNCT
aiua-13880	337	10	et	et	PROPN
aiua-13880	337	11	al	al	PROPN
aiua-13880	337	12	.	.	PUNCT
aiua-13880	338	1	the	the	DET
aiua-13880	338	2	baseline	baseline	PROPN
aiua-13880	338	3	hemoglobin	hemoglobin	NOUN
aiua-13880	338	4	level	level	NOUN
aiua-13880	338	5	is	be	AUX
aiua-13880	338	6	a	a	DET
aiua-13880	338	7	positive	positive	ADJ
aiua-13880	338	8	biomarker	biomarker	NOUN
aiua-13880	338	9	for	for	ADP
aiua-13880	338	10	immunotherapy	immunotherapy	NOUN
aiua-13880	338	11	response	response	NOUN
aiua-13880	338	12	and	and	CCONJ
aiua-13880	338	13	can	can	AUX
aiua-13880	338	14	improve	improve	VERB
aiua-13880	338	15	the	the	DET
aiua-13880	338	16	predictability	predictability	NOUN
aiua-13880	338	17	of	of	ADP
aiua-13880	338	18	tumor	tumor	NOUN
aiua-13880	338	19	mutation	mutation	NOUN
aiua-13880	338	20	burden	burden	NOUN
aiua-13880	338	21	for	for	ADP
aiua-13880	338	22	immunotherapy	immunotherapy	NOUN
aiua-13880	338	23	response	response	NOUN
aiua-13880	338	24	in	in	ADP
aiua-13880	338	25	cancer	cancer	NOUN
aiua-13880	338	26	.	.	PUNCT
aiua-13880	339	1	front	front	ADJ
aiua-13880	339	2	pharmacol	pharmacol	PROPN
aiua-13880	339	3	.	.	PUNCT
aiua-13880	340	1	2024	2024	NUM
aiua-13880	340	2	;	;	PUNCT
aiua-13880	340	3	15:1456833	15:1456833	NUM
aiua-13880	340	4	.	.	PUNCT
aiua-13880	340	5	archivio	archivio	NOUN
aiua-13880	340	6	italiano	italiano	PROPN
aiua-13880	340	7	di	di	PROPN
aiua-13880	340	8	urologia	urologia	PROPN
aiua-13880	340	9	e	e	PROPN
aiua-13880	340	10	andrologia	andrologia	NOUN
aiua-13880	340	11	2025	2025	NUM
aiua-13880	340	12	;	;	PUNCT
aiua-13880	340	13	97(2):13880	97(2):13880	NUM
aiua-13880	340	14	11	11	NUM
aiua-13880	340	15	pembrolizumab	pembrolizumab	NOUN
aiua-13880	340	16	in	in	ADP
aiua-13880	340	17	advanced	advanced	ADJ
aiua-13880	340	18	/	/	SYM
aiua-13880	340	19	metastatic	metastatic	ADJ
aiua-13880	340	20	urothelial	urothelial	ADJ
aiua-13880	340	21	carcinoma	carcinoma	NOUN
aiua-13880	340	22	33	33	NUM
aiua-13880	340	23	.	.	PUNCT
aiua-13880	341	1	zhuang	zhuang	PROPN
aiua-13880	341	2	y	y	PROPN
aiua-13880	341	3	,	,	PUNCT
aiua-13880	341	4	liu	liu	PROPN
aiua-13880	341	5	k	k	PROPN
aiua-13880	341	6	,	,	PUNCT
aiua-13880	341	7	he	he	PRON
aiua-13880	341	8	q	q	AUX
aiua-13880	341	9	,	,	PUNCT
aiua-13880	341	10	et	et	PROPN
aiua-13880	341	11	al	al	PROPN
aiua-13880	341	12	.	.	PROPN
aiua-13880	341	13	hypoxia	hypoxia	PROPN
aiua-13880	341	14	signaling	signal	VERB
aiua-13880	341	15	in	in	ADP
aiua-13880	341	16	cancer	cancer	NOUN
aiua-13880	341	17	:	:	PUNCT
aiua-13880	341	18	implications	implication	NOUN
aiua-13880	341	19	for	for	ADP
aiua-13880	341	20	therapeutic	therapeutic	ADJ
aiua-13880	341	21	interventions	intervention	NOUN
aiua-13880	341	22	.	.	PUNCT
aiua-13880	342	1	medcomm	medcomm	NOUN
aiua-13880	342	2	.	.	PUNCT
aiua-13880	343	1	2023	2023	NUM
aiua-13880	343	2	;	;	PUNCT
aiua-13880	343	3	4	4	NUM
aiua-13880	343	4	:	:	PUNCT
aiua-13880	343	5	e203	e203	NUM
aiua-13880	343	6	.	.	PUNCT
aiua-13880	344	1	34	34	NUM
aiua-13880	344	2	.	.	PUNCT
aiua-13880	345	1	templeton	templeton	PROPN
aiua-13880	345	2	aj	aj	PROPN
aiua-13880	345	3	,	,	PUNCT
aiua-13880	345	4	mcnamara	mcnamara	PROPN
aiua-13880	345	5	mg	mg	PROPN
aiua-13880	345	6	,	,	PUNCT
aiua-13880	345	7	šeruga	šeruga	PROPN
aiua-13880	345	8	b	b	PROPN
aiua-13880	345	9	,	,	PUNCT
aiua-13880	345	10	et	et	PROPN
aiua-13880	345	11	al	al	PROPN
aiua-13880	345	12	.	.	PUNCT
aiua-13880	345	13	prognostic	prognostic	ADJ
aiua-13880	345	14	role	role	NOUN
aiua-13880	345	15	of	of	ADP
aiua-13880	345	16	neutrophil	neutrophil	ADJ
aiua-13880	345	17	-	-	PUNCT
aiua-13880	345	18	to	to	ADP
aiua-13880	345	19	-	-	PUNCT
aiua-13880	345	20	lymphocyte	lymphocyte	ADJ
aiua-13880	345	21	ratio	ratio	NOUN
aiua-13880	345	22	in	in	ADP
aiua-13880	345	23	solid	solid	ADJ
aiua-13880	345	24	tumors	tumor	NOUN
aiua-13880	345	25	:	:	PUNCT
aiua-13880	345	26	a	a	DET
aiua-13880	345	27	systematic	systematic	ADJ
aiua-13880	345	28	review	review	NOUN
aiua-13880	345	29	and	and	CCONJ
aiua-13880	345	30	meta	meta	ADJ
aiua-13880	345	31	-	-	PUNCT
aiua-13880	345	32	analysis	analysis	NOUN
aiua-13880	345	33	.	.	PUNCT
aiua-13880	346	1	j	j	PROPN
aiua-13880	346	2	natl	natl	PROPN
aiua-13880	346	3	cancer	cancer	PROPN
aiua-13880	346	4	inst	inst	PROPN
aiua-13880	346	5	.	.	PUNCT
aiua-13880	346	6	2014	2014	NUM
aiua-13880	346	7	;	;	PUNCT
aiua-13880	346	8	106	106	NUM
aiua-13880	346	9	:	:	PUNCT
aiua-13880	346	10	dju124	dju124	NOUN
aiua-13880	346	11	.	.	PUNCT
aiua-13880	347	1	35	35	NUM
aiua-13880	347	2	.	.	PUNCT
aiua-13880	348	1	zidar	zidar	PROPN
aiua-13880	348	2	da	da	PROPN
aiua-13880	348	3	,	,	PUNCT
aiua-13880	348	4	al	al	PROPN
aiua-13880	348	5	-	-	PUNCT
aiua-13880	348	6	kindi	kindi	ADJ
aiua-13880	348	7	sg	sg	ADP
aiua-13880	348	8	,	,	PUNCT
aiua-13880	348	9	liu	liu	PROPN
aiua-13880	348	10	y	y	PROPN
aiua-13880	348	11	,	,	PUNCT
aiua-13880	348	12	et	et	PROPN
aiua-13880	348	13	al	al	PROPN
aiua-13880	348	14	.	.	PROPN
aiua-13880	348	15	association	association	PROPN
aiua-13880	348	16	of	of	ADP
aiua-13880	348	17	lymphopenia	lymphopenia	NOUN
aiua-13880	348	18	with	with	ADP
aiua-13880	348	19	risk	risk	NOUN
aiua-13880	348	20	of	of	ADP
aiua-13880	348	21	mortality	mortality	NOUN
aiua-13880	348	22	among	among	ADP
aiua-13880	348	23	adults	adult	NOUN
aiua-13880	348	24	in	in	ADP
aiua-13880	348	25	the	the	DET
aiua-13880	348	26	us	us	PROPN
aiua-13880	348	27	general	general	ADJ
aiua-13880	348	28	population	population	NOUN
aiua-13880	348	29	.	.	PUNCT
aiua-13880	349	1	jama	jama	PROPN
aiua-13880	349	2	netw	netw	PROPN
aiua-13880	349	3	open	open	ADJ
aiua-13880	349	4	.	.	PUNCT
aiua-13880	350	1	2019	2019	NUM
aiua-13880	350	2	;	;	PUNCT
aiua-13880	350	3	2	2	NUM
aiua-13880	350	4	:	:	PUNCT
aiua-13880	350	5	e1916526	e1916526	NOUN
aiua-13880	350	6	.	.	NOUN
aiua-13880	351	1	36	36	NUM
aiua-13880	351	2	.	.	X
aiua-13880	351	3	aggarwal	aggarwal	PROPN
aiua-13880	351	4	bb	bb	PROPN
aiua-13880	351	5	,	,	PUNCT
aiua-13880	351	6	vijayalekshmi	vijayalekshmi	PROPN
aiua-13880	351	7	rv	rv	PROPN
aiua-13880	351	8	,	,	PUNCT
aiua-13880	351	9	sung	sung	PROPN
aiua-13880	351	10	b.	b.	PROPN
aiua-13880	351	11	targeting	target	VERB
aiua-13880	351	12	inflammatory	inflammatory	ADJ
aiua-13880	351	13	pathways	pathway	NOUN
aiua-13880	351	14	for	for	ADP
aiua-13880	351	15	prevention	prevention	NOUN
aiua-13880	351	16	and	and	CCONJ
aiua-13880	351	17	therapy	therapy	NOUN
aiua-13880	351	18	of	of	ADP
aiua-13880	351	19	cancer	cancer	NOUN
aiua-13880	351	20	:	:	PUNCT
aiua-13880	351	21	short	short	ADJ
aiua-13880	351	22	-	-	PUNCT
aiua-13880	351	23	term	term	NOUN
aiua-13880	351	24	friend	friend	NOUN
aiua-13880	351	25	,	,	PUNCT
aiua-13880	351	26	long	long	ADJ
aiua-13880	351	27	-	-	PUNCT
aiua-13880	351	28	term	term	NOUN
aiua-13880	351	29	foe	foe	NOUN
aiua-13880	351	30	.	.	PUNCT
aiua-13880	352	1	clin	clin	PROPN
aiua-13880	352	2	cancer	cancer	NOUN
aiua-13880	352	3	res	re	NOUN
aiua-13880	352	4	.	.	PUNCT
aiua-13880	352	5	2009	2009	NUM
aiua-13880	352	6	;	;	PUNCT
aiua-13880	352	7	15:425	15:425	NUM
aiua-13880	352	8	-	-	SYM
aiua-13880	352	9	30	30	NUM
aiua-13880	352	10	.	.	PUNCT
aiua-13880	353	1	37	37	NUM
aiua-13880	353	2	.	.	PUNCT
aiua-13880	354	1	ohsugi	ohsugi	PROPN
aiua-13880	354	2	y.	y.	PROPN
aiua-13880	354	3	recent	recent	ADJ
aiua-13880	354	4	advances	advance	NOUN
aiua-13880	354	5	in	in	ADP
aiua-13880	354	6	immunopathophysiology	immunopathophysiology	NOUN
aiua-13880	354	7	of	of	ADP
aiua-13880	354	8	interleukin-6	interleukin-6	NUM
aiua-13880	354	9	:	:	PUNCT
aiua-13880	354	10	an	an	DET
aiua-13880	354	11	innovative	innovative	ADJ
aiua-13880	354	12	therapeutic	therapeutic	ADJ
aiua-13880	354	13	drug	drug	NOUN
aiua-13880	354	14	,	,	PUNCT
aiua-13880	354	15	tocilizumab	tocilizumab	NOUN
aiua-13880	354	16	(	(	PUNCT
aiua-13880	354	17	recombinant	recombinant	ADJ
aiua-13880	354	18	humanized	humanize	VERB
aiua-13880	354	19	anti	anti	ADJ
aiua-13880	354	20	-	-	ADJ
aiua-13880	354	21	human	human	ADJ
aiua-13880	354	22	interleukin-6	interleukin-6	NUM
aiua-13880	354	23	receptor	receptor	NOUN
aiua-13880	354	24	antibody	antibody	NOUN
aiua-13880	354	25	)	)	PUNCT
aiua-13880	354	26	,	,	PUNCT
aiua-13880	354	27	unveils	unveil	VERB
aiua-13880	354	28	the	the	DET
aiua-13880	354	29	mysterious	mysterious	ADJ
aiua-13880	354	30	etiology	etiology	NOUN
aiua-13880	354	31	of	of	ADP
aiua-13880	354	32	immune	immune	NOUN
aiua-13880	354	33	-	-	PUNCT
aiua-13880	354	34	mediated	mediate	VERB
aiua-13880	354	35	inflammatory	inflammatory	ADJ
aiua-13880	354	36	diseases	disease	NOUN
aiua-13880	354	37	.	.	PUNCT
aiua-13880	355	1	biol	biol	PROPN
aiua-13880	355	2	pharm	pharm	PROPN
aiua-13880	355	3	bull	bull	PROPN
aiua-13880	355	4	.	.	PUNCT
aiua-13880	356	1	2007	2007	NUM
aiua-13880	356	2	;	;	PUNCT
aiua-13880	356	3	30:2001	30:2001	NUM
aiua-13880	356	4	-	-	SYM
aiua-13880	356	5	6	6	NUM
aiua-13880	356	6	.	.	NOUN
aiua-13880	357	1	38	38	NUM
aiua-13880	357	2	.	.	PUNCT
aiua-13880	358	1	li	li	PROPN
aiua-13880	358	2	w	w	PROPN
aiua-13880	358	3	,	,	PUNCT
aiua-13880	358	4	luo	luo	PROPN
aiua-13880	358	5	x	x	PROPN
aiua-13880	358	6	,	,	PUNCT
aiua-13880	358	7	liu	liu	PROPN
aiua-13880	358	8	z	z	PROPN
aiua-13880	358	9	,	,	PUNCT
aiua-13880	358	10	et	et	PROPN
aiua-13880	358	11	al	al	PROPN
aiua-13880	358	12	.	.	PROPN
aiua-13880	358	13	prognostic	prognostic	ADJ
aiua-13880	358	14	value	value	NOUN
aiua-13880	358	15	of	of	ADP
aiua-13880	358	16	c	c	NOUN
aiua-13880	358	17	-	-	PUNCT
aiua-13880	358	18	reactive	reactive	ADJ
aiua-13880	358	19	protein	protein	NOUN
aiua-13880	358	20	levels	level	NOUN
aiua-13880	358	21	in	in	ADP
aiua-13880	358	22	patients	patient	NOUN
aiua-13880	358	23	with	with	ADP
aiua-13880	358	24	bone	bone	NOUN
aiua-13880	358	25	neoplasms	neoplasm	NOUN
aiua-13880	358	26	:	:	PUNCT
aiua-13880	358	27	a	a	DET
aiua-13880	358	28	meta	meta	ADJ
aiua-13880	358	29	-	-	PUNCT
aiua-13880	358	30	analysis	analysis	NOUN
aiua-13880	358	31	.	.	PUNCT
aiua-13880	359	1	plos	plos	PROPN
aiua-13880	359	2	one	one	NUM
aiua-13880	359	3	.	.	PUNCT
aiua-13880	359	4	2018	2018	NUM
aiua-13880	359	5	;	;	PUNCT
aiua-13880	359	6	13	13	NUM
aiua-13880	359	7	:	:	PUNCT
aiua-13880	359	8	e0195769	e0195769	NOUN
aiua-13880	359	9	.	.	PUNCT
aiua-13880	359	10	doi	doi	NOUN
aiua-13880	359	11	:	:	PUNCT
aiua-13880	359	12	10.1371	10.1371	NUM
aiua-13880	359	13	/	/	SYM
aiua-13880	359	14	journal.pone.0195769	journal.pone.0195769	PROPN
aiua-13880	359	15	.	.	PUNCT
aiua-13880	360	1	39	39	NUM
aiua-13880	360	2	.	.	PUNCT
aiua-13880	361	1	gao	gao	PROPN
aiua-13880	361	2	gd	gd	PROPN
aiua-13880	361	3	,	,	PUNCT
aiua-13880	361	4	sun	sun	PROPN
aiua-13880	361	5	b	b	PROPN
aiua-13880	361	6	,	,	PUNCT
aiua-13880	361	7	wang	wang	PROPN
aiua-13880	361	8	xb	xb	PROPN
aiua-13880	361	9	,	,	PUNCT
aiua-13880	361	10	wang	wang	PROPN
aiua-13880	361	11	sm	sm	PROPN
aiua-13880	361	12	.	.	PUNCT
aiua-13880	362	1	neutrophil	neutrophil	ADJ
aiua-13880	362	2	to	to	ADP
aiua-13880	362	3	lymphocyte	lymphocyte	ADJ
aiua-13880	362	4	ratio	ratio	NOUN
aiua-13880	362	5	as	as	ADP
aiua-13880	362	6	prognostic	prognostic	ADJ
aiua-13880	362	7	indicator	indicator	NOUN
aiua-13880	362	8	for	for	ADP
aiua-13880	362	9	patients	patient	NOUN
aiua-13880	362	10	with	with	ADP
aiua-13880	362	11	esophageal	esophageal	ADJ
aiua-13880	362	12	squamous	squamous	ADJ
aiua-13880	362	13	cell	cell	NOUN
aiua-13880	362	14	cancer	cancer	NOUN
aiua-13880	362	15	.	.	PUNCT
aiua-13880	363	1	int	int	NOUN
aiua-13880	363	2	j	j	PROPN
aiua-13880	363	3	biol	biol	PROPN
aiua-13880	363	4	markers	marker	NOUN
aiua-13880	363	5	.	.	PUNCT
aiua-13880	364	1	2017	2017	NUM
aiua-13880	364	2	;	;	PUNCT
aiua-13880	364	3	32:409	32:409	NUM
aiua-13880	364	4	-	-	SYM
aiua-13880	364	5	14	14	NUM
aiua-13880	364	6	.	.	PUNCT
aiua-13880	365	1	40	40	NUM
aiua-13880	365	2	.	.	PUNCT
aiua-13880	366	1	akashi	akashi	PROPN
aiua-13880	366	2	y	y	PROPN
aiua-13880	366	3	,	,	PUNCT
aiua-13880	366	4	yamamoto	yamamoto	PROPN
aiua-13880	366	5	y	y	PROPN
aiua-13880	366	6	,	,	PUNCT
aiua-13880	366	7	hashimoto	hashimoto	NOUN
aiua-13880	366	8	m	m	PROPN
aiua-13880	366	9	,	,	PUNCT
aiua-13880	366	10	et	et	PROPN
aiua-13880	366	11	al	al	PROPN
aiua-13880	366	12	.	.	PUNCT
aiua-13880	367	1	prognostic	prognostic	ADJ
aiua-13880	367	2	factors	factor	NOUN
aiua-13880	367	3	of	of	ADP
aiua-13880	367	4	platinum	platinum	NOUN
aiua-13880	367	5	-	-	PUNCT
aiua-13880	367	6	refractory	refractory	NOUN
aiua-13880	367	7	advanced	advanced	ADJ
aiua-13880	367	8	urothelial	urothelial	ADJ
aiua-13880	367	9	carcinoma	carcinoma	NOUN
aiua-13880	367	10	treated	treat	VERB
aiua-13880	367	11	with	with	ADP
aiua-13880	367	12	pembrolizumab	pembrolizumab	NOUN
aiua-13880	367	13	.	.	PUNCT
aiua-13880	368	1	cancers	cancer	NOUN
aiua-13880	368	2	.	.	PUNCT
aiua-13880	369	1	2023	2023	NUM
aiua-13880	369	2	;	;	PUNCT
aiua-13880	369	3	15:5780	15:5780	X
aiua-13880	369	4	.	.	PROPN
aiua-13880	369	5	41	41	NUM
aiua-13880	369	6	.	.	PUNCT
aiua-13880	370	1	fukata	fukata	PROPN
aiua-13880	370	2	s	s	PROPN
aiua-13880	370	3	,	,	PUNCT
aiua-13880	370	4	mizutani	mizutani	X
aiua-13880	370	5	k	k	NOUN
aiua-13880	370	6	,	,	PUNCT
aiua-13880	370	7	yamamoto	yamamoto	PROPN
aiua-13880	370	8	s	s	PROPN
aiua-13880	370	9	,	,	PUNCT
aiua-13880	370	10	et	et	PROPN
aiua-13880	370	11	al	al	PROPN
aiua-13880	370	12	.	.	PUNCT
aiua-13880	370	13	sarcopenia	sarcopenia	PROPN
aiua-13880	370	14	and	and	CCONJ
aiua-13880	370	15	the	the	DET
aiua-13880	370	16	rate	rate	NOUN
aiua-13880	370	17	of	of	ADP
aiua-13880	370	18	change	change	NOUN
aiua-13880	370	19	of	of	ADP
aiua-13880	370	20	the	the	DET
aiua-13880	370	21	neutrophil	neutrophil	ADJ
aiua-13880	370	22	/	/	SYM
aiua-13880	370	23	lymphocyte	lymphocyte	ADJ
aiua-13880	370	24	ratio	ratio	NOUN
aiua-13880	370	25	as	as	ADP
aiua-13880	370	26	predictors	predictor	NOUN
aiua-13880	370	27	of	of	ADP
aiua-13880	370	28	pembrolizumab	pembrolizumab	NOUN
aiua-13880	370	29	efficacy	efficacy	NOUN
aiua-13880	370	30	in	in	ADP
aiua-13880	370	31	advanced	advanced	ADJ
aiua-13880	370	32	urothelial	urothelial	ADJ
aiua-13880	370	33	carcinoma	carcinoma	NOUN
aiua-13880	370	34	.	.	PUNCT
aiua-13880	371	1	anticancer	anticancer	NOUN
aiua-13880	371	2	drugs	drug	NOUN
aiua-13880	371	3	.	.	PUNCT
aiua-13880	372	1	2022	2022	NUM
aiua-13880	372	2	;	;	PUNCT
aiua-13880	372	3	33:459	33:459	NUM
aiua-13880	372	4	-	-	SYM
aiua-13880	372	5	66	66	NUM
aiua-13880	372	6	.	.	PUNCT
aiua-13880	373	1	42	42	NUM
aiua-13880	373	2	.	.	PUNCT
aiua-13880	374	1	furubayashi	furubayashi	PROPN
aiua-13880	374	2	n	n	CCONJ
aiua-13880	374	3	,	,	PUNCT
aiua-13880	374	4	minato	minato	PROPN
aiua-13880	374	5	a	a	X
aiua-13880	374	6	,	,	PUNCT
aiua-13880	374	7	negishi	negishi	PROPN
aiua-13880	374	8	t	t	PROPN
aiua-13880	374	9	,	,	PUNCT
aiua-13880	374	10	et	et	PROPN
aiua-13880	374	11	al	al	PROPN
aiua-13880	374	12	.	.	PUNCT
aiua-13880	375	1	the	the	DET
aiua-13880	375	2	eosinophil	eosinophil	ADJ
aiua-13880	375	3	changes	change	NOUN
aiua-13880	375	4	,	,	PUNCT
aiua-13880	375	5	efficacy	efficacy	NOUN
aiua-13880	375	6	and	and	CCONJ
aiua-13880	375	7	safety	safety	NOUN
aiua-13880	375	8	of	of	ADP
aiua-13880	375	9	pembrolizumab	pembrolizumab	NOUN
aiua-13880	375	10	in	in	ADP
aiua-13880	375	11	advanced	advanced	ADJ
aiua-13880	375	12	urothelial	urothelial	ADJ
aiua-13880	375	13	carcinoma	carcinoma	NOUN
aiua-13880	375	14	patients	patient	NOUN
aiua-13880	375	15	with	with	ADP
aiua-13880	375	16	an	an	DET
aiua-13880	375	17	older	old	ADJ
aiua-13880	375	18	age	age	NOUN
aiua-13880	375	19	and	and	CCONJ
aiua-13880	375	20	a	a	DET
aiua-13880	375	21	poor	poor	ADJ
aiua-13880	375	22	performance	performance	NOUN
aiua-13880	375	23	status	status	NOUN
aiua-13880	375	24	.	.	PUNCT
aiua-13880	376	1	oncotargets	oncotarget	NOUN
aiua-13880	376	2	ther	ther	ADV
aiua-13880	376	3	.	.	PUNCT
aiua-13880	377	1	2022	2022	NUM
aiua-13880	377	2	;	;	PUNCT
aiua-13880	377	3	15:1321	15:1321	NUM
aiua-13880	377	4	-	-	SYM
aiua-13880	377	5	30	30	NUM
aiua-13880	377	6	.	.	PUNCT
aiua-13880	378	1	43	43	NUM
aiua-13880	378	2	.	.	PUNCT
aiua-13880	379	1	ito	ito	PROPN
aiua-13880	379	2	k	k	PROPN
aiua-13880	379	3	,	,	PUNCT
aiua-13880	379	4	kobayashi	kobayashi	PROPN
aiua-13880	379	5	t	t	PROPN
aiua-13880	379	6	,	,	PUNCT
aiua-13880	379	7	kojima	kojima	PROPN
aiua-13880	379	8	t	t	PROPN
aiua-13880	379	9	,	,	PUNCT
aiua-13880	379	10	et	et	PROPN
aiua-13880	379	11	al	al	PROPN
aiua-13880	379	12	.	.	PROPN
aiua-13880	379	13	pembrolizumab	pembrolizumab	NOUN
aiua-13880	379	14	for	for	ADP
aiua-13880	379	15	treating	treat	VERB
aiua-13880	379	16	advanced	advanced	ADJ
aiua-13880	379	17	urothelial	urothelial	ADJ
aiua-13880	379	18	carcinoma	carcinoma	NOUN
aiua-13880	379	19	in	in	ADP
aiua-13880	379	20	patients	patient	NOUN
aiua-13880	379	21	with	with	ADP
aiua-13880	379	22	impaired	impaired	ADJ
aiua-13880	379	23	performance	performance	NOUN
aiua-13880	379	24	status	status	NOUN
aiua-13880	379	25	:	:	PUNCT
aiua-13880	379	26	analysis	analysis	NOUN
aiua-13880	379	27	of	of	ADP
aiua-13880	379	28	a	a	DET
aiua-13880	379	29	japanese	japanese	ADJ
aiua-13880	379	30	nationwide	nationwide	ADJ
aiua-13880	379	31	cohort	cohort	NOUN
aiua-13880	379	32	.	.	PUNCT
aiua-13880	380	1	cancer	cancer	NOUN
aiua-13880	380	2	med	med	PROPN
aiua-13880	380	3	.	.	PUNCT
aiua-13880	380	4	2021	2021	NUM
aiua-13880	380	5	;	;	PUNCT
aiua-13880	380	6	10:3188	10:3188	NUM
aiua-13880	380	7	-	-	SYM
aiua-13880	380	8	96	96	NUM
aiua-13880	380	9	.	.	PUNCT
aiua-13880	381	1	44	44	NUM
aiua-13880	381	2	.	.	PUNCT
aiua-13880	382	1	kawashima	kawashima	PROPN
aiua-13880	382	2	a	a	PROPN
aiua-13880	382	3	,	,	PUNCT
aiua-13880	382	4	yamamoto	yamamoto	PROPN
aiua-13880	382	5	y	y	PROPN
aiua-13880	382	6	,	,	PUNCT
aiua-13880	382	7	sato	sato	PROPN
aiua-13880	382	8	m	m	PRON
aiua-13880	382	9	,	,	PUNCT
aiua-13880	382	10	et	et	PROPN
aiua-13880	382	11	al	al	PROPN
aiua-13880	382	12	.	.	PUNCT
aiua-13880	383	1	fan	fan	PROPN
aiua-13880	383	2	score	score	NOUN
aiua-13880	383	3	comprising	comprise	VERB
aiua-13880	383	4	fibrosis-4	fibrosis-4	NUM
aiua-13880	383	5	index	index	NOUN
aiua-13880	383	6	,	,	PUNCT
aiua-13880	383	7	albumin	albumin	ADJ
aiua-13880	383	8	-	-	PUNCT
aiua-13880	383	9	bilirubin	bilirubin	NOUN
aiua-13880	383	10	score	score	NOUN
aiua-13880	383	11	and	and	CCONJ
aiua-13880	383	12	neutrophil	neutrophil	ADJ
aiua-13880	383	13	-	-	PUNCT
aiua-13880	383	14	lymphocyte	lymphocyte	ADJ
aiua-13880	383	15	ratio	ratio	NOUN
aiua-13880	383	16	is	be	AUX
aiua-13880	383	17	a	a	DET
aiua-13880	383	18	prognostic	prognostic	ADJ
aiua-13880	383	19	marker	marker	NOUN
aiua-13880	383	20	of	of	ADP
aiua-13880	383	21	urothelial	urothelial	ADJ
aiua-13880	383	22	carcinoma	carcinoma	NOUN
aiua-13880	383	23	patients	patient	NOUN
aiua-13880	383	24	treated	treat	VERB
aiua-13880	383	25	with	with	ADP
aiua-13880	383	26	pembrolizumab	pembrolizumab	NOUN
aiua-13880	383	27	.	.	PUNCT
aiua-13880	384	1	sci	sci	PROPN
aiua-13880	384	2	rep	rep	PROPN
aiua-13880	384	3	.	.	PROPN
aiua-13880	384	4	2021	2021	NUM
aiua-13880	384	5	;	;	PUNCT
aiua-13880	384	6	11:21199	11:21199	X
aiua-13880	384	7	.	.	X
aiua-13880	385	1	45	45	NUM
aiua-13880	385	2	.	.	PUNCT
aiua-13880	385	3	kita	kita	PROPN
aiua-13880	385	4	y	y	PROPN
aiua-13880	385	5	,	,	PUNCT
aiua-13880	385	6	ito	ito	PROPN
aiua-13880	385	7	k	k	PROPN
aiua-13880	385	8	,	,	PUNCT
aiua-13880	385	9	kanda	kanda	PROPN
aiua-13880	385	10	s	s	PROPN
aiua-13880	385	11	,	,	PUNCT
aiua-13880	385	12	et	et	PROPN
aiua-13880	385	13	al	al	PROPN
aiua-13880	385	14	.	.	PUNCT
aiua-13880	385	15	tolerability	tolerability	NOUN
aiua-13880	385	16	and	and	CCONJ
aiua-13880	385	17	treatment	treatment	NOUN
aiua-13880	385	18	outcome	outcome	NOUN
aiua-13880	385	19	of	of	ADP
aiua-13880	385	20	pembrolizumab	pembrolizumab	NOUN
aiua-13880	385	21	in	in	ADP
aiua-13880	385	22	patients	patient	NOUN
aiua-13880	385	23	with	with	ADP
aiua-13880	385	24	advanced	advanced	ADJ
aiua-13880	385	25	urothelial	urothelial	ADJ
aiua-13880	385	26	carcinoma	carcinoma	NOUN
aiua-13880	385	27	and	and	CCONJ
aiua-13880	385	28	severe	severe	ADJ
aiua-13880	385	29	renal	renal	ADJ
aiua-13880	385	30	dysfunction	dysfunction	NOUN
aiua-13880	385	31	.	.	PUNCT
aiua-13880	386	1	urol	urol	PROPN
aiua-13880	386	2	oncol	oncol	PROPN
aiua-13880	386	3	semin	semin	PROPN
aiua-13880	386	4	orig	orig	PROPN
aiua-13880	386	5	investig	investig	PROPN
aiua-13880	386	6	.	.	PROPN
aiua-13880	386	7	2022	2022	NUM
aiua-13880	386	8	;	;	PUNCT
aiua-13880	386	9	40:410.e11	40:410.e11	X
aiua-13880	386	10	-	-	PUNCT
aiua-13880	386	11	410.e18	410.e18	NUM
aiua-13880	386	12	.	.	PUNCT
aiua-13880	387	1	46	46	NUM
aiua-13880	387	2	.	.	PUNCT
aiua-13880	388	1	kobayashi	kobayashi	PROPN
aiua-13880	388	2	t	t	PROPN
aiua-13880	388	3	,	,	PUNCT
aiua-13880	388	4	ito	ito	PROPN
aiua-13880	388	5	k	k	PROPN
aiua-13880	388	6	,	,	PUNCT
aiua-13880	388	7	kojima	kojima	PROPN
aiua-13880	388	8	t	t	PROPN
aiua-13880	388	9	,	,	PUNCT
aiua-13880	388	10	et	et	PROPN
aiua-13880	388	11	al	al	PROPN
aiua-13880	388	12	.	.	PUNCT
aiua-13880	389	1	risk	risk	NOUN
aiua-13880	389	2	stratification	stratification	NOUN
aiua-13880	389	3	for	for	ADP
aiua-13880	389	4	the	the	DET
aiua-13880	389	5	prognosis	prognosis	NOUN
aiua-13880	389	6	of	of	ADP
aiua-13880	389	7	patients	patient	NOUN
aiua-13880	389	8	with	with	ADP
aiua-13880	389	9	chemoresistant	chemoresistant	ADJ
aiua-13880	389	10	urothelial	urothelial	ADJ
aiua-13880	389	11	cancer	cancer	NOUN
aiua-13880	389	12	treated	treat	VERB
aiua-13880	389	13	with	with	ADP
aiua-13880	389	14	pembrolizumab	pembrolizumab	NOUN
aiua-13880	389	15	.	.	PUNCT
aiua-13880	390	1	cancer	cancer	PROPN
aiua-13880	390	2	sci	sci	PROPN
aiua-13880	390	3	.	.	PROPN
aiua-13880	390	4	2021	2021	NUM
aiua-13880	390	5	;	;	PUNCT
aiua-13880	390	6	112:760	112:760	X
aiua-13880	390	7	-	-	PUNCT
aiua-13880	390	8	73	73	NUM
aiua-13880	390	9	.	.	PUNCT
aiua-13880	391	1	47	47	NUM
aiua-13880	391	2	.	.	PUNCT
aiua-13880	392	1	komura	komura	PROPN
aiua-13880	392	2	k	k	PROPN
aiua-13880	392	3	,	,	PUNCT
aiua-13880	392	4	tokushige	tokushige	PROPN
aiua-13880	392	5	s	s	PROPN
aiua-13880	392	6	,	,	PUNCT
aiua-13880	392	7	ishida	ishida	PROPN
aiua-13880	392	8	m	m	PROPN
aiua-13880	392	9	,	,	PUNCT
aiua-13880	392	10	et	et	PROPN
aiua-13880	392	11	al	al	PROPN
aiua-13880	392	12	.	.	PUNCT
aiua-13880	392	13	tertiary	tertiary	ADJ
aiua-13880	392	14	lymphoid	lymphoid	ADJ
aiua-13880	392	15	structure	structure	NOUN
aiua-13880	392	16	and	and	CCONJ
aiua-13880	392	17	neutrophil	neutrophil	ADJ
aiua-13880	392	18	-	-	PUNCT
aiua-13880	392	19	lymphocyte	lymphocyte	NOUN
aiua-13880	392	20	ratio	ratio	NOUN
aiua-13880	392	21	coordinately	coordinately	ADV
aiua-13880	392	22	predict	predict	VERB
aiua-13880	392	23	outcome	outcome	NOUN
aiua-13880	392	24	of	of	ADP
aiua-13880	392	25	pembrolizumab	pembrolizumab	NOUN
aiua-13880	392	26	.	.	PUNCT
aiua-13880	393	1	cancer	cancer	PROPN
aiua-13880	393	2	sci	sci	PROPN
aiua-13880	393	3	.	.	PROPN
aiua-13880	393	4	2023	2023	NUM
aiua-13880	393	5	;	;	PUNCT
aiua-13880	393	6	114:4622	114:4622	NUM
aiua-13880	393	7	-	-	SYM
aiua-13880	393	8	31	31	NUM
aiua-13880	393	9	.	.	PUNCT
aiua-13880	394	1	48	48	NUM
aiua-13880	394	2	.	.	PUNCT
aiua-13880	395	1	miyama	miyama	PROPN
aiua-13880	395	2	y	y	PROPN
aiua-13880	395	3	,	,	PUNCT
aiua-13880	395	4	kaneko	kaneko	PROPN
aiua-13880	395	5	g	g	PROPN
aiua-13880	395	6	,	,	PUNCT
aiua-13880	395	7	nishimoto	nishimoto	PROPN
aiua-13880	395	8	k	k	PROPN
aiua-13880	395	9	,	,	PUNCT
aiua-13880	395	10	yasuda	yasuda	PROPN
aiua-13880	395	11	m.	m.	PROPN
aiua-13880	395	12	lower	low	ADJ
aiua-13880	395	13	neutrophil	neutrophil	NOUN
aiua-13880	395	14	-	-	PUNCT
aiua-13880	395	15	to	to	ADP
aiua-13880	395	16	-	-	PUNCT
aiua-13880	395	17	lymphocyte	lymphocyte	ADJ
aiua-13880	395	18	ratio	ratio	NOUN
aiua-13880	395	19	and	and	CCONJ
aiua-13880	395	20	positive	positive	ADJ
aiua-13880	395	21	programmed	programmed	ADJ
aiua-13880	395	22	cell	cell	NOUN
aiua-13880	395	23	death	death	NOUN
aiua-13880	395	24	ligand-1	ligand-1	NUM
aiua-13880	395	25	expression	expression	NOUN
aiua-13880	395	26	are	be	AUX
aiua-13880	395	27	favorable	favorable	ADJ
aiua-13880	395	28	prognostic	prognostic	ADJ
aiua-13880	395	29	markers	marker	NOUN
aiua-13880	395	30	in	in	ADP
aiua-13880	395	31	patients	patient	NOUN
aiua-13880	395	32	treated	treat	VERB
aiua-13880	395	33	with	with	ADP
aiua-13880	395	34	pembrolizumab	pembrolizumab	NOUN
aiua-13880	395	35	for	for	ADP
aiua-13880	395	36	urothelial	urothelial	ADJ
aiua-13880	395	37	carcinoma	carcinoma	NOUN
aiua-13880	395	38	.	.	PUNCT
aiua-13880	396	1	cancer	cancer	NOUN
aiua-13880	396	2	med	med	PROPN
aiua-13880	396	3	.	.	PUNCT
aiua-13880	396	4	2022	2022	NUM
aiua-13880	396	5	;	;	PUNCT
aiua-13880	396	6	11:4236	11:4236	NUM
aiua-13880	396	7	-	-	SYM
aiua-13880	396	8	45	45	NUM
aiua-13880	396	9	.	.	NOUN
aiua-13880	396	10	49	49	NUM
aiua-13880	396	11	.	.	PUNCT
aiua-13880	397	1	nagasaka	nagasaka	PROPN
aiua-13880	397	2	h	h	PROPN
aiua-13880	397	3	,	,	PUNCT
aiua-13880	397	4	yamamoto	yamamoto	PROPN
aiua-13880	397	5	s	s	PROPN
aiua-13880	397	6	,	,	PUNCT
aiua-13880	397	7	suzuki	suzuki	PROPN
aiua-13880	397	8	a	a	X
aiua-13880	397	9	,	,	PUNCT
aiua-13880	397	10	et	et	PROPN
aiua-13880	397	11	al	al	PROPN
aiua-13880	397	12	.	.	PUNCT
aiua-13880	398	1	c	c	X
aiua-13880	398	2	-	-	PUNCT
aiua-13880	398	3	reactive	reactive	ADJ
aiua-13880	398	4	protein	protein	NOUN
aiua-13880	398	5	is	be	AUX
aiua-13880	398	6	a	a	DET
aiua-13880	398	7	prognostic	prognostic	ADJ
aiua-13880	398	8	factor	factor	NOUN
aiua-13880	398	9	for	for	ADP
aiua-13880	398	10	survival	survival	NOUN
aiua-13880	398	11	in	in	ADP
aiua-13880	398	12	metastatic	metastatic	ADJ
aiua-13880	398	13	upper	upper	ADJ
aiua-13880	398	14	tract	tract	NOUN
aiua-13880	398	15	urothelial	urothelial	ADJ
aiua-13880	398	16	carcinoma	carcinoma	NOUN
aiua-13880	398	17	patients	patient	NOUN
aiua-13880	398	18	receiving	receive	VERB
aiua-13880	398	19	pembrolizumab	pembrolizumab	NOUN
aiua-13880	398	20	.	.	PUNCT
aiua-13880	399	1	in	in	ADP
aiua-13880	399	2	vivo	vivo	NOUN
aiua-13880	399	3	.	.	PUNCT
aiua-13880	400	1	2024	2024	NUM
aiua-13880	400	2	;	;	PUNCT
aiua-13880	400	3	38:1823	38:1823	NUM
aiua-13880	400	4	-	-	SYM
aiua-13880	400	5	8	8	NUM
aiua-13880	400	6	.	.	NOUN
aiua-13880	401	1	50	50	NUM
aiua-13880	401	2	.	.	PUNCT
aiua-13880	402	1	nishio	nishio	PROPN
aiua-13880	402	2	k	k	PROPN
aiua-13880	402	3	,	,	PUNCT
aiua-13880	402	4	higashio	higashio	PROPN
aiua-13880	402	5	t	t	PROPN
aiua-13880	402	6	,	,	PUNCT
aiua-13880	402	7	komura	komura	NOUN
aiua-13880	402	8	k	k	PROPN
aiua-13880	402	9	,	,	PUNCT
aiua-13880	402	10	et	et	PROPN
aiua-13880	402	11	al	al	PROPN
aiua-13880	402	12	.	.	PROPN
aiua-13880	402	13	predicting	predict	VERB
aiua-13880	402	14	objective	objective	ADJ
aiua-13880	402	15	response	response	NOUN
aiua-13880	402	16	of	of	ADP
aiua-13880	402	17	pembrolizumab	pembrolizumab	NOUN
aiua-13880	402	18	in	in	ADP
aiua-13880	402	19	platinum	platinum	NOUN
aiua-13880	402	20	-	-	PUNCT
aiua-13880	402	21	refractory	refractory	NOUN
aiua-13880	402	22	urothelial	urothelial	ADJ
aiua-13880	402	23	carcinoma	carcinoma	NOUN
aiua-13880	402	24	based	base	VERB
aiua-13880	402	25	on	on	ADP
aiua-13880	402	26	neutrophil	neutrophil	ADJ
aiua-13880	402	27	-	-	PUNCT
aiua-13880	402	28	lymphocyte	lymphocyte	NOUN
aiua-13880	402	29	ratio	ratio	NOUN
aiua-13880	402	30	fluctuation	fluctuation	NOUN
aiua-13880	402	31	and	and	CCONJ
aiua-13880	402	32	liver	liver	NOUN
aiua-13880	402	33	metastases	metastasis	NOUN
aiua-13880	402	34	.	.	PUNCT
aiua-13880	403	1	oncology	oncology	NOUN
aiua-13880	403	2	.	.	PUNCT
aiua-13880	404	1	2024	2024	NUM
aiua-13880	404	2	;	;	PUNCT
aiua-13880	404	3	102:457	102:457	NUM
aiua-13880	404	4	-	-	SYM
aiua-13880	404	5	64	64	NUM
aiua-13880	404	6	.	.	PUNCT
aiua-13880	405	1	51	51	NUM
aiua-13880	405	2	.	.	PUNCT
aiua-13880	406	1	ogihara	ogihara	PROPN
aiua-13880	406	2	k	k	PROPN
aiua-13880	406	3	,	,	PUNCT
aiua-13880	406	4	kikuchi	kikuchi	PROPN
aiua-13880	406	5	e	e	PROPN
aiua-13880	406	6	,	,	PUNCT
aiua-13880	406	7	shigeta	shigeta	ADJ
aiua-13880	406	8	k	k	PROPN
aiua-13880	406	9	,	,	PUNCT
aiua-13880	406	10	et	et	PROPN
aiua-13880	406	11	al	al	PROPN
aiua-13880	406	12	.	.	PUNCT
aiua-13880	407	1	the	the	DET
aiua-13880	407	2	pretreatment	pretreatment	NOUN
aiua-13880	407	3	neutrophil	neutrophil	NOUN
aiua-13880	407	4	-	-	PUNCT
aiua-13880	407	5	to	to	ADP
aiua-13880	407	6	-	-	PUNCT
aiua-13880	407	7	lymphocyte	lymphocyte	ADJ
aiua-13880	407	8	ratio	ratio	NOUN
aiua-13880	407	9	is	be	AUX
aiua-13880	407	10	a	a	DET
aiua-13880	407	11	novel	novel	ADJ
aiua-13880	407	12	biomarker	biomarker	NOUN
aiua-13880	407	13	for	for	ADP
aiua-13880	407	14	predicting	predict	VERB
aiua-13880	407	15	clinical	clinical	ADJ
aiua-13880	407	16	responses	response	NOUN
aiua-13880	407	17	to	to	PART
aiua-13880	407	18	pembrolizumab	pembrolizumab	VERB
aiua-13880	407	19	in	in	ADP
aiua-13880	407	20	platinum	platinum	NOUN
aiua-13880	407	21	-	-	PUNCT
aiua-13880	407	22	resistant	resistant	ADJ
aiua-13880	407	23	metastatic	metastatic	ADJ
aiua-13880	407	24	urothelial	urothelial	ADJ
aiua-13880	407	25	carcinoma	carcinoma	NOUN
aiua-13880	407	26	patients	patient	NOUN
aiua-13880	407	27	.	.	PUNCT
aiua-13880	408	1	urol	urol	PROPN
aiua-13880	408	2	oncol	oncol	PROPN
aiua-13880	408	3	.	.	PUNCT
aiua-13880	409	1	2020	2020	NUM
aiua-13880	409	2	;	;	PUNCT
aiua-13880	409	3	38:602.e1	38:602.e1	NUM
aiua-13880	409	4	-	-	PUNCT
aiua-13880	409	5	602.e10	602.e10	NUM
aiua-13880	409	6	.	.	PUNCT
aiua-13880	410	1	52	52	NUM
aiua-13880	410	2	.	.	PUNCT
aiua-13880	411	1	rijnders	rijnder	NOUN
aiua-13880	411	2	m	m	PROPN
aiua-13880	411	3	,	,	PUNCT
aiua-13880	411	4	robbrecht	robbrecht	NOUN
aiua-13880	411	5	dgj	dgj	ADJ
aiua-13880	411	6	,	,	PUNCT
aiua-13880	411	7	oostvogels	oostvogels	PROPN
aiua-13880	411	8	aam	aam	PROPN
aiua-13880	411	9	,	,	PUNCT
aiua-13880	411	10	et	et	PROPN
aiua-13880	411	11	al	al	PROPN
aiua-13880	411	12	.	.	PUNCT
aiua-13880	412	1	a	a	DET
aiua-13880	412	2	bloodbased	bloodbase	VERB
aiua-13880	412	3	immune	immune	ADJ
aiua-13880	412	4	marker	marker	NOUN
aiua-13880	412	5	for	for	ADP
aiua-13880	412	6	resistance	resistance	NOUN
aiua-13880	412	7	to	to	PART
aiua-13880	412	8	pembrolizumab	pembrolizumab	NOUN
aiua-13880	412	9	in	in	ADP
aiua-13880	412	10	patients	patient	NOUN
aiua-13880	412	11	with	with	ADP
aiua-13880	412	12	metastatic	metastatic	ADJ
aiua-13880	412	13	urothelial	urothelial	ADJ
aiua-13880	412	14	cancer	cancer	NOUN
aiua-13880	412	15	.	.	PUNCT
aiua-13880	413	1	cancer	cancer	NOUN
aiua-13880	413	2	immunol	immunol	PROPN
aiua-13880	413	3	immunother	immunother	PROPN
aiua-13880	413	4	.	.	PUNCT
aiua-13880	414	1	2023	2023	NUM
aiua-13880	414	2	;	;	PUNCT
aiua-13880	414	3	72:759	72:759	NUM
aiua-13880	414	4	-	-	SYM
aiua-13880	414	5	67	67	NUM
aiua-13880	414	6	.	.	PUNCT
aiua-13880	414	7	53	53	NUM
aiua-13880	414	8	.	.	PUNCT
aiua-13880	415	1	sato	sato	PROPN
aiua-13880	415	2	r	r	PROPN
aiua-13880	415	3	,	,	PUNCT
aiua-13880	415	4	inamoto	inamoto	NOUN
aiua-13880	415	5	t	t	PROPN
aiua-13880	415	6	,	,	PUNCT
aiua-13880	415	7	matsushita	matsushita	PROPN
aiua-13880	415	8	y	y	PROPN
aiua-13880	415	9	,	,	PUNCT
aiua-13880	415	10	et	et	PROPN
aiua-13880	415	11	al	al	PROPN
aiua-13880	415	12	.	.	PROPN
aiua-13880	415	13	significance	significance	NOUN
aiua-13880	415	14	of	of	ADP
aiua-13880	415	15	second	second	ADJ
aiua-13880	415	16	progression	progression	NOUN
aiua-13880	415	17	-	-	PUNCT
aiua-13880	415	18	free	free	ADJ
aiua-13880	415	19	survival	survival	NOUN
aiua-13880	415	20	in	in	ADP
aiua-13880	415	21	patients	patient	NOUN
aiua-13880	415	22	with	with	ADP
aiua-13880	415	23	advanced	advanced	ADJ
aiua-13880	415	24	urothelial	urothelial	ADJ
aiua-13880	415	25	cancer	cancer	NOUN
aiua-13880	415	26	who	who	PRON
aiua-13880	415	27	received	receive	VERB
aiua-13880	415	28	platinum	platinum	NOUN
aiua-13880	415	29	-	-	PUNCT
aiua-13880	415	30	based	base	VERB
aiua-13880	415	31	combination	combination	NOUN
aiua-13880	415	32	chemotherapy	chemotherapy	NOUN
aiua-13880	415	33	followed	follow	VERB
aiua-13880	415	34	by	by	ADP
aiua-13880	415	35	pembrolizumab	pembrolizumab	NOUN
aiua-13880	415	36	.	.	PUNCT
aiua-13880	416	1	int	int	PROPN
aiua-13880	416	2	j	j	PROPN
aiua-13880	416	3	urol	urol	PROPN
aiua-13880	416	4	.	.	PUNCT
aiua-13880	417	1	2023	2023	NUM
aiua-13880	417	2	;	;	PUNCT
aiua-13880	417	3	30:730	30:730	NUM
aiua-13880	417	4	-	-	SYM
aiua-13880	417	5	6	6	NUM
aiua-13880	417	6	.	.	NUM
aiua-13880	417	7	54	54	NUM
aiua-13880	417	8	.	.	PUNCT
aiua-13880	418	1	shimizu	shimizu	PROPN
aiua-13880	418	2	t	t	PROPN
aiua-13880	418	3	,	,	PUNCT
aiua-13880	418	4	miyake	miyake	PROPN
aiua-13880	418	5	m	m	PROPN
aiua-13880	418	6	,	,	PUNCT
aiua-13880	418	7	hori	hori	PROPN
aiua-13880	418	8	s	s	PROPN
aiua-13880	418	9	,	,	PUNCT
aiua-13880	418	10	et	et	PROPN
aiua-13880	418	11	al	al	PROPN
aiua-13880	418	12	.	.	PROPN
aiua-13880	419	1	clinical	clinical	ADJ
aiua-13880	419	2	impact	impact	NOUN
aiua-13880	419	3	of	of	ADP
aiua-13880	419	4	sarcopenia	sarcopenia	NOUN
aiua-13880	419	5	and	and	CCONJ
aiua-13880	419	6	inflammatory	inflammatory	ADJ
aiua-13880	419	7	/	/	SYM
aiua-13880	419	8	nutritional	nutritional	ADJ
aiua-13880	419	9	markers	marker	NOUN
aiua-13880	419	10	in	in	ADP
aiua-13880	419	11	patients	patient	NOUN
aiua-13880	419	12	with	with	ADP
aiua-13880	419	13	unresectable	unresectable	ADJ
aiua-13880	419	14	metastatic	metastatic	ADJ
aiua-13880	419	15	urothelial	urothelial	ADJ
aiua-13880	419	16	carcinoma	carcinoma	NOUN
aiua-13880	419	17	treated	treat	VERB
aiua-13880	419	18	with	with	ADP
aiua-13880	419	19	pembrolizumab	pembrolizumab	NOUN
aiua-13880	419	20	.	.	PUNCT
aiua-13880	420	1	diagnostics	diagnostic	NOUN
aiua-13880	420	2	.	.	PUNCT
aiua-13880	421	1	2020	2020	NUM
aiua-13880	421	2	;	;	PUNCT
aiua-13880	421	3	10:310	10:310	NUM
aiua-13880	421	4	.	.	PUNCT
aiua-13880	422	1	55	55	NUM
aiua-13880	422	2	.	.	PUNCT
aiua-13880	423	1	tamura	tamura	PROPN
aiua-13880	423	2	d	d	PROPN
aiua-13880	423	3	,	,	PUNCT
aiua-13880	423	4	jinnouchi	jinnouchi	PROPN
aiua-13880	423	5	n	n	CCONJ
aiua-13880	423	6	,	,	PUNCT
aiua-13880	423	7	abe	abe	PROPN
aiua-13880	423	8	m	m	PROPN
aiua-13880	423	9	,	,	PUNCT
aiua-13880	423	10	et	et	PROPN
aiua-13880	423	11	al	al	PROPN
aiua-13880	423	12	.	.	PUNCT
aiua-13880	424	1	prognostic	prognostic	ADJ
aiua-13880	424	2	outcomes	outcome	NOUN
aiua-13880	424	3	and	and	CCONJ
aiua-13880	424	4	safety	safety	NOUN
aiua-13880	424	5	in	in	ADP
aiua-13880	424	6	patients	patient	NOUN
aiua-13880	424	7	treated	treat	VERB
aiua-13880	424	8	with	with	ADP
aiua-13880	424	9	pembrolizumab	pembrolizumab	NOUN
aiua-13880	424	10	for	for	ADP
aiua-13880	424	11	advanced	advanced	ADJ
aiua-13880	424	12	urothelial	urothelial	ADJ
aiua-13880	424	13	carcinoma	carcinoma	NOUN
aiua-13880	424	14	:	:	PUNCT
aiua-13880	424	15	experience	experience	NOUN
aiua-13880	424	16	in	in	ADP
aiua-13880	424	17	real	real	ADJ
aiua-13880	424	18	-	-	PUNCT
aiua-13880	424	19	world	world	NOUN
aiua-13880	424	20	clinical	clinical	ADJ
aiua-13880	424	21	practice	practice	NOUN
aiua-13880	424	22	.	.	PUNCT
aiua-13880	425	1	int	int	NOUN
aiua-13880	426	1	j	j	PROPN
aiua-13880	426	2	clin	clin	PROPN
aiua-13880	426	3	oncol	oncol	PROPN
aiua-13880	426	4	.	.	PUNCT
aiua-13880	427	1	2020	2020	NUM
aiua-13880	427	2	;	;	PUNCT
aiua-13880	427	3	25:899	25:899	X
aiua-13880	427	4	-	-	SYM
aiua-13880	427	5	905	905	NUM
aiua-13880	427	6	.	.	PUNCT
aiua-13880	428	1	56	56	NUM
aiua-13880	428	2	.	.	PUNCT
aiua-13880	428	3	uchimoto	uchimoto	PROPN
aiua-13880	428	4	t	t	PROPN
aiua-13880	428	5	,	,	PUNCT
aiua-13880	428	6	komura	komura	NOUN
aiua-13880	428	7	k	k	PROPN
aiua-13880	428	8	,	,	PUNCT
aiua-13880	428	9	fukuokaya	fukuokaya	NOUN
aiua-13880	428	10	w	w	PROPN
aiua-13880	428	11	,	,	PUNCT
aiua-13880	428	12	et	et	PROPN
aiua-13880	428	13	al	al	PROPN
aiua-13880	428	14	.	.	PUNCT
aiua-13880	429	1	risk	risk	NOUN
aiua-13880	429	2	classification	classification	NOUN
aiua-13880	429	3	for	for	ADP
aiua-13880	429	4	overall	overall	ADJ
aiua-13880	429	5	survival	survival	NOUN
aiua-13880	429	6	by	by	ADP
aiua-13880	429	7	the	the	DET
aiua-13880	429	8	neutrophil	neutrophil	ADJ
aiua-13880	429	9	-	-	PUNCT
aiua-13880	429	10	lymphocyte	lymphocyte	NOUN
aiua-13880	429	11	ratio	ratio	NOUN
aiua-13880	429	12	and	and	CCONJ
aiua-13880	429	13	the	the	DET
aiua-13880	429	14	number	number	NOUN
aiua-13880	429	15	of	of	ADP
aiua-13880	429	16	metastatic	metastatic	ADJ
aiua-13880	429	17	sites	site	NOUN
aiua-13880	429	18	in	in	ADP
aiua-13880	429	19	patients	patient	NOUN
aiua-13880	429	20	treated	treat	VERB
aiua-13880	429	21	with	with	ADP
aiua-13880	429	22	pembrolizumab	pembrolizumab	NOUN
aiua-13880	429	23	—	—	PUNCT
aiua-13880	429	24	a	a	DET
aiua-13880	429	25	multicenter	multicenter	ADJ
aiua-13880	429	26	collaborative	collaborative	ADJ
aiua-13880	429	27	study	study	NOUN
aiua-13880	429	28	in	in	ADP
aiua-13880	429	29	japan	japan	PROPN
aiua-13880	429	30	.	.	PUNCT
aiua-13880	430	1	cancers	cancer	NOUN
aiua-13880	430	2	.	.	PUNCT
aiua-13880	430	3	2021	2021	NUM
aiua-13880	430	4	;	;	PUNCT
aiua-13880	430	5	13:3554	13:3554	NUM
aiua-13880	430	6	.	.	PUNCT
aiua-13880	431	1	57	57	NUM
aiua-13880	431	2	.	.	PUNCT
aiua-13880	432	1	uchimoto	uchimoto	PROPN
aiua-13880	432	2	t	t	PROPN
aiua-13880	432	3	,	,	PUNCT
aiua-13880	432	4	nakamura	nakamura	PROPN
aiua-13880	432	5	k	k	PROPN
aiua-13880	432	6	,	,	PUNCT
aiua-13880	432	7	komura	komura	NOUN
aiua-13880	432	8	k	k	PROPN
aiua-13880	432	9	,	,	PUNCT
aiua-13880	432	10	et	et	PROPN
aiua-13880	432	11	al	al	PROPN
aiua-13880	432	12	.	.	PROPN
aiua-13880	432	13	prognostic	prognostic	ADJ
aiua-13880	432	14	value	value	NOUN
aiua-13880	432	15	of	of	ADP
aiua-13880	432	16	the	the	DET
aiua-13880	432	17	fluctuation	fluctuation	NOUN
aiua-13880	432	18	in	in	ADP
aiua-13880	432	19	the	the	DET
aiua-13880	432	20	neutrophil	neutrophil	ADJ
aiua-13880	432	21	-	-	PUNCT
aiua-13880	432	22	lymphocyte	lymphocyte	NOUN
aiua-13880	432	23	ratio	ratio	NOUN
aiua-13880	432	24	at	at	ADP
aiua-13880	432	25	6	6	NUM
aiua-13880	432	26	weeks	week	NOUN
aiua-13880	432	27	of	of	ADP
aiua-13880	432	28	pemdeclarations	pemdeclaration	NOUN
aiua-13880	432	29	ethical	ethical	ADJ
aiua-13880	432	30	approval	approval	NOUN
aiua-13880	432	31	:	:	PUNCT
aiua-13880	432	32	not	not	PART
aiua-13880	432	33	applicable	applicable	ADJ
aiua-13880	432	34	.	.	PUNCT
aiua-13880	433	1	consent	consent	NOUN
aiua-13880	433	2	for	for	ADP
aiua-13880	433	3	publication	publication	NOUN
aiua-13880	433	4	:	:	PUNCT
aiua-13880	433	5	not	not	PART
aiua-13880	433	6	applicable	applicable	ADJ
aiua-13880	433	7	.	.	PUNCT
aiua-13880	434	1	availability	availability	NOUN
aiua-13880	434	2	of	of	ADP
aiua-13880	434	3	data	datum	NOUN
aiua-13880	434	4	and	and	CCONJ
aiua-13880	434	5	material	material	NOUN
aiua-13880	434	6	:	:	PUNCT
aiua-13880	434	7	all	all	DET
aiua-13880	434	8	data	datum	NOUN
aiua-13880	434	9	generated	generate	VERB
aiua-13880	434	10	or	or	CCONJ
aiua-13880	434	11	analyzed	analyze	VERB
aiua-13880	434	12	during	during	ADP
aiua-13880	434	13	this	this	DET
aiua-13880	434	14	study	study	NOUN
aiua-13880	434	15	are	be	AUX
aiua-13880	434	16	included	include	VERB
aiua-13880	434	17	in	in	ADP
aiua-13880	434	18	this	this	DET
aiua-13880	434	19	published	publish	VERB
aiua-13880	434	20	article	article	NOUN
aiua-13880	434	21	.	.	PUNCT
aiua-13880	435	1	competing	compete	VERB
aiua-13880	435	2	interests	interest	NOUN
aiua-13880	435	3	:	:	PUNCT
aiua-13880	435	4	the	the	DET
aiua-13880	435	5	authors	author	NOUN
aiua-13880	435	6	declare	declare	VERB
aiua-13880	435	7	that	that	SCONJ
aiua-13880	435	8	they	they	PRON
aiua-13880	435	9	have	have	VERB
aiua-13880	435	10	no	no	DET
aiua-13880	435	11	competing	compete	VERB
aiua-13880	435	12	interests	interest	NOUN
aiua-13880	435	13	.	.	PUNCT
aiua-13880	436	1	funding	funding	NOUN
aiua-13880	436	2	:	:	PUNCT
aiua-13880	436	3	this	this	DET
aiua-13880	436	4	research	research	NOUN
aiua-13880	436	5	did	do	AUX
aiua-13880	436	6	not	not	PART
aiua-13880	436	7	receive	receive	VERB
aiua-13880	436	8	any	any	DET
aiua-13880	436	9	specific	specific	ADJ
aiua-13880	436	10	grant	grant	NOUN
aiua-13880	436	11	from	from	ADP
aiua-13880	436	12	funding	fund	VERB
aiua-13880	436	13	agencies	agency	NOUN
aiua-13880	436	14	in	in	ADP
aiua-13880	436	15	the	the	DET
aiua-13880	436	16	public	public	ADJ
aiua-13880	436	17	,	,	PUNCT
aiua-13880	436	18	commercial	commercial	ADJ
aiua-13880	436	19	,	,	PUNCT
aiua-13880	436	20	or	or	CCONJ
aiua-13880	436	21	not	not	PART
aiua-13880	436	22	-	-	PUNCT
aiua-13880	436	23	for	for	ADP
aiua-13880	436	24	-	-	PUNCT
aiua-13880	436	25	profit	profit	NOUN
aiua-13880	436	26	sectors	sector	NOUN
aiua-13880	436	27	.	.	PUNCT
aiua-13880	437	1	authors	author	NOUN
aiua-13880	437	2	'	'	PART
aiua-13880	437	3	contributions	contribution	NOUN
aiua-13880	437	4	:	:	PUNCT
aiua-13880	437	5	kyu	kyu	PROPN
aiua-13880	437	6	:	:	PUNCT
aiua-13880	437	7	study	study	NOUN
aiua-13880	437	8	concept	concept	NOUN
aiua-13880	437	9	,	,	PUNCT
aiua-13880	437	10	data	datum	NOUN
aiua-13880	437	11	collection	collection	NOUN
aiua-13880	437	12	,	,	PUNCT
aiua-13880	437	13	statistical	statistical	ADJ
aiua-13880	437	14	analyses	analysis	NOUN
aiua-13880	437	15	,	,	PUNCT
aiua-13880	437	16	manuscript	manuscript	VERB
aiua-13880	437	17	original	original	ADJ
aiua-13880	437	18	drafting	drafting	NOUN
aiua-13880	437	19	;	;	PUNCT
aiua-13880	437	20	jnr	jnr	PROPN
aiua-13880	437	21	:	:	PUNCT
aiua-13880	437	22	study	study	NOUN
aiua-13880	437	23	concept	concept	NOUN
aiua-13880	437	24	,	,	PUNCT
aiua-13880	437	25	data	datum	NOUN
aiua-13880	437	26	collection	collection	NOUN
aiua-13880	437	27	,	,	PUNCT
aiua-13880	437	28	manuscript	manuscript	VERB
aiua-13880	437	29	original	original	ADJ
aiua-13880	437	30	drafting	drafting	NOUN
aiua-13880	437	31	;	;	PUNCT
aiua-13880	437	32	ndf	ndf	NOUN
aiua-13880	437	33	:	:	PUNCT
aiua-13880	437	34	study	study	NOUN
aiua-13880	437	35	concept	concept	NOUN
aiua-13880	437	36	,	,	PUNCT
aiua-13880	437	37	data	datum	NOUN
aiua-13880	437	38	analysis	analysis	NOUN
aiua-13880	437	39	,	,	PUNCT
aiua-13880	437	40	contribution	contribution	NOUN
aiua-13880	437	41	to	to	PART
aiua-13880	437	42	manuscript	manuscript	VERB
aiua-13880	437	43	writing	writing	NOUN
aiua-13880	437	44	and	and	CCONJ
aiua-13880	437	45	editing	editing	NOUN
aiua-13880	437	46	;	;	PUNCT
aiua-13880	437	47	rev	rev	VERB
aiua-13880	437	48	:	:	PUNCT
aiua-13880	437	49	study	study	NOUN
aiua-13880	437	50	concept	concept	NOUN
aiua-13880	437	51	,	,	PUNCT
aiua-13880	437	52	data	datum	NOUN
aiua-13880	437	53	analysis	analysis	NOUN
aiua-13880	437	54	,	,	PUNCT
aiua-13880	437	55	contribution	contribution	NOUN
aiua-13880	437	56	to	to	PART
aiua-13880	437	57	manuscript	manuscript	VERB
aiua-13880	437	58	writing	writing	NOUN
aiua-13880	437	59	and	and	CCONJ
aiua-13880	437	60	editing	editing	NOUN
aiua-13880	437	61	;	;	PUNCT
aiua-13880	437	62	zar	zar	NOUN
aiua-13880	437	63	:	:	PUNCT
aiua-13880	437	64	study	study	NOUN
aiua-13880	437	65	concept	concept	NOUN
aiua-13880	437	66	,	,	PUNCT
aiua-13880	437	67	data	datum	NOUN
aiua-13880	437	68	interpretation	interpretation	NOUN
aiua-13880	437	69	,	,	PUNCT
aiua-13880	437	70	critical	critical	ADJ
aiua-13880	437	71	revision	revision	NOUN
aiua-13880	437	72	of	of	ADP
aiua-13880	437	73	manuscript.all	manuscript.all	DET
aiua-13880	437	74	authors	author	NOUN
aiua-13880	437	75	have	have	AUX
aiua-13880	437	76	read	read	VERB
aiua-13880	437	77	and	and	CCONJ
aiua-13880	437	78	approved	approve	VERB
aiua-13880	437	79	the	the	DET
aiua-13880	437	80	final	final	ADJ
aiua-13880	437	81	version	version	NOUN
aiua-13880	437	82	of	of	ADP
aiua-13880	437	83	the	the	DET
aiua-13880	437	84	manuscript	manuscript	NOUN
aiua-13880	437	85	.	.	PUNCT
aiua-13880	438	1	acknowledgments	acknowledgment	NOUN
aiua-13880	438	2	:	:	PUNCT
aiua-13880	438	3	the	the	DET
aiua-13880	438	4	authors	author	NOUN
aiua-13880	438	5	would	would	AUX
aiua-13880	438	6	like	like	VERB
aiua-13880	438	7	to	to	PART
aiua-13880	438	8	thank	thank	VERB
aiua-13880	438	9	dr	dr	PROPN
aiua-13880	438	10	.	.	PROPN
aiua-13880	438	11	zakaria	zakaria	PROPN
aiua-13880	438	12	aulia	aulia	PROPN
aiua-13880	438	13	rahman	rahman	PROPN
aiua-13880	438	14	for	for	ADP
aiua-13880	438	15	his	his	PRON
aiua-13880	438	16	guidance	guidance	NOUN
aiua-13880	438	17	and	and	CCONJ
aiua-13880	438	18	assistance	assistance	NOUN
aiua-13880	438	19	in	in	ADP
aiua-13880	438	20	the	the	DET
aiua-13880	438	21	study	study	NOUN
aiua-13880	438	22	.	.	PUNCT
aiua-13880	439	1	further	further	ADJ
aiua-13880	439	2	information	information	NOUN
aiua-13880	439	3	:	:	PUNCT
aiua-13880	439	4	parts	part	NOUN
aiua-13880	439	5	of	of	ADP
aiua-13880	439	6	this	this	DET
aiua-13880	439	7	study	study	NOUN
aiua-13880	439	8	were	be	AUX
aiua-13880	439	9	presented	present	VERB
aiua-13880	439	10	at	at	ADP
aiua-13880	439	11	the	the	DET
aiua-13880	439	12	2024	2024	NUM
aiua-13880	439	13	bandung	bandung	NOUN
aiua-13880	439	14	urological	urological	ADJ
aiua-13880	439	15	meeting	meeting	NOUN
aiua-13880	439	16	held	hold	VERB
aiua-13880	439	17	in	in	ADP
aiua-13880	439	18	bandung	bandung	PROPN
aiua-13880	439	19	,	,	PUNCT
aiua-13880	439	20	indonesia	indonesia	PROPN
aiua-13880	439	21	.	.	PUNCT
aiua-13880	440	1	archivio	archivio	PROPN
aiua-13880	440	2	italiano	italiano	PROPN
aiua-13880	440	3	di	di	PROPN
aiua-13880	440	4	urologia	urologia	PROPN
aiua-13880	440	5	e	e	PROPN
aiua-13880	440	6	andrologia	andrologia	NOUN
aiua-13880	440	7	2025	2025	NUM
aiua-13880	440	8	;	;	PUNCT
aiua-13880	440	9	97(2):13880	97(2):13880	NUM
aiua-13880	440	10	k	k	PROPN
aiua-13880	440	11	..	..	PUNCT
aiua-13880	440	12	yuwono	yuwono	PROPN
aiua-13880	440	13	,	,	PUNCT
aiua-13880	440	14	j.	j.	PROPN
aiua-13880	440	15	nimasratu	nimasratu	PROPN
aiua-13880	440	16	rahmatsani	rahmatsani	PROPN
aiua-13880	440	17	,	,	PUNCT
aiua-13880	440	18	nadhifah	nadhifah	VERB
aiua-13880	440	19	,	,	PUNCT
aiua-13880	440	20	et	et	PROPN
aiua-13880	440	21	al	al	PROPN
aiua-13880	440	22	.	.	PROPN
aiua-13880	440	23	12	12	NUM
aiua-13880	440	24	brolizumab	brolizumab	NOUN
aiua-13880	440	25	treatment	treatment	NOUN
aiua-13880	440	26	is	be	AUX
aiua-13880	440	27	specific	specific	ADJ
aiua-13880	440	28	to	to	ADP
aiua-13880	440	29	the	the	DET
aiua-13880	440	30	clinical	clinical	ADJ
aiua-13880	440	31	response	response	NOUN
aiua-13880	440	32	in	in	ADP
aiua-13880	440	33	metastatic	metastatic	ADJ
aiua-13880	440	34	urothelial	urothelial	ADJ
aiua-13880	440	35	carcinoma	carcinoma	NOUN
aiua-13880	440	36	.	.	PUNCT
aiua-13880	441	1	urol	urol	PROPN
aiua-13880	441	2	oncol	oncol	PROPN
aiua-13880	441	3	semin	semin	PROPN
aiua-13880	441	4	orig	orig	PROPN
aiua-13880	441	5	investig	investig	PROPN
aiua-13880	441	6	.	.	PROPN
aiua-13880	441	7	2022	2022	NUM
aiua-13880	441	8	;	;	PUNCT
aiua-13880	441	9	40:344.e11	40:344.e11	NUM
aiua-13880	441	10	-	-	PUNCT
aiua-13880	441	11	344.e17	344.e17	NUM
aiua-13880	441	12	.	.	PUNCT
aiua-13880	441	13	58	58	NUM
aiua-13880	441	14	.	.	PUNCT
aiua-13880	442	1	umeda	umeda	PROPN
aiua-13880	442	2	k	k	PROPN
aiua-13880	442	3	,	,	PUNCT
aiua-13880	442	4	tanaka	tanaka	PROPN
aiua-13880	442	5	n	n	CCONJ
aiua-13880	442	6	,	,	PUNCT
aiua-13880	442	7	yasumizu	yasumizu	PROPN
aiua-13880	442	8	y	y	PROPN
aiua-13880	442	9	,	,	PUNCT
aiua-13880	442	10	et	et	PROPN
aiua-13880	442	11	al	al	PROPN
aiua-13880	442	12	.	.	PROPN
aiua-13880	442	13	site	site	NOUN
aiua-13880	442	14	-	-	PUNCT
aiua-13880	442	15	specific	specific	ADJ
aiua-13880	442	16	differences	difference	NOUN
aiua-13880	442	17	in	in	ADP
aiua-13880	442	18	pd-1	pd-1	ADP
aiua-13880	442	19	blockade	blockade	NOUN
aiua-13880	442	20	success	success	NOUN
aiua-13880	442	21	and	and	CCONJ
aiua-13880	442	22	biomarkers	biomarker	NOUN
aiua-13880	442	23	in	in	ADP
aiua-13880	442	24	urothelial	urothelial	ADJ
aiua-13880	442	25	carcinoma	carcinoma	NOUN
aiua-13880	442	26	treated	treat	VERB
aiua-13880	442	27	with	with	ADP
aiua-13880	442	28	pembrolizumab	pembrolizumab	NOUN
aiua-13880	442	29	.	.	PUNCT
aiua-13880	443	1	clin	clin	PROPN
aiua-13880	443	2	genitourin	genitourin	PROPN
aiua-13880	443	3	cancer	cancer	NOUN
aiua-13880	443	4	.	.	PUNCT
aiua-13880	444	1	2023	2023	NUM
aiua-13880	444	2	;	;	PUNCT
aiua-13880	444	3	21:128	21:128	NUM
aiua-13880	444	4	-	-	SYM
aiua-13880	444	5	35	35	NUM
aiua-13880	444	6	.	.	PUNCT
aiua-13880	445	1	59	59	NUM
aiua-13880	445	2	.	.	PUNCT
aiua-13880	446	1	yamamoto	yamamoto	PROPN
aiua-13880	446	2	s	s	PROPN
aiua-13880	446	3	,	,	PUNCT
aiua-13880	446	4	fukushima	fukushima	PROPN
aiua-13880	446	5	h	h	PROPN
aiua-13880	446	6	,	,	PUNCT
aiua-13880	446	7	fukuda	fukuda	PROPN
aiua-13880	446	8	s	s	PROPN
aiua-13880	446	9	,	,	PUNCT
aiua-13880	446	10	et	et	PROPN
aiua-13880	446	11	al	al	PROPN
aiua-13880	446	12	.	.	PROPN
aiua-13880	447	1	early	early	ADJ
aiua-13880	447	2	cancer	cancer	NOUN
aiua-13880	447	3	cachexia	cachexia	PROPN
aiua-13880	447	4	phenotype	phenotype	NOUN
aiua-13880	447	5	predicts	predict	VERB
aiua-13880	447	6	survival	survival	NOUN
aiua-13880	447	7	of	of	ADP
aiua-13880	447	8	advanced	advanced	ADJ
aiua-13880	447	9	urothelial	urothelial	ADJ
aiua-13880	447	10	cancer	cancer	NOUN
aiua-13880	447	11	patients	patient	NOUN
aiua-13880	447	12	treated	treat	VERB
aiua-13880	447	13	with	with	ADP
aiua-13880	447	14	pembrolizumab	pembrolizumab	NOUN
aiua-13880	447	15	.	.	PUNCT
aiua-13880	448	1	asia	asia	PROPN
aiua-13880	448	2	pac	pac	PROPN
aiua-13880	448	3	j	j	PROPN
aiua-13880	448	4	clin	clin	PROPN
aiua-13880	448	5	oncol	oncol	PROPN
aiua-13880	448	6	.	.	PUNCT
aiua-13880	449	1	2022	2022	NUM
aiua-13880	449	2	;	;	PUNCT
aiua-13880	449	3	18:410	18:410	NUM
aiua-13880	449	4	-	-	SYM
aiua-13880	449	5	8	8	NUM
aiua-13880	449	6	.	.	PUNCT
aiua-13880	450	1	60	60	NUM
aiua-13880	450	2	.	.	PUNCT
aiua-13880	451	1	yamashita	yamashita	PROPN
aiua-13880	451	2	s	s	PROPN
aiua-13880	451	3	,	,	PUNCT
aiua-13880	451	4	wada	wada	PROPN
aiua-13880	451	5	t	t	PROPN
aiua-13880	451	6	,	,	PUNCT
aiua-13880	451	7	deguchi	deguchi	PROPN
aiua-13880	451	8	r	r	PROPN
aiua-13880	451	9	,	,	PUNCT
aiua-13880	451	10	et	et	PROPN
aiua-13880	451	11	al	al	PROPN
aiua-13880	451	12	.	.	PROPN
aiua-13880	452	1	prognostic	prognostic	ADJ
aiua-13880	452	2	significance	significance	NOUN
aiua-13880	452	3	of	of	ADP
aiua-13880	452	4	pre	pre	ADJ
aiua-13880	452	5	-	-	ADJ
aiua-13880	452	6	treatment	treatment	ADJ
aiua-13880	452	7	albumin	albumin	ADJ
aiua-13880	452	8	-	-	PUNCT
aiua-13880	452	9	bilirubin	bilirubin	NOUN
aiua-13880	452	10	grade	grade	NOUN
aiua-13880	452	11	in	in	ADP
aiua-13880	452	12	metastatic	metastatic	ADJ
aiua-13880	452	13	urothelial	urothelial	ADJ
aiua-13880	452	14	carcinoma	carcinoma	NOUN
aiua-13880	452	15	receiving	receive	VERB
aiua-13880	452	16	pembrolizumab	pembrolizumab	NOUN
aiua-13880	452	17	.	.	PUNCT
aiua-13880	453	1	jpn	jpn	PROPN
aiua-13880	453	2	j	j	PROPN
aiua-13880	453	3	clin	clin	PROPN
aiua-13880	453	4	oncol	oncol	PROPN
aiua-13880	453	5	.	.	PUNCT
aiua-13880	454	1	2023	2023	NUM
aiua-13880	454	2	;	;	PUNCT
aiua-13880	454	3	53:845	53:845	NUM
aiua-13880	454	4	-	-	SYM
aiua-13880	454	5	50	50	NUM
aiua-13880	454	6	.	.	PUNCT
aiua-13880	455	1	correspondence	correspondence	NOUN
aiua-13880	455	2	kevin	kevin	PROPN
aiua-13880	455	3	yuwono	yuwono	PROPN
aiua-13880	456	1	yuwonokvn@gmail.com	yuwonokvn@gmail.com	PROPN
aiua-13880	456	2	junjungan	junjungan	PROPN
aiua-13880	456	3	nimasratu	nimasratu	PROPN
aiua-13880	456	4	rahmatsani	rahmatsani	PROPN
aiua-13880	456	5	junjungan.nr@gmail.com	junjungan.nr@gmail.com	PROPN
aiua-13880	456	6	nadhifah	nadhifah	PROPN
aiua-13880	456	7	nadhifah	nadhifah	VERB
aiua-13880	457	1	nadhifahmahfudi@gmail.com	nadhifahmahfudi@gmail.com	X
aiua-13880	457	2	revina	revina	PROPN
aiua-13880	457	3	maharani	maharani	PROPN
aiua-13880	457	4	10maharanirevina@gmail.com	10maharanirevina@gmail.com	PROPN
aiua-13880	457	5	faculty	faculty	NOUN
aiua-13880	457	6	of	of	ADP
aiua-13880	457	7	medicine	medicine	NOUN
aiua-13880	457	8	,	,	PUNCT
aiua-13880	457	9	brawijaya	brawijaya	PROPN
aiua-13880	457	10	university	university	PROPN
aiua-13880	457	11	,	,	PUNCT
aiua-13880	457	12	indonesia	indonesia	PROPN
aiua-13880	457	13	zakaria	zakaria	PROPN
aiua-13880	457	14	aulia	aulia	PROPN
aiua-13880	457	15	rahman	rahman	PROPN
aiua-13880	457	16	zakariaaulia04@gmail.com	zakariaaulia04@gmail.com	PROPN
aiua-13880	457	17	department	department	PROPN
aiua-13880	457	18	of	of	ADP
aiua-13880	457	19	urology	urology	NOUN
aiua-13880	457	20	,	,	PUNCT
aiua-13880	457	21	faculty	faculty	NOUN
aiua-13880	457	22	of	of	ADP
aiua-13880	457	23	medicine	medicine	NOUN
aiua-13880	457	24	,	,	PUNCT
aiua-13880	457	25	airlangga	airlangga	PROPN
aiua-13880	457	26	university	university	PROPN
aiua-13880	457	27	,	,	PUNCT
aiua-13880	457	28	indonesia	indonesia	PROPN
aiua-13880	457	29	mayjen	mayjen	PROPN
aiua-13880	457	30	prof	prof	PROPN
aiua-13880	457	31	.	.	PUNCT
aiua-13880	458	1	dr	dr	PROPN
aiua-13880	458	2	.	.	PROPN
aiua-13880	458	3	moestopo	moestopo	PROPN
aiua-13880	458	4	,	,	PUNCT
aiua-13880	458	5	47	47	NUM
aiua-13880	458	6	,	,	PUNCT
aiua-13880	458	7	60131	60131	NUM
aiua-13880	458	8	,	,	PUNCT
aiua-13880	458	9	indonesia	indonesia	PROPN